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Translation dysregulation is a common occurrence in the tumour environment. In 
cancer cells, numerous regulatory features are perturbed to increase protein 
output and thus enhance cellular growth. This can be achieved either through 
overexpression of certain translational factors or dampening translation 
repression. Importantly, translation initiation is the crucial step at which most 
regulatory elements converge. Moreover, highly structured 5’UTRs of oncogenic 
mRNAs often require helicase activity in order to be translated. Interestingly, 
humans have two highly identical helicases, eIF4A1 and eIF4A2, which have been 
shown to not only promote different outcomes for cancer patients but also to 
have divergent translational roles. eIF4A1 is the canonical factor associated with 
eukaryotic translation initiation complex eIF4F, whereas eIF4A2 has been shown 
to interact with CCR4-NOT complex, and thus has been implicated in miRNA-
mediated translational repression.  
The aim of this thesis was to understand what drives the distinct activities of the 
highly identical paralogues on a molecular level, and what influence the 
different interaction partners confer on the two helicases.  
Using biochemical and structural approaches as well as cell imaging methods, 
the previously unexplored mechanisms that govern eIF4A2 and the distinct 
activities between the two paralogues were investigated.  
The work presented in this thesis led to description and in-depth investigation of 
the novel RNA-dependent oligomeric formation of both paralogues. Most 
importantly, it was demonstrated that the potential to oligomerise dictates the 
catalytic properties of the paralogues, and that it is the RNA sequence and not 
the affinity that determines the extent of oligomerisation. Moreover, both 
helicases have different propensity to form oligomeric complexes. Additionally, 
regions responsible for divergent functions of eIF4A1 and eIF4A2 were identified. 
And the different functions imparted by their interaction partners were 
determined.  
This study provides new understanding of the functions of eIF4A1 and eIF4A2 in 
the translational control and how functionally distinct oligomeric assemblies of 
the two paralogues can re-sculpture RNA landscapes.  
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A major goal in biomedical science is to understand the biological mechanisms 
that lead to human disease. Protein synthesis is a cornerstone of biological 
processes and is discussed in Chapter 1.3. It is a tightly regulated mechanism 
that plays a crucial role in cell growth, proliferation, and differentiation. 
However, it is just one essential component of the gene expression pathway, and 
many upstream cellular gene expression decisions affect the translational 
response. Thus, in Chapter 1.2, the entirety of gene expression is briefly 
discussed, with focus on those steps that affect the translation pathway.  
Aberrant protein synthesis is one of the many features of cancer, a disease that 
stems from within the organism, in which normal cells are transformed into 
cancer cells. In order to stop tumorigenesis, understanding how cancer exploits 
protein translation is indispensable (Chapter 1.4). As many cancer associated 
mRNAs contain features that require the activity of helicases, understanding how 
helicases function is crucial (Chapter 1.5). Helicases such as the eIF4A family, 
which have been shown to play opposite roles in cancer setting, are an 
attractive target for chemotherapeutic intervention. However, to better develop 
these drugs, we need to understand how these helicases work and how to target 
the appropriate one. Finally, in Chapter 1.6, the overarching aims of this thesis 




1.2. Gene expression 
 
The processes within the cell that sustain and allow life are inherently chemical, 
catalysed by the activity of proteins within numerous and vast networks. The 
levels of each protein within these networks need to be carefully maintained for 
cellular homeostasis or modulated to adapt to changes in the environment. 
Thus, central to all cellular processes is the constant generation of new proteins. 
This involves the translation of the sequence within an mRNA that was in turn 
transcribed from a gene within the genomic DNA (Figure 1.2-1). This sequential 
flow of information from DNA to RNA to protein is true for all life and forms the 







Figure 1.2-1 Central dogma of molecular biology  
Central dogma of molecular biology is based on the unilateral flow of information. First, 
DNA is transcribed into RNA, containing both introns and exons. The splicing machinery 
removes introns, and mRNA is matured by adding the mRNA cap and polyA tail. The 
processed mRNA is subsequently exported from the nucleus into the cytoplasm where 
the mRNA translation into the polypeptide chain can begin. Finally, the amino acid (aa) 
chain can be folded into a functional protein. Figure drawn using Inkscape 1.1, ribosome 









1.2.1. The human genome 
 
The human genome consists of 22 pairs of autosomal chromosomes, the 23rd pair 
of sex chromosomes, and the mitochondrial DNA, totalling 3 billion base pairs of 
DNA sequence (Lander et al., 2001; International Human Genome Sequencing 
Consortium, 2004; Miga et al., 2020). The human genome comprises both 
protein-coding and non-coding DNA in the form of genes. As an oversimplified 
definition, genes are the units of information within the genome. While there 
are around 20,000 protein coding genes, this in fact only represents a small 
portion of the human genome (Ezkurdia et al., 2014; Salzberg, 2018). The non-
coding portion of the genome represents DNA that will never become a protein. 
Among the most prominent examples of non-coding DNA are genes transcribed 
into non-coding RNA like the portion of the genome encoding 1) transfer RNA 
(tRNA), 2) ribosomal RNA (rRNA), 3) about 2300 human mature miRNAs (Alles et 
al., 2019), and 4) other regulatory RNAs (Li and Liu, 2019). Coding DNA is 
transcribed into mRNA and translated into proteins, whereas non-coding DNA is 
thought to take part in the regulation of gene expression.  
Even though the majority of the genome does not encode a protein, the vast 
non-coding portion of the genome can affect protein translation; therefore, the 
small variations between the genomes of individual humans (Abecasis et al., 
2012; The 1000 Genomes Project Consortium, 2015) can affect their 
translational output.  
The first step of gene expression involves the generation of numerous copies of a 
gene in the form of RNA. This process is known as transcription (Chapter 1.2.2).  
 
1.2.2. Transcription and mRNA maturation 
 
As this thesis pertains to regulation of protein translation, this transcription 
subchapter will introduce principles that lead to creation of a mature messenger 
RNA (mRNA), that in turn can be translated into a protein.  
The transcription of a gene to form a mature mRNA is a complex, multi-step 
process that is subjected to regulation at every stage.  
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Generally, the genomic DNA can be found wrapped tightly around histones 
forming a structure referred to as chromatin. The purpose of chromatin is to 
condense and protect the genome, but also serves as the first regulatory hurdle 
that a gene must overcome to be expressed. When chromatin is in a highly 
condensed state the DNA itself is inaccessible and incapable of being 
transcribed. Thus, the first step of transcription is the unwinding of chromatin 
(Saha, Wittmeyer and Cairns, 2006; Wang, Allis and Ping, 2007; Phillips and 
Shaw, 2008). Chromatin remodelling factors modify the “tails” of histones with 
the addition or subtraction of several chemical modifications. Histone 
modifications are binding sites for further modifying factors that reinforce a 
histone “code” that dictates whether a particular genomic region is open and 
accessible (euchromatin), or condensed and inaccessible (heterochromatin) 
(Strahl and Allis, 2000; Jenuwein and Allis, 2001; Saha, Wittmeyer and Cairns, 
2006; Tropberger and Schneider, 2013). Actively transcribing genes are thus 
found in euchromatin, while inactive genes are found in heterochromatin. This 
process is one of the major regulatory control points in the cell, acting through 
both histone and DNA modifications.  
Once the DNA is found in a form of ‘active’ euchromatin it can be bound by RNA 
polymerase II (Pol II) and other transcription factors at the DNA promoter site 
(Travers, 1974; Kornberg, 1999; Sims, Mandal and Reinberg, 2004). Pol II, which 
is a multiprotein complex, proceeds to separate two strands of DNA by breaking 
the hydrogen bonds between the DNA base pairs. Subsequently, Pol II adds RNA 
nucleotides at the transcription start site, proximal to the DNA promoter 
(transcription initiation) and further translocates the DNA while transcribing its 
sequence into RNA (transcription elongation). The formed RNA strand is 5’ to 3’ 
and complementary bound to 3’ to 5’ DNA template strand. Subsequently the 
hydrogen bonds between the newly created RNA and DNA template strand are 
broken, and the newly synthetised RNA is released (transcription termination). 
Transcription termination by Pol II can occur in two different stages: 1) 
recognition of the polyadenylation signal and joining of the cleavage and 
polyadenylation factor (CPF) and the cleavage factors IA, IB, 2) ‘torpedo’ model, 
where Pol II is removed from the template by collision with other termination 
factors (Lykke-Andersen and Jensen, 2007).  
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It should be noted that, while the steps of transcription are often conceptualised 
as a linear progression of events, many steps occur concurrently. One of the 
examples of simultaneous processes are the so-called post-transcriptional 
modifications of the newly synthetised RNA.  
The first of these is the important step of the addition of the cap structure. The 
cap is present on all mature human mRNAs (apart from mitochondrial mRNAs 
(Temperley et al., 2010)) and is added by the capping enzyme complex (CEC) 
associated with Pol II. The CEC adds a non-templated guanosine to the 5’-most 
nucleotide and methylates this at the N7 position soon after the first few 
nucleotides are transcribed (Cho et al., 1997). As will be described later 
(Section 1.3.2), the resulting mRNA m7G cap is the docking point for the factors 
involved in translation initiation. Furthermore, it protects the mRNA from 5’-3’ 
nucleolytic degradation in both the nucleus and the cytoplasm (Filipowicz et al., 
1976; Shatkin, 1976).  
Additional modifications that are added co-transcriptionally and influence the 
translation of that mRNA are additional nucleotide methylations. One of the 
most common methylations is found on the N6 position of adenosine (m6A), 
which is deposited by METLL3/METLL14 on around 25 % of all mRNAs (Dominissini 
et al., 2012; Meyer et al., 2012). This modification has been shown to have a 
strong role in destabilisation of the mRNA (Zaccara and Jaffrey, 2020).  
A key stage of mature mRNA production is the splicing of the precursor mRNA 
(Berget, Moore and Sharp, 1977). The process of splicing involves the removal of 
introns (DNA segments located between two exons) by the spliceosome (Will and 
Luhrmann, 2011; Herzel et al., 2017). Due to existence of the process called 
alternative splicing, a single precursor mRNA can become a range of mature 
mRNAs, which in turn could be translated into different proteins (Pan et al., 
2008). After the mRNA is spliced, a protein complex called exon junction 
complex (EJC) binds around the junction of the two exons (after intron 
excision), which can affect the translational output of the given mRNA (Nott, Le 
Hir and Moore, 2004; Tange, Nott and Moore, 2004).  
Another important step is addition of the polyadenylate (polyA) tail to the 3’ end 
of the newly synthetised mRNA (precursor mRNA) after its release by the above-
mentioned cleavage and polyadenylation factors. As will be discussed later, the 
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polyA tail is a crucial cis-regulatory component of the mature mRNA (Chapter 
1.2.4, 1.3.6). The addition of polyA is performed by polyadenylate polymerase, 
which adds adenosine monophosphates to the RNA (Bienroth, Keller and Wahle, 
1993; Balbo and Bohm, 2007). It is worth noting that, until recently, polyA tail 
was considered to be entirely homogenous; however, a recent publication (Lim 
et al., 2018) demonstrated that the polyA can in fact be heterogenous.  
 
1.2.3. Protein synthesis  
 
Following transcription, the newly synthetised mRNA is subjected to one of the 
two fates: 1) binding by a number of factors and nuclear export, 2) degradation 
by the nuclear exosome in case of improper mRNA processing (Bousquet-
Antonelli, Presutti and Tollervey, 2000; Liu, Luo and Wen, 2014). In the first 
instance, the newly synthesised cap of the mature mRNA is bound in the nucleus 
by the cap-binding complex (CBC), which is a heterodimer consisting of CBP20 
and CBP80 (Izaurralde et al., 1995). Similarly, the 3’end of the newly 
synthetised mRNA is bound by a nuclear polyA-binding protein, PABP2 (Dreyfuss, 
Kim and Kataoka, 2002). The mature RNA, ready for export, remains bound by 
the above-mentioned exon junction complex (Chapter 1.2.2). The nuclear 
export of mRNA is atypical and differs from the export of proteins, tRNA and 
miRNA and is mediated through the membrane associated protein TAP (Herold et 
al., 2000). The presence of the CBC has also been implicated in the mediation of 
nuclear export (Izaurralde et al., 1992). After the export from the nucleus 
through the nuclear pore complex, the mRNA can be translated by the ribosome 
to generate a protein.  
All protein synthesis across all of life is catalysed by the ribosome. While there 
are differences between prokaryotes, archaea, and eukaryotes, the ribosome is 
broadly the same machine consisting of two subunits, each of which is made of 
ribosomal RNA (rRNA) and numerous proteins. The ribosome utilises transfer RNA 
(tRNA) to decode an mRNA and assemble the polypeptide chain that ultimately 
folds into a mature protein. 
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The pioneer round of translation (Figure 1.2.3-1), in contrast to the steady-
state rounds of translation which generate the bulk of cellular proteins, offers a 
quality control of gene expression (Isken and Maquat, 2008). It is employed by 
the cell to detect splicing errors that resulted in the introduction of premature 
translation stop sequences (codons; see Chapters 1.3.1, 1.3.4). The 
consequence of unchecked premature stop codons is that a nonsense protein 
could be made that may be detrimental to the cell. When the pioneering 
ribosome encounters this premature stop codon which is usually located at more 
than 50 nucleotides upstream of the EJC on that mRNA, a nonsense-mediated 
decay  process is triggered (Maquat, Tarn and Isken, 2010). The CBC itself has 
been shown to play a role in nonsense-mediated decay of mRNA due to direct 
interaction between CBP80 and up-frameshift 1 (UPF1) nonsense-mediated decay 
factor, which is a part of SURF complex involved in recognition of premature 
stop codons (Lykke-andersen, Shu and Steitz, 2000; Hosoda et al., 2005; Kashima 
et al., 2006; Isken and Maquat, 2008).  
If the pioneering ribosome completes translation of protein from a given mRNA 
without encountering premature stop codons, the canonical steady-state 
translation can begin. In that case the nuclear proteins are exchanged for 
cytoplasmic factors: 1) CBC is replaced by eIF4E, 2) nuclear PABP2 is exchanged 
for cytoplasmic PABP1, and 3) EJC is displaced by the translating ribosome 
(Maquat, Tarn and Isken, 2010). Steady-state translation consists of 3 steps: 
initiation, elongation and termination and leads to production of polypeptide 
chain that can subsequently be folded into a mature protein. For the detailed 











Figure 1.2.3-1 Pioneer round of protein translation 
In the pioneer round of protein translation, the mature mRNA cap is bound by the CBC 
complex consisting of CBP20 and CBP80. The first round of translation consists of the 
same 3 steps as steady-state translation: initiation, elongation, and termination. During 
the pioneer round the ribosome encounters exon junction complexes (EJC) bound to the 
mRNA at the exon-exon junctions created after mRNA splicing. Ribosome dislocates EJC 
while it translocates the mRNA and produces first amino acid chain. Pioneer round of 
translation is used by the cell as a quality control measure to detect mRNAs with 
premature translation stop codons. Figure drawn using Inkscape 1.1; ribosome outline 
exported from BioRender.  
 
1.2.4. mRNA turnover 
 
Translation of a given mRNA into a protein is only one of its possible fates. To 
account for rapidly changing needs of the cell, mRNA can also be stored or 
degraded. In fact, the average mRNA half-life is around 4 hours (Herzog et al., 
2017), however this can vary from few minutes to days (Aviv et al., 1976; Ross 
and Sullivan, 1985; Wisdom and Lee, 1991).  
Actively translated mRNAs are bound by ribosomes and other translation factors, 
including 1) the cap binding protein, which prevents mRNA decapping by the 
decapping enzymes DCP1/DCP2, and 2) the polyA binding protein, which 
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prevents deadenylation (i.e., removal of 3’ adenosines) (Parker and Song, 2004) 
(Figure 1.2.4-1). When the mRNA is ‘unprotected’ and deadenylation and 
decapping occur, the mRNA can be degraded either in a 1) 3’-to-5’ direction by 
the cytoplasmic exosome (Schmidt et al., 2016; Zinder and Lima, 2017), or in 2) 
5’-to-3’ direction by XRN1 exonuclease (Parker and Song, 2004; Mugridge, Coller 
and Gross, 2018). It is worth noting that recent reports suggest that mRNA 
degradation can happen co-translationally, meaning the ribosomes can still be 
detected on an mRNA that is degraded from 5’-to-3’ direction (Hu et al., 2009; 




Figure 1.2.4-1 mRNA turnover  
Simplified schematic of first steps of mRNA degradation. CCR4-NOT complex, presented 
here as CNOT1 scaffold protein with two deadenylases CNOT6 and CNOT7, and the 
decapping complex shown as DCP1/DCP2. Figure drawn in Inkscape 1.1.   
 
Generally, in humans, deadenylation can be mediated by various enzymes such 
as the CCR4-NOT complex, polyA-specific ribonuclease (PARN), PAN2-PAN3 
complex, Nocturin, or Angel (Godwin et al., 2013; Shirai et al., 2014). The bulk 
of deadenylation in mammalian cells is thought to be performed by PAN2-PAN3 
and the CCR4-NOT complex. Previous reports suggested that PAN2-PAN3 primes 
the polyA tail for subsequent deadenylation by CCR4-NOT (Yamashita et al., 
2005; Bartlam and Yamamoto, 2010), however a more recent report proposed 
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deadenylation of different subsets of mRNAs by the two complexes  (Yi et al., 
2018). Moreover, contrary to previous reports (Parker and Song, 2004), the 
polyA-binding protein has been show to promote deadenylation by inhibiting 
premature decay (Yi et al., 2018). However, deadenylation is far from a simple 
process, where the recently described heterogeneity of polyA tail can impede 
removal or shortening of polyA tail (Lim et al., 2018). Additionally, the length of 
polyA tail itself can play a role in mRNA stability, with both too-short and too-
long polyA tails prompting mRNA degradation (Jalkanen, Coleman and Wilusz, 
2014). This evidence further rationalises that the mRNA life is regulated not only 
in trans, i.e., through factors outside of the mRNA, such as RNA-binding 
proteins, but also in cis through the mRNA features themselves.  
Depending on the type of degradation, deadenylation of an mRNA can trigger 
mRNA decapping. As written above, mRNA can be degraded in the 5’-to-3’ 
direction following deprotection of the 5’ end by removal of the m7G cap. 5’-to-
3’ mRNA decay occurs during the above-mentioned nonsense-mediated mRNA 
decay (Chapter 1.2.3) that usually arises during the pioneer round of translation 
upon detection of premature RNA stop codons upstream of EJC (Karousis and 
Mühlemann, 2016). However, there have been reports in the literature about 
EJC-independent nonsense-mediated mRNA decay (Zhang et al., 1998; Matsuda 
et al., 2007; Karousis and Mühlemann, 2016).  
Moreover, additional features of mRNA can promote or restrict degradation, 
i.e.,1) the described above m6A found mostly in the 3’UTR of 25 % of all mRNAs 
(Zaccara and Jaffrey, 2020), 2) the cap proximal modifications, as m6Am, which 
enhances resistance to DCP2 decapping enzyme (Mauer et al., 2017), 3) AU-rich 
elements (AREs), which can be bound by RNA binding proteins like tristetraprolin 
(TTP), which in turn interacts with CNOT1, part of the CCR4-NOT complex 
(Fabian et al., 2013), 4) miRNA binding sites, which recruits miRNA-RISC 
complex, which in turn can recruit other complexes, like CCR4-NOT and prompt 
mRNA turnover (Wilczynska and Bushell, 2015). As miRNA can also mediate 
mRNA repression and not simply degradation, this concept is further explored in 
Chapter 1.3.6. 
Moreover, mRNA can be damaged, e.g., through oxidation, or it can be simply 
degraded by endonucleases.  
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Finally, mRNA can also be stored in highly conserved cytoplasmic structures 
called P-bodies. Recent studies have implicated P-bodies as a storage location 
for mRNAs on which translation can be re-initiated (Brengues, Teixeira and 
Parker, 2005; Bhattacharyya et al., 2006; Mozziconacci et al., 2017). However, 
the precise role of P-bodies is still debated. Many mRNA decay factors such as 
the CCR4-NOT complex, DCP1/DCP2 decapping complex, and 5’-to-3’ 
exonuclease XRN1 are found in P-bodies, which would suggest that mRNA can be 
degraded inside P-bodies (Morales, Kwon and Hecht, 1991; Ingelfinger et al., 
2002; Sheth and Parker, 2003; Cougot, Babajko and Séraphin, 2004; Andrei et 
al., 2005). Therefore, more research is required to understand the precise 
function of P-bodies.  
Moreover, upon cellular stress mRNAs can enter different cytoplasmic 
formations, called stress granules (SG). As with P-bodies, the exact function of 
mRNAs in SGs is widely debated, with some reports suggesting that SGs are a 
location of mRNA storage (Mollet et al., 2008; Khong et al., 2017; Lee and 
Seydoux, 2019) and others indicating that mRNA can actually be actively 
translated inside the SG (Mateju et al., 2020).  
In all, life of an mRNA is far from simple, with many regulatory elements 
dictating its fate, which in turn affects its final output – protein.  
 
1.2.5. Protein turnover 
 
The last component of gene expression is the degradation of a protein. Steady-
state levels of a protein are a function of its synthesis rate and the degradation 
rate. The synthesis rate itself is determined by the rates of transcription, mRNA 
processing, and translation. While the modulation of translation rate determines 
a greater proportion of overall protein levels (Schwanhüusser et al., 2011), 
degradation rate can be the major regulation step for subsets of proteins in 
particular conditions (Jovanovic et al., 2015). For example, mitophagy during 
infection (Jovanovic et al., 2015) or autophagy during starvation (Wang et al., 
2015; Kocaturk and Gozuacik, 2018; Chen, Chen and Huang, 2019).  
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Protein degradation is an active and predominantly controlled process, meaning 
there are cellular pathways to specifically deplete proteins in a regulated 
manner. This can be done to allow protein levels to be changed rapidly in 
response to stimuli. There are two major protein degradation pathways: 1) the 
ubiquitin-proteasome pathway (UPP), and 2) lysosomal proteolysis. The first 
UPP, is perhaps the most well understood, and starts with post-translational 
modification, called ubiquitination. Ubiquitin is a small, 8.6 kDa protein, that is 
covalently attached to the target protein’s lysine residues by ubiquitin ligases 
(Goldstein et al., 1975; Ciechanover et al., 1980; Hershko et al., 1980). This is a 
marker for degradation, however degradation-independent functions of 
ubiquitinylated proteins have been described, such as altered cellular 
localisation or inhibition of protein-protein interactions (Schnell and Hicke, 
2003; Debdyuti and Howard, 2007). The protein marked for degradation is 
subsequently translocated to the proteasome, a large tube-like multimeric 
protein complex, and degraded through proteolysis (Glickman and Ciechanover, 
2002). Unlike UPP, the second pathway, lysosomal proteolysis, is not selective in 
normal conditions, meaning that the protein does not need to bear a marker for 
degradation. Inside the lysosome, which is an organelle that contains a range of 
acidic proteases, proteins are entirely digested.  
Interestingly, histones, which as described above (Chapter 1.2.2) modulate the 
structure of chromatin, can be ubiquitinated. This ubiquitination therefore 
alters the structure of chromatin and changes the transcription of genes 
(Hammond-Martel, Yu and Affar, 2012). This is an example how the end point of 
the gene expression pathway can affect the very start.  
All proteins in the cell have a specific half-life, which can vary between 
individual proteins, and can be based on their intracellular location or function. 
The average range is between 4 and 14 hours, and the median at 8.7 hours 
(Chen, Smeekens and Wu, 2016). The notion that each protein has its half-life, 
affects also the proteins involved in protein translation. In fact, the median half-
life of eukaryotic translation initiation factors is 7.1 hours (Chen, Smeekens and 
Wu, 2016), suggesting that a faster turnover of initiation factors might be 




1.3. Mechanisms in translation 
 
Protein synthesis is a multistep process that involves the decoding of mRNA to 
generate the proteins that can carry out the majority of cellular processes. 
Practically every step of protein synthesis can be exploited in disease (Chapter 
1.4). This chapter discusses how these mechanisms act in concert to produce the 
final protein. 
The first step of translation is initiation, which is the process of ribosome loading 
onto the mRNA (Chapter 1.3.2). This is the rate-limiting step of translation and 
has the biggest impact on overall translation rates. Next, the assembled 
ribosome enters the elongation phase, and the polypeptide chain is formed 
(Chapter 1.3.3). Eventually, the ribosome terminates and can begin the cycle 
all over again (Chapters 1.3.4 and 1.3.5). Before these steps are discussed, the 
features of the mature mRNA that are relevant to translation are introduced 
(Chapter 1.3.1). Finally, an overview of mechanisms that repress translation to 
regulate synthesis rates is given (Chapter 1.3.6). 
 
1.3.1. mRNA features  
 
To understand protein translation, one must recognise and appreciate the 
features of mRNA and its regulatory elements that together with translation 
factors can dictate the protein output from a given mRNA.  
Each mature mRNA consists of three regions: a 5’ untranslated region (5’UTR), a 
coding sequence (CDS), and a 3’ untranslated region (3’UTR) (Figure 1.3.1-1).  
The 5’UTR starts with the m7G cap, directly upstream of the first transcribed 
nucleotide. The length of the 5’UTR can vary between different mRNAs from a 
few nucleotides to hundreds of nucleotides, with the average human 5’UTR 
length of around 200 nt (Pesole et al., 2001; Leppek, Das and Barna, 2018). Very 
short 5’UTRs can possess a “translation initiator of short 5’UTR” (TISU) element, 
found in around 4% of human genes (Elfakess and Dikstein, 2008; Elfakess et al., 
2011). The start of translation from TISU is independent of other 5’UTR features 
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and does not require some of the translation factors that are indispensable for 
translation from longer 5’UTRs (Elfakess et al., 2011).  
In contrast, the more numerous longer 5’UTRs can contain more regulatory 
elements. Apart from the cap and cap proximal modifications that act as 
translation regulators (Chapter 1.2.2), different RNA sequence motifs can be 
found in the 5’UTR. One of the most widely studied motifs, found immediately 
adjacent to the cap, is the TOP (terminal oligopyrimidine) motif. This group of 
mRNAs start with a cytosine followed by 4 to 14 uninterrupted pyrimidines (Levy 
et al., 1991; Avni, Biberman and Meyuhas, 1997; Biberman and Meyuhas, 1999). 
The TOP motif is found on mRNAs encoding ribosomal proteins and translation 
factors, and is thought to be regulated by nutrient availability (Iadevaia et al., 
2008; Hsieh et al., 2012; Thoreen et al., 2012; Meyuhas and Kahan, 2015). Other 
examples of 5’UTR motifs occur further downstream of the mRNA cap, such as 
the pyrimidine-rich translational element (PRTE) (Hsieh et al., 2012; Thoreen et 
al., 2012), and the cytosine-enriched regulator of translation (CERT) motif 
(Truitt et al., 2015). PRTE, as in the case of TOP motifs, confers regulation in cis 
depending on nutrient availability (Hsieh et al., 2012; Thoreen et al., 2012); in 
contrast the exact regulatory function of the CERT motif is unknown (Truitt et 
al., 2015; Calviello et al., 2021).  
Longer 5’UTRs can also contain structured regions, such as stem loops, or G-
quadruplexes (Wolfe et al., 2014; Hinnebusch, Ivanov and Sonenberg, 2016; 
Leppek, Das and Barna, 2018; Waldron et al., 2019). Structural elements are 
generally thought to be repressive elements that require activity of proteins to 
resolve the secondary structures (see Chapter 1.5). However, some mRNA 
structures are reported to act as an internal ribosome entry site (IRES), which 
allow for start of translation without the recruitment of the cap binding 
proteins. IRESs, which were first identified in viral genomes (Pelletier and 
Sonenberg, 1988), allow viruses to hijack human translation initiation factors to 
promote translation of viral RNA (Bushell and Sarnow, 2002; Kieft, 2008). 
However, later IRES structures have also been shown to exist in a subset of 
human mRNAs (Johannes and Sarnow, 1998; Jackson, 2013; Weingarten-Gabbay 
et al., 2016). Additionally, a preference for IRES-mediated translation start has 
been observed after cell stress (Spriggs et al., 2008).  
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Moreover, long 5’UTRs can contain upstream open reading frames (uORFs), 
which are coding sequences upstream of the main CDS. uORFs have been shown 
to be present in nearly 50% of human mRNAs (Iacono, Mignone and Pesole, 2005; 
Matsui et al., 2007; Calvo, Pagliarini and Mootha, 2009). While uORFs could 
encode small peptides that may have a function, these peptides are not thought 
to be the primary role of uORFs. Instead, the process of translation of a uORF 
itself is inhibitory to translation from the main ORF (CDS) (see also Chapter 
1.3.5); however, this is not always the case (Hinnebusch, Ivanov and Sonenberg, 
2016).  
The CDS encodes the part of mRNA that will be translated into protein. Three-
nucleotide sequences (codons) encode different amino acids throughout the CDS. 
The CDS starts with a translation start site, for which the most common is an 
AUG (adenine, uracil, guanine) codon, that is read by the translation machinery 
as a methionine. Moreover, the AUG start codon in many mRNAs is flanked by a 
favourable sequence named Kozak consensus, i.e., GCC(A/G)CCAUGG (Kozak, 
1986, 1989). The AUG start codons without the Kozak consensus are thought to 
be in ‘poor context’ and translation from those codons is not as efficient (Kozak, 
2002). It should be noted that, translation can also start from a non-cognate 
(non-AUG) start codon, such as CUG, GUG, UUG, ACG, AUA, and AUU 
(Gerashchenko, Su and Gladyshev, 2010; Lobanov et al., 2010; Ivanov et al., 
2011). Translation from non-cognate start codons has been thought to be very 
unfavourable, however a more recent study suggested that translation from non-
cognate codons is more prevalent than originally thought (Kearse and Wilusz, 
2017).  
The 3’UTR region of mRNA starts right after the translation termination codon. 
There are three translation stop codons in humans, UAA, UAG, UGA, with the 
exception of the two mitochondrial codons: AGA, AGG (Barrell, Bankier and 
Drouin, 1979). Unlike other codons, the stop codons, do not correspond to any 
amino acids, with the exception of UGA, which can be read as selenocysteine 
(Zinoni et al., 1986; Copeland, 2003). However, in humans there are only 25 
identified selenoproteins (Kryukov et al., 2003), and the incorporation of 
selenocysteine requires specific structural motif (selenocysteine insertion 
sequence - SECIS) in mRNA in the proximity of the UGA stop codon (Mix, Lobanov 
and Gladyshev, 2007). The presence of selenoproteins adds to growing evidence 
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that not only coding sequence matters when it comes to protein translation but 
also the structural and sequence elements of the mRNA.  
Similarly, as with the 5’UTR, the length of 3’UTR can vary between different 
mRNAs. On average the 3’UTR is longer at around 800 nucleotides in humans 
(Mignone and Pesole, 2018), spanning between 60 and 4000 nucleotides between 
different mRNAs (Hesketh, 2005).  As 3’UTRs are long, they can contain many 
regulatory elements, like the above-mentioned (Chapter 1.2.4) destabilising 
AREs or miRNA binding sites. Binding of miRNAs to the 3’UTR can lead to 
translation repression, which is described further in Chapter 1.3.6. Alike the 
5’UTR, the 3’UTR can contain ORFs (downstream ORF – dORF) (Bazzini et al., 
2014; Mackowiak et al., 2015; Chen et al., 2020). Unlike uORFs, dORFs are 
proposed to enhance the protein translation from the main ORF (Wu et al., 
2020). Albeit the identification of dORFs and their functions is a new and rapidly 
growing field, therefore full influence of their presence on mRNA stability and 
translation cannot be assessed.  
Finally, the most well-known 3’UTR feature is the polyA tail, which acts as a 
stabiliser of mRNA and provides a binding location for other regulatory proteins.  
Apart from the described features of specific regions of mRNA, cis and trans 
regulatory elements can act in concert to provide a link between 5’- and 3’UTR. 
This link, known as mRNA circularisation (Wells et al., 1998; Tomek and 
Wollenhaupt, 2012; Alekhina et al., 2020) happens through interactions of 
proteins bound to the 5’UTR with the proteins bound to the 3’UTR of a given 










Figure 1.3.1-1 mRNA features 
Mature mRNA consists of 1) 5’untranslated region (5’UTR), also known in the literature 
as mRNA leader, 2) coding sequence (CDS), that encodes the genetic information of a 
protein, and 3) 3’untranslated region (3’UTR). Each mRNA has m7G cap (with exception 
of mitochondrial mRNAs) and a polyA tail, length, and homogeneity of which can vary. 
Additionally, mRNAs can have upstream or downstream open reading frames (uORF, 
dORF), which are a coding sequence outside of the main CDS and can lead to creation of 
different isoforms of the same protein, inhibition of translation from the main ORF, or 
to translation of small peptides. Moreover, mRNAs can have secondary structures, 
usually found in the 5’UTR, miRNA binding sites (typically found in the 3’UTR), and post-
transcriptional modification, as commonly found in 3’UTR m6A or, modifications close to 
the mRNA cap. Features of all mRNAs labelled in black, features not present in all 
mRNAs labelled in grey. Figure drawn in Inkscape 1.1.   
 
1.3.2. Translation initiation 
 
Translation initiation is considered to be the most complex phase of protein 
translation, as it requires a large number of protein factors and is highly 
controlled (Sonenberg and Hinnebusch, 2009; Jackson, Hellen and Pestova, 
2010). Being the most controlled stage of translation, initiation is also 
considered to be rate-limiting. The rates of initiations can vary depending on 
presence of regulatory elements in the 5’UTR (as described in Chapter 1.3.1) as 
well as on availability and activity of translation initiation factors. Translation 
initiation is a consecutive process, where each stage has to precede the next. 
Translation initiation on the majority of mRNAs can be divided in a few basic 
steps: 1) mRNA binding by the cap binding complex – eIF4F, 2) formation of 43S 
preinitiation complex (43S PIC) consisting of 40S ribosomal subunit, cofactors 
and methionine-bearing tRNA, 3) recruitment of the 43S PIC to the mRNA, 4) 
ribosome scanning through the 5’UTR in order to localise the initiation codon, 
and 5) joining of the 60S ribosomal subunit to form the fully mature 80S 
ribosome to enable elongation (Figure 1.3.2-1) (Jackson, Hellen and Pestova, 




Figure 1.3.2-1 Stages of translation initiation  
Translation initiation is the most rate-limiting step of protein synthesis and requires the 
largest amount of highly specialised translation factors. Cap-dependent translation 
starts by eIF4E cap-binding protein binding m7G, which is joined by eIF4G and eIF4A, 
forming together eIF4F complex. On the other end of mRNA, PABP protein binds the 
polyA sequence and due to interaction between eIF4G and PABP, mRNA can be 
circularised. Separately, 43S PIC is assembled from 40S ribosomal subunit, and 
translation initiation factors eIF1, eIF1A, eIF3, eIF5, joined by the ternary complex 
(eIF2-GTP Met-tRNA). Assembled 43S PIC is subsequently recruited to the mRNA due to 
interaction between eIF4G and eIF3, as well as the help of eIF4A. Next, secondary 
structures within the 5’UTR are unwound by the helicases involved in translation, like 
eIF4A or DHX29 (not shown). Unwinding of the structures allows for translocation of 43S 
PIC along the 5’UTR to find translation start codon (marked as AUG). Upon binding of 
the AUG, 60S ribosomal subunit is recruited to the 40S with help of eIF5B, and due to 
activation of eIF2 by eIF5. Assembled 40S and 60S form 80S translation competent 
ribosome. Figure drawn in Inkscape 1.1; ribosome outline exported from BioRender.  
37 
 
In the first step the 25 kDa cap binding protein eIF4E recognises and binds the 
m7G cap on the 5’ end of the mRNA. Interestingly, eIF4E is the least abundant 
initiation factor and has been thought to be the limiting factor for mRNA 
translation (Duncan, Milburn and Hershey, 1987). However, this observation has 
been challenged. It has been reported that only about a quarter of total eIF4E in 
rabbit reticulocyte lysate associates with ribosomes, and eIF4E depletion has 
only a moderate effect on protein translation (Rau et al., 1996). Similarly, a 
more recent study (Truitt et al., 2015), showed that 50 % of the normal level of 
eIF4E is not detrimental to the global protein synthesis or normal development.  
eIF4E is joined by another subunit of the eIF4F complex, eIF4G. However, it is 
not clear whether the cap binding is necessary for eIF4G recruitment, or 
whether the complex binds to the cap together. eIF4G, at 220 kDa, is the largest 
component of the heterotrimeric eIF4F and joins eIF4E opposite to the eIF4E’s 
cap binding pocket (Marcotrigiano et al., 1999). eIF4G is considered to be a 
scaffold protein, as it provides binding sites for other proteins involved in 
translation (Gingras, Raught and Sonenberg, 1999), such as 1) eIF4A, another 
component of the eIF4F complex, 2) the polyA binding protein PABP, which 
interaction, as mentioned above (Chapter 1.3.1), allows for mRNA 
circularisation, 3) eIF3, a thirteen subunit multi protein complex, and 4) 
mitogen activated protein kinase interacting kinase 1 – Mnk1 (Figure 1.3.2-2) 
(Lamphear et al., 1995; Imataka, Olsen and Sonenberg, 1997; Imataka, Gradi 
and Sonenberg, 1998; Pyronnet et al., 1999; Korneeva et al., 2001).  
The only factor known to have a catalytic activity in the eIF4F complex is the 46 
kDa DEAD-box RNA helicase eIF4A (Rogers, Richter and Merrick, 1999; Rogers et 
al., 2001). Its canonical role, which is often aided by auxiliary factors eIF4H, 
eIF4B, and the other components of eIF4F (Korneeva et al., 2005; Nielsen et al., 
2011; Özeş et al., 2011; Feoktistova et al., 2013), is to unwind secondary 
structures within the mRNA to offset their repressive influence on protein 
translation. However, a recent report suggested an additional RNA unwinding-
independent role of eIF4A helicase in mRNA recruitment to the ribosome (Sokabe 




To add to the complexity of translation initiation and different functions 
performed by the proteins in the eIF4F complex, each of the components of 
eIF4F has their own paralogues. The differences can be minor, such as the ones 
between eIF4G1 and eIF4G3, or larger, with the paralogue missing multiple 
binding sites for interaction partners, as is the case with eIF4G2 (Figure 
1.3.2-2). This could lead to formation of multiple different, specialised eIF4F 
complexes (Robert et al., 2020), with different paralogues, performing diverse 
functions (Imataka, Olsen and Sonenberg, 1997; Osborne et al., 2013; Liberman 
et al., 2015; Alard et al., 2019). However, as this thesis pertains to investigation 
of eIF4A, the following text is focused solely on differentiation between the 
three eIF4A paralogues, i.e., eIF4A1, eIF4A2, and eIF4A3. eIF4A1 is the more 
abundant paralogue (Nielsen and Trachsel, 1988; Galicia-Vazquez et al., 2012), 
thought to be the dominant one in the eIF4F complex, while the 90% identical 
eIF4A2 has a recently identified role in translational repression (Meijer et al., 
2013, 2019; Wilczynska et al., 2019), and the 60% identical eIF4A3, forms a part 
of the exon junction complex (Holzmann et al., 2000; Chan et al., 2004). The 








Figure 1.3.2-2 eIF4G paralogues  
Schematic of human eIF4G paralogues, i.e., eIF4G1, DAP5, eIF4G3; and CBP80, a protein 
involved in the pioneer round of translation. Regions responsible for recruitment of 
eIF4G interaction partners marked in light red boxes, with amino acid boundaries 
underneath. Conserved domains marked above, with RNA binding regions pointed with 
an arrow. Regions responsible for interactions taken from Nielsen et al., 2011; Shatsky 
et al., 2014; and UniProt database: The UniProt Consortium, 2021. As an important 
aside, it should be noted that there is a discrepancy in the scientific literature, with 
some publications referring to eIF4G3 as eIF4G2.  
 
The primed mRNA, loaded with the eIF4F complex, is ready for joining by the 
43S PIC. However, first the 43S PIC has to be assembled. To appreciate how the 
different initiation factors influence the ribosomal subunit and together form 
the 43S PIC, understanding how the ribosomal subunit can interact with RNA is 
indispensable. The mRNA binding and decoding site is located across the 40S 
ribosomal subunit (Fraser et al., 2007; Lorsch and Dever, 2010). The ribosome 
has three sites, identified as the transfer RNA (tRNA) binding sites i.e., tRNA exit 
site – E, peptidyl-tRNA site – P, aminoacyl-tRNA site – A; each occupied by 





Figure 1.3.2-3 tRNA binding sites on a ribosome  
Each ribosome has 3 tRNA binding sites 1) tRNA exit site E, 2) peptidyl-tRNA site P, 3) 
aminoacyl-tRNA site A. Figure drawn in Inkscape 1.1, 40S ribosomal subunit outline 
exported from BioRender.  
 
The ternary complex (eIF2-TC), formed with 1) initiator tRNA charged with 
methionine and bearing anticodon for the start codon AUG, 2) eIF2, and 3) GTP 
binds the 40S ribosomal subunit independently or as a part of a larger complex 
with eIF1, eIF3 and eIF5 (Asano et al., 2000; Sokabe, Fraser and Hershey, 2012). 
The initiator tRNA binds in the P site of the 40S, and the eIF2, which itself has 3 
subunits (α, β, γ), interacts with GTP, tRNA, and the 40S (Kapp and Lorsch, 
2004). eIF1 and eIF1A aid the interaction between eIF2-TC and 40S, as well as 
alter the mRNA decoding site by opening the mRNA entry channel, which in turn 
facilitates the mRNA to enter the ribosomal subunit (Pestova, Borukhov and 
Hellen, 1998; Passmore et al., 2007). eIF3, consisting of 13 individual subunits 
(eIF3a to eIF3m), is involved in almost all of the steps of translation. eIF3 
stabilises interaction between eIF2-TC and 40S, binds both eIF1 and eIF1A, as 
well as prevents premature 80S ribosome formation together with eIF1 and eIF2 
(Benne and Hershey, 1978; Valasek et al., 2004; Kolupaeva et al., 2005). From 
the site of 60S ribosomal subunit, eIF6, bound to the 60S, inhibits premature 
ribosome formation (Miluzio et al., 2009; Gartmann et al., 2010).     
The recruitment of the 43S PIC to the primed mRNA happens through the 
interaction between eIF4G and eIF3 (see Figure 1.3.2-3). However, additional 
interactions can be bridged through eIF4B, i.e., a stimulating cofactor of eIF4A 
helicase (Rogers et al., 2001; Nielsen et al., 2011), and eIF3, 40S and PABP 
(Methot, Song and Sonenberg, 1996; Le et al., 1997; Bushell et al., 2001), 
bringing all the complexes together. Moreover, the interaction between 40S and 
41 
 
mRNA is suggested to be additionally mediated through eIF4A (Sokabe and 
Fraser, 2017).  
At this stage mRNA is stably bound to the decoding region of the 40S ribosomal 
subunit, containing the initiator tRNA. From there, the 40S ribosomal subunit 
translocates the mRNA in the 5’-to-3’ direction in order to locate the translation 
start codon. The generally accepted mechanism of start codon recognition 
indicates that the initiator tRNA sample base-pairs the mRNA until it finds 
perfect complementarity to AUG codon (Mark, Lan and F., 1988). As only single-
stranded mRNA can be bound to the ribosomal decoding site, any secondary 
structure present on that mRNA needs to be unwound before it enters the 
ribosome entry site. In the literature (Marintchev et al., 2009; Jackson, Hellen 
and Pestova, 2010; Aitken and Lorsch, 2012; Marintchev, 2013), there are two 
models of how the mRNA can be de-structured in order to enter the ribosome: 1) 
the ‘ratchet’ model in which initiation factors are bound to the mRNA upstream 
of the ribosome, preventing backwards motion, and ‘pulling’ the mRNA through 
the ribosome, 2) RNA helicases dependent model in which helicases such as 
eIF4A, or DHX29 (Pisareva et al., 2008; Parsyan et al., 2009) unwind mRNA 
secondary structure. The recent CryoEM structure (Querido et al., 2020) 
supports the ‘ratchet’ model, where the eIF4F complex is found behind the 40S 
ribosomal subunit. However, the importance of RNA helicases in translation of 
the mRNAs with highly structured 5’UTRs suggests that the second model is 
preferred. Thus, none of the current data can exclude the possibility of the two 
models coexisting. In fact, the authors of the CryoEM structure of 48S PIC (43S 
with eIF4F complex) (Querido et al., 2020) did not exclude a possibility of 
additional eIF4A molecules, which exist in high excess in cells at 3 eIF4A per 
ribosome (Roger Duncan and Hershey, 1983), carrying out functions ahead of the  
ribosome (Figure 1.3.2-4).  
Another major question that has for long perplexed many scientists, was 
recently solved. Until recently, the literature could not agree what happens with 
the eIF4F-eIF3 complex once the 40S ribosome is loaded onto mRNA and scans 
for the start codon. Recent translation complex profile sequencing studies 
(Bohlen et al., 2020; Wagner et al., 2020), proposed a revised model in which 
the eIF4F-eIF3 complex remains bound to the 43S PIC, and subsequently 80S until 
it has translocated approximately 12 amino acids, at which point these factors 
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are released (Figure 1.3.2-4). The implication of this is that only one initiation 
event can occur at a time, i.e., that initiation rates alone dictate the majority 
of overall translation rates. As an interesting aside, these studies also explain 
the long-standing mystery about how translation of the main ORF could be 
reinitiated after uORF translation (Chapter 1.3.5).  
 
 
Figure 1.3.2-4 Alternative model of translation initiation – 5’ end-tethered 
Schematic of an alternative model of translation initiation. eIF4F complex remains 
bound to both the mRNA cap and eIF3, linking the eIF4F with the scanning ribosome. In 
this model the mRNA is looped around. Possibility of additional eIF4A next to the mRNA 
entry channel of the ribosome cannot be excluded, here presented with a question 
mark. Figure drawn in Inkscape 1.1; ribosome outline exported from BioRender.  
 
As the ribosome scans for the codon, regulatory elements in both the cis and 
trans are important in the codon selection. As previously mentioned (Chapter 
1.3.1), the sequence context of the start codon plays a role in translation start 
from that codon. Additionally, eIF1 prevents translation start from non-cognate 
codons, and AUG codons in poor context (Pestova, Borukhov and Hellen, 1998). 
Upon base-pairing between the initiator tRNA and the start codon of the mRNA, 
eIF1, which was bound closely to P-site, is displaced, causing conformational 
change in the 40S (Passmore et al., 2007). This affects the position of eIF1A and 
eIF5, as well as activation of eIF2 GTPase. The release of the phosphate from 
GTP triggers dissociation of eIF1, and subsequent dissociation of eIF2-GDP 
(Algire, Maag and Lorsch, 2005). The released eIF2-GDP can be regenerated by 
eIF2B to be available for new rounds of translation initiation (Proud, 2005).  
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After recognition of the translation start codon and dissociation of the above-
mentioned cofactors, the 60S ribosomal subunit can finally join the 40S 
ribosomal subunit to form the mature translation-competent 80S ribosome. The 
joining of the subunits is mediated by eIF5B-GTP, which binds between the two 
subunits, and upon GTP hydrolysis leaves the fully assembled 80S ribosome 
(Pestova et al., 2000). Finally, eIF1A dissociates (Acker et al., 2009), leaving 
behind the 80S ribosome, which in the revised model might be bound by eIF3 and 
eIF4F (see Figure 1.3.2-1).  
 
1.3.3. Translation elongation 
 
After the assembly of the 80S ribosome with the initiator tRNA positioned in the 
ribosome P-site and paired with the start codon, the next paired aminoacyl-tRNA 
(charged tRNA) can join the vacated ribosome A-site. Elongation has been shown 
to be overall a consistent and invariant process, with each round of elongation 
consisting of: 1) delivery of a charged tRNA by GTP-bound eEF1A to a 
complimentary codon on an mRNA in the ribosomal A-site, 2) GTP hydrolysis 
upon codon-anticodon recognition mediated by eEF1A and 60S ribosomal subunit, 
leading to eEF1A/GDP release, 3) formation of a peptide bond by peptidyl 
transferase centre in 60S ribosomal subunit, 4) ribosome translocation by one 
codon induced by peptide bond formation and mediated by GTP-bound eEF2, 5) 
GTP hydrolysis and eEF2 release, 6) change in tRNA position in the ribosomal E, 
P, A sites, following the translocation, with site E occupied by uncharged tRNA, 
ready to be released, P site occupied by peptidyl tRNA, and A site empty for new 
round of elongation (Zhang, Dunkle and Cate, 2009; Voorhees et al., 2010; Chen 





Figure 1.3.3-1 Translation elongation cycle  
Elongation starts after assembly of the 80S ribosome and continues as a cycle until the 
translation stop codon is encountered by the ribosome. Each elongation cycle consists of 
(starting from the top left): 1) charged tRNA (aa-tRNA) being brought to the ribosomal A 
site by eEF1A-GTP, 2) positioning of the aa-tRNA in the A site, through the hydrolysis of 
GTP and release of eEF1A-GDP, 3) formation of the peptidyl bond between the newly 
deposited aa and the polypeptide chain, 4) GTP-eEF2 mediated ribosome translocation 
and eEF2-GDP release, 5) change in the position of tRNAs on the ribosomal tRNA binding 
sites, with emptying of the A channel, and release of deacylated tRNA from the E 
channel. Figure drawn in Inkscape 1.1; ribosome outline exported from BioRender.  
 
The ribosome decodes the coding sequence by interpreting every three bases 
(codons) as one of the 21 amino acids (including the rare selenocysteine 
(Copeland, 2003; Longtin, 2004)). As there are 64 possible codons and only 21 
amino acids, there is inherent redundancy in the codon code.  
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The elongating ribosome proceeds through the coding sequence with an average 
incorporation rate of six amino acids per second (Bostrom et al., 1986; Ingolia, 
Lareau and Weissman, 2011). However, there are some notable exceptions to 
this rule: 1) ribosomes can pause for several seconds, allowing for binding of co-
translational chaperones (Ingolia, Lareau and Weissman, 2011), 2) incorporation 
of certain amino acids can cause elongation pausing, i.e., proline has been 
shown to have a slow incorporation rate and peptide bond formation (Pavlov et 
al., 2009) which causes the ribosome to stall (Artieri and Fraser, 2014), and 3) 
the abundance of particular charged tRNAs may be lower than the mRNA codon 
requirements (Torrent et al., 2018; Torres et al., 2019; Behrens, Rodschinka and 
Nedialkova, 2021). This last concept is related to a phenomenon where some 
mRNAs are enriched in certain codons and thus require more of a particular tRNA 
than there is available in the charged tRNA pool for a given cell type. When the 
ribosome encounters these codons, it will stall as the A site will remain empty 
for longer (Koutmou, Radhakrishnan and Green, 2015; Yu et al., 2015). The tRNA 
abundance and existence of rare tRNAs is related to codon optimality, a concept 
in which more optimal codons are correlated with more efficient translation 
efficiency (Gingold et al., 2014; Saikia et al., 2016; Hanson and Coller, 2018; 
Medina-Muñoz et al., 2021).  
The elongation process continues until the A site of the ribosome is occupied by 
a stop codon and termination begins. 
 
1.3.4. Translation termination 
 
When the A site of the ribosome encounters one of the three stop codons, i.e., 
UAA, UAG, UGA, it is joined by eukaryotic release factors eRF1 and eRF3-GTP 
(Frolova et al., 1996; Alkalaeva et al., 2006; Mitkevich et al., 2006; Pisareva et 
al., 2006; Jackson, Hellen and Pestova, 2012) (Figure 1.3.4-1). eRF1 mimics 
tRNA and positions in the ribosomal A site which induces GTP hydrolysis by eRF3 
(Frolova et al., 1996; Song et al., 2000). Next, eRF3 is released from the 
complex, which triggers full accommodation of eRF1, which promotes peptide 
hydrolysis and release (Song et al., 2000). Generally, stop codon recognition is 
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highly efficient and there is little to no evidence for stop codon read-through in 
human cells.  
 
 
Figure 1.3.4-1 Translation termination 
Translation termination begins with encountering of one of the translation stop codons 
UAA, UAG, UGA in the ribosome A site. As there are no tRNAs recognising the stop 
codons (apart from rare selenocysteine, see Chapter 1.3.1), the ribosome is joined by 
eRF1 resembling tRNA, and eRF3-GTP. After GTP hydrolysis and eRF3-GDP release, full 
accommodation of eRF1 triggers polypeptide chain release. Figure drawn in Inkscape 
1.1; ribosome outline exported from BioRender.  
 
1.3.5. Ribosome recycling and reinitiation 
 
After peptide release both eRF1 and uncharged tRNA remain bound to the 80S 
ribosome in its A and P sites, respectively. This prompts joining of the ATP-
binding cassette subfamily E member 1 (ABCE1), which acts as a ribosome 
recycling factor, by separating the 40S and 60S ribosomal subunits in an ATP-
dependent manner (Pisarev et al., 2010) (Figure 1.3.5-1). Additional eukaryotic 
translation factors have been implicated in having a role in full ribosomal 
subunits disintegration. eIF1 is thought to release the tRNA from the 40S 
ribosomal subunit, eIF1A is supposed to help with dissociation of eRF1 (Jackson, 
Hellen and Pestova, 2012), and eIF3j has been shown to aide with mRNA release 







Figure 1.3.5-1 Ribosome recycling 
After polypeptide chain release ribosome with deacylated tRNA and eRF1 remains bound 
to the mRNA, this prompts joining of ABCE1 complex which upon ATP hydrolysis 
separates 40 and 60S ribosomal subunits, which can be reused in new rounds of 
translation. Figure drawn in Inkscape 1.1; ribosome outline exported from BioRender.  
 
As described in Chapter 1.3.1 many mRNAs contain additional ORFs (uORF and 
dORFs). The newly described model in which eIF4F and eIF3 remain bound to the 
ribosome (see Chapter 1.3.2 and Figure 1.3.2-4), provide a model for how 
multiple ORFs can be translated. Albeit due to presence of the initiation factors 
directly downstream of the 40S, the translation from a new ORF could happen 
only in the 5’-to-3’, prohibiting start from a start codon directly upstream of 
stop codon. Indeed, whether translation can be reinitiated at the next available 
ORF depends on a few factors, such as the distance between the ORFs, presence 
of secondary structures, and length of the ORF itself (Kozak, 2001).  
A famous example of uORF control of translation, requiring reinitiation is 
translation of a transcription factor ATF4 (Vattem and Wek, 2004). Human ATF4 
contains two uORFs upstream of the main ORF. Therefore, the translation of the 
second uORF would only happen if the ribosome can be reassembled and there is 
abundance of the eIF2-TC. However, translation of the second uORF causes lack 
of translation from the main ORF, as the AUG start codon of the main ORF is 
located within the coding sequence of the second uORF. This causes repression 
of the main ORF, that is dependent on reinitiation. In a situation of cellular 
stress, with low eIF2-TC, the second uORF is not translated, and ATF4 is 
translated instead.  
This control of transcription factor by translation of uORFs and ribosome 





1.3.6. Translational repression 
 
One mechanism to ensure the correct translation rate is the repression of 
translation. Many pathways of translational repression exist in cells, however in 
this chapter, main focus is emphasised on the repression of translation involving 
the eIF4A paralogues.  
This regulation can occur at several stages, typically at the level of initiation. 
The most well-known control is exerted through nutrient availability, i.e., if 
nutrients are high, translation is unrestricted, however when nutrients are 
deprived, translation is significantly hindered to conserve energy. The major 
sensor of nutrient availability is the mTOR (mammalian Target Of Rapamycin) 
pathway (Sabatini et al., 1994). The mTOR complexes (mTORC1 and mTORC2) 
can sense amino acid levels, and signals related to levels of glucose and ATP. 
mTOR itself is a kinase that is active during times of nutrient availability. Among 
the many mTOR substrates are proteins directly associated with translational 
repression (Figure 1.3.6-1). These are the eIF4E binding proteins (4EBP1-3), and 
LARP1 (Hara et al., 1998; Fonseca et al., 2015). When the 4EBPs and LARP1 are 
phosphorylated, they are inactive and eIF4E-dependent translation proceeds as 
normal (Pause et al., 1994; Gingras et al., 1999; Hong et al., 2017). When mTOR 
is inactivated due to starvation, these mTOR targets are unphosphorylated and 
are now able to repress translation. In this case, 4EBP1-3 can bind eIF4E by 
displacing eIF4G, thus repressing downstream initiation (Mader et al., 1995). 
More recently, LARP1 has been shown to specifically repress the translation of 
TOP mRNAs, which themselves are present on mRNAs encoding proteins involved 
in translation, by displacing eIF4E from the cap of these transcripts (Lahr et al., 
2015, 2017; Smith et al., 2021). Additional indirect control of translation 
through mTOR pathway is the influence exerted on eIF4A helicase. In the case of 
active mTOR, S6K (ribosomal protein S6 kinase beta-1) is phosphorylated (Hara 
et al., 1998), which subsequently phosphorylates PDCD4, rendering it inactive 
(Hannan et al., 2003; Dorrello et al., 2006). PDCD4 in its active form has been 
shown to inhibit eIF4A (Yang et al., 2002; LaRonde-LeBlanc et al., 2006; Suzuki 
et al., 2008; Fay et al., 2014). An additional modulation of eIF4A function 





Figure 1.3.6-1 mTOR mediated regulation of protein synthesis  
Schematic of translation regulation through mTOR. Active mTOR can phosphorylate 
proteins directly involved in repression of translation, such as 4EBP, which in its 
phosphorylated state does not inhibit eIF4E activity, or LARP which in its phosphorylated 
state does not repress TOP-motif mRNAs. mTOR imparts also indirect activity through 
phosphorylation of S6K kinase which itself phosphorylates 1) PDCD4, rendering it 
incapable of eIF4A repression, 2) eIF4B, in order to activate it, 3) eEF2K, which is then 
prohibited from inhibiting elongation factor eEF2. Upstream signalling pathways not 
shown. Figure drawn in Inkscape 1.1; ribosome outlines exported from BioRender.  
 
Another major pathway is the microRNA (miRNA) mediated translational 
repression (Figure 1.3.6-2). miRNA are small (around 22 nt) single-stranded, 
non-coding RNAs (Lagos-Quintana et al., 2001), that are processed from longer 
double-stranded regions by the Drosha and Dicer endonucleases (Rana, 2007; 
Park et al., 2011; Kwon et al., 2016). Following processing by Dicer, a single 
strand of the miRNA duplex is loaded into one of the four main miRNA effector 
proteins known as Argonaute (Ago1-4). The miRNA-Ago complex is known as the 
RNA-induced silencing complex (RISC) (Pratt and MacRae, 2009). The loading of a 
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single strand of the miRNA duplex is reported to involve additional factors such 
as helicases, as was reported for the DEAH-box helicase DHX9 (Fu and Yuan, 
2013). After assembly of the complex, RISC scans cytoplasmic mRNA until a 
target is located. This process involves base-pair recognition between the target 
mRNA and the approximately 5-8 nt region of the miRNA known as the seed 
sequence (Lewis, Burge and Bartel, 2005; Didiano and Hobert, 2006). The 
consequence of such a short seed sequence means that at least around 30% of 
human protein coding genes can be miRNA targets (Lewis, Burge and Bartel, 
2005). When a stable RISC-mRNA interaction is made, translational repression 
can occur. This relies on the further recruitment of factors such as TRNC6A-C, 
which additionally interacts with PABP and CCR4-NOT complex (Braun et al., 
2011; Chekulaeva et al., 2011; Fabian et al., 2011). The translational repression 
may require the activity of other auxiliary factors, which interact with CCR4-
NOT, including helicases such as DDX6 or eIF4A2 (Meijer et al., 2013; Chen et 
al., 2014; Rouya et al., 2014; Kuzuoğlu‐Öztürk et al., 2016; Wilczynska et al., 
2019). The precise downstream mechanisms of miRNA-mediated repression are 
still debated. However, it has been shown that translational repression 
associated with eIF4A2 happens at translation initiation (Meijer et al., 2013; 
Wilczynska et al., 2019). Albeit no evidence so far excluded the possibility of 
repression mediated through other auxiliary factors existing at different stages 
of translation. Moreover, the translational repression has been shown as a 
primary event, which can lead either to storage of repressed mRNAs or to their 
degradation (Mathonnet et al., 2007; Selbach et al., 2008; Djuranovic, Nahvi and 
Green, 2012; Larsson and Nadon, 2013; Meijer et al., 2013).  
Curiously, miRNA have been shown to promote dissociation of both eIF4A1 and 
eIF4A2 from their target mRNAs (Fukao et al., 2014), yet in the study from the 
Bushell lab (Wilczynska et al., 2019) the messages bound by eIF4A2 where shown 
to be repressed. Moreover, eIF4G1 was implicated in facilitating miRNA 
mediated translational repression (Ryu et al., 2013), however how this role is 




Figure 1.3.6-2 Translational repression via miRNA pathway  
Schematic of translational repression via miRNA pathway. Upon recognition of miRNA 
binding site in the 3’UTR of an mRNA the RISC complex recruits TRNC6. That further 
recruits CCR4-NOT (presented here as CNOT1 and CNOT7), as well as associated 
helicases eIF4A2, or DDX6 (question mark indicates that it might depend on the type of 
repression which helicase is preferred by the complex). That can possibly promote 
dissociation of eIF4A1 from the translated message (possibility indicated with a question 
mark). The translational repression leads to dissociation of the 40S. Figure drawn in 

















1.4. Dysregulation of translation in cancer 
 
Translation, as described in Chapter 1.3 is a highly controlled process, driven by 
cis regulatory elements, the ribosome, tRNA availability, translational factors, 
and their interaction partners. Any dysregulation of this intricate process can 
lead to production of aberrant proteins, or overexpression of proteins that can 
promote malignancy. In normal cells, translation initiation and repression act in 
concert to maintain homeostasis. As a major hallmark of cancer is proliferation 
(Hanahan and Weinberg, 2011), the protein output demand of the cancer cell is 
significantly higher than in a normal cell. Thus, to meet these demands, the 
delicate balance between initiation and repression is tipped in favour of 
unrestricted translation of favourable proteins.  
Cancer exploits many pathways, however here the main focus will be on 
dysregulation of translation initiation, as both eIF4A1 and eIF4A2 are thought to 
exert their functions at translation initiation. As increased demand for protein 
synthesis requires more translation factors, many of the factors involved in the 
rate-limiting steps of initiation are oncogenes themselves. For example, even 
modest overexpression of eIF4E is transformative (Lazaris-Karatzas, Montine and 
Sonenberg, 1990; Ruggero et al., 2004), and as shown in Truitt et al., 2015, 
eIF4E haploinsufficient mice are protected from oncogenesis without a 
detrimental effect on their development. This indicates that interventions to 
reduce eIF4E levels would hinder cancer growth without causing distress to 
regular cells. Intriguingly, eIF4E is post-translationally modified by 
phosphorylation at serine 209 by the kinases MNK1/2. This phosphorylation has 
been shown to be critical for the oncogenic activity of eIF4E (Wendel et al., 
2007). For these reasons, perturbation of MNK1/2 has great promise as a cancer 
therapy (Ueda et al., 2010; Knight et al., 2021), and already a specific and 
potent MNK1/2 inhibitor has entered clinical trials (Reich et al., 2018).  
Another pathway that can modulate eIF4E activity is the described in Chapter 
1.3.6 mTOR pathway. Interestingly, there are two major signalling pathways, 
i.e., the PI3K-AKT and RAS-MAPK pathways, which converge on the TSC complex 
immediately upstream of the master nutrient sensor complex, mTORC1/2 (Inoki 
et al., 2002; Ma et al., 2005). Notably, the RAS-MAPK pathway is also directly 
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upstream of MNK1/2. Activation of PI3K-AKT and RAS-MAPK pathways lead to 
inhibition of TSC, which prevents it from deactivating mTORC1/2. While these 
signalling complexes are beyond the scope of this thesis, it should be noted that 
the PI3K-AKT and RAS-MAPK pathways are frequently mutated and constitutively 
active in cancers (Barault et al., 2008; Yuan and Cantley, 2008; Prior, Lewis and 
Mattos, 2012). The result of this is a constitutive activation of mTORC1/2. This 
can lead to indirect inhibition of PDCD4 via the S6K intermediate, and activation 
of eIF4A through eIF4B. Hyperactive mTOR1/2 is thus a constitutively de-
repressed translation initiation complex, leading to the high protein synthesis 
rates that a cancer cell demands. Many pro-oncogenes contain repressive mRNA 
features such as highly structured 5’UTRs. This the case for c-Myc the 
transcription factor (O’Leary et al., 2019), translation of which is promoted in 
state of high eIF4A activation. This a beautiful example, of how cancer can 
harness translational control in order to amplify proteins involved in 
transcription, which themselves can control for production of more mRNAs, 
which encode proteins, that can aide cancer progression. Intriguingly, 
overexpression of eIF4A2, the eIF4A paralogue implicated in miRNA-mediated 
translational repression (Chapter 1.3.6) has been shown to also have negative 
influence on cancer progression (consult Table 1.5.1-1). Interestingly, eIF4A2 is 
not the only one of the many paralogues of translation initiation factors that has 
been shown to have cancer repressive role. Indeed, eIF4E3 has also been 
reported to have antitumorigenic properties (Osborne et al., 2013). However 
other cofactors of eIF4A, involved in translation initiation, such as eIF4H, or 
eIF4G1 as well as many other factors, have also been shown to have pro-
tumourigenic roles (Fukuchi-Shimogori et al., 1997; Silvera et al., 2009; Wu et 
al., 2011; Gatza et al., 2014; Sendoel et al., 2017). 
Amplification of initiation factors is only one of the mechanisms that lead to 
dysfunction of the protein synthesis pathway. Another broad mechanism that 
cancers exploit to enhance translation is perturbation of the RNAs themselves. 
For example, aberrant ribosomal RNA modifications, which are guided by other 
small RNAs, can also lead to cancer (McMahon et al., 2019). Moreover, it has 
been observed in cancer cells that mRNAs encoding proteins beneficial for 
cancer undergo alternative polyadenylation, resulting in shortening of 3’UTRs, 
and a loss of miRNA binding sites, thus leading to upregulation of these 
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oncogenes (Mayr and Bartel, 2009; Lembo, Di Cunto and Provero, 2012). 
Interestingly, cancer cells can also exploit the miRNA pathway by expression of 
pseudogenes which titrate away the miRNA destined to repress an oncogene 
























1.5. RNA helicases  
 
RNA helicases are one of the largest groups of enzymes that participate in mRNA 
metabolism (Tanner and Linder, 2001; Jankowsky, 2012; Bourgeois, Mortreux and 
Auboeuf, 2016) and exist in virtually all classes of organisms (Anantharaman, 
Koonin and Aravind, 2002). Contrary to their name, RNA helicases have been 
shown to not only unwind secondary structure within the mRNA but also to 
anneal, clamp, and remodel RNA as well as alter RNA-protein complexes 
(Jankowsky, 2012; Bourgeois, Mortreux and Auboeuf, 2016). Due to their impact 
both on the RNA as well as ribonucleoprotein complexes they serve as molecular 
switches, that can impact the entire gene expression pathway.  
This thesis is focused primarily on the activity of two DEAD-box helicases, eIF4A1 
and eIF4A2, which have been shown to play a crucial role in both translation 
initiation as well as repression (Chapters 1.3.2, 1.3.6). To understand the 
experiments and rationales in this thesis, recognising the important 
characteristics of this group of enzymes (Chapter 1.5.1), as well as the already 
established differences between the paralogues (Chapter 1.5.2) is 
indispensable.  
 
1.5.1.   DEAD/H-box helicases 
 
All helicases belong to six superfamilies, categorised by the differences in their 
structures and function (Corbalenya and Koonin, 2007; Singleton, Dillingham and 
Wigley, 2007). Out of those six, two are represented by RNA helicases, i.e., 
Superfamily 1, and Superfamily 2 (SF1, SF2). Eukaryotic RNA helicases belonging 
to SF1 and SF2 are non-ring forming, a structural characteristic associated 
mostly with eukaryotic DNA helicases (Corbalenya and Koonin, 2007; Jankowsky, 
2012). One of the largest helicase families in humans belong to SF2; these are 
the DEAD-box and closely related DEAH-box (DHX) helicases (Fairman-Williams, 
Guenther and Jankowsky, 2011; Linder and Jankowsky, 2011; Jankowsky, 2012).  
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DEAD-box proteins are so named due to the presence of conserved DEAD (Asp-
Glu-Ala-Asp) sequence motif. DEAD-box helicases have two similar RecA domains 
named after a particular fold of the recombination protein RecA (Singleton, 
Dillingham and Wigley, 2007). The two domains form the helicase core and are 
joined by a flexible linker, which allows the domains to modify their position to 
each other (Andreou and Klostermeier, 2012). The conserved helicase core has a 
total of nine amino acid sequence motifs (Figure 1.5.1-1, panel A) (Linder et 
al., 1989; Tanner et al., 2003). Motifs Ia, Ib, IV, V are responsible for RNA 
binding, with motif VI involved in both RNA binding and ATP binding and 
hydrolysis. Other motifs of dual function are motif II, involved in both ATP 
binding and hydrolysis, and Mg2+ coordination; and motif III, responsible for ATP-
dependent RNA unwinding. The final two motifs, I, Q, are involved in ATP 
binding and hydrolysis. These conserved motifs structurally fall inside the 
helicase core, creating the ATP and RNA binding pocket (Figure 1.5.1-1, panel 
B) (Schütz et al., 2010). The positioning of the pocket permits the DEAD-box 
helicases to shift though the conformational cycle through RNA binding and 
release, coupled with ATP hydrolysis (Theissen et al., 2008; Hilbert, Karow and 
Klostermeier, 2009; Andreou and Klostermeier, 2012; Henn, Bradley and De La 
Cruz, 2012). However, the presence of interaction partners has also been 
demonstrated to shift DEAD-box proteins through their conformation (Rudolph 








Figure 1.5.1-1 DEAD-box helicase motifs 
A. Nine conserved motifs in DEAD-box RNA helicases. Each motif is represented by a 
box, with colour coded function represented in the scheme. Names of the motifs 
above each box and conserved amino acid sequence in one letter code presented 
inside the box, x – amino acid varying between different helicases.  
B. AlphaFold 2.0 predicted structure of eIF4A2 (AF-Q14240-F1), with conserved 
motifs indicated in colour: motifs Q, I – deep red, Ia, Ib, IV, V, VI – light brown, II 











Outside of the helicase core, i.e., the two RecA domains, the DEAD- (as well as 
DHX-) box proteins can have additional regions that modulate their functions. 
Examples of alternative functions regulated through extensions include 1) DHX36 
with an N-terminal extension that binds specific RNA structures, i.e., G-
quadruplexes (Lattmann et al., 2010), 2) DDX21 with its additional GUCT 
domain, which despite similarities to RNA recognition motif (RRM) is not thought 
to interact with RNA but rather with other proteins (Ohnishi et al., 2009), 3) 
DDX5 and its P68HR domain responsible for interaction with m6A writer METTL3 
and nuclear localisation, and 4) DDX3 and its autoinhibitory domain (Floor et al., 
2016) as well as its low complexity domain that is thought to have a function in 
phase-separation (Hondele et al., 2019). On the other side of the spectrum is 
the eIF4A family which is considered to be a minimal helicase (Tanner and 
Linder, 2001) with only about 50 amino acids proceeding the Q motif and around 
40 amino acids downstream of motif VI (Figure 1.5.1-1, panel A). The described 
minimal functional core of the DEAD-box helicases starts two amino acid 
upstream of a conserved phenylalanine of the Q motif and ends 35 amino acids  
beyond motif VI (Banroques et al., 2011). Therefore, the N-terminal regions of 
the eIF4A paralogues should not be overlooked as possible regions promoting 
divergent functions.  
Generally, DEAD-box helicases are thought to bind the substrate through an 
interaction with the nucleic acid phosphate backbone, therefore implicating a 
lack of sequence specificity (Peck and Herschlag, 1999; George W. Rogers, Lima 
and Merrick, 2001; Hilbert, Karow and Klostermeier, 2009). However, the direct 
contact with 2’OH group of the ribose allows for discrimination against DNA as a 
potential substrate (Peck and Herschlag, 1999; George W. Rogers, Lima and 
Merrick, 2001). In contrast to the above-mentioned lack of RNA sequence 
specificity, some of the DEAD/H-box helicases have been shown to preferentially 
bind specific RNA sequences. For example, the implicated in RISC assembly DHX9 
(also known as RNA helicase A, or RHA) is thought to be RNA sequence specific in 
the conserved region of the DEAD- and DEAH- box proteins (Parsyan et al., 
2011). In contrast, other RNA-sequence specific DEAD/H-box helicases are 
thought to confer their substrate specificity through regions outside of the main 
helicase core, such as is the case with Vasa (Drosophila melanogaster orthologue 
of human DDX4) and its C-terminal region  (Liu, Han and Lasko, 2009), or DDX43, 
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which KH domain facilitates substrate specificity (Yadav et al., 2021). 
Interestingly, even the ‘minimal’ helicases eIF4A2 and eIF4A3, as is discussed in 
greater detail below (Chapter 1.5.2),  has been shown to have a sequence 
preference (Saulière et al., 2012; Wilczynska et al., 2019).  
As this conserved group of enzymes plays a role in practically all parts of mRNA 
metabolism, it is perhaps not surprising that aberrations of DEAD-box helicases 
have been shown to have a function in cancer (Table 1.5.1-1). Interestingly, 
some of the helicases can have positive influence on outcome for cancer 
patients. Crucially, specific helicases can have opposite effect depending on the 
type of cancer, suggesting that those enzymes can act as molecular ‘double 
agents’ which action is imparted upon them based on their environment or 
interaction partners. Most importantly, from the published data (Table 1.5.1-1), 
that seems to be the crucial difference between the paralogues eIF4A1 and 




Table 1.5.1-1 Role of DEAD-box helicases in cancer 
Helicase Cancer Study Outcome 
DDX1 
breast  (Germain et al., 2011) 
relocalisation has 
negative impact  
testicular  (Tanaka et al., 2009) 
overexpression has 
negative impact 
ovarian (Han et al., 2014) 
miRNA axis – positive 
impact on outcome  
DDX2A / 
eIF4A1 
breast  (Modelska et al., 2015)  
overexpression has 
negative impact 
cervical  (Liang et al., 2014)  
endometrial (Lomnytska et al., 2012) 
gastric (Gao et al., 2020) 
lung (Ji et al., 2003) 
DDX2B / 
eIF4A2 
breast  (Yan et al., 2011)  downregulation has 
negative impact lung (Shaoyan et al., 2013) 
breast (Liu et al., 2019) 
overexpression has 
negative impact 
colorectal  (Chen et al., 2019)  










(Lin et al., 2018; Ling et al., 
2020; Zhu, Ren and Yang, 
2021) 
DDX3 
breast (Botlagunta et al., 2008) 
overexpression has 
negative impact 
colorectal  (Wu et al., 2016)  
liver (Huang et al., 2004) 
lung (Bol et al., 2015) 
liver (C.-H. Chan et al., 2019) loss has negative impact  
DDX5 colorectal 
(Causevic et al., 2001; Yang, 








(Tajirika et al., 2018; 
Taniguchi et al., 2018) 
liver (Miyaji et al., 2003 




colon (Shin et al., 2007) 
overexpression has 
negative impact 




breast (Cai et al., 2017) 
loss has negative impact 
liver (Takata et al., 2012) 
DDX27 colorectal (Tang et al., 2018) 
overexpression has 
negative impact 





(Martelange et al., 2000) 
overexpression has 
negative impact 
















1.5.2. eIF4A  
 
As described throughout this chapter there are three eIF4A paralogues in 
humans: eIF4A1 and eIF4A2, which share 90% amino acid sequence identity, and 
the less identical eIF4A3, with 60% amino acid sequence identity. eIF4A1 is the 
most abundant and well-recognised paralogue, the function of which is thought 
to be mainly within the eIF4F complex, reviewed in Chapter 1.3.2. In contrast, 
eIF4A2 has been shown to associate with CCR4-NOT complex and therefore take 
part in miRNA-mediated translational repression (Chapter 1.3.6). Despite, the 
differences in the preferable binding partners, both paralogues have been shown 
to associate with eIF4F (Yoder-Hill et al., 1993; Wilczynska et al., 2019; Robert 
et al., 2020), possibly forming different complexes. Opposite to this, eIF4A3 role 
is mainly within the exon junction complex (Chan et al., 2004).  
Intriguingly, the overexpression of both eIF4A1 and eIF4A3 is associated with 
negative outcomes for cancer patients (see Chapter 1.4 and Table 1.5.1-1). 
This is contrary to the few instances where eIF4A2 overexpression had a positive 
impact on the outcome for cancer patients (Table 1.5.1-1). Albeit as eIF4A2 
overexpression has also been shown in other studies to instead have a negative 
impact, a possible double role of eIF4A2 cannot be disregarded.  
As this thesis is focused mainly on discerning the molecular mechanisms that 
drive the distinct functions of eIF4A1 and eIF4A2, this chapter describes the 
known differences between those two paralogues. Moreover, as plethora of data 
in the protein translation field pertains to the yeast system, some important 
discoveries about the Saccharomyces cerevisiae eIF4A, named for the purpose of 
this thesis Sc eIF4A, are explored.  
As has been described in the literature, eIF4A1 and not eIF4A2 is the dominant 
paralogue which associates with eIF4G (Galicia-Vazquez et al., 2012). However, 
as has been observed (Galicia-Vazquez et al., 2012) the two proteins are 
interconnected on a transcriptional level, where knockdown of eIF4A1 enhances 
both transcription and the protein levels of eIF4A2. However, this compensatory 
upregulation of eIF4A2 is not capable of rescuing the primary function of eIF4A1 
in translation initiation (Galicia-Vazquez et al., 2012). Moreover, it has been 
observed that complete loss of eIF4A1 is detrimental to cell growth, which has 
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not been observed for eIF4A2 (Galicia-Vazquez et al., 2012). From the other 
side, depletion of eIF4A2 cannot be rescued by eIF4A1 for the activity of the 
miRNA-mediated translational repression pathway (Meijer et al., 2013). eIF4A2 
but not eIF4A1 has been implicated in uORF translation and the mRNAs bound by 
eIF4A2 are demonstrated to be both miRNA targets, and translationally 
repressed (Wilczynska et al., 2019). Moreover, eIF4A2 has been shown to 
preferentially bind polypurine (AG) motifs and confer its repressive functions 
through those motifs (Wilczynska et al., 2019). Interestingly, chemical inhibition 
of eIF4A1 renders it polypurine selective, reminiscent of the uninhibited eIF4A2 
(Iwasaki, Floor and Ingolia, 2016; Wilczynska et al., 2019). Although the exact 
mechanism of eIF4A2-mediated repression remains elusive, it has been 
demonstrated that eIF4A2 inhibits the deadenylase activity of CCR4-NOT 
complex (Meijer et al., 2019). This suggests that the repressive activity of 
eIF4A2 leads to mRNA storage rather than mRNA degradation (Chapter 1.3.6). 
The sequence specificity of eIF4A2 contrasts with what was described above for 
other DEAD-box helicases (Chapter 1.5.1), which are thought to be mostly 
sequence unspecific. However, it is worth noting that the third eIF4A paralogue, 
eIF4A3, has been shown to also preferentially bind polypurine motifs, as well as 
specifically clamp them (Saulière et al., 2012). It is possible that conserved 
regions between eIF4A2 and eIF4A3 could be responsible for this sequence 
preference.  
Interestingly, despite the high degree of identity between the eIF4A1 and eIF4A2 
amino acid sequence, there are many differences between the two paralogues 
on the transcriptional level, perhaps those differences could explain how the 
two paralogues are transcriptionally linked. eIF4A2 is located on chromosome 3, 
whereas eIF4A1 transcript is on chromosome 17. Moreover, the two paralogues 
differ in the untranslated regions of their mRNAs. Curiously, both paralogues 
have short and unstructured 5’UTRs, with 5’UTR of eIF4A1 at only 17 nucleotides 
and 5’UTR of eIF4A2 at 34 nucleotides, suggesting that the translation of both is 
not dependent on helicase activity or even the scanning mechanism of 40S 
ribosomal subunit. However, eIF4A2 3’UTR, unlike eIF4A1, has a miRNA binding 
site (miR-21) (Cho, 2007; Yan et al., 2011). Moreover, the 5’UTR of eIF4A2 has a 
TOP motif. Both the presence of miRNA binding site and the TOP motif in case of 
the eIF4A2, makes both of the paralogues subject to different forms of 
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translational control. Additionally, the coding sequence of the two mRNAs vary 
greatly due to the use of alternative codons (NCBI RefSeq). The implication of 
this is that the two paralogues require a different pool of charged tRNA. As 
discussed in Chapter 1.3.3, this mode of regulation is known as codon 
optimality. Those differences could perhaps explain the divergent expression of 
eIF4A1 in proliferative cells, and eIF4A2 in differentiated cells (Williams-Hill et 
al., 1997).  
In yeast, only a single eIF4A orthologue exist. Sc eIF4A has been shown to be a 
conserved ATP-dependent DEAD-box helicase. Its activity is also modulated by 
co-factors, which enhance its catalytic activity and alter its conformation 
(Schutz et al., 2008; Andreou and Klostermeier, 2012, 2014; Harms et al., 2014). 
In contrast to the human orthologues, no RNA sequence specificity has been 
observed for Sc eIF4A. However, the catalytic activities are thought to be 
modulated, similarly to the human eIF4As, through length of the single-stranded 
region as well as the stability of the RNA duplex (Andreou, Harms and 
Klostermeier, 2019). Additionally, apart from the considered canonical 
unwinding role of the helicase, both human and yeast eIF4A have been 
implicated in unwinding-independent loading of mRNAs onto the ribosome 
(Sokabe and Fraser, 2017; Yourik et al., 2017). Perhaps, the most interesting 
difference between human and yeast proteins can stem from their interaction 
partners. Human eIF4G bears two eIF4A binding sites (Figure 1.3.2-2) whereas 
the yeast orthologue has only one eIF4A binding MIF4G domain (Schutz et al., 
2008; Shatsky et al., 2014). Intriguingly, CNOT1, the scaffold protein of CCR4-
NOT complex, shown to interact with eIF4A2 (Meijer et al., 2019), has both 
MIF4G, and MA3 domain, however only MIF4G domain has been shown to interact 
with DDX6 helicase, and the role of MA3 domain in this context is unexplored 
(Mathys et al., 2014).  
Despite the known differences between the human paralogues, the mechanism 
of how they exert their specific functions remains unsolved. Furthermore, the 
question of whether it is the features of each eIF4A that drives the differences 





1.5.3. eIF4A inhibitors 
 
Due to the overwhelming evidence implicating overexpression of eIF4A1 in 
promoting malignant growth, targeting eIF4A pharmacologically has been a 
major goal. Several natural compounds have been shown to inhibit eIF4A, and 
many synthetic analogues are currently under investigation.  
Interestingly, despite inhibiting translation, many small molecule inhibitors exert 
completely different function on eIF4A. Some of the most well-known eIF4A 
inhibitors are hippuristanol, pateamine A and a large group of compounds known 
as rocaglamides.  
Hippuristanol, isolated from the coral Isis hippuris (M. Bordeleau et al., 2006) 
binds to the C-terminal domain of eIF4A and serves as an allosteric inhibitor by 
impeding ATP-binding (Lindqvist et al., 2008). Lack of ATP binding impedes 
eIF4A RNA binding and unwinding. Moreover, hippuristanol has been shown to 
lock eIF4A in a closed conformation (Sun et al., 2014).  
Pateamine A (PatA), isolated from the sea sponge Mycale hentscheli has been 
shown to inhibit cap-dependent translation (Northcote, Blunt and Munro, 1991; 
Bordeleau et al., 2005). PatA has been shown to increase the affinity of eIF4A 
for both ATP and RNA, and this strong association between eIF4A and RNA was 
demonstrated to sequester eIF4A from the eIF4F complex (M. E. Bordeleau et 
al., 2006). Moreover, PatA has been shown to increase eIF4A helicase activity 
(Bordeleau et al., 2005), implying that translational repression can be achieved 
through both inhibitors of gain and loss of function.  
Rocaglamides belong to the class of flavaglines, isolated from Agalia genus of 
plants (Ebada et al., 2011). Rocaglamide A (RocA) has been shown to interact 
with both eIF4A and RNA and bind in the molecular cavity of eIF4A (Iwasaki et 
al., 2019), as well as induce RNA-sequence specific clamping of eIF4A (Iwasaki, 
Floor and Ingolia, 2016). Similar RNA-sequence specificity can be induced by 
silvestrol, another flavagline family member (Wilczynska et al., 2019).    
As eIF4A inhibition seems to be beneficial in reducing growth of cancer cell 
lines, there is a growing search for new inhibitors that are better suited for 
chemotherapeutic application. Some of these are of natural origin (Chu et al., 
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2019) whereas others are synthetic derivatives (Zhang et al., 2019; Müller et al., 
2020). Another synthetised eIF4A inhibitor, eFT226 (Zotatifin) (Ernst et al., 
2020) is currently undergoing clinical trials for COVID-19 (Effector Therapeutics 
NCT04632381).  
Thus, eIF4A inhibitors show a promising avenue for repressing malignant 
growths. However, none of the available inhibitors seem to differentiate 
between the paralogues, as is the case of rocaglamides which target the 
conserved region. Due to the divergent roles of eIF4A1 and eIF4A2, as well as 
their differential effect on cancer there is a major need to understand how the 
inhibitors target each paralogue, and to preferentially find a paralogue-specific 
inhibitor. However, this need to differentiate between the paralogues and how 
they are targeted only recently became apparent in the scientific community 


















1.6. Project aims  
 
The overarching aim of this thesis is to understand the molecular processes that 
drive the different functions of the eIF4A paralogues. As eIF4A2 is underexplored 
in comparison to eIF4A1, the initial goal was to establish properties of eIF4A2 
before moving on to comparisons between the two helicases.  
Specific aims: 
I. To determine the biochemical properties that drive the functions 
of the mostly unexplored eIF4A2.  
II. To investigate how both the canonical eIF4A interaction partners, 
as well as the miRNA pathway related CNOT1 influence the 
activities of eIF4A2.  
III. To compare the activities of eIF4A1 and eIF4A2 and further our 
understanding in their divergent functions by exploring their 
activities alone and in presence of interaction partners. As well as 
to investigate the specific regions of the helicases that could be 
responsible for the divergent functions in vivo. And finally, to 
examine whether the functions of human eIF4As could be 












2. Materials and Methods  
2.1. Preparation of plasmid constructs  
 
All primers used in this thesis were purchased from Sigma-Aldrich and contain 
appropriate restriction site with an overhang for digestion efficiency. Primers 10 
to 16 were designed for the purpose of this thesis (Table 2.1-1).  
 
Table 2.1-1 List of all the primers used in this thesis  
No Primer name Sequence 
1 eIF4A1_fw TTGGTCTCATGGTTCTGCGAGCCAGGATTCC 
2 eIF4A1_rv AATAGCGGCCGCTCAGATGAGGTCAGCAACATTG 
3 eIF4A2_fw TTGGTCTCATGGTTCTGGTGGCTCCGCGGATTATAAC 
4 eIF4A2_rv AATAGCGGCCGCTTAAATAAGGTCAGCCACATTCATGG 
5 eIF4A1_FLIM_fw GTTGAAGCTTCATCTGCGAGCCAGGATTCC 
6 eIF4A1_FLIM_rv GAATAGGATCCTCAGATGAGGTCAGCAACATTG 
7 eIF4A2_FLIM_fw GTTGAAGCTTCATCTGGTGGCTCCGCGGATTATAAC 
8 eIF4A2_FLIM_rv GAATAGGATCCTTAAATAAGGTCAGCCACATTCATGG 
9 Citr/turq_to_SUMO_fw TTGGTCTCATGGTGTGAGCAAGGGCGAG 
10 Sc_eIF4G_fw TTGGTCTCATGGTCTTGTTCCAAGTGCTAATAGGTG 
11 Sc_eIF4G-M_rv AATAGCGGCCGCTTAGTTCCAGTTCTTGTCGT 
12 Sc_eIF4G-MC_rv AATAGCGGCCGCTTACTCTTCGTCATCACTTTCTCC 
13 eIF4A1_D265R_E268K_fw AGCTGGACACACTATGTCGCTTGTATAAAACCCTGACCATC 





16 eIF4A1_D296A _T298K_rv CATATCTCCATGCATGGCGGATACCTTGAAAGCTCGAGCATGCATC 
 
To prepare constructs used in this thesis for cloning into expression vectors for 
either protein production or in cell work PCR reactions and site directed 
mutagenesis were performed (see Tables 2.1-2, 2.1-3, 2.1-4, 2.1-5), using 
constructs presented below and primers (Table 2.1-1):  
• previously cloned in the Bushell lab constructs of eIF4A1 1-18 A2 and 
eIF4A2 1-18 A1 were cloned into petSUMO expression plasmid using 
primers no 3 and 2 or 1 and 4, respectively, 
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• Sc eIF4G constructs were cloned from a vector purchased from Addgene 
(#37232) (Mitchell et al., 2010) using primers no 10, 11 for shorter 
construct, and 10, 12 for longer construct into petSUMO vector, 
• mCitrine and mTruquoise2 containing vectors were purchased from 
Addgene (#54587 and #54842) (Griesbeck et al., 2001; Goedhart et al., 
2012) and used for cloning in eIF4A1 and eIF4A2, with primers no 5, 6 and 
7, 8 correspondingly, 
• mTurquoise2-eIF4A2 and mCitrine-eIF4A2 were also subcloned from the 
vector backbone into petSUMO plasmid for protein expression using 
primers no 9, 4, 
• using primers, no 13, 14 and 15, 16 mutagenesis on petSUMO-eIF4A1 
plasmids were performed to obtain eIF4A1 mutants deficient in eIF4G 
binding,  
• eIF4G binding deficient mutants were also cloned into vectors containing 
mTurquoise2 and mCitrine using primers no 7, 8 (Table 2.1-1).  
It should be noted that the vectors purchased from Addgene arrive as an agar 
stab culture and preparation of plasmid according to the manufacturer’s 
guidelines is needed prior to any cloning.  
 
Table 2.1-2 PCR reaction settings used for cloning of different constructs 
Step Temperature Time Cycles 
Initial denaturation 98°C 1 min 1 
Denaturation 98°C 30 s 
30 Annealing Ta = Tm - 3°C 30 s 
Polymerisation 72°C 30 s per 1 kb 
Elongation 70°C 5 min 1 
Hold 10°C ∞ 1 
Ta – annealing temperature is based on calculated Tm (melting temperature) of primers,  














Table 2.1-3 Example of site directed mutagenesis reaction mix  
Component Supplier & Cat. No. Final amount 
Phusion HF polymerase NEB M0530 1 U (0.5 µL)  
5 x Phusion HF or GC buffer NEB B0518 or B0519 1 x  
DNA template  - ~ 100 ng 
dNTP (10 mM stock of each) Thermo Scientific R0182 0.2 mM 
Forward primer  Sigma-Aldrich 0.5 µM 
Reverse primer Sigma-Aldrich 0.5 µM 
H2O (nuclease-free) Invitrogen AM9937 Up to 50 µL 
Note that the polymerase should be added last  
 
Table 2.1-4 Site directed mutagenesis settings  
Step Temperature Time Cycles 
Initial denaturation 95°C 1 min 1 
Denaturation 95°C 30 s 
40 Annealing 66°C 30 s 
Polymerisation 68°C 7 min 
Elongation 72°C 15 min 1 
Hold 10°C ∞ 1 
Ta – annealing temperature is based on calculated Tm (melting temperature) of primers,  
IDT OligoAnalyzer Tool was used for determination of Tm 
 
Table 2.1-5 Example of PCR reaction mix  
Component Supplier & Cat. No. Final amount 
PfuTurbo Agilent 600250 2.5 U (1 µL)  
10 x PfuTurbo buffer Agilent 600250 1 x  
DMSO NEB B0515 1.5 µL 
DNA template  - ~ 10 ng 
dNTP (10 mM stock of each) Thermo Scientific R0182 0.2 mM 
Forward primer  Sigma-Aldrich 0.3 µM 
Reverse primer Sigma-Aldrich 0.3 µM 
H2O (nuclease-free) Invitrogen AM9937 Up to 50 µL 
Note that the polymerase should be added last  
 
After PCR and site directed mutagenesis 2 µL of DpnI (Agilent 500402) were 
added to the reaction mix, and the samples were incubated for 1 h at 37°C. DpnI 
recognises methylated DNA and therefore cleaves the DNA template leaving the 
PCR product intact. Subsequently the PCR reaction mix was purified either using 
QIAquick PCR Purification Kit (Qiagen 28104) or resolved on 1.2% w/v agarose  
(Melford 9012-36-6) gel with SYBR Safe DNA gel stain (Thermo Fisher Scientific 
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S33102) in TAE buffer (provided by Beatson Central Services). For identification 
of sizes of PCR products HyperLadder 1kb (Bioline BIO-33026) DNA marker was 
used. If agarose gel was resolved, PCR products were extracted from the gel 
using Zymoclean Gel DNA Recovery Kit (Zymo Research D4008) or QIAquick Gel 
Extraction Kit (Qiagen 28706). The concentration of purified PCR product was 
estimated by A260 nm measurements using Nanodrop (Thermo Scientific ND-
ONE-W).  
Next, double enzymatic digestions were performed:  
• for cloning into petSUMO vector and the petSUMO vector itself with BsaI-
HFv2 (NEB R3733) and NotI-HF (NEB R3189), 
• for cloning into the mCitrine and mTurquoise2 plasmids and the vectors 
themselves with HindIII-HF (NEB R3104) and BamHI-HF (NEB R3136). 
Enzymatic digestions were assembled in CutSmart buffer (NEB B6004) and 
performed at 37°C for at least 2 h. The amount of enzyme used was based on 
the quantity of PCR product and manufacturer’s guidelines. After digestion, the 
enzymes were inactivated by heating up the samples to 80°C for 20 min. Next, 
the samples were purified using either QIAquick PCR Purification Kit or gel 
extraction method, as above. Vectors were purified using gel extraction method.  
Next, ligation reactions were performed using 3 to 1 insert to vector ratio (see 
Equation 2.1-1). Ligations were performed using LigaFast Rapid DNA Ligation 
System (Promega M8221) at RT for 10 min and subsequently half of the mixture 
was used for bacterial transformations. Alternatively, T4 DNA Ligase (NEB 
M0202) was used at 16°C overnight, after which the samples were inactivated 
for 10 min at 65°C before transformation.  
 
Equation 2.1-1 Determination of insert and vector amounts for ligation  
 𝑛𝑔 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 ∗   𝑘𝑏 𝑖𝑛𝑠𝑒𝑟𝑡




= 𝑛𝑔 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡 
 
Transformations into E. coli DH5α were performed using standard protocol, i.e., 
1) thawing of the bacteria on ice, 2) adding of the ligation mix or plasmid to the 
bacteria, 3) incubation on ice for 10 to 20 min, 4) heat-shock for 45 s in 42°C, 5) 
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outgrowth step in S.O.C medium (Invitrogen 15544034) at 37°C for 1 h with 
vigorous shaking, 6) spreading bacteria on agar plates with appropriate 
antibiotics, 7) overnight incubation at 37°C.  
Next, 5 mL LB media with appropriate antibiotic in culture tubes (Falcon 352051) 
were inoculated with single colony each and grown overnight at 37°C with 
shaking. Subsequently, DNA was purified by the Beatson Institute Molecular 
Technology Services using Qiagen Universal Robot and sequenced on an Applied 
Biosystems 3130xl sequencer. When necessary, for cell work, plasmids were 
regrown at larger scale, purified by the Beatson Institute Molecular Technology 
Services using Invitrogen Purelink HiPure Plasmid Filter Purification Kits and 
sequenced again.  
    
2.2. Protein expression and purification   
 
The properties of all the protein constructs used in this thesis are presented in 
Table 2.2-1. Residues denote the amino acid limits of each construct. Mass in Da 
can be used for estimation of either elution profile on size exclusion 
chromatography or migration on SDS-PAGE. Extinction coefficient (ε) is needed 
for estimation of molar concentration using the Beer-Lambert equation 
(Equation 2.2-1). The isoelectric point (pI) allows for determination of 
electrical charge of the protein at a given pH, which is useful for determination 
which ion exchange resin should be used in a purification step. In pH higher than 
pI the protein should be negatively charged, in pH lower than pI positively 
charged and at pH equal to pI the protein should remain neutral. Mass, ε and pI 
presented here are calculated using ExPASy Server, ProtParam tool (Gasteiger et 
al., 2005).  
 
Equation 2.2-1 The Beer-Lambert law  







Table 2.2-1 Properties of all the proteins used in this thesis  
Construct Residues Mass (Da) ε (M-1 cm-1) pI 








































 eIF4A1 DQAD 1 – 406 46152 34630 5.40 

































































 CNOT1 ma3-mif_1 842 – 1317 54596 42080 7.32 
CNOT1 ma3_1 800 – 1057 29520 23505 8.85 
CNOT1 ma3_2 842 - 1092 28529 18005 7.87 
Parameters calculated using Expasy ProtParam tool (Duvaud et al., 2021) 
2.2.1. Protein expression  
 
Transformations of E. coli BL21 Codon Plus RP (strain containing more Met-tRNA 
and Arg-tRNA) with 10 ng of plasmids were performed as described above 
(Chapter 2.1). Constructs that were not tested previously, were subjected to 
test expressions: 1) 5 mL bacterial cultures were grown overnight with 
antibiotics at 37°C, and subsequently 2) used for inoculation of fresh antibiotic 
free 5 mL LB and grown at 37°C for 5 hours, 3) the day culture was split into two 
samples with one induced with 1 mM IPTG (Indofine MB1008), 4) cultures were 
grown for additional 2 hours. 50 µL samples were collected before induction and 
after 2 h expression. Collected samples were mixed in 4 to 1 ratio with SDS-
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loading buffer (100 mM Tris pH 6.8, 40% w/v sucrose, 8 % SDS, 0.3% bromophenol 
blue, 2 mM EDTA, 20% β-mercaptoethanol) and heated to 95°C for 5 min. 
Subsequently 20 µL of each sample was applied onto a gel and resolved using 
SDS-PAGE. The non-induced culture corresponding to the highest level of 
expression of the correct protein was used for preparation of a stock. In general, 
once transformed and tested, bacteria expressing the correct proteins were kept 
as a glycerol stock, i.e., 0.5 mL of bacterial sample collected in the growth 
phase mixed with 0.5 mL of 50% sterile glycerol, frozen in dry ice and stored at -
80°C.  
Biomass production for large scale protein purification was as follows: 200 - 500 
mL LB containing 20 µg/mL kanamycin and 20 µg/mL chloramphenicol were 
inoculated from a glycerol stock and grown over night in 37°C, 5% CO2, with 
shaking 225 rpm. In the morning cultures were poolled together and the optical 
density at 600 nm (OD600) was measured. Fresh LB media (3 – 12 L) was 
inoculated from the overnight culture to OD600 ~ 0.1 and grown without 
antibiotics in 37°C, 5% CO2, with shaking 225 rpm, till either OD600 around 0.8, or 
OD600 around 0.4 if the cultures were to be cooled before the induction (refer to  
Table 2.2.1-1 for details about individual proteins). Subsequently 1 mM final 
concentration of IPTG was added to the cultures and proteins were expressed at 
temperature and time as stated in Table 2.2.1-1 in 5% CO2, with 225 rpm 
shaking. After expression, bacteria were pelleted by centrifugation in 1 L tubes 
at 4°C, 15 minutes, 4000 rpm in J6-MI centrifuge (Beckman JS-4.2 swing bucket 
rotor). The process was repeated until the whole culture was spun down. 
Subsequently pellets were resuspended in ice cold PBS, transferred into 50 mL 
conical-bottom tubes and centrifugated again at the same settings. PBS was 
decanted, the tubes with pellets were placed in a tub with dry ice and ethanol 








Table 2.2.1-1 Expression conditions and tags used for protein purification  
Construct Expression Tags 
eIF4A1 4 h, 37°C His-SUMO 
eIF4A2 4 h, 37°C His-SUMO 
eIF4A1 Δ N-20 4 h, 37°C His-SUMO 
eIF4A1 1 – 18 A2 4 h, 37°C His-SUMO 
eIF4A2 1 – 18 A1 4 h, 37°C His-SUMO 
eIF4A2-7-mut 4 h, 37°C His-SUMO 
eIF4A1 4G-mut 4 h, 37°C His-SUMO 
mTurquoise2-eIF4A2 3 h, 37°C His-SUMO 
mCitrine-eIF4A2 3 h, 37°C His-SUMO 
eIF4G-MC 16 h, 18°C His-SUMO 
Sc eIF4G-MC 16 h, 18°C His-SUMO 
Sc eIF4G-M 16 h, 18°C His-SUMO 
eIF4H 4 h, 37°C His-SUMO 
PDCD4 4 h, 37°C His-SUMO 
CNOT1 MIF 4 h, 37°C His-SUMO 
CNOT1 MA3 4 h, 37°C His-SUMO 
CNOT1 MA3-MIF 4 h, 37°C; 4h, 30°C; 16 h 18°C see figure legends 
CNOT7 4 h, 37°C His (TEV cleavage) 
DDX6 4 h, 37°C His-SUMO 
CNOT1 ma3-mif_1 4 h, 37°C; 4h, 30°C; 16 h 18°C see figure legends 
CNOT1 ma3_1 4 h, 37°C His-SUMO 
CNOT1 ma3_2 16 h, 18°C His-SUMO 
 
2.2.2. Protein purification 
 
Proteins were purified in buffers as stated below prepared out of: Tris-HCl 
(prepared by Beatson Institute Central Services), HEPES (Sigma-Aldrich H4034),  
KCl (Sigma-Aldrich P9541), NaCl (Fisher Scientific 7647-14-5), imidazole (Sigma-
Aldrich 1047161000), EDTA (prepared by Beatson Institute Central Services), 
glycerol (Fisher Scientific G/0600/17), DTT (Sigma-Aldrich D0632), TCEP (Melford 
T26500).  
A. 20 mM Tris-HCl, pH 7.5, 1 M NaCl, 30 mM imidazole, 10 % w/v glycerol  
B. 20 mM Tris-HCl, pH 7.5, 0.1 M NaCl, 500 mM imidazole, 10 % w/v glycerol  
C. 20 mM Tris-HCl, pH 7.5, 10% w/v glycerol, 0.1 mM EDTA, 1 mM DTT 
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D. 20 mM Tris-HCl, pH 7.5, 0.1 mM KCl, 1% w/v glycerol, 0.1 mM EDTA, 1 mM 
DTT 
E. 20 mM Tris-HCl, pH 7.5, 1 M KCl, 1% w/v glycerol, 0.1 mM EDTA, 1 mM 
DTT 
F. 20 mM Tris-HCl, pH 7.5, 0.1 mM KCl, 1% w/v glycerol, 0.1 mM EDTA, 1 mM 
TCEP 
G. 20 mM Tris-HCl, pH 7.5, 0.1 M KCl, 30 mM imidazole, 1 % w/v glycerol  
H. 20 mM Tris-HCl, pH 7.5, 0.1 M NaCl, 30 mM imidazole, 1 % w/v glycerol  
I. 20 mM Tris-HCl, pH 7.5, 0.25 mM KCl, 1% w/v glycerol, 0.1 mM EDTA, 1 
mM TCEP 
 
The frozen bacterial pellets were thawed on ice with addition of buffer A 
supplemented with 1 mM PMSF (Sigma-Aldrich 93482) and 1 tablet of Complete™ 
EDTA-free Protease Inhibitor Cocktail (Roche 5056489001) per 50 mL of buffer. 
After the pellets were dissolved final 1 mg/mL lysozyme (Sigma-Aldrich 62971) 
was added, the bacterial mixture was incubated for 30 min at RT, and 
subsequently for 30 min on ice. After the incubation time bacterial cells were 
lysed either 1) using a microfluidizer (Microfluidics M-110P) set on 20000 psi, 
with each sample lysed twice, in the case of a large-scale, or 2) in the case of a 
small-scale purification, using a sonicator (Sonics Vibra-cell  VCX 130) set to 60 % 
amplitude with 10 pulses of 10 s on 10 s off, repeated 4 times, with sample 
cooling in between. Subsequently bacterial lysates were pre-cleared by 
centrifugation for 35 minutes at 4°C either at 1) 19 000 rpm in a Beckman Avanti 
J-25 or J-25i Beckman centrifuges (rotor Beckman JA-25.5, fixed angle) or in 
Thermo Scientific SORVALL RC 6+ centrifuge (rotors Thermo Scientific F21-8x50y, 
SORVALL SS-34) in the case of large-scale purification, or 2) at 13 300 rpm  in 
Thermo Scientific Fresco 17 centrifuge (75003424 rotor) in the case of small 
scale. Supernatant from centrifugation was filtered through 0.45 µm pore filter.  
• In the case of small-scale purification, the filtered lysate was applied to 
washed in buffer A Ni2+ resin (Ni-NTA Agarose Qiagen 30210), and 
incubated with rotation for 30 min at RT. Subsequently, the supernatant 
was collected, and 3 washes in buffer A were performed. Final wash was 
done in 200 µL of buffer H with 5 µL of 80 µM ULP1 protease and 
incubated for 1 h at room temperature with gentle rotation. Next, 
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supernatant was collected off the Ni2+ resin, and remaining fraction bound 
was eluted in buffer B.  
• In the case of large-scale purification filtered lysate was applied on an 
equilibrated in buffer A HisTrap HP column (GE Healthcare / Cytiva 29-
0510-21) using a peristaltic pump. All large-scale purifications (unless 
otherwise stated in the figure legend) were performed using either ÅKTA 
Explorer purification system (GE Healthcare) or NGC Chromatography 
System (Bio-Rad). Columns were washed in buffer A, and subsequently 
bound fractions were eluted in a linear gradient of buffer B. Pooled 
fractions containing protein of interest were diluted twice in buffer C and 
subjected to His-SUMO tag cleavage with ULP1 protease or His cleavage 
with TEV protease; for either 1 h at RT or 4°C overnight. Subsequently 
proteins were diluted again to a final dilution of 5 to 6 in buffer C. Next 
the diluted proteins were subjected either to reverse affinity 
chromatography using buffers G or ion exchange chromatography in buffer 
D, with a linear gradient elution using buffer E. Size exclusion 
chromatography was usually the final step of purification, performed in 
buffer F.  
All columns were equilibrated before applying the samples: HisTrap HP either in 
buffer A, G or H, ion exchange columns (anion – RESOURCE Q; Cytvia 17117901; 
cation – HiTrap Heparin; Cytvia 17040701) in buffer D, and size exclusion column 
(Superdex S200 HiLoad 16/600; Cytvia 28989335) in buffer F. For information 
about purification of individual proteins consult Table 2.2.2-1. eIF4G-MC was 
eluted from SEC and stored in buffer I.  
As a final step, all proteins were concentrated using either Vivaspin or Amicon 
Ultra centrifugal filters with an appropriate molecular weight cut off (MWCO). 
And concentrated proteins were aliquoted into 500 µL tubes (aliquot size 
between 10 and 200 µL), snap frozen in liquid nitrogen and stored at - 80°C.  
Absorbance spectra (230 – 350 nm) of final products were measured and molar 
concentrations were calculated based on Equation 2.2-1. Moreover, nucleic acid 
contaminations were estimated using OD260 to OD280 ratio, and proteins used 
for further studies were deemed to not have contaminants.  
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Additionally, throughout the purification steps, SDS-PAGE was used to determine 
the purity and fractions containing the purified proteins. For this, gels were cast 
(see Table 2.2.2-2) and resolved in SDS-PAGE running buffer (25 mM Tris, pH 
8.3, 0.192 M glycine, 0.1% SDS). Alternatively, pre-cast gels were used (NuPAGE 
4 – 12 % Bis-Tris, Invitrogen NP0322BOX, NP0323BOX, NP0335BOX) and resolved 
in MOPS (Invitrogen NP0001) for larger proteins, or MES (Invitrogen, NP0002) for 
smaller proteins. Gels were either stained with Coomassie stain (5 volumes of 
methanol, 1 volume of acetic acid, 5 volumes of H2O, and 1 g per 1L of stain 
Brilliant blue) and de-stained with de-staining buffer (3 volumes of methanol, 1 
volume of acetic acid and 6 volumes of H2O). Alternatively, gels were stained 
with InstantBlue (Abcam ab119211) and de-stained with H2O. Precision Plus 
Protein Dual Color Standards (Bio-Rad 1610374) was used as marker.  
 
Table 2.2.2-1 Purification steps of proteins used in this thesis  




eIF4A1 Ni2+ column Anion +  - 
eIF4A2 Ni2+ column Anion +  - 
eIF4A1 Δ N-20 Ni2+ column Anion +  - 
eIF4A1 1 – 18 A2 Ni2+ column Anion +  - 
eIF4A2 1 – 18 A1 Ni2+ column Anion +  - 
eIF4A2-7-mut Ni2+ column Anion +  - 
eIF4A1 4G-mut Ni2+ column Anion - FT +  + 
mTurquoise2-eIF4A2 Ni2+ agarose - - - 
mCitrine-eIF4A2 Ni2+ agarose - - - 
eIF4G-MC Ni2+ column Cation  +  - 
Sc eIF4G-MC Ni2+ column - + Reverse affinity 
Sc eIF4G-M Ni2+ column - + Reverse affinity 
eIF4H Ni2+ column Cation +  - 
PDCD4 Ni2+ column Anion +  - 
CNOT1 MIF Ni2+ column Anion - FT +  Reverse affinity + SEC 
CNOT1 MA3 Ni2+ column Anion - FT -  Reverse affinity 
CNOT1 MA3-MIF Ni2+ column Anion - FT +  - 
CNOT7 Ni2+ column Anion + - 
DDX6 Ni2+ column Cation +  - 
CNOT1 ma3-mif_1 Ni2+ column Anion - FT +  +/- 
CNOT1 ma3_1 Ni2+ column - -  - 
CNOT1 ma3_2 Ni2+ column Anion - FT +  - 
FT means that the protein of interest was found in the flow through from that purification step 
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Table 2.2.2-2 SDS-PAGE gel casting protocol for 2 gels  
Components Supplier & Cat. No. Resolving gel Stacking gel 
H2O MiliQ - 5 mL 1.5 mL 
buffer * - 5 mL 1.5 mL 
30 % 
acrylamide 
ProtoGel 37.5:1 National 
Diagnostics EC-980 
10 mL 3 mL  
10% w/v APS  Sigma-Aldrich A3678 200 µL 60 µL 
TEMED Sigma-Aldrich T22500 30 µL 10 µL 
* 4 x resolving buffer (1.5 M Tris, pH 8.8, 1% SDS), 4 x stacking buffer (0.25 M Tris, pH 
6.8, 1% SDS) 
Resolving gel was cast first and after polymerisation stacking gel was cast on top 
(stacking gel was about 20% of the length of the whole gel).  
 
2.3. In vitro methods 
2.3.1. RNA binding assays  
 
All RNA binding assays were performed in the binding buffer: 20 mM HEPES 
(Sigma-Aldrich H4034), 100 mM KCl (Sigma-Aldrich P9541), 1 mM MgCl2 (Sigma-
Aldrich M8266), 1 mM DTT (Sigma-Aldrich D0632), supplemented with 1 mM AMP-
PNP (Sigma-Aldrich A2647), unless stated otherwise in the figure legends. For 
binding in presence of ATP 1 mM ATP (Sigma-Aldrich A2647) was used instead of 
1 mM AMP-PNP. RNAs used in all RNA binding assays can be found in Table 
2.3.1-1, and were purchased from Integrated DNA Technologies (IDT). All the 
reactions containing 0 µM protein had equivalent volume (to the volume of 












Table 2.3.1-1 Single-stranded RNAs used in binding assays  
RNA name RNA sequence Length (nt) Label Application 
(AG)10 AGAGAGAGAGAGAGAGAGAG 20 Dy780 EMSA 
(AG)10 AGAGAGAGAGAGAGAGAGAG 20 - aSEC 
(AG)10 AGAGAGAGAGAGAGAGAGAG 20 FAM FP, EMSA 
(CAA)6CA CAACAACAACAACAACAACA 20 Dy680 EMSA 
(CAA)6CA CAACAACAACAACAACAACA 20 - aSEC 
(CAA)6CA CAACAACAACAACAACAACA 20 FAM FP, EMSA 
(AG)5 / 10 nt AG AGAGAGAGAG 10 Dy780 EMSA 
(AG)5 / 10 nt AG AGAGAGAGAG 10 - aSEC 
(AG)7.5 / 15 nt AG AGAGAGAGAGAGAGA 15 Dy780 EMSA 
(AG)7.5 / 15 nt AG AGAGAGAGAGAGAGA 15 - aSEC 




50 Dy780 EMSA 




50 - aSEC 
A20 AAAAAAAAAAAAAAAAAAAA 20 - aSEC 
A20 AAAAAAAAAAAAAAAAAAAA 20 FAM EMSA 
(GAAG)5 GAAGGAAGGAAGGAAGGAAG 20 - aSEC 
(GAAG)5 GAAGGAAGGAAGGAAGGAAG 20 FAM EMSA 
(GUGCU)4 GUGCUGUGCUGUGCUGUGCU 20 - aSEC 
(GUGCU)4 GUGCUGUGCUGUGCUGUGCU 20 FAM EMSA 
(AGUG)5 AGUGAGUGAGUGAGUGAGUG 20 FAM FP, EMSA 
(UCUC)5 UCUCUCUCUCUCUCUCUCUC 20 FAM FP, EMSA 
(UGUU)5 UGUUUGUUUGUUUGUUUGUU 20 FAM FP, EMSA 
(AG)5U10 AGAGAGAGAGUUUUUUUUUU 20 FAM EMSA 
U5(AG)5U5 UUUUUAGAGAGAGAGUUUUU 20 FAM EMSA 
(AG)2U12(AG)2 AGAGUUUUUUUUUUUUAGAG 20 FAM EMSA 
(AG)2U8(AG)2U4 AGAGUUUUUUUUAGAGUUUU 20 FAM EMSA 
(AG)2U4 AGAGUUUUAGAGUUUUAGAG 20 FAM EMSA 
(AG)2U2 AGAGUUAGAGUUAGAGUUAG 20 FAM EMSA 





2.3.1.1. Electrophoretic mobility shift assay 
 
Electrophoretic mobility shift assay (EMSA) is a technique that allows for 
visualisation of protein – nucleic acid complexes in their native state.  
RNA protein complexes were assembled as presented in Table 2.3.1.1-1 and 
preincubated for 1 hour at room temperature. After the preincubation 2.5 µL of 
5% w/v Ficoll 400 (Sigma-Aldrich F2637) solution was added to the reaction. 
Prepared samples were loaded on a 7% acrylamide native gel (Table 2.3.1.1-2) 
and resolved for 45 minutes at 100 V. Separation of complexes on a native gel is 
based on both the mass of the complex and its charge. The resolved native gels 
were visualised using Li-COR Odyssey and respective channels (700 for Dy680, 
800 for Dy780) or Typhoon FLA7000 imager (for FAM labelled RNAs). Band shifts 
can be observed on the gels corresponding to 1) negatively charged nucleic acids 
that migrate to the bottom to the gel 2) eIF4A-RNA complexes that stay in the 
upper part of the gel due to the positive charge of the proteins at pH 7.5.  
 
Table 2.3.1.1-1 Example of assembly of RNA binding reaction for use in EMSA 
assay  
Components Volume (µL) 
10 x binding buffer 1 
10 mM AMP-PNP / ATP 1 
DMSO / 10 mM silv 0.1 
100 nM RNA (Dy680 or Dy780) 2.5  
protein (10 x µM conc) 1  
H2O RNAse free 4.4 
Reactions were often assembled as a master mix with omission of a varying component, 
which was pipetted separately to the tubes.  
In the case of reactions with competition RNA 3.4 µL of H2O was used, and 1 µL of 
competitor RNA was added after initial preincubation for 45 min and incubated for 
another 45 min before applying the sample to a gel.  








Table 2.3.1.1-2 Native gel protocol for two 7% gels  
Components Supplier & Cat. No.  Volume (mL) 
40% acrylamide  AccuGel 19:1 National Diagnostics EC-850 3.5 
5x TB buffer Supplied by CRUK BI central services 4 
RNAse free H2O RNAse free MiliQ 12.28 
10% w/v APS  Sigma-Aldrich A3678 0.2  
TEMED Sigma-Aldrich T22500 0.02 
 
Additionally, the KD of the protein for RNA was calculated from EMSAs where 
protein titration (0, 0.01, 0.02, 0.06, 0.2, 0.5, 1, 3, 5, 7 µM) was used. For this, 
fraction bound was assessed using analysis feature in Image Studio Lite Ver 5.2. 
Briefly, the signal of unbound (free RNA at the bottom of the gel) and the bound 
(complexes, top of the gel) was calculated. The obtained values were added, 
and fraction bound was calculated by dividing the signal of bound fraction by 
total. Subsequently fraction bound data were exported to GraphPad Prism 
(versions from 7 to 9.2) and KD was calculated by applying Hill equation to the 
data (Equation 2.3.1.1-1).  
 
Equation 2.3.1.1-1 Hill equation  
Y =
𝐵𝑚𝑎𝑥  × 𝑋
ℎ
𝐾𝐷
ℎ +  𝑋ℎ
+ 𝑜𝑓𝑓𝑠𝑒𝑡 
X – concentration of titrant 
Y – specific binding  
Bmax – maximum binding  
KD – dissociation constant  
h – hill coefficient  
 
2.3.1.2. Analytical size exclusion chromatography  
 
Analytical gel filtration chromatography (aSEC), alike EMSA allows for 
visualisation of native complexes. However, advantageously in aSEC RNA 
substrates do not need to be labelled and if a chromatography system (here, 
ÅKTA Explorer from GE Healthcare) with multiple wavelength detection is used 
both RNA (at 260 nm) and protein (at 280 nm or peptide bonds at 220 nm) can be 
observed in the sample. In a size exclusion chromatography larger molecules 
(complexes) elute faster, at a smaller retention volume, and smaller molecules  
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are trapped in the pores of the chromatography column resin and are eluted at 
higher retention volume.  
Reactions were set up as presented in Table 2.3.1.2-1 and incubated for 1 h at 
RT. Subsequently, complexes were loaded on a preequilibrated in the binding 
buffer 2.2 mL size exclusion column (Superdex™ 200 Increase 3.2/300 Cytvia 
28990946). Samples were run at a maximum flow rate of 50 µL/min.  
 
Table 2.3.1.2-1 Example of aSEC sample preparation  
 Final concentration 
Components protein only protein-RNA complexes 
binding buffer 1 x 
1 AMP-PNP 1 mM 
1 DMSO / 10 mM silv 100 µM (equal volume in case of DMSO) 
0.1 Unlabelled RNA 0 µM 4 µM 
protein 16 µM 
H2O RNAse free to 70 µL 
 
Some of the obtained chromatograms were additionally analysed to estimate 
protein to RNA ratio as well as the proportion of different complexes in the 
sample. For this exported chromatograms data were analysed using the area 
under curve function in GraphPad Prism (versions from 7 to 9.2), with setting 
limits for analysis of individual peaks. For complexes ratio analysis data from A 
260 nm was used. The contribution of each complex was calculated by dividing 
area under curve of individual peak by the combined areas of all peaks in the 
sample. To understand the protein to RNA ratio in each complex molar 
concentrations of proteins and RNA were calculated in each peak based on the 
total concentrations in the sample and the ratio of area under the curve of 
individual peaks (A 260 nm for RNA, and A 220 nm for protein).  
  
2.3.1.3. Fluorescence Polarisation 
 
Fluorescence polarisation (FP) is a method that allows for measuring of 
molecules binding in solution. However, in this method distinction between 
different complexes that can contribute to the observed binding cannot be 
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made. FP is based on the changes in polarisation upon molecules binding (in this 
case protein and RNA) due to the change in the rotation of the fluorophore and 
can be described by Equation 2.3.1.3-1. Briefly, upon excitation with polarised 
lights, small, unbound molecules (with fluorescent probes, in this case FAM), 
rotate rapidly in solution therefore the emitted light is depolarised resulting in 
low FP value. When the fluorescently labelled molecule (short RNA) is bound by 
a larger one (protein) the rotation is slower, leading to emission of polarised 
light and high FP signal.  
 
Equation 2.3.1.3-1 Fluorescence polarisation  
𝐹𝑃 =  
(𝐹‖ − 𝐹⊥) 
(𝐹‖ +  𝐹⊥)
 
F‖ - fluorescence intensity parallel to the excitation plane  
F⊥ - fluorescence intensity perpendicular to the excitation plane 
Often F is referred as I for intensity, however here F was used to not confuse with I – scattering 
intensity  
 
Complexes for fluorescence polarisation assays were assembled in a similar 
manner as presented in Table 2.3.1.1-1, with the difference in total reaction 
volume (20 µL) and use of 50 nM final concentration of FAM RNA. Reactions here 
were also prepared as master-mixes excluding variable elements (such as 
proteins) which were mixed separately. For the competition experiments either 
0, equimolar amount, 10-fold excess or 50-fold excess of competitor RNA was 
used. For the competition experiments master-mixes were prepared as follows: 
buffer, FAM-RNA, DMSO, AMP-PNP, and H2O were mixed together, then 
separated into 4 tubes and appropriate amount of competitor RNA added. 
Subsequently mixture was added to the different concentrations of proteins 
(titration from 0 to 10 µM). In the case of eIF4As binding in presence of 
additional proteins (for example CNOT1 or eIF4G both human and yeast) the 
additional proteins were included in the master-mix and preincubated for 5 - 10 
minutes before pipetting the master-mix to the appropriate concentrations of 
eIF4As.  
For reactions with AMP-PNP measurements after 1 hour of incubation were used, 
for ATP measurements were performed within the first 5 – 10 minutes of 
reaction assembly. FP was measured on either PerkinElmer 2030 Explorer or 
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Tecan Spark, with excitation at 485 nm and emission at 535 nm. Reactions were 
measured in 384-well plates (black, round bottom, non-binding surface; Corning 
#4514), covered with transparent film to avoid evaporation (Optical Adhesive 
Covers, Applied biosystems 4360954), at 30°C. Obtained data was analysed in 
GraphPad Prism, and KD values were calculated using Hill equation (Equation 
2.3.1.1-1).  
 
2.3.2. RNA release assay 
 
RNA release experiments were performed employing FP method (Chapter 
2.3.1.3). RNA release assays were measured using Tecan Spark, and 384-well 
plates (Corning #4514), covered with optical adhesive film.  
In this case either free RNA or RNA with 5 µM of either eIF4A1 or eIF4A2 or their 
mutants were used. The reactions were assembled in the same manner as for 
the FP assays with the only difference in the reaction start. Reactions were 
started with addition of either 1 mM ATP or 1 mM AMP-PNP. Subsequently kinetic 
measurements were performed at 30°C with intervals between 2.5 to 10 min for 
15 hours. Obtained data was fitted to the ‘Dissociation – One phase exponential 
decay’ model in GraphPad Prism 9.2 (Equation 2.3.2-1) and half-lives were 
calculated.  
   
Equation 2.3.2-1 Dissociation – One phase exponential decay  
𝑌 = (𝑌0 − 𝑁𝑆) × exp(−𝐾 × 𝑋) + 𝑁𝑆 
X – time  
Y – binding  
Y0 – binding at time 0  
NS – binding at a long time (plateau)  






2.3.3. Unwinding assays  
 
Unwinding assays were performed using Tecan Spark and PerkinElmer 2030 
Explorer. 384-well plates with transparent bottom (Corning CLS3544 and Thermo 
Scientific 242764), covered with optical adhesive film were used. It should be 
noted that use of different machines, plates or adhesive films can affect the 
result, therefore, to make obtained measurements comparable internal controls 
need to be present in each experiment, such as sample with free RNA, free 
buffer, and maximal fluorescence reference control. Unwinding reactions were 
assembled and preincubated for 30 – 60 min before the reaction start with 
Mg2+/ATP. After kinetic cycles were measured with intervals between 45 – 120 s 
for at least 1 h, with excitation wavelength at 535 nm and emission at 595 nm.  
 
2.3.3.1. RNA annealing 
 
All RNAs used in the unwinding assays were purchased from IDT as single 
stranded RNAs which were either unlabelled or labelled with fluorophore (Cy3) 
or quencher (BHQ2) (Table 2.3.3.1-1).  
To use the RNAs in unwinding reactions a double-stranded region is necessary. 
Therefore, the RNAs presented in Table 2.3.3.1-1 were mixed in an annealing 
buffer (20 mM Tris acetate pH 7.5, 100 mM KCl, 2 mM DTT) with a 1.1 : 1 : 1 
ratio of unlabelled overhang strand, reporter, and quencher respectively. For 
overhang RNA substrates labelled with 3’BHQ 1.1 to 1 of overhang to reporter 
ratio was used. For reference strands only overhang strand and reporter strand 
were mixed. That mixed RNAs with a final concentration of at least 500 nM each 
were heated to 85 – 90 °C in a water bath and cooled slowly to RT (at least for 5 
h, often overnight). Annealed RNAs were stored either at -80°C or at -20°C if 







Table 2.3.3.1-1 List of RNA oligos used in unwinding and ATPase assays  







































3’ reporter CUUUUUUAAUUUUUUAAUUUUUUG 5’ Cy3 
3’ quencher AGCCUCCCCGGCCACCCCGG 3’ BHQ2 
 5’ reporter GUUUUUUAAUUUUUUAAUUUUUUC 5’ Cy3 
5’ quencher GGCCCCACCGGCCCCUCCGA 3’ BHQ2 
 
2.3.3.2. Unwinding reaction and analysis 
 
Unwinding reactions were assembled in 20 µL reactions as presented in (Table 
2.3.3.2-1). Reactions were started with adding Mg2+/ATP as the binding buffer 
for unwinding reactions was depleted of MgCl2. As mostly protein titrations (from 
0 to 15 µM) were performed, master-mixes of reactions presented in in (Table 
2.3.3.2-1) were made. As ATPase reactions were performed in conjunction to 
unwinding reactions, ATPase mix (as described in Chapter 2.3.4) was added 
straight to the wells designated for ATPase measurements before addition of 
other components of reaction. Wells without ATPase mix had 1 x binding buffer 
instead.  
Unwinding reactions with competitor RNAs were assembled in a way where eIF4A 
was preincubated for 45 min with the RNA substrate and other components of 
the reaction (excluding Mg2+/ATP) and then for another 45 min with competitor 
RNA. In reactions with interaction partners the proteins were preincubated 
together for 15 - 30 min before preincubation for 1 h with other components.  
87 
 
Wells in which no proteins were added (RNA only control) had an equivalent 
volume of protein storage buffer added instead of proteins (see buffer F Chapter 
2.2.2).  
 
Table 2.3.3.2-1 Example of unwinding reaction assembly 







4 x binding buffer 5 5 5 
DMSO / 10 mM silv  0.2 0.2 0.2 
500 nM annealed RNA 2 2 2 
H2O RNAse free  up to 20 µL total 
protein (10 x µM conc) 2  2 2 
10 mM ATP 2 2 2 
Competitor RNA (10 x µM conc) 0 2 0 
interaction partner 1 (10 x µM conc) 0 0 2 
interaction partner 2 (10 x µM conc) 0 0 0/2 
ATPase mix 0/2 0/2 0/2 
 
Obtained data were analysed using GraphPad Prism (versions 7 to 9.2). First, a 
baseline (value measured before the start of the reaction multiplied by 0.9 to 
account for dilution) was removed from each sample. Next, values were 
normalised to references. Reference value (total signal change) was calculated 
by subtracting the average of final reaction points for RNA only conditions (0 µM 
protein; the lowest fluorescence signal obtained for RNA) from the average of 
final points in the reaction of highest protein concentration with RNA substrate 
that did not contain quencher strand (the highest signal obtained for that RNA). 
The obtained reference value was used to normalise the unwinding results and 
allowed for comparison of fraction unwound. Next, first 200 s of reactions were 
fitted using linear model (Equation 2.3.3.2-1), where Yintercept was set to 0. 
Obtained slope value from straight line fitting corresponded to fraction unwound 





Equation 2.3.3.2-1 Straight line fitting   
𝑌 = 𝑌𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 + 𝑋 × 𝑠𝑙𝑜𝑝𝑒 
Y – value on Y axis  
Intercept – value at which Y axis is crossed  
X – value on X axis  
Slope = (Ymax - Ymin)/(Xmax – Xmin) 
 
Initial velocity plotted against titrant protein concentration was further analysed 
with Hill equation (Equation 2.3.1.1-1), which resulted in obtaining a Hill 
coefficient (h, measurement of cooperativity), and an apparent KD for the 
unwinding substrate in the unwinding reaction.  
2.3.4. ATPase assays  
 
ATPase reactions were performed in conjunction with unwinding reactions 
(Chapter 2.3.3) from the same master-mix (Table 2.3.3.2-1) in separate wells 
on a 384-well plate supplemented with ATPase mix. Here, dependency of NADH 
conversion and ATP conversion was employed (Figure 2.3.4-1). ATPase mix 
contains final concentrations of 1 mM NADH (Sigma-Aldrich 43420), 1 mM PEP 
(Alfa Aesar B20358) and 1/250 v/v enzyme mix PK/LDH (pyruvate kinase and 
lactic dehydrogenase) (Sigma-Aldrich P0294). Reactions were started in the same 
manner and at the same time as the unwinding reactions. Each reaction 
containing ATPase mix had its separate control without Mg2+/ATP. The turnover 
of NADH was monitored by measuring absorbance at 340 nm during the same 








Figure 2.3.4-1 Dependence of ATP conversion and NADH conversion 
NADH has absorbance at 340 nm, which decreases with NADH conversion. In the ATPase 
NADH coupled assay ATP hydrolysis is coupled with oxidation of NADH, therefore 
decrease in absorbance at 340 nm can be used for ATPase measurements.  
 
Obtained data were analysed in GraphPad Prism (versions 7.0 – 9.2). The raw 
absorbance data (see example Figure 2.3.4-2) were converted to the 
concentration of NADH using machine and plate specific ε of 0.62 mM for Thermo 
Scientific plates and 1.22 mM for Corning plates. Next, the slope in the linear 
region between 1000 and 3600 s was measured (Equation 2.3.3.2-1). The 
ATPase was calculated using Equation 2.3.4-1 for each individual condition. 
 
 
Figure 2.3.4-2 Example of raw ATPase data 
Change in Abs at 340 nm for selected protein concentrations, with ATP (left) and 





Equation 2.3.4-1 Calculation used for determination of ATPase activity 
𝐴𝑇𝑃𝑎𝑠𝑒 =  −(𝑠𝑙𝑜𝑝𝑒+𝐴𝑇𝑃 − 𝑠𝑙𝑜𝑝𝑒−𝐴𝑇𝑃) 
Slope calculated from line fitting 
 
2.3.5. Small-angle X-ray scattering  
 
Small-angle X-ray scattering (SAXS) experiments were performed to obtain 
structural information about protein-RNA complexes in solution. From a SAXS 
experiment information about size, shape, flexibility, and aggregation of the 
complex can be obtained.  
All samples were prepared in the binding buffer (20 mM HEPES pH 7.5, 100 mM 
KCl, 2 mM MgCl2, 1 mM DTT) and preincubated for an hour, to allow for 
complexes formation. Sample containing free protein was diluted to final 
concentration of 100 µM eIF4A2 in 100 µL of binding buffer. Sample containing 
ATP-bound state was prepared in the manner as the free protein supplemented 
with 1 mM AMPPNP (non-hydrolysable ATP analogue). Samples containing RNA, 
were also prepared in the binding buffer, containing 1 mM AMP-PNP, with final 
ratio of RNA to protein of 1:1 and 1:3 for monomeric, and oligomeric conditions, 
respectively. The concentration of RNA varied, while the concentration of 
protein was kept at ~ 100 µM. RNAs used in SAXS experiments are presented in 
Table 2.3.5-1. Subsequently the samples were snap frozen in liquid nitrogen and 
shipped on dry ice together with 50 mL of 10 x concentrated binding buffer to 
Diamond Light Source (DLS) in Oxford, UK. At DLS samples were run on size 
exclusion column Superdex 200 increase 3.2 coupled with X-ray radiation (SEC-
SAXS) on B21 beamline. 620 frames were collected for each sample. The 
collected data were analysed with the use of Scatter IV and ATSAS 3.0.3 package 







Table 2.3.5-1 Unlabelled RNA oligos used in SAXS studies  
RNA name RNA sequence 
(AG)10 AGAGAGAGAGAGAGAGAGAG 
(CAA)6CA  CAACAACAACAACAACAACA 
(AG)1024BP 
AGAGAGAGAGAGAGAGAGAGGUUUUUUAAUUUUUUAAUUUUUUC                                                   
CUUUUUUAAUUUUUUAAUUUUUUG 
(AG)524BP 
AGAGAGAGAGGAAAAAAUUAAAAAAUUAAAAAAC    
                           CUUUUUUAAUUUUUUAAUUUUUUG 
 
(CAA)6CA24BP 
CAACAACAACAACAACAACAGAAAAAAUUAAAAAAUUAAAAAAC                                                            
CUUUUUUAAUUUUUUAAUUUUUUG 
 
Unlabelled RNAs ordered from IDT. RNAs were ordered either as single-stranded or as double-
stranded. The double stranded regions are indicated in bold.  
The obtained data represent the intensities of the scattered X-rays after the 
beam hits the sample. Scattering Intensity (I) was collected for both the 
complexes and the buffer. First, scattering intensity of the buffer was 
subtracted from the protein scattering intensity. Scattering intensity, I, is 
represented as a function with scattering vector q. Next, frames corresponding 
to the peak with eluted protein and most constant radius of gyration (Rg) were 
selected. Rg represents the distance from the centre of gravity of the molecule, 
in this case protein or protein complex. Radius of gyration changes upon protein 
folding, conformational change, or formation of a complex. Generally, 10 % 
difference in radius of gyration for small proteins (~50 kDa) is considered a 
significant change. Next, the Guinier region (region at low q values, close to 0 
scattering angle) was analysed (Guinier, Fournet and Yudowitch, 1955; Putnam 
et al., 2007; Behrens et al., 2012; Kachala, M., Valentini, E. and Svergun, 2015; 
Kikhney and Svergun, 2015). In the Guinier region a linear region was 
determined at the q*Rg limit of 1.3. For this only the very first few points at the 
starting q2 value were removed (Kachala, M., Valentini, E. and Svergun, 2015). 
The fit in the Guinier region provides information about sample aggregation 
(Figure 2.3.5-1, panel A), in this case no aggregation in the collected samples 
was observed. From this analysis information about both the Rg as well as I(0), 
intensity at 0 scattering angle can be extracted. After determination of Rg 
different samples were compared in the dimensionless Kratky plot. Here, based 
on the shape of the curve and changes between the samples information about 
the proteins folded state, globularity or existence of multiple domains was 
derived (Figure 2.3.5-1, panel B). Next, flexibility analysis was performed in by 
searching for plateau in one of the three plots: Porod-Debye, Kratky-Debye, or 
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SIBYLS plot. Here, the flexibility of the protein is determined based on the plot 
in which plateau was reached first (Rambo and Tainer, 2011; Brosey and Tainer, 
2019). Proteins which reach plateau first in the Porod-Debye plot are considered 
to be rigid, proteins with plateau in Kratky-Debye are disordered, and the ones 
with plateau in SIBYLS plot are characterised as being flexible and often 
multidomain. After flexibility analysis pair distance distribution P(r) was 
analysed, which provides information about the real dimension, (maximum 











Figure 2.3.5-1 Example of SAXS data evaluation 
Representative examples of protein behaviour in SAXS experiment and the 
interpretation of data. Figures created in Inkscape 1.1 and based on Putnam et al., 
2007. I – intensity, q – scattering vector, r – radius, P(r) – pair distance distribution.  
A. Interpretation of log10 intensity plots in the low q region (Guinier region). Sample 
that follows a linear trend is not aggregated (left), sample that skews out of the 
linear region is aggregated (middle), sample that skews from the linear fit at the 
lowest q value (right) might be ameliorated by changing the conditions (for 
example protein concentration or buffer). In case on the right if aggregation is 
very small, sometimes data can be clipped and processed further (Putnam et al., 
2007).   
B. Example of a Kratky plot for proteins that are globular (burgundy), multidomain 
(blue), partially folded or partially flexible (orange), or unfolded (yellow). 
C. Example of pair distance distribution function (P(r)) for proteins that are 
globular (burgundy), multidomain (blue) or unfolded (yellow). The P(r) provides 
information about protein’s dmax (maximum distance). Here, in the Scatter IV dmax 
was determined by analysis of the curve, and the Chi-square score for the 
possible dmax calculated, the lower the score, the better dnax value fits the data. 
Notice the smooth end of the globular and multidomain proteins versus the sharp 





After these analyses dummy atom envelope models were calculated that 
corresponded to the shape and size of molecules. Briefly, the data from previous 
analyses are read by the DAMMIF package from ATSAS 3.0.3 (Franke and Svergun, 
2009; Manalastas-Cantos et al., 2021).  The DAMMIF program was set to run 17 
possible iterations of data interpretation, which resulted in creation of 17 .pdb 
files. Then programs from DAMAVER (Volkov and Svergun, 2003) package were 
executed. DAMSEL was used to compare all 17 models and determine the most 
probable model and find the outliers. DAMSEL also provides information about 
resolution (Tuukkanen, Kleywegt and Svergun, 2016), all resolved envelopes had 
a resolution around 40 Å. Next, DAMSUP was used to align the models with the 
most probable one. Then, DAMAVER averaged the aligned models and provided 
information about probability of fit. DAMFILT filtered the average model and 
generated the most representative envelope. This processes can be repeated for 
refinement. Additionally, obtained envelopes were superposed using SUBCOMB 
package from ATSAS 3.0.3.  
 
2.3.6. Deadenylation assay  
 
Deadenylation assay is an assay that allows for visualisation of deadenylation 
activity of proteins by using labelled RNA substrates (Table 2.3.6-1), which can 
be visualised on a gel. Removal of the polyA tail can be seen as a migration of 
the RNA substrate on a gel similar to the migration of the deadenylated marker.  
 
Table 2.3.6-1 RNAs used for deadenylation assay 















Here, the helicases and CNOT1 constructs were mixed at 3 µM each, with 1 µM 
deadenylation RNA substrate and 1 mM AMP-PNP in the binding buffer (20 mM 
HEPES pH 7.5, 100 mM KCl, 1 mM MgCl2, 1 mM DTT) and pre-incubated for 1 h at 
RT. In case of reaction without a helicase (or both helicase and CNOT1 
construct) an amount of protein storage buffer (buffer F, see purification 
Chapter 2.2.2) corresponding to the volume of a protein was added. After 1 h 
pre-incubation an aliquot (5 µL) of the reaction mix was taken and mixed in 1 to 
1 ratio with stop solution (0.5 x TBE, 10 mM EDTA, 0.2 % w/v SDS, 85 % v/v 
formamide) – timepoint 0 min. After taking an aliquot, 0.5 µM CNOT7 
deadenylase was added to reaction and 5 µL aliquots were taken at time points 
20 min, 40 min and 60 min and mixed immediately with 5 µL stop solution. 
Samples were then heated at 95°C for 2 min and loaded on an acrylamide-8M-
urea TBE gels (see below for gel details). After electrophoresis gels were 
scanned immediately using Licor Odyssey (channel 700 for deadenylation marker 
and channel 800 for deadenylation substrate).  
The 20% gels were assembled from SequaGel UreaGel Sequencing System 
(Scientific laboratory supplies NAT1138) by mixing 4 volumes of Concentrate 
with 0.5 volume of Diluent and 0.5 volume of Buffer. After polymerisation gels 
were pre-warmed by running in 0.5 x TBE at 400 V (~40 W) for at least 1 h. 
Temperature of the gel was assessed by reading from a temperature indicating 
strip (Bio-Rad) attached to the glass plate of a gel above the buffer line in the 
electrophoresis tank. After loading the samples gels were run at 400 V for 45 
min.  
 
2.3.7. Recombinant protein immunoprecipitation 
 
Recombinant protein immunoprecipitations (IP) were used to examine 
interactions between CNOT1 protein constructs and the helicases. In an IP a 
mounted antibody binds to the protein and any other proteins that interact with 
the protein of interest stay bound with it.  
All IP and beads coating steps were done in Protein LoBind Tubes (Eppendorf 
0030108116 and 0030108094). First, 50 µL of Dynabeads Protein G (Invitrogen 
10004D) superparamagnetic beads per IP were washed three times in binding 
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buffer supplemented with 0.1% v/v IGEPAL CA-630 (Sigma-Aldrich I3021). IGEPAL 
CA-630 is a non-ionic and non-denaturating detergent, which here reduces 
nonspecific binding. Magnetic rack was used to remove liquid without aspirating 
the magnetic beads. After the washes the beads were coated with anti-IgG 
(control), anti-eIF4A2, or anti-DDX6 antibodies (see Table 2.4.6-1 for details 
about antibodies) by incubating the beads with antibodies in binding buffer with 
IGEPAL CA-630 for 10 min at RT with gentle rotation. After incubation, excess of 
unbound antibodies was washed off (three washes). Next, the protein reactions 
(Table 2.3.7-1) were added to the beads and incubated for 15 min at RT with 
gentle rotation. After incubation beads were washed four times with buffer with 
IGEPAL CA-630 to reduce unspecific binding of proteins. Next beads were mixed 
with 3 times diluted SDS loading buffer (see Chapter 2.2.1 for loading buffer 
details). Next samples were heated to 95°C for 5 min and subjected to SDS-PAGE 
(pre-cast gels used: Invitrogen NuPAGE 4 – 12 % Bis-Tris); Precision Plus Protein 
Dual Color Standards (Bio-Rad 1610374) was used as a marker. Care was taken to 
not aspirate the beads and not load them on a gel. After electrophoresis gels 
were stained with InstantBlue Comassie (Abcam ab119211) and de-stained with 
H2O. Bands were visualised using Licor Odyssey.  
 
Table 2.3.7-1 Reaction assembly for recombinant proteins IP 
Components Final concentration  Volume (µL) 
10 x binding buffer 1 x 22 
(AG)10 RNA (10 µM) 0 /1 µM 0 / 22 
helicase (50 µM) 5 µM 22 
H2O RNAse free  up to 220 µL total reaction volume 
AMP-PNP / ADP + Pi / AMP (10 µM) 0 / 1 µM   0/ 22 
interaction partner 1 (50 µM) 5 µM 22 
interaction partner 2 (50 µM) 0 / 5 µM 0 / 22 
Each reaction was prepared in 220 µL – 100 µL per IP and 10 µL for input lane (10 µL excess for 
pipetting errors). For components in each lane see figure legends. AMP-PNP (Sigma-Aldrich 





2.4. Cell based methods  
2.4.1. Cell culture  
 
HeLa cells were purchased from ATCC and additionally authenticated by the 
Beatson Institute of Molecular Technology Service using Promega GenePrint 10. 
Additionally, cells were tested for mycoplasma on a regular basis. No 
mycoplasma contamination was detected.  
HeLa cells were cultured in DMEM (Gibco, 21969035), supplemented with 10 % 
v/v FBS (Gibco 10270-106) and 2 mM final concentration of L-glutamine (Gibco 
25030024), and passaged when cells reached around 90% confluency. For 
detaching the cells, for passaging and seeding, trypsin (Gibco 15090046) was 
used. Stock aliquots of early cell passages were frozen in 90% v/v FBS and 10% 
v/v DMEM and stored in liquid nitrogen. Cells were kept in tissue culture 
incubator with settings: 37°C, 5% CO2. All reagents were warmed up to 37°C (or 
RT in case of transfection reagent) before applying to the cells.  
 
2.4.2. Plasmid transfection 
 
HeLa cells were transfected with:  
• 1 µg of plasmid, or 1 µg of each plasmid in case of co-transfection for 
FLIM-FRET assays, and Wester Blots – per 35 mm dish,  
• 6 µg of plasmid, or 6 µg of each plasmid in case of co-transfection for IPs – 
per 15 cm dish, 
using GeneJammer (Agilent 204131) at a reagent (in µL) to plasmid (in µg) ratio 
of 3 to 1, according to the manufacturer’s guidelines. Briefly, HeLa cells were 
seeded with cell density of ~120,000 cells per 35 mm sterile dish with glass 
bottom (MatTek P35G-1.5-20-C), or ~5 million cells per 15 cm sterile dish. After 
24 h post seeding, the media were exchanged, and transfection protocol was 
followed. Pre-warmed reagents were mixed as follows for 35 mm dish (A) and 15 
cm dish (B).  
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A. 3 µL of GeneJammer were mixed with 97 µL of DMEM (without FBS or 
L-glutamine) and incubated for 5 min at RT; subsequently the 
appropriate amount of plasmid diluted in 10 µL sterile H2O was added.  
B. 18 µL of GeneJammer were mixed with 582 µL of DMEM (without FBS 
or L-glutamine) and incubated for 5 min at RT; subsequently the 
appropriate amount of plasmid diluted in 60 µL sterile H2O was added.  
After 40 min incubation the transfection mixture was added dropwise onto the 
pre-plated cells. 48 h post transfection media were exchanged, and cells were 
used for further assays.  
 
2.4.3. Protein extraction  
 
Protein extraction differed depending on whether samples were subsequently 
used only for Western Blot (WB) analysis (A) or for immunoprecipitation followed 
with WB (B).  
A. Transfected HeLa cells and untransfected controls were detached from 
the 35 mm dishes using trypsin and transferred to 1.5 mL tubes. Next the 
cells were washed twice in ice cold PBS with centrifugation steps (0.8 rpm 
for 5 min in Eppendorf MiniSpin plus) to remove PBS. Subsequently cell 
pellet was either frozen in dry ice / ethanol and stored at -80°C for 
further processing or immediately used. To lyse cells 100 µL RIPA buffer 
(50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100 (Sigma-Aldrich X100), 
0.5 % sodium deoxycholate (Sigma-Aldrich, D6750), 0.1 % SDS), 
supplemented with 5 mM DTT, 0.5 mM PMSF, 5 mM NaF and Protease 
Inhibitor cocktail (Roche 11873580001, from a made stock to final 
concentration 1x) was used per sample. Cells were incubated on ice for 20 
min and subsequently sonicated in an ultrasonic bath (Diagenode 
Bioruptor CD-200TM-EX) for 10 min at medium setting. Lysed cells were 
centrifugated at 13 300 rpm for 10 min at 4°C in an Thermo Scientific 
Fresco 17 centrifuge. Supernatant from centrifugation (containing soluble 
material, i.e., proteins) was used for subsequent analysis.  
B. Transfected HeLa cells and untransfected controls were scraped from 15 
cm dishes in total 12 mL ice-cold PBS using cell scrapers, transferred to 50 
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mL conical tubes and centrifugated for 5 min at 4°C at 1500 rpm in 
Eppendorf 5810R centrifuge (swing bucket rotor A-4-62). Pellet was 
resuspended in 1 mL of ice-cold PBS and transferred to 1.5 mL tubes and 
centrifugated at 2000 rpm for 5 min at 4°C in Thermo Scientific Fresco 17 
centrifuge (75003424 rotor). Next each sample of cell pellet was 
resuspended in 1 mL of lysis buffer (20 mM Tris pH 7.5, 200 mM NaCl, 2.5 
mM MgCl2, 0.5 % Triton-X100) supplemented with 1 mM DTT, 5 mM NaF, 1 
x Roche Inhibitor cocktail (from a stock). Each sample was then split into 
2 tubes containing 0.5 mL lysis buffer/cell mixture and either 2 µL of 
RNAse inhibitor (RiboLock, 40 U/µL, Thermo Scientific EO0381) or 10 µL of 
RNAse 1 (100 U/µL, Invitrogen AM2295) was added to the samples. 
Samples treated with RiboLock were incubated on ice and samples 
treated with RNAse 1 were incubated at RT. Total incubation time for 
both was 20 min. At this point 50 µL from each sample was taken for RNA 
analysis (see Chapter 2.4.4). Next, the cell lysates were centrifugated for 
15 min at 5000 rpm at 4°C in Thermo Scientific Fresco 17 centrifuge. 
Supernatant was used for subsequent analysis.    
Protein concentrations were determined using Bio-Rad Protein Assay (#5000006), 
based on Bradford assay, and following manufacturer’s guidelines. Briefly, 970 
µL of the diluted reagent (5 x concentrated stock) was added to a 10 times 
diluted protein sample of total volume 30 µL in a cuvette. Equal volume of BSA 
with known concentrations (0, 20, 50, 70, 100, 300, 500, 700, 1000 µg/mL) was 
used to establish protein concentration in the samples. After 5 min incubation, 
absorbance of all the samples and controls was measured at 595 nm.  
 
2.4.4. RNA integrity analysis 
 
For the control of RNA stability and digestion in the IP samples 50 µL of each 
sample after RNAse / RNAse inhibitor treatment was subjected to RNA extraction 
using RNeasy Mini Kit (Qiagen 74104). The concentration of eluted RNA was 
measured using Nanodrop (Thermo Scientific ND-ONE-W). Subsequently 500 ng of 
RNA from each sample was resolved on 1.2% w/v agarose (Melford 9012-36-6) gel 
with SYBR Safe DNA gel stain (Thermo Fisher Scientific S33102) in TAE buffer for 
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35 min at 200 V. The RNA on the gels was exposed using ChemiDoc (Bio-Rad 
1708370). Integrity of RNA was assessed based on visibility of 28 and 18S rRNA.   
2.4.5. Immunoprecipitations  
 
Similarly, as for recombinant proteins immunoprecipitations (Chapter 2.3.7)  
Dynabeads Protein G (Invitrogen 10004D) were washed three times (using 
magnetic rack to avoid bead aspiration) in IP lysis buffer (see Chapter 2.4.3) 
supplemented with 10 % w/v BSA. Again, all the steps were performed in 
LoBinding tubes and 18 µL of Dynabeads per IP was used. Next, 4 µg of 
appropriate antibody (Table 2.4.6-1) diluted in 200 µL of lysis buffer (containing 
BSA) was added to the Dynabeads and incubated for 1 to 2.5 h at 4°C with gentle 
rotation. After incubation time lapsed unbound antibodies were removed by 
washing the beads three times in lysis buffer (without BSA). Next, the equal 
protein concentration of each sample (in equal volume, samples of different 
concentrations were diluted in lysis buffer to match) was added to the beads 
and incubated for 30 min at 4°C with gentle rotation. Next, the supernatant 
containing unbound proteins was discarded and beads were washed three times 
in 600 µL per wash of lysis buffer. The final wash was removed and 50 µL of 3 
times diluted SDS-PAGE loading buffer was added (see Chapter 2.2.1 for 
components of loading buffer). Samples were heated to 95°C for 5 minutes and 
subjected to SDS-PAGE electrophoresis, again care was taken to avoid aspiration 
of the beads. Pre-cast gels were used, either NuPAGE 4 – 12 % Bis-Tris 
(Invitrogen) or Criterion 4-15 % (Bio-Rad #5671084), and Precision Plus Protein  









2.4.6. Western blotting  
 
Western blotting (WB) was performed to visualise results from 
immunoprecipitations as well as to test the transfection efficiency (HeLa cells 
treated with RIPA buffer).  
First the SDS-PAGE was performed (as described for IP Chapter 2.4.5, similarly 
RIPA extracted lysates were run on NuPAGE gels). Next, a wet transfer from the 
gels onto 0.45 µm nitrocellulose membranes (Amersham Protran, Cytvia GE106 
00002) was performed in a pre-chilled transfer buffer (50 mM Tris pH 8.3, 192 
mM glycine, 20 % methanol, 1 % SDS) for 1 h 15 min with settings 100 V / 0.8 A. 
Transfer quality was checked by staining the membranes with Ponceau S solution 
(Sigma-Aldrich P7170) for 5 min after which the stain was washed off with H2O. 
The membranes were blocked in 5 % w/v milk (Marvel) in TBST (supplied by the 
Beatson Institute Central Services) for 30 to 60 min at RT while gently nutating. 
Next, the blocking solution was decanted, and membranes were washed in TBST. 
Subsequently primary antibodies (directed against epitopes of proteins of 
interest; Table 2.4.6-1) were diluted in blocking solution and applied to 
membranes. Membranes were incubated with antibodies, while gently nutating, 
for 1 h at RT or 4°C (only anti-eIF4A1/2 and anti-GFP antibodies could be used 
for 1 h RT incubation). Next, the membranes were washed five times in TBST (2 
quick rinses, and 3 longer ~10 min washes) and incubated with secondary 
antibody (directed against an epitope on primary antibody, secondary antibodies 
are directed against host species of primary antibody), while nutating. After 
incubation the membranes were washed again in TBST (5 washes as above), and 
the results were visualised using LI-COR Odyssey (with 700 and 800 channels).  
Anti-GFP antibody was used for detection of mTurqoise2 and mCitrine due to 
large similarities of epitopes (in general, 227 out of 238 amino acids matched for 







Table 2.4.6-1 List of antibodies used in this thesis  
Antibody Supplier Cat. No. Host Application Dilution 
eIF4A1 Abcam 
 
ab31217 rabbit WB 1:2000 WB 
eIF4A1 Abcam 
 
ab31217 rabbit IP 4 µg per cell IP 
eIF4A2 Abcam ab31218 rabbit IP 4 µg per cell IP  
eIF4A2 Abcam ab31218 rabbit IP 5 µg per in vitro IP 
eIF4A2 Santa Cruz 137148 mouse WB 1:1000 
GFP Abcam ab290 rabbit IP 4 µg per cell IP 
GFP Abcam ab6556 rabbit IP 4 µg per cell IP 
GFP Abcam ab6556 rabbit WB 1:5000 WB 
GFP Abcam ab13970 chicken WB 1:5000 
eIF4G1 CST 2498 rabbit WB 1:1000 
eIF4G2 CST 5169 rabbit WB 1:1000 
PDCD4 Abcam ab51495 rabbit WB 1:2000 
DDX6 Abcam ab70455 rabbit IP 5 µg per in vitro IP 
Vinculin Abcam ab12900
2 
rabbit WB 1:10000 
IgG CST 2729 rabbit IP 4 µg per cell IP 







































































Fluorescence lifetime imaging microscopy – fluorescence (Förster) resonance 
energy transfer (FLIM-FRET) was used to assess protein-protein interactions in 
live cells.  
Measurements were performed using Nikon TE2000 microscope (60 x 
magnification) with the Lambert Instruments Fluorescence Attachment system 
equipped for FLIM frequency domain method. Briefly, to use the frequency 
domain the system has to be equipped in a modulated light source and a 
modulated detector. Then the sample (and reference) can be excited with light 
that is modulated in intensity, which causes the fluorescence emission to be 
intensity-modulated. As the emission decays the emitted light displays a phase-
shift (time delay) and a decrease in modulation-depth (in reference to excitation 
light). Both the phase shift and the decrease in modulation depth are directly 
contingent on the decay constants of the fluorophore (fluorescence lifetime) as 
well as on the modulation frequency. As those parameters depend also on the 
fluorophore decay constants with each measurement a reference of a known 
fluorescence lifetime needs to be used (Figure 2.4.7-1). For experiments 
contained in this thesis 10 µM fluorescein (in Tris, pH above 11) was used 
(provided by the Beatson Institute Advance Imaging Resource), with a known 







Figure 2.4.7-1 Frequency domain FLIM  
A schematic of phase shift observed between a reference of a known fluorescence 
lifetime and the sample, as well as the observed decrease modulation depth. Schematic 
based on (Lambert Instruments ).  
 
To perform a FLIM-FRET experiment a good pair of spectrally overlapping 
fluorophores needs to be chosen. For experiments used in this thesis 
mTurquoise2 was chosen as a donor (ex 437, em 474) and mCitrine as an 
acceptor (ex 516, em 529) (Figure 2.4.7-2).  
 
 
Figure 2.4.7-2 Overlapping spectra of mTurquoise2 and mCitrine 
Excitation spectrum (ex) of mTurqoise2 show in blue, with emission (em) in light blue, 
ex of mCitrine show in light green, and its excitation in yellow. Overlap of mTurqoise2 
emission and mCitrine excitation is show with stripe pattern. Figure created using 




48 h post-transfection (as described in Chapter 2.4.2) cells were subjected to 
FLIM-FRET experiment. Each sample (as well as the reference) were excited with 
LED light source at 445 nm (bandwidth 20 nm). Per each dish (dishes in technical 
duplicate) 3 to 4 regions were chosen and imaged. For total amount of cells 
measured for each experiment refer to figure legends. The information about 
the fluorescence lifetime of individual cells was extracted using LI-FLIM software 
(version 1.2.12.30; Lambert Instruments), which automatically calculated the 
phase shift and decrease in modulation depth of selected region and compared it 
to the reference. From each image, selected regions corresponded to different 
cells (one large region per cell). Next, images were exported in a cyan-magenta 
lifetime scale (setting the limits of fluorescence lifetime from 3.6 to 3.9 ns). The 
collected data from each individual image was exported as a .csv file. As that 
created a large (hundreds) number of files, lifetime values from individual 
experiments were combined in one .csv file and analysed using R. For statistical 


















3. Characterisation of eIF4A2 
3.1. Chapter introduction 
 
Translation dysregulation is a common feature of tumourigenesis (Bhat et al., 
2015) with cancer cells adjusting to the cellular environment and enhancing 
their growth by increasing the production of pro-survival proteins (see also 
Chapter 1.4). Many mRNAs of pro-oncogenes are characterised by highly 
structured 5’ untranslated regions (5’UTRs) (Wolfe et al., 2014). As many mRNA 
structures in the 5’UTR are inhibitory to translation (Pelletier and Sonenberg, 
1985; Taliaferro et al., 2016; Leppek, Das and Barna, 2018), and the translation 
initiation is the most rate limiting step of protein synthesis (Shah et al., 2013; 
Alekhina et al., 2020), the expression of oncogenes is especially dependent on 
proteins which can resolve these structures, including helicases (Chapter 1.5). 
One of the helicases that has been shown to play a role in cancer development 
and progression is eIF4A1 (Liang et al., 2014; Modelska et al., 2015; Gao et al., 
2020). eIF4A1 is a part of the heterotrimeric eukaryotic translation initiation 
complex 4F (eIF4F), responsible for cap-dependent translation initiation. eIF4F 
comprises the mRNA cap-binding protein eIF4E, the scaffold protein eIF4G and 
the DEAD-box helicase eIF4A1 (Grifo et al., 1983). Recent studies have shown 
that eIF4A1 acts both as a helicase to unwind secondary structure within the 
5’UTR of the mRNA and as an ATP-dependent protein that facilitates mRNA 
loading onto the ribosomes (Sokabe and Fraser, 2017; Yourik et al., 2017). This 
dual role of the eIF4A1 and its involvement in tumourigenesis makes it an ideal 
target for anti-cancer therapies. Indeed, there is a growing search for eIF4A1 
inhibitors. Currently, the available inhibitors are being tested in vitro and in 
pre-clinical studies, showing promising results (Jin et al., 2013; Cunningham, 
Chapman and Schatz, 2018; Chu et al., 2019; K. Chan et al., 2019; Zhang et al., 
2019; Naineni et al., 2020). However, the efficacy of eIF4A1 inhibition could be 
compromised by presence of highly similar eIF4A1 paralogue, eIF4A2. 
Intriguingly, the existing inhibitors lack specificity towards one paralogue. 
However this has been largely overlooked with only a few instances where the  
influence of the inhibitors on both paralogues was examined (Bordeleau et al., 
2005; Cunningham, Chapman and Schatz, 2018; Chu et al., 2019).  
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The high similarity between the eIF4A paralogues (90 % of amino acid sequence 
identity) has led many researchers to believe that they are functionally 
redundant. Surprisingly, recent discoveries, demonstrated eIF4A2 to have an 
opposing translational function to eIF4A1 (Meijer et al., 2013, 2019; Wilczynska 
et al., 2019). eIF4A2 assembles with the Ccr4-Not complex and is involved in 
miRNA-mediated translational repression, executed at the stage of translational 
initiation (Meijer et al., 2013). Moreover, the paralogues are associated with 
different states of the cell, i.e., eIF4A1 being associated with a proliferative 
state of the cell and eIF4A2 with a differentiated one (Galicia-Vazquez et al., 
2014). Additionally, high expression of eIF4A1 (Modelska et al., 2015) and low 
expression of eIF4A2 (Shaoyan et al., 2013) has been associated with poor cancer 
patient prognosis (see also Table 1.5.1-1), further emphasising the requirement 
to find inhibitors targeting one paralogue without affecting the other.   
In contrast to the studies describing repressive function of eIF4A2, there have 
been a few recent reports linking eIF4A2 overexpression in colorectal and 
oesophageal cancers with poor cancer patients prognosis (Chen et al., 2019; Liu 
et al., 2019; Lyu et al., 2020). This may suggest that eIF4A2 performs a dual 
role, depending on the type of cancer, or the complex it is in, as a suppressor of 
translation in some events and as a protein that promotes tumourigenesis, 
calling for further investigation of the two paralogues.  
While structural information of eIF4A1 alone (Schütz et al., 2010; Iwasaki et al., 
2019; Jiang et al., 2019) and in complex with its interacting partners (LaRonde-
LeBlanc et al., 2006; Schutz et al., 2008; Chang et al., 2009) have been 
generated, only a single C-terminal domain of eIF4A2 has been resolved (Schütz 
et al., 2010). Considering the ability of paralogues to interact with different co-
factors in cells, understanding the structural differences may hold a key to 
distinguishing the paralogues and their behaviour, while providing an information 
necessary to design inhibitors targeting the right paralogue at the right time.  
As eIF4A2 has for long been considered functionally redundant, and it is believed 
to have low expression in many cell types (Sudo, Takahashi and Nakamura, 1995) 
it has not been studied extensively in the past. The quest to distinguish the 
paralogues, understand their functions, mechanisms of action and target them in 
an appropriate manner where necessary, with reduction of pro-oncogenic 
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activities without inhibiting potential anti-oncogenic ones is still open. 
Therefore, the aims of this PhD project were to elucidate the mechanisms 
governing eIF4A2 to uncover the activities that distinguish it from eIF4A1.  
As it has been shown previously (Wilczynska et al., 2019), eIF4A2 has an inherent 
preference for binding polypurine RNAs. Therefore, pivotal to this project were 
biochemical approaches to uncover how eIF4A2 interacts with different RNA 
substrates, how it performs its helicase activity and what influences its ATPase 
activity.  
The heterologously produced eIF4A2’s binding capacity to different RNA 
sequences was examined, using biochemical and biophysical techniques such as 
electrophoretic mobility shift assay (EMSA) (Fried and Crothers, 1981; Garner 
and Revzin, 1981), analytical size exclusion chromatography (aSEC) (Lathe and 
Ruthven, 1955; Eisenstein, 2006), and fluorescence anisotropy (Albrecht, 1961; 
Lea and Simeonov, 2011). In an EMSA a fluorescently labelled RNA is used to 
form complexes with the protein of interest, and subsequently visualised on a 
native polyacrylamide gel (see also Chapter 2.3.1.1). The separation on a native 
gel is based on the electric charge of the molecules involved in the reaction, as 
well as their size and shape. A negatively charged free RNA will migrate to the 
bottom of the gel, whereas a protein bound one, due to the positive charge of 
the protein, will stay in an upper part of the gel. Alternatively, aSEC allows for 
separation of the molecules based on their size, disregarding the charge of the 
molecules (see also Chapter 2.3.1.2). Additionally, absorbance of the sample 
can be measured, to distinguish RNA and protein parts of the complex. Here, 
bigger molecules elute faster from the chromatography column resin, whereas 
smaller ones are trapped in the pores. The fluorescence anisotropy, or 
fluorescence polarisation, is a solution-based method, used to study molecular 
interactions. It relies on the change exerted on a labelled RNA molecule by 
binding of the protein, where the degree of polarisation of a fluorophore is 
inversely related to its molecular rotation. The molecule rotation is dependent 
on its size. Quantitatively, fluorescence polarisation is the difference in 
fluorescence intensity (emission light) parallel and perpendicular to the 
excitation light plane (see Chapter 2.3.1.3).  
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Pivotal to this chapter was structural characterisation by small-angle X-ray 
scattering (SAXS) of how eIF4A2-RNA complexes are assembled on various RNA 
substrates (see also Chapter 2.3.5). Here, the pre-equilibrated complexes were 
set up with a use of a non-hydrolysable ATP analogue, AMP-PNP, that allows for 
stable eIF4A2-RNA complex formation by inhibiting ATP hydrolysis thus 
prohibiting RNA release. Therefore, the complexes are trapped in an RNA-bound 
state. SAXS allows for measuring complexes in solution, which omits the crystal 
formation, a step necessary for crystallography methods. Additionally, as the 
measurements are done in solution instead of a solid crystal, the obtained 
structure models resemble a more natural, unpacked state. SAXS does not 
provide atomic resolution, however the easiness of sample preparation is a great 
benefit as it allows for rapid detection of various complexes. Moreover, the 
resolved SAXS structure models are of high enough resolution to distinguish 
conformational changes between differently formed complexes.  
Furthermore, advanced imaging approaches were utilised to establish eIF4A2 
behaviour in live cells. In fluorescence lifetime imaging microscopy – 
fluorescence resonance energy transfer (FLIM-FRET) (Bastiaens and Squire, 1999) 
live cells are transfected with two variants of a protein of interest, one tagged 
with a donor and the other one with the acceptor, that together form a FRET 
pair (see also Chapter 2.4.7). For this the excitation of an acceptor molecule 
has to overlap with the emission spectrum of the donor (Bajar et al., 2016) (see 
also Figure 2.4.7-2). Additionally, it is important that the donor fluorophore 
chosen for FLIM-FRET has a high quantum yield (QY), defined as a ratio of the 
number of photons emitted to the ones absorbed (Lakowicz, 2006, p.10). In this 
project, mTurquoise2 with a QY = 0.93 (Bajar et al., 2016) was used. Moreover, 
it is vital that the fluorophores exist in the monomeric state, as the 
oligomerisation of the fluorophores can mask real interactions happening in the 
cells.  
Finally, unwinding and ATPase assays were performed in vitro to further 
understand the enzymatic activities of eIF4A2. For this various RNA substrates 
containing double-stranded region were used following established protocols 
(Özeş et al., 2014). Briefly, RNA unwinding was measured by monitoring the 
change in fluorescence over time of the reaction, in which ongoing strand 
separation correlated with de-quenching of the substrate (see also Chapter 
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2.3.3). These measurements provide quantitative value of velocity of unwinding 
(fraction unwound per second), measured as the linear region in the first few 
timepoints (200 s) of a reaction, as well as fraction unwound (change between 
the starting and end value normalised to the reference) that can be compared 
for different RNA substrates. ATP-turnover (ATPase) was measured UV-
spectroscopically by monitoring the ATP-dependent conversion of NADH to NAD+ 
at 340 nm in an enzyme-coupled reaction. For this, unwinding reactions were 
supplemented with ATPase mix (see also Chapter 2.3.4).  
In all, this chapter, provides an extensive characterisation of eIF4A2 DEAD-box 




3.2. eIF4A2 purification 
 
As molecular activities of eIF4A2 have not previously been described in great 
detail, in vitro characterisation of its function was necessary. To study the 
enzymatic activity of eIF4A2, a previously cloned full length eIF4A2 construct 
(pET-SUMO-eIF4A2, performed by Dr Tobias Schmidt) containing a His-SUMO tag 
was expressed in E. coli strain BL21 DE3 RP codon+. The bacterial pellet after 
lysis, centrifugation and filtration of the supernatant (see Chapter 2.2.2) was 
subjected to the affinity chromatography, where the lysate was applied on a Ni2+ 
column and eluted in a linear imidazole gradient (Figure 3.2-1, panel A). Flow-
through from the column and the wash contained unbound proteins. His-SUMO 
tagged eIF4A2 eluted from the column in a linear imidazole gradient and was 
subsequently treated with ULP1 (ubiquitin like protease 1) to cleave off the His-
SUMO tag. After the cleavage eIF4A2 was subjected to ion exchange 
chromatography (Figure 3.2-1, panel B, left). As eIF4A2 (pI = 5.33) is negatively 
charged in pH = 7.5 it bound to anion exchange column (ResourceQ) and was 
eluted from the column in a linear gradient of increasing potassium chloride 
concentration. Fractions of interest were visualised using SDS-PAGE (Figure 
3.2-1, panel B, right) and chosen for the next purification step. The final step 
comprised size exclusion chromatography (Figure 3.2-1, panel C) followed by 
protein concentration. The final product of purification was analysed by SDS-
PAGE (Figure 3.2-1, panel D). Purity of the protein was determined, and no 
detectable protein contaminants were visible in the gel. Additionally, 
absorbance spectrum from 230 to 350 nm was measured (Figure 3.2-1, panel E). 
A clear peak at 280 nm and the 260/280 ratio of below 0.6 (0.55) indicated 
absence of nucleic acid contamination. Together, this indicates that the eIF4A2 







Figure 3.2-1 eIF4A2 3-step purification 
A. Representative chromatogram of an elution profile of His-SUMO tagged eIF4A2 
using a linear imidazole gradient on a 5 mL HisTrap HP column.  
B. Peak fractions pooled from HisTrap HP shown in panel A were subjected to 
cleavage by ULP1 at room temperature for 1 hour and subsequently loaded on a 
6 mL ResourceQ anion exchange column. The elution profile in presented 
chromatogram of eIF4A2 eluted in linear potassium chloride gradient shows signs 
of peak tailing (marked by a red arrow). Fractions were collected and 
subsequently run on SDS-PAGE (shown on the right). Pooled fractions (marked on 
the gel) were run on size exclusion chromatography column. Numbers on the left 
side of the gel represent the kDa sizes of the protein marker. The apparent 
aggregation in the wells is caused by high KCl concentration and disappeared 
after buffer change.  
C. Representative size exclusion chromatography elution profile on Superdex S200 
HiLoad 16/600 column. Purified eIF4A2 elutes around 85 mL.  
D. Representative Coomassie stained SDS-PAGE gels of purified, full length, tag 
free, 46 kDa eIF4A2. Numbers on the left indicate sizes of the protein marker.  
E. Representative absorbance spectrum (230 – 350 nm) of 12 times diluted eIF4A2 







3.3. eIF4A2 unwinds secondary structure of RNA  
Many previous reports have focused solely on the enzymatic activities of eIF4A1 
and disregarded the highly identical paralogue eIF4A2 (Grifo et al., 1984; 
Abramson et al., 1987; Rogers, Richter and Merrick, 1999; G. W. Rogers, Lima 
and Merrick, 2001). First, to answer a question about the activity of purified 
eIF4A2, its unwinding activity was scrutinised. In a similar manner to published 
data about eIF4A1 (Rogers, Richter and Merrick, 1999; Özeş et al., 2011) the 
unwinding activity was tested with the protein in excess over the RNA substrate. 
Previous studies revealed a preference of eIF4A to bind single-stranded RNA 
(Rogers, Richter and Merrick, 1999; Andreou, Harms and Klostermeier, 2019). 
Thus, the RNA substrate for the unwinding reaction was designed to contain a 
single-stranded overhang (Figure 3.3-1, panel A). Additionally, the substrate 
included a fluorophore labelled double-stranded region (Cy3-reporter) and 
guanidine-rich double-stranded region with a fluorophore quencher (BHQ-
quencher). The choice of the single-stranded RNA sequence (overhang) was 
based on a study, in which the authors performed an RNA bind-n-seq experiment 
to determine eIF4A binding preferences (Iwasaki, Floor and Ingolia, 2016). The 
study suggested that polypurine-rich motifs are preferentially bound by the 
helicase. Therefore, the unwinding activity of eIF4A2 was tested on a double-
stranded substrate containing a polypurine (AG)10 single-stranded 5’overhang 
(Figure 3.3-1, panel B). As expected, an increase of the unwinding activity 
(measured as initial velocity) with increasing eIF4A2 concentration was 
observed. Notably, the obtained result resembled a sigmoidal shape, indicative 
of potential cooperativity. To test this, the Hill equation was fitted to the data. 
The derived Hill coefficient is a measurement of cooperativity in the reaction 
(Hill, 1913; Giraldo, 2008; Prinz, 2010). In a situation without cooperativity in 
the reaction the curve does not follow a sigmoidal trend and the Hill coefficient 
is less or equal to 1. Alternatively, a Hill coefficient above 1 for sigmoidal 
curves, suggests cooperativity in the reaction (Figure 3.3-1, panel C). Indeed, 
the calculated Hill coefficient (2.60 ± 0.31) for eIF4A2 unwinding reaction on the 
(AG)10 5’overhang substrate indicated cooperativity of the protein. As eIF4A2 has 
a single unwinding core (see also Figure 1.5.1-1), the co-operativity points to 
the possibility that more than one eIF4A2 molecule might be needed for 




Figure 3.3-1 eIF4A2 can unwind RNA substrates in a cooperative manner 
A. Schematic of the unwinding substrate consisting of a 20 nt single-stranded 
overhang (loading) RNA region, a double-stranded Cy3-labelled region, and 
double-stranded region labelled with Black Hole Quencher (BHQ).  
B. Unwinding activity of eIF4A2 on an RNA substrate with (AG)10 single-stranded 
region plotted as velocity of the unwinding versus the concentration of the 
helicase. The obtained Hill coefficient for the reaction marked as h, showed in 
the upper left corner, suggests co-operativity in the reaction. Each point n=3, 
with error bars as SEM, fit – Hill equation.  
C. Schematic of plotted velocity of reaction versus titrant concentration. Graph 
shows the change in the shape of a reaction curve where Vmax and K0.5 is the 
same, but the Hill coefficient (labelled as n) varies. Graph created using an 









3.4. eIF4A2 can bind to RNA as a multimeric enzyme 
The observed cooperativity in unwinding (Chapter 3.3), in a situation wherein 
the protein does not have multiple catalytic cores performing the same function, 
could be a sign of a possible co-operation between separate proteins. Such co-
operation can potentially indicate protein multimerisation (Giraldo, 2008, 2013). 
To understand how the cooperativity is exerted and whether it is possible that 
multiple eIF4A2 act on one RNA, the binding of eIF4A2 to single-stranded RNA 
was tested. For this purpose, electrophoretic mobility shift assays (EMSA) were 
employed. This technique allows for a visualisation of pre-formed complexes in a 
native state in a polyacrylamide gel. Upon protein binding, a band shift of a 
labelled RNA is observed, with each subsequent protein molecule binding to the 
RNA seen as further shifts. A series of titrations of eIF4A2 on two different 
single-stranded RNA sequences (selection based on the bind-n-seq experiment 
from Iwasaki, Floor and Ingolia, 2016) (AG)10 and (CAA)6CA labelled with Dy780 
and Dy680 respectively was performed (Figure 3.4-1). With increasing eIF4A2 
concentration multiple shifts were observed, suggesting binding of multiple 
eIF4A2 molecules to the single-stranded RNA and thus potential protein 
oligomerisation. Two sequences promoted oligomer formation to a different 






Figure 3.4-1 eIF4A2 has capacity to bind to a single-stranded RNA both as a 
monomer and oligomer 
Electrophoretic mobility shift assay of increasing concentration of eIF4A2 bound to 
single-stranded RNA, (AG)10 upper panel and (CAA)6CA lower panel. Each incremental 
band shift corresponds to higher-order complex formation. Complexes were pre-
incubated for 1h at room temperature in presence of 1 mM AMP-PNP and subsequently 
run on 7% native polyacrylamide gels, for 50 minutes at 100 V, and visualised using Licor 














3.5. eIF4A2 multimerises in presence of RNA and it is 
dependent on its sequence and length  
 
To further understand how eIF4A2 oligomers are formed, a series of analytical 
gel filtrations were performed. This technique allows for detection of the 
formed complexes and their separation by size. One of the advantages of 
analytical gel filtration over an EMSA is the possibility to detect unlabelled 
proteins and RNA by monitoring the UV-absorbance at 260 nm for RNA and at 280 
nm for protein, as well as at 220 nm to observe peptide bonds. Bigger complexes 
elute faster, with smaller retention volume, whereas smaller molecules, for 
example monomers, are trapped in the resin pores and elute later, in a higher 
retention volume. 
To answer whether eIF4A2 can form oligomers independently of RNA a sample 
containing 16 µM eIF4A2 in the binding buffer (see Chapter 2.3.1) was applied 
to a Superdex 200 increase 3.2/300 column resin. This resulted in a single peak 
eluted at 1.6 mL of retention volume (Figure 3.5-1, panel A, brown A220, 
orange A260). The previously run reference sample of Ovalbumin (45 kDa) 
similarly eluted at 1.6 mL, which suggested that the observed peak of eIF4A2 
contains monomeric protein and that eIF4A2 does not form oligomers without 
presence of RNA. Given that the oligomers observed in the EMSAs (Figure 3.4-1) 
appeared with increasing concentration of eIF4A2, a mixture containing eIF4A2 
(16 µM) in excess over RNA (4 µM) was applied to the resin. Intriguingly, this 
time multiple peaks were recorded on the chromatogram (Figure 3.5-1, panel A, 
A220 red, A260 pink). The previously run as a reference Conalbumin (76 kDa) 
eluted at 1.5 mL, and the free AG-RNA at 2.05 mL. This suggested that eIF4A2, 
based on the peaks’ elution, is capable of forming at least detectable 
monomeric, dimeric, and trimeric complexes. To explore the stoichiometry of 
the formed complexes the molar ratio of protein and RNA in monomeric, 
dimeric, and trimeric peaks was calculated (Figure 3.5-1, panel B). As 
expected, in the monomeric peak there was an excess of protein over RNA, 
which could be explained by contribution of unbound fraction. As eIF4A2 did not 
form multimeric complexes without RNA, the assumption that all the RNA is 
bound in the dimeric and trimeric complexes can be made. As there is a 2.3 – 4-
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fold excess of protein over RNA in those conditions, multiple proteins are 
involved in formation of oligomer on a single RNA. 
In all, this implies that eIF4A2 oligomerisation is dependent on RNA being 
present, and when the helicase is in excess over RNA, which allows for multiple 
proteins oligomerising on a single RNA substrate.  
 
 
Figure 3.5-1 eIF4A2 forms oligomeric complexes only in the presence of RNA  
A. 16 µM of free eIF4A2 (A220 brown, A260 orange) and 16 µM of eIF4A2 in presence of 
4 µM (AG)10 single-stranded AG-RNA (A220 red, A260 pink) run on a Superdex 200 
increase 3.2/300 column. The free helicase eluted as a single – monomeric peak, 
whereas the RNA-bound eIF4A2, formed multiple complexes, corresponding to 
monomeric, dimeric, and trimeric eIF4A2. Note that the observed shift in 
retention volume between RNA free and RNA-containing eIF4A2 sample indicates 
presence of the RNA-bound state of monomeric eIF4A2 in the presence of RNA.  
Trace for eIF4A2-(AG)10 recorded by Dr Tobias Schmidt.  
B. eIF4A2 forms dimers and trimers in excess over RNA. Area under the curve for 
each individual peak (monomer, dimer, and trimer) for the eIF4A2-RNA sample 
from panel A was calculated, using GraphPad Prism. Molar concentrations of 
both protein and RNA in each peak were calculated based on the ratio of areas 
of each peak; with total of 16 µM protein and 4 µM RNA present in all three 
peaks. In the monomer there is a great excess of protein over RNA which 
suggests presence of the unbound fraction. In case of the dimer, there is twice 
as much protein in the sample than RNA, and in the case of trimer at least 3 
proteins are formed on one RNA. The graph on the right is the zoomed in data 





As eIF4A2 oligomerises only in presence of RNA (Figure 3.5-1) and the previously 
tested (AG)10 and (CAA)6CA RNA (Figure 3.4-1) induced oligomerisation to a 
different extent, the propensity to multimerise in presence of different RNA 
sequences was investigated. This time, aSEC was performed on eIF4A2 
complexes formed on adenosine only RNA – (A)20, polypurine RNA containing 
more adenosine nucleotides than guanosine ones – (GAAG)5, RNA without 
adenosines - (GUGCU)4, as well as the previously tested (AG)10 and (CAA)6CA. The 
traces presented in Figure 3.5-2, panel A were recorded by Dr Tobias Schmidt. 
Here, similarly as in Figure 3.5-1 distribution of RNA and protein differed 
(Figure 3.5-2, panel A, A220 left, A260 right). As the protein was in excess over 
RNA (16 µM and 4 µM respectively), the contribution of unbound protein in the 
monomeric fraction was to be expected. As previously, (AG)10 RNA supported 
oligomerisation to the highest extent, with creation of trimeric complexes. 
Trimeric complexes were also detected in the samples with (GAAG)5 and 
(GUGCU)4 RNA.  
Next, the contribution of the monomer (1-mer), dimer (2-mer), and trimer  
(3-mer) was quantified (Figure 3.5-2, panel B) based on the distribution of RNA 
to exclude the influence of unbound protein (Figure 3.5-2, panel A, right). 
Additionally, previously obtained in the Bushell lab dissociation constants (KD) 
for RNAs used in Figure 3.5-2, panel A were compared to the formation of 
oligomers on tested sequences (Figure 3.5-2, panel B). Oligomerisation did not 
follow a trend, where the RNAs with higher KD (lower affinity) would not form 
oligomers. As an example, trimers formed on (GAAG)5 and (GUGCU)4 but did not 
form on (CAA)6CA RNA, regardless of the lower KD in the case of (CAA)6CA.  
As an additional way of visualisation of oligomer formation, eIF4A2-RNA ((AG)10, 
(CAA)6CA, (GUGCU)4, (A)20, (GAAG)5) complexes were scrutinised by an EMSA 
(Figure 3.5-2, panel C). As in an EMSA the detection is dependent on the 
labelled RNA, the detection can depend on the label itself. Moreover, in this 
assay it is not clear how much of an unbound protein is in the sample. However, 
one undeniable advantage of an EMSA is that the samples can be prepared, 
incubated, and visualised at the same time on the same gel. It should be noted 
that the results from both experiments differed (i.e., not detectable dimer for 
(CAA)6CA RNA in these conditions), therefore a detailed validation of the 
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obtained results with use of variety of techniques was applied throughout this 
thesis. Here (Figure 3.5-2, panel C), again, all of the tested RNAs (apart from 
(CAA)6CA) supported dimer formation, however the trimeric complexes were 
only detected on (AG)10 RNA.  
In all, sequence of the RNA is the main determinant of oligomer formation, and 
the collected data suggest that the oligomerisation is independent of affinity. 
Again, the (AG)10 RNA supported oligomerisation to the greatest extent, however 
other sequences supported formation of at least a dimer. Furthermore, 
validation of the results, proved that different techniques have different 












Figure 3.5-2 RNA sequence determines the extent of eIF4A2 oligomerisation 
A. Representative aSEC run on a Superdex 200 increase 3.2/300 column of 16 µM 
eIF4A2 in complex with 4 µM 20 nucleotide single-stranded RNA of the following 
sequences: (AG)10, (CAA)6CA, (GUGCU)4, A20, (GAAG)5. Panel on the left 
corresponds to A220 for protein detection (peptide bonds), panel on the right 
corresponds to A260 for RNA detection.  
Note that the monomeric peak in the A220 is higher than the dimer due to 
contribution of unbound protein.  
Various RNAs promote oligomerisation to a different extent, with (AG)10 having 
the greatest propensity to induce trimer formation.  
B. Quantification of contribution of monomer (1mer), dimer (2mer) and trimer 
(3mer) to the total of formed complexes for each RNA in aSEC experiment from 
A260 panel A (left axis) with dissociation constant (KD) marked for each RNA as a 
red dot (right axis). 
C. Representative EMSA for 1 µM free RNAs used in panel A and RNA-eIF4A2 
complexes (with concentrations of 1 and 5 µM respectively). RNAs used were 
5’FAM labelled, samples were prepared and run in the same manner as in the 





Next, to understand more about the binding interface of eIF4A2 and how the 
oligomers are formed, a series of EMSAs and analytical gel filtrations were 
performed (Figures 3.4-1, 3.5-3, 3.5-4, 3.5-5). RNA substrates of different 
lengths were employed to identify whether the oligomerisation happens through 
multiple proteins binding to the same RNA next to each other or through protein-
protein interactions. Here, in the case of eIF4A2 binding to the RNA substrate 
independently next to each other, the formation of multimeric complexes should 
only be observed on RNAs that provide multiple binding sites. Additionally, the 
KD should remain constant if the full binding site is provided.  
Increasing length of RNA was found to be necessary to support oligomerisation 
(Figures 3.5-3, 3.5-4), with trimeric complexes of eIF4A2 forming only on the 
20 nucleotide AG-RNA stretch (Figure 3.5-4, panel A). However, the measured 
binding affinities towards 10, 15, 20, and 50 nucleotide AG-RNA stretches 
showed an increase in the binding affinity of eIF4A2, i.e., a decrease in KD, on 
AG-RNAs from 10 to 15 nucleotides (Figure 3.5-4, panels B, C). Additionally, as 
shown in one study (Iwasaki et al., 2019) 6 and 8 nucleotide AG-RNA stretch did 
not support binding of eIF4A1, suggesting that increase of the RNA length from 
10 to 15 nucleotide does not provide an additional independent binding site. The 
binding affinity remained the same from 20 to 50 nucleotides, however, the 50 
nucleotide RNA stretch supported binding of up to 6 visible proteins (Figure 
3.5-5, panel A), in turn suggesting possible formation of two trimers. This 
supports a model in which the RNA binding interface increases from 10 to 15 
nucleotides  (Abramson et al., 1987; A. Z Andreou and Klostermeier, 2013), with 
the full binding site allowing for oligomer formation. As the 20 nucleotide AG-
RNA stretch allows for trimer formation, in the case of multiple binding sites, in 
saturating conditions on different RNA sequences (as shown Figure 3.5-2) 
formation of trimers would be expected. However, the lack of trimeric 
complexes suggests that 20 nt RNA stretch is not long enough to accommodate 
multiple binding sites of eIF4A2 and hints at oligomers forming through protein-
protein interaction. This leads to creation of a model in which at least one of 
the protomers in the oligomer needs to come into direct contact with RNA and 
allow for binding of other protomers (Figure 3.5-5, panel B). In case of RNA 
length permitting for two optimal binding sites formation of 2 oligomeric species 
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(6 proteins bound to RNA) is visible. This concept is further explored in section 
3.9 (Figure 3.9-2).  
 
 
Figure 3.5-3 eIF4A2 requires optimal length of RNA to fit into the binding site 
to oligomerise  
Representative EMSAs of eIF4A2 binding to polypurine (AG) RNA of 10 nt length (top 
panel) and 15 nt length (bottom panel), n = 3. Titration of eIF4A2 from 0 to 7 µM, 
constant concentration Dy780 labelled AG RNA (25 nM). Complexes were preincubated 
for 1h at room temperature in the binding buffer (20 mM HEPES, pH 7.5, 2 mM MgCl2, 
100 mM KCl, 1mM DTT), supplemented with 1 mM AMP-PNP. Complexes were resolved 
on 7% native EMSA for 50 minutes, at 100V. 10 nt RNA stretch does not provide optimal 








Figure 3.5-4 Optimal RNA length for the binding site correlates with 
oligomerisation  
A. Representative (n = 3) elution profiles from aSEC on a Superdex 200 increase 
3.2/300 column of 16 µM eIF4A2 in complex with 4 µM AG-repeat single-stranded 
RNA of varying length (10, 15, 20 nucleotides). Complexes were incubated for 1 
hour at room temperature in presence of binding buffer (20 mM HEPES pH 7.5, 
100 mM KCl, 2 mM MgCl2, 1 mM DTT) and 1 mM AMP-PNP, and subsequently 
injected onto the column.  
B. Representation of fraction bound based on the image analysis of EMSAs  
(n = 3 for each condition) of titration of eIF4A2 (0 to 7 µM) in presence of 10, 15, 
20, 50 nucleotide AG-RNA (25 nM) as shown in Figure 3.4-1, Figure 3.5-3, 
Figure 3.5-5.  Error bars – SEM, fit – Hill equation.  
C. Dissociation constants obtained from image analysis of EMSAs as shown in the 








Figure 3.5-5 RNA containing double binding site for eIF4A2 promotes 
formation of multiple oligomers 
A. Representative EMSA of eIF4A2 binding to 50 nucleotide AG RNA. Experiment 
performed as in the Figure 3.5-3. RNA that comprises multiple binding sites 
allows for formation of multiple oligomeric species next to each other, n = 3.  
B. Model of eIF4A2 binding to RNA, where RNA needs to comprise optimal binding 
site, and have a preferred sequence. Upon RNA binding, subsequent eIF4A2 
protomers can bind, forming an oligomer. Where the RNA length allows for 











Since 1) the polypurine-rich AG-RNA promotes oligomerisation to the highest 
extent, 2) a 10 nucleotide AG-RNA stretch allows for binding of one protein but 
does not support oligomerisation, 3) and native mRNA substrates rarely have 
long stretches of uninterrupted polypurine motifs, it was essential to understand 
whether eIF4A2 tolerates different sequence arrangements to form oligomers. 
To achieve that, EMSAs on 20 nucleotide long RNAs with varying polypurine 
motifs were performed (Figure 3.5-6, panel A). This showed that eIF4A2 
oligomerisation can be achieved on different sequences containing AG-stretches. 
However, differences in the extent of oligomerisation were observed. Sequences 
in wells 1, 3, and 6 promoted oligomerisation the most. A visible difference 
between sequences in wells 2 and 3 was observed. Both sequences contain the 
same number of uninterrupted purines, however only for sequence 3 trimeric 
complex and clearly defined dimer are visible. This difference could be 
explained by the location of polypurine motif within the RNA sequence. Given 
that eIF4A2 binds preferentially (with the highest affinity) to AG-repeats it is 
probable that in the case of sequence 2 eIF4A2 binds the RNA exactly at the 
external 10-nucleotide polypurine motif, and therefore does not have the full 
binding interface. The situation is different in the case of sequence 3, where the 
polypurine motif is internal and flanked by uracil. This could be further 
explained by very low oligomerisation on sequence 4, where the external purines 
flank a long stretch of uracil. Furthermore, sequences 5, 6, and 7 promote 
oligomerisation to a greater extent than sequence 8. Here, the dissimilarity 
stems from length of AG-stretches, where sequences 5-7 contain motifs of 4 
purines, whereas sequence 8 has only 2 purines next to each other. Additionally, 
previously obtained in the Bushell lab by Dr Tobias Schmidt eIF4A2 affinities 
towards sequences 1-6 presented in Figure 3.5-6, panel B, further demonstrated 
that oligomerisation is independent of the KD. Sequences 3 and 4 have similar 
affinities yet differ in propensity to promote oligomerisation. Similarly, 
sequences 5 and 6 have higher dissociation constant than sequence 4, which 
promotes mostly monomeric binding.  
In all, eIF4A2 is capable of oligomerisation on interrupted polypurine motifs, 
however the presence of flanking regions, and the length of polypurine motifs 





Figure 3.5-6 eIF4A2 oligomerises on RNAs containing different arrangements 
of AG-repeats 
A. Representative (n = 2) EMSA of 5 µM eIF4A2 formed complexes with 1 µM 5’FAM 
labelled RNAs containing different arrangements of AG-motifs. The samples were 
prepared and visualised in the same manner as in Figure 3.5-2, panel C.  
B. Dissociation constants (n = 3), obtained by Dr Tobias Schmidt through titrations 













To sum up, eIF4A2 oligomerises only in presence of RNA, and when the protein is 
in excess over RNA allowing for formation of both the dimer and trimer in these 
conditions. It is still unclear what causes the disparities in oligomerisation on 
various RNA sequences. As the differences in KD do not seem to correlate with 
the extent of oligomerisation, it appears that the RNA sequence itself plays a 
crucial role in stimulating the oligomerisation, with AG-RNA having the greatest 
propensity to induce trimeric complexes. Another good example is the (A)20 RNA, 
that had the highest KD amongst the tested RNAs and a large fraction of the RNA 
remained unbound, however it promoted dimer formation.  
Moreover, an optimal length of the RNA is necessary to provide full binding 
interface to induce oligomerisation. Interestingly, as shorter RNA fragments (less 
than 8 nt) do not support binding, the formation of a dimer on RNA as short as 15 
nt suggests that the oligomerisation happens through the protein-protein 
interactions. Expanding the length of RNA allows for formation of multiple 
oligomers, however the amount of bound eIF4A2 does not grow linearly, 
providing further evidence towards a model of protein-protein interaction 
induced oligomerisation.  
Finally, the specific preferences of eIF4A2 to the particular arrangements of AG 
motifs, regardless of KD, point again towards the RNA sequence being the largest 














3.6. Oligomers have different shape and conformation than 
monomers 
The previous results described RNA dependent oligomerisation of eIF4A2 and 
pointed towards the RNA sequence being the main determinant of formation of 
oligomers. However, how the oligomers are formed and whether distinct RNA 
binding modes can be responsible for differences in oligomerisation still 
remained elusive. To explore the potential differences a structural approach was 
indispensable. Here, the changes in shape and size of eIF4A2 under free, AMP-
PNP bound, monomeric, and oligomeric (bound to various RNAs) conditions were 
investigated using small-angle X-ray scattering (SAXS). This technique provides 
structural information in solution, without the need of crystal formation, making 
it advantageous in this aspect over crystallography. Additionally, the structures 
may resemble a more natural state without experiencing crystal packing widely 
observed in crystallography. The simplicity of sample preparation without the 
need to grow crystals allows for obtaining data for various conditions, i.e., 
different RNA substrates, in a shorter time. However, SAXS does not provide as 
high resolution as crystallography, rendering it not suitable for determination of 
atomic resolution. Overall, the sample preparation, the resolution high enough 
to observe conformational changes, and the possibility to couple the obtained 
information with the biochemical data, made it the preferred method to use in 
this project.  
Here, preincubated complexes were snap frozen in liquid nitrogen, and shipped 
on dry ice to Diamond Light Source (DLS) in Oxford, UK. Collected data on DLS 
Beamline B21 were analysed with the use of Scatter IV and ATSAS 3.0.3 package 
deposited at EMBL (Bioisis: Tutorial, Manalastas-Cantos et al., 2021). Samples 
containing apo-eIF4A2 (free protein), AMP-PNP-bound eIF4A2, monomeric eIF4A2 
bound to (AG)10 and (CAA)6CA as well as oligomeric eIF4A2 bound to (AG)10 were 
reanalysed for the purpose of this thesis and consistency between the samples, 
based on a previous analysis by Dr Mads Gabrielsen using Scatter III. More details 
about the method, sample preparation and analysis can be found in the Chapter 
2.3.5.  
The SAXS experiments at the DSL are coupled with size exclusion 
chromatography (SEC-SAXS), which allows for separation and analysis of multiple 
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species in heterogenous sample. The eluted sample from the SEC column is 
subjected to X-ray radiation, which in turn results in SAXS data embedded within 
the SEC profiles of the samples.  
First the elution profile of apo-eIF4A2 was examined (Figure 3.6-1, panel A). A 
main peak corresponding to the monomeric eIF4A2 was observed (at around 450 
frames – frames correspond to the SAXS frames collected), additional, very 
minor peaks, i.e., small molecule contaminants were observed (around 550 
frames). Next, a region of the peak (Figure 3.6-1, panel B, pink selection) was 
selected for further analysis. Selected region corresponded to the frames with 
most constant Rg (radius of gyration; distance from the centre of gravity of a 
molecule), assuring similarity between the analysed data (Bioisis: Tutorial). 
After the selection of the frames, the first step of analysis consisted of 
determining the Guinier region (Figure 3.6-1, panel C). This is the most 
important step that allows for scaling the data and further analysis. For the 
Guinier region analysis, the scattering data is analysed in the region where the 
scattering angle is close to zero (Guinier, Fournet and Yudowitch, 1955; Putnam 
et al., 2007; Behrens et al., 2012) (see also Chapter 2.3.5). This analysis 
provides information about both the Rg and intensity (I) at zero scattering angle 
(I(0)), as well as allows for detection of aggregation in the sample. Here, the Rg 
was determined, and no aggregation was observed. The same initial analysis was 
performed for AMP-PNP-eIF4A2, monomeric eIF4A2 bound to (AG)10 and (CAA)6CA 
as well as oligomeric eIF4A2 bound to (AG)10 (see Appendix 1 Figures 1-1, 1-2, 











Figure 3.6-1 Apo-eIF4A2 forms a single monomeric species in solution  
A. Size exclusion chromatography (Superdex 200 increase 3.2) of the sample 
containing 100 µM eIF4A2 in binding buffer (20 mM HEPES pH 7.5, 100 mM KCl, 2 
mM MgCl2, 1 mM DTT) run at the Diamond Light Source (Oxford, UK) before the 
sample was subjected to X-ray radiation, frame corresponds to fraction collected 
during SAXS. One main peak is visible, eluting around 450 frames, corresponding 
to monomeric eIF4A2. Grey region corresponds to buffer subtracted as 
background.  
B. Intensity plot of the sample presented in panel A. Frames with most constant Rg 
(red dots) selected for further analysis (marked in light pink). 
C. Guinier region fitting (top) with residuals of the linear fit (bottom) of the sample 
from panel A. It shows the linearisation of scattering data in the region close of 
scattering angle close to 0. Establishing the correct region is important for all 
further analysis and comparisons. I = Intensity, q = scattering vector.  
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As the initial analysis was performed, and the Guinier region was determined, 
the samples could be compared between each other. In Figure 3.6-2, panel A, 
Intensity plots were compared between apo-eIF4A2 (dark green) and AMP-PNP-
bound state (lime green; graph on the left), free eIF4A2 and monomeric eIF4A2-
(AG)10 (blue-violet; middle graph) and monomeric and oligomeric (purple) 
eIF4A2-(AG)10 (graph on the right). The log10 intensity plots provide the 
information about the shape of the proteins and possible aggregation. None of 
the samples had any aggregation. Signs of aggregation would be visible both in 
the intensity plot and Guinier analysis in the low q region as the absence of 
linear dependence of log(I(q)) versus q2 (Putnam et al., 2007; Grishaev, 2012). 
Additionally, the shape of the proteins could be determined from the log10 
intensity plots (Volkov and Svergun, 2003; Putnam et al., 2007; Kikhney and 
Svergun, 2015). Apo-eIF4A2, AMP-PNP-bound, and monomeric follow the same 
trend, however oligomeric (AG)10-bound eIF4A2 seems to be the least globular 
(see the difference in graph on the right, Figure 3.6-2, panel A).  
Next, the dimensionless Kratky plots (Figure 3.6-2, panel B) provide information 
about the folded state of the complexes (Volkov and Svergun, 2003; Putnam et 
al., 2007; Kikhney and Svergun, 2015) (see Figure 2.3.5-1). Here, both the apo-
eIF4A2 and AMP-PNP-bound eIF4A2 (panel on the left) seem to follow a partially 
unfolded trend (upward trend) in the Kratky plot, whereas (AG)10-bound 
monomeric (middle panel) seems to follow a more folded trend. Finally, both 
the (AG)10 formed monomer and oligomer follow a similar, folded trend (graph 
on the right). However, the oligomer could be potentially less folded (higher 
values for q*Rg ~ 4). Additionally, both oligomer and monomer seem to be rigid, 
however, similarly as described in publication by Behrens et al., 2012, there 
might be some degree of flexibility in the monomeric species due to slight 
upturn of the data in high q*Rg (~7-8).  
Finally, the P(r) distribution (pair distance distribution function) of each sample 
was assessed. This analysis allows for representation of real space and 
determination of the maximum distance in the analysed particle (dmax) (Kachala, 
M., Valentini, E. and Svergun, 2015). To discover the correct P(r) it is necessary 
to find the dmax value that provides a distribution above 0 and is smooth (no 
sharp changes in the curve) (Bioisis: Tutorial). To obtain the positive 
distribution, appropriate dmax, and minimise artefacts data at high q can be 
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trimmed (Bioisis: Tutorial). Using the programme Scatter IV, each fit is assigned 
a Chi-square score (the lower score the better). After finding the distribution 
that is positive and has low score, the value can be further refined. Here, in the 
Figure 3.6-2, panel C, P(r) shows that fits for all the samples are positive. 
Additionally, for apo-eIF4A2 and the AMP-PNP-bound state the P(r) plot suggests 
that the majority of the distances between the atoms of the sample are around 
30 Å. However, the distribution also suggests that there are parts of the protein 
that extend over the 30 Å core (more for the apo-eIF4A2), with dmax reaching 104 
Å and 99 Å, respectively. Monomeric eIF4A2 has a less pronounced peak at 30 Å, 
suggesting more even distribution of distances, with the dmax reaching 108 Å. 
Lastly, the distribution for oligomeric eIF4A2 shows that the peak is shifted to 
40- 50 Å, the distribution is broader both suggesting that the particle is bigger 
than apo-eIF4A2, and additionally, the calculated dmax is the largest from the 






Figure 3.6-2 Monomeric RNA bound eIF4A2 differs from the free species and 
the oligomer  
A. Comparison of scattering curves (log10 intensity plots) of (from left to right) 1) 
apo-eIF4A2 and AMP-PNP bound eIF4A2, 2) apo-eIF4A2 and monomeric (AG)10 
bound eIF4A2, 3) monomeric and oligomeric eIF4A2 bound to (AG)10. The biggest 
difference is visible between the monomeric and oligomeric eIF4A2. The curves 
suggest that there is no aggregation in the samples.  
B. Dimensionless Kratky plots based on the Guinier regions. Compared samples 
correspond to the same samples as in panel A. Monomer adopts more globular 
shape, whereas the free protein and AMP-PNP bound one follow partially 
unfolded trend in the dimensionless Kratky plot. There is a difference visible in 
the compactness of monomer and oligomer.  
C. P(r) distribution, that allows for determination of dmax (maximum distance in the 






Analysed SAXS data allows for modelling of dummy atom models (envelopes) that 
represent the shape of measured molecules at a low resolution (Svergun and 
Stuhrmann, 1991; Svergun, 1999). The calculated models represent a fit to the 
experimental curves analysed above. Here, the data was modelled first using the 
DAMMIF method (17 individual runs per sample), further refined by DAMAVER 
package to obtain the highest confidence in the models (Volkov and Svergun, 
2003; Franke and Svergun, 2009). Obtained envelopes are presented in Figure 
3.6-3. In panel A, apo-eIF4A2 can be seen with two visible RecA domains in an 
open conformation (see Chapter 1.5.1), with a region expanding out of the main 
core, further demonstrating the elongated nature as described by the P(r) 
(Figure 3.6-2, panel C). In panel B of Figure 3.6-3 the AMP-PNP-bound state is 
presented. The change in conformation upon AMP-PNP binding is elucidated. In 
panel C, a more closely shaped and rigid monomeric eIF4A2 is visible. A clear 
change in conformation upon RNA binding is detected. And finally, in panel D, 
oligomeric (AG)10 bound eIF4A2, proves that the shape, size and conformation of 






Figure 3.6-3 Envelope models of eIF4A2 support differences in shape, size, 
and conformation of eIF4A2 depending on the AMP-PNP, RNA binding and 
oligomerisation status  
Envelope models (dummy atom model fitting using DAMMIF and DAMAVER packages from 
ATSAS 3.0.3) – for more information about analysis please refer to Chapter 2.3.5. 
Models created based on the Guinier region analysis and P(r) distribution. 
A. Apo-eIF4A2. Extended region is visible. 
B. AMP-PNP-bound eIF4A2.  
C. (AG)10 monomeric eIF4A2. RNA bound state adopts more globular, closed shape.  




As previous studies have shown a preference of eIF4A2 to bind to polypurine 
motifs (Wilczynska et al., 2019), the potential differences between the 
monomer bound to (AG)10 and (CAA)6CA was examined. For this, a sample with 
equimolar concentration of eIF4A2 and (CAA)6CA was prepared in the same 
manner as the previous samples and analysed using SAXS. Again, the size 
exclusion profile was examined, and the Guinier region was established (see 
Appendix 1 Figure 1-4).  
As before, the intensity and dimensionless Kratky plots of the two monomers 
were compared (Figure 3.6-4, panel A and B). The monomers followed the same 
trend in the intensity plot, suggesting that both tested conditions yield globular 
proteins without sings of aggregation. A slight difference was detected in the 
dimensionless Kratky plot, similar to the one between (AG)10 formed monomer 
and oligomer, indicating that the (CAA)6CA monomer could potentially be less 
compact than the one on (AG)10 RNA. In addition, a flexibility comparison was 
performed for those two conditions (Figure 3.6-4, panel C). For this analysis, 
using Scatter IV, it is assessed in which of the following three correlation plots 
(see below) the data reach a plateau: Porod-Debye, Kratky-Debye, SIBYLS plots. 
Depending on which of the graphs produces a plateau, the flexibility of the 
sample can be determined: Porod-Debye - rigid, globular, Kratky-Debye - 
disordered formation, SIBYLS - ordered and disordered elements (Rambo and 
Tainer, 2011; Brosey and Tainer, 2019). Here, in the Figure 3.6-4, panel C, both 
of the monomers reach the plateau in the Porod-Debye plot, suggesting that 








Figure 3.6-4 Monomers of eIF4A2 formed on (AG)10 and (CAA)6CA RNA follow 
similar pattern.  
A. Comparison of scattering curves (log10 intensity plots) of monomeric (AG)10 bound 
eIF4A2 and monomeric (CAA)6CA eIF4A2. Scattering plots follow identical trend. 
No aggregation in the samples is visible. 
B. Dimensionless Kratky plots based on previous analysis of the Guinier regions.  
C. Flexibility analysis based on Porod, Porod-Debye, Kratky-Debye, SIBYLS plots. 
Plateau of both samples in the Porod-Debye plot suggests that the monomers are 







Lastly, the envelope model of (CAA)6CA monomer was created in the same way 
as previous samples (Figure 3.6-3). In the Figure 3.6-5, panel A, globular shape 
is observed, with a small extension. Subsequently, monomers formed on (AG)10 
and (CAA)6CA RNA were superimposed onto each other using SUPCOMB package 
(Kozin and Svergun, 2001). Both monomers seem to adopt a very similar shape 




Figure 3.6-5 Envelope models of (AG)10 and (CAA)6CA eIF4A2 monomers show 
high similarities  
Envelope models (dummy atom model fitting using DAMMIF and DAMAVER packages from 
ATSAS 3.0.3) – for more information about analysis please refer Chapter 2.3.5.  
A. Envelope model of (CAA)6CA bound monomer. 
B. Superposition of envelope models of the eIF4A2 monomers bound to (AG)10 (blue) 





As eIF4A2 is a helicase that is believed to unwind double-stranded regions within 
mRNAs it was important to test whether a longer RNA substrate containing a 
double-stranded region influences the conformation and the variety of protein 
species formed. First, eIF4A2 complexes were formed on an RNA substrate 
containing 24 bp double-stranded region with a 5’(AG)10 single-stranded overhang 
(RNA sequence as previously used in Figure 3.3-1) in a protein to RNA ratio 
supporting oligomer formation. As shown in Figure 3.6-6, panel A, two distinct 
peaks were observed, spanning between 350-470 frames. As only two peaks were 
detected, covering the same region in which the sample of oligomeric eIF4A2-
AG10 RNA revealed three peaks, it was not possible to determine whether the 
sample consisted of monomers and dimers, or trimers or mixtures of few 
species. For the next analysis, the two regions were selected and analysed 
separately as oligomer and monomer (Figure 3.6-6, panel B), and Guinier 
analysis was performed (Figure 3.6-6, panel C). Larger biomolecules are 
characterised by linear region at lower q2 (Putnam et al., 2007). Here, the linear 
region of the oligomer is achieved at q2 0.0010 versus 0.0016 for the monomeric 
species. The same analysis was performed for complexes formed on (CAA)6CA 
24BP (RNA sequence as previously used in Figure 3.3-1), and a substrate with 
shorter single-stranded overhang (AG)5 24BP (see Appendix 1 Figures 1-5, 1-6). 
As seen in the size exclusion profiles of complexes formed on both (CAA)6CA 
24BP and (AG)5 24BP, oligomeric complexes were formed less readily than on the 












Figure 3.6-6 eIF4A2 forms oligomers more readily on a substrate with double-
stranded region  
A. Size exclusion chromatography (Superdex 200 increase 3.2) of the sample 
containing 90 µM eIF4A2, 30 µM (AG)10 24BP RNA, and 1 mM AMP-PNP run at the 
DLS before the sample was subjected to X-ray radiation, frame corresponds to 
frames collected during SAXS. Two peaks are visible, spanning from 350 to 450 
frames. Grey region corresponds to buffer subtracted as background. 
B. Intensity plot of the sample presented in panel A. Frames with most constant Rg 
(red dots), corresponding to the monomer, and oligomer, selected for further 
analysis (marked in light pink). 
C. Guinier region fitting (top) with residuals in linear region (bottom) of the 
samples from panel A, oligomer on the left (deep purple) and monomer on the 
right (cyan).  
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Next, the log10 intensity and normalised Kratky plots were compared between 
the obtained oligomers and monomers for each RNA respectively (Figure 3.6-7, 
panel A for log10 intensity plots and panel B for dimensionless Kratky plots). The 
obtained data for the complexes formed on (AG)10 24BP (panel A and B, graphs 
on the left), suggest that the monomer was both less globular and less folded 
than the oligomer. In the case of eIF4A2 complexes formed on (CAA)6CA 24BP 
RNA (panel A and B, graphs in the middle) the monomer is less globular but 
more folded than the oligomer. Finally, for complexes formed on (AG)5 24BP the 
monomer was less globular, however both the monomer and oligomer had the 
same folded state (panel A and B, graphs on the right). However, as the 
distinction between the peaks for complexes formed on (CAA)6CA 24BP and (AG)5 
24BP was less pronounced than for the ones formed on (AG)10 24BP (Appendix 1 
Figures 1-5, 1-6 and Figure 3.6-6, panel A), caution has to be taken with 
interpretation of this data. Nonetheless, the obtained complexes, provide 
further evidence that both the RNA sequence as well as length of the single-












Figure 3.6-7 Monomers and oligomers formed on substrates with double-
stranded region differ   
A. Comparison of scattering curves (log10 intensity plots) of monomers and 
oligomers of eIF4A2 formed on (AG)10 24BP (left, monomer - cyan, oligomer – 
deep purple), (CAA)6CA 24BP (middle, monomer - salmon, oligomer – deep pink), 
and (AG)5 24BP (right, monomer - blue, oligomer – navy blue).  
B. Dimensionless Kratky plots based on the Guinier region analysis (see Appendix 















Next, comparisons between all of the monomers and oligomers formed on the 
substrates with double-stranded region were produced (Figure 3.6-8). Based on 
the analysis and data gathered in the log10 intensity and dimensionless Kratky 
plots (panel A and B respectively), all of the monomers (graphs on the left) 
behaved in exactly the same manner and had the same characteristics when it 
comes to the shape and folded state. However, there were visible differences 
between the formed oligomers (graphs on the right), suggesting distinct shape. 
The oligomer formed on the substrate containing (AG)10 single-stranded region 
was the most distinct, being the most globular and the most folded. However, 
caution has to be taken with interpretation of this data, as there is a possibility 
that the oligomers formed on (AG)10 24BP and (AG)5 24 BP as well as (CAA)6CA 
24BP can be of different species – trimer versus dimer (see Figure 3.6-6 and 
Appendix 1 Figure 1-5, 1-6).  
Additional flexibility analysis was performed, similarly as in the Figure 3.6-4, 
panel C between the eIF4A2 oligomers formed on (AG)10 24BP and (CAA)6CA 
24BP. Here (Figure 3.6-8, panel C) the (AG)10 24BP oligomer (purple) reached 
plateau in the Porod-Debye plot, suggesting a rigid and well-defined structure, 
however the (CAA)6CA 24BP oligomer (dark pink) achieved plateau first in the 
SIBYLS plot suggesting both flexible and inflexible regions (Rambo and Tainer, 
2011; Brosey and Tainer, 2019). This indicated that the oligomers created on 
(AG)10 24BP RNA not only form more readily but additionally are more rigid, 






Figure 3.6-8 Comparison of scattering data for eIF4A2 monomers and 
oligomers formed on substrates with 24 BP double-stranded region 
A. Comparison of scattering curves (log10 intensity plots) of eIF4A2 monomers (graph 
on the left) formed on (AG)10 24BP (cyan), (CAA)6CA 24BP (pink-salmon), and 
(AG)5 24BP (blue), and oligomers (graph on the right) formed on (AG)10 24BP 
(deep purple), (CAA)6CA 24BP (deep pink), and (AG)5 24BP (navy blue). No 
aggregation in the samples is visible, all the monomers followed the same trend, 
slight differences are visible in the oligomer samples.  
(figure legend continues on the next page) 
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B. Dimensionless Kratky plots based on the Guinier regions analysis, graph on the 
left presenting monomers, and graph on the right portraying oligomers. Colour 
scheme the same as in panel A. All monomeric samples follow the same trend, 
associated with globular proteins. Oligomer formed on (AG)10 24 BP substrate 
again shows a distinct trend to the other oligomers.  
C. Flexibility analysis eIF4A2 oligomer formed on (AG)10 24BP (deep purple), and 
(CAA)6CA 24BP (dark pink). The analysis shows plateau in SIBYLS plot for 
(CAA)6CA 24BP suggesting mixture of flexible and inflexible domains, whereas 
plateau in the Porod-Debye plot for the (AG)10 24 BP oligomer suggests that this 
oligomer is more rigid. 
 
Finally, envelope models were created, as described above (Figure 3.6-3). For 
envelope models of each individual complex please refer to Appendix 1 Figure 
1-7. Superimposed monomeric eIF4A2 complexes formed on RNAs with double-
stranded region adopt similar conformation, however the (AG)10 24 BP substrate 
formed one is the largest of the three (Figure 3.6-9, panel A). As 1) the 
complexes were formed with the use of AMP-PNP, i.e., non-hydrolysable ATP 
analogue, permitting RNA binding, but hindering RNA release, 2) the dmax of the 
tested monomers is larger than the one of free protein (see Table 3.6-1), and 3) 
eIF4A does not bind directly to the double-stranded RNA (Lorsch and Herschlag, 
1998a), it is possible that the extended region corresponds to the double-
stranded region of the RNA. Next, the (AG)10 24BP oligomer was compared to the 
oligomer formed on (CAA)6CA 24 BP (Figure 3.6-9, panel B, left) and to the 
oligomer formed on (AG)5 24BP (right). Clear distinction in size and shape was 
observed in both instances. The lesser distinction of the size exclusion 
chromatography peaks (see Appendix 1 Figure 1-5, 1-6) of the complexes 
formed on (CAA)6CA 24 BP and (AG)5 24BP RNA, the clear smaller size based on 
the created envelope models (Figure 3.6-9, panel B), and the differences in the 
Rg and dmax (Table 3.6-1) suggest that the oligomeric complexes possibly 
represent different species. As the collected dmax values (Table 3.6-1) were 
larger than the ones of the monomeric species, the oligomer in this case could 







Figure 3.6-9 eIF4A2 adopts different conformation based on RNA substrate 
and oligomerisation status 
Envelope models (dummy atom model fitting using DAMMIF and DAMAVER packages from 
ATSAS 3.0.3) – for more information about analysis please refer to Chapter 2.3.5. 
Superposition created using SUPCOMB package from ATSAS 3.0.3.  
A. Superposition of monomers formed on (AG)10 24BP (cyan), (AG)5 24BP (blue) and 
(CAA)6CA 24BP (pink). Monomers adopt similar conformation, however the 
monomer created on (AG)10 24BP seems to be the largest.  
B. Superposition of oligomers formed on (AG)10 24BP (deep purple), (CAA)6CA 24BP 
(dark purple) – left, and oligomers formed on (AG)10 24BP (deep purple), (AG)5 
24BP (navy blue) – right. Oligomer formed on (AG)10 24BP appears to be the 




Table 3.6-1 Rg and Dmax values obtained from SAXS analysis of eIF4A2 
complexes 
Sample Rg (Å) dmax (Å) 
apo-eIF4A2 30.1 104 
AMP-PNP bound eIF4A2 30 99 
(AG)10 monomeric eIF4A2 27 112 
(AG)10 oligomeric eIF4A2 34.2 131 
(CAA)6CA monomeric eIF4A2 27.5 97 
(AG)10 24BP monomeric eIF4A2 29.6 114 
(AG)10 24BP oligomeric eIF4A2 39.1 139 
(CAA)6CA 24BP monomeric eIF4A2 29.1 117 
(CAA)6CA 24BP oligomeric eIF4A2 35 134 
(AG)5 24BP monomeric eIF4A2 30.5 109 
(AG)5 24BP oligomeric eIF4A2 30.2 132 
 
 
In conclusion, SAXS was proven to be a method with sufficient resolution to 
distinguish different dimensions (Table 3.6-1) of the investigated samples. 
Additionally, distinct shapes and conformations were detected between apo-
eIF4A2 and AMP-PNP bound state suggesting that this method has satisfactory 
sensitivity to detect small changes upon binding of different RNAs. The extended 
arm of apo-eIF4A2 disappeared upon AMP-PNP binding, and the monomeric RNA 
bound samples are more globular than the RNA unbound state. The analysis of 
monomeric species formed on single-stranded (AG)10 and (CAA)6CA RNA however 
did not show large differences between the formed complexes. The flexibility 
analysis suggested that both investigated monomers are rigid and globular. The 
monomers also have similar Rg, indicating similar mass distribution around the 
centre of gravity of both monomers, suggesting that the conformation adopted 
on distinct RNAs as a monomer might not influence oligomerisation potential 
(see different oligomerisation propensity Figures 3.4-1, 3.5-2). However, the 
maximum dimension and slight difference in the dimensionless Kratky plot 
(Table 3.6-1, Figure 3.6-4, panel B), could potentially indicate that those small 
variances can indeed play a role in oligomerisation. Additionally, the oligomeric 
(AG)10 bound eIF4A2 was more rigid, folded, and most importantly larger than 
the monomeric species.  
Finally, as a cooperativity was observed in an unwinding reaction (Figure 3.3-1), 
the propensity of eIF4A2 to form oligomeric complexes on RNA substrates with 
double-stranded region was investigated. The double-stranded substrate 
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containing (AG)10 single-stranded region (sequence and length that promoted 
oligomerisation to the highest extent, Figures 3.5-2, 3.5-4) did not promote 
formation of additional species not seen on single-stranded RNA (compare 
Appendix 1 Figure 1-3 and Figure 3.6-6). Further suggesting that eIF4A2 
interacts mostly with the single-stranded region, and this interaction promotes 
oligomerisation. Additionally, double-stranded RNA substrate with (AG)5 single-
stranded overhang did not produce oligomers as readily as (AG)10 single-stranded 
region (compare Appendix 1 Figure 1-5 and Figure 3.6-6), further emphasising 
the importance of single-stranded RNA in oligomerisation. However, as the dmax -
(Table 3.6-1) between monomeric and oligomeric (possibly dimeric) (AG)5 24BP 
sample differed and no oligomers were detected on single-stranded 10 nt AG-
RNA (Figures 3.5-3, 3.5-4) at least partial influence of the double-stranded 
region cannot be excluded. Intriguingly, regardless of the similarities between 
monomers formed on RNAs with double-stranded regions, oligomers formed on 
substrates with (AG)10 and (CAA)6CA single-stranded overhangs differed 
significantly, with oligomers forming on (CAA)6CA-containing RNA less readily 
(Appendix 1 Figure 1-6). Finally, the extended region in all of the complexes 
formed on RNA with double-stranded region, as previously described, is possibly 
the double-stranded RNA itself. As there is only one extension visible both per 
monomeric and oligomeric complex, this suggests again (see Figure 3.5-1) that 
the oligomers are formed through protein-protein interaction on single RNA.  
In all, information gathered through SAXS experiments provided another level of 
assurance that eIF4A2 can form oligomeric complexes, and that their existence 
is dependent on the sequence and length of a single-stranded region of RNA. 
Moreover, the different capacities to form oligomeric species in presence of 
double-stranded region indicate the need to explore the influence of presence of 








3.7. eIF4A2 interacts in live cells supporting oligomerisation 
model  
 
As phenomena observed in vitro do not always turn out to be true in cells, and 
the in vitro research serves as a tool to discover how things might work in vivo, 
it was important to determine whether eIF4A2 can oligomerise in live cells. For 
this a FLIM-FRET (fluorescence lifetime imaging microscopy – fluorescence 
resonance energy transfer) method was used. It is a technique that allows to 
study molecular interactions between two fluorescently tagged proteins of 
interest in live cells. In this method it is the fluorescence lifetime of a donor 
molecule that is measured. The principles of this method are shown in the 
Figure 3.7-1 (see also Chapter 2.4.7). For the purpose of this thesis the method 
is explained with the use of eIF4A2 as the protein of interest. As shown in Figure 
3.7-1, panel A (left), in which cells transfected with donor-eIF4A2 only, the 
donor molecule transitions from the ground state (S0) to the excited state (S2) 
through the absorption of energy in the form of light. Subsequently the donor 
molecule undergoes internal conversion (change from S2 to S1) and emits a 
photon (S1 to S0). The time the donor molecule remains in the excited state 
before emitting a photon is called fluorescence lifetime, τ. Conversely, when 1) 
a  suitable pair of donor and acceptor molecules are present in the same cell, 
i.e. the donor has a high quantum yield and its emission spectrum overlaps with 
the acceptor excitation spectrum, and 2) they are in a close proximity (less than 
10 nm) (Förster, 1948; Spiegel et al., 2016), the donor molecule can relax from 
the excited state by non-radioactive transfer of energy to the acceptor (FRET). 
As the process of energy transfer to the acceptor is faster than the emission of a 
photon (as in the case of no FRET), the donor molecule returns to S0 in shorter 
time, in turn decreasing the fluorescence lifetime (Figure 3.7-1, panel A, right). 
In Figure 3.7-1, panel B a situation is described in which the two fluorophores 
do not come into direct contact with each other. It is important to choose 
fluorophores which do not dimerise on their own. In this case, due to absence of 
interaction, a change between the fluorescence lifetime in cells transfected 
with the donor molecule alone and the ones transfected with both donor and 





Figure 3.7-1 Diagram of mechanism behind FLIM-FRET method 
A. The diagram on the left presents a situation in which eIF4A2 is N-terminally 
tagged with a donor molecule (mTurquoise2). When the cells are excited with 
light at 436 nm (20 nm bandwidth), the donor molecule absorbs a photon and 
changes its electronic state from ground (S0) to the excited one (S2). Then the 
molecule transfers through the internal conversion (change from S2 to S1) and 
emits a photon (S1 to S0). The period of existence in the excited state is called 
fluorescence lifetime of a donor, τD.  
The diagram on the right portrays the situation in which cells were transfected 
with mTurquoise2-eIF4A2 (donor) and mCitrine-eIF4A2 (acceptor). Here, due to 
expected interaction of two eIF4A2 proteins, and the mTurquoise2 and mCitrine 
being a suitable FRET pair, the donor returns to the ground state not through 
emission of a photon but to transfer of energy to the acceptor molecule. This, in 
turn, results in shortened fluorescence lifetime.  
B. The two diagrams represent cells transfected with either mTurquoise2 or both 
mTruquoise2 and mCitrine. Here, due to lack of interaction between the donor 
and acceptor molecules, the decrease of fluorescence lifetime is not to be 
expected. The donor in both cases (left for donor alone, and right for both donor 




First, a suitable pair of fluorophores was chosen, mTurquoise2 was selected as a 
donor (Goedhart et al., 2012), and mCitrine as an acceptor (Hoffmann, Chen and 
Campbell, 2018). The monomeric features of both fluorophores make them ideal 
candidates for determining oligomerisation of eIF4A2. Additionally, the high 
quantum yield, i.e., the ratio of photons absorbed to the ones emitted, of 
mTurquoise2 means that the fluorophore is brighter and has a strong signal. 
Another advantage of mTurquoise2 is its sufficiently long fluorescence lifetime  
(4 ns).  
Next, the possibility of a tag interfering with eIF4A2 oligomerisation had to be 
excluded. Since 1) the recombinant eIF4A2 was N-terminally tagged (His-SUMO) 
through the first step of purification and this did not interfere with obtaining 
active protein and 2) many published reports (Li, Belsham and Proud, 2001; 
Oberer, Marintchev and Wagner, 2005; Hosmillo et al., 2016) used N-terminally 
tagged eIF4A, it was decided to place the fluorophore on the N-terminus. 
Therefore, to test the oligomerisation, mTurquoise2-eIF4A2 and mCitrine-eIF4A2 
were cloned and then purified using agarose resin (see Chapter 2.2, Figure 
3.7-2, panels A, B). The proteins were cleaved of the resin and assessed to be of 
sufficient purity to use in this test. 
Next, unlabelled eIF4A2 (WT), mTurquoise2-eIF4A2, mCitrine-eIF4A2, or an 
equimolar mixture of both mTurquoise2-eIF4A2 and mCitrine-eIF4A2 were 
incubated with Dy780 labelled (AG)10 RNA for 1 hour in binding buffer (20 mM 
HEPES pH 7.5, 100 mM KCl, 2 mM MgCl2, 1 mM DTT) supplemented with 1 mM 
AMP-PNP. Subsequently, the prepared samples were visualised using EMSA 
(Figure 3.7-2, panel C). For the WT eIF4A2 three bands were observed, 
suggesting formation of monomer, dimer, and trimer. For the fluorophore-
tagged eIF4A2 two bands of different size were visible. The change in size in 
comparison to WT could be explained due to the larger size of the fluorophore-
tagged eIF4A2 (46 kDa for WT and 73 kDa for the tagged one). Additionally, the 
lack of the third band could potentially stem from 1) the inability of eIF4A2 to 
form trimers when tagged, 2) formation of only two species, i.e., either 
monomer and dimer or monomer and trimer, 3) apparent lower concentration of 
tagged eIF4A2, or 4) size of the protein being too large to resolve fully on 7% 
acrylamide gel.  
153 
 
In the first, and second case, if the tagged eIF4A2 could form any of the 
multimeric species, the fluorophore tagged eIF4A2 was still a good candidate for 
FLIM-FRET studies. As the detection of interaction can only be seen between two 
tagged proteins, any of the permutations of an interaction would be sufficient to 
detect a change in fluorescence lifetime as long as the complex consists of at 
least one donor and one acceptor.  
In the third case, as the concentration was determined UV-spectroscopically 
using protein specific extinction coefficients calculated with Expasy PotParam 
(Duvaud et al., 2021), the active concentration could be masked by 
contaminants from purification. One way to avoid this situation would be to 
purify the proteins through the regular multi-step purification used for other 
proteins in this thesis. Alternatively, 1) a ratio of the protein of interest to the 
contaminants could be calculated from the Coomassie stained gel, 2) protein 
concentration could be then established with a Bradford method, 3) the 
obtained mg/mL concentration of tagged-eIF4A2 could be calculated using the 
established ratio, 4) it could be converted to molar concentration using the 
provided above extinction coefficients. Trying to establish concentration without 
including contaminants simply from absorption at 280 is not recommended as 
extinction coefficients and the amount of aromatic amino acids of contaminants 
are not known.  
The fourth, and probably the easiest explanation of lack of clearly visible three 
bands could be resolved by choosing a different type of native gel: either of 
lower percentage of acrylamide or gradient percentage.  
In all, the clearly visible multimeric complexes, proved the N-terminally tagged 





Figure 3.7-2 N-terminally tagged eIF4A2 is capable of oligomerisation 
A. Purification of mTurquoise2-eIF4A2, using agarose resin. Lane 1 shows the flow 
through collected from resin. Lane 2 indicates the wash 1 from the resin. After 2 
washes subsequent washes, ULP1 protease was added to the resin in the buffer 
containing reduced salt concentration. Lane 3 represents the supernatant 
containing cleaved mTurquoise2-eIF4A2. Additionally, lane 4 corresponds to 
elution from the resin. Protein visible in lane 3 was used for subsequent tests.  
B. Purification of mCitrine-eIF4A2. All the steps were done in the same manner as 
in the panel A. The lanes 1, 2, 3, and 4 correspond to the same steps as in the 
mTurquoise2-eIF4A2 purification.  
C. Test EMSA showing RNA binding of eIF4A2 (WT and fluorophore-tagged) to Dy780 
labelled (AG)10 RNA. Proteins (5 µM total per lane) were preincubated with the 
RNA (25 nM) for 1 h at room temperature in the binding buffer with 1 mM AMP-
PNP. The shift corresponding to the protein-RNA binding is visible in all the lanes 
in comparison to the RNA only one. Two arrows indicate monomer and multimer 
in the tagged-eIF4A2 lanes. Note the visible change between the WT monomer 










To address the question of whether eIF4A2 can oligomerise in cells, FLIM-FRET 
was performed. Briefly, HeLa cells were transfected with either a plasmid 
containing mTurquoise2-eIF4A2 or both the mTurquoise2-eIF4A2 and the 
mCitrine-eIF4A2 plasmids for 48 hours (see Chapter 2.4.2). Next, fluorescence 
lifetime of the donor was measured using a FLIM Lambert system. Here, the 
mTurquoise2 donor was excited with LED emitting at 445 nm. Together with 
each experiment, a reference fluorophore with known fluorescence lifetime was 
measured to calibrate the instrument. Representative images from 3 different 
experiments (4 experiments in total) are presented in Figure 3.7-3, panel A, 
left, each donor-eIF4A2 (top) is paired with donor-eIF4A2 and acceptor-eIF4A2 
(bottom) measured on the same day. As expected, eIF4A2 fluorescence was 
restricted to the cytoplasm, indicating these constructs follow the proteins 
endogenous localisation. Quantification of FLIM-FRET showed that the donor-
eIF4A2 alone had the expected average fluorescence lifetime of around 3.9 ns. 
However, in cells co-transfected with both donor and acceptor tagged eIF4A2 a 
statistically significant decrease of fluorescence lifetime to around 3.7 ns was 
observed (Figure 3.7-3, panel A, right). As FRET can only occur between 
fluorophores in close proximity, this decrease in fluorescence lifetime suggests 
that eIF4A2 may indeed multimerise in cells. Moreover, the observed change was 
similar to what has been communicated for other interactions using mTurquoise2 
as a donor (Bertolin et al., 2019). As described in the study Bertolin et al., 2019, 
mTurquoise2 coupled in a tandem construct with superYFP (a fluorophore that as 
mCitrine belongs to the YFP family) reached the change of fluorescence lifetime 
of 0.6 ns. In the case of in cell interaction, the change was only around 0.2 ns.  
As a control, HeLa cells were transfected with a free donor (mTurquoise2) or co-
transfected with free donor (mTurquoise2) and free acceptor (mCitrine). Unlike 
tagged-eIF4A2, free fluorophores were dispersed throughout the cell (Figure 
3.7-3, panel B, left, each donor (top) is paired with corresponding donor and 
acceptor (bottom)). Furthermore, co-expression of the free fluorophores did not 
result in a significant change of fluorescence lifetime. This indicates that FLIM-
FRET is not driven by chance. Together, these findings support that the decrease 
observed for the samples with fluorophore-eIF4A2 stems from the interaction 
between the two eIF4A2. 
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Additionally, transfection efficiency for both the tagged-eIF4A2 as well as free 
fluorophores was tested through Figure 3.7-3, panel C. Briefly, HeLa cells were 
treated in the same way as the ones used for FLIM-FRET, samples were 
collected, and Western Blot was performed using a standard protocol (see 
Chapters 2.4.3, 2.4.6). Anti-vinculin antibody was used to determine the 
loading control. Anti-eIF4A2 antibody detected 2 bands. Bands visible in all the 
lanes just below 50 kDa marker corresponded to WT eIF4A2. Additional bands 
around the marker size 75 kDa in wells containing cells with eIF4A2 transfections 
matched the tagged-eIF4A2 with the calculated size of 73 kDa. Since the anti-
GFP antibody can effectively detect GFP derivatives like m-Turquoise2 and m-
Citrine due to high similarity between them anti-GFP antibody was used. It 
detected bands between 25 and 37 kDa marker size in lanes with fluorophores 
transfections, as well as the tagged-eIF4A2 in lanes with eIF4A2 transfections. 
Less eIF4A2 was observed in lanes with free fluorophores transfection, however 
the amount of loading control (vinculin) seems to be lower in those lanes as 
well. In all, eIF4A2 with both tagged fluorophores, as well as both of the free 





Figure 3.7-3 eIF4A2 oligomerises in live cells  
A. Fluorophore tagged eIF4A2 oligomerises in live cells. Left side of the panel 
contains representative images of transfected HeLa cells expressing either 
mTurquoise2-eIF4A2 (top) or both mTurquoise2-eIF4A2 and mCitrine-eIF4A2 
(bottom). The images are presented from three separate experiments, each top 
panel with a corresponding bottom panel from the same experiment. Images 
have a scale bar of 20 µm and are colour coded with a magenta fluorescence 
lifetime scale from 3.9 to 3.6 ns. Right side of the panel shows box plot with 
median as a black bar for each condition. Each box contains all the measured 
fluorescence lifetimes, collected from 4 different experiments, with the total of 
131 cells measured for the mTurquoise2-eIF4A2 and 146 cells for the co-
transfection. The p-value = 0.029 was calculated using T-test (two-tailed 
distribution, two-sample equal variance).  




B. Free mTurqoise2 and mCitrine do not oligomerise. This panel is presented in the 
same way as the panel A. The p-value = 0.1, calculated in the same manner 
proved the change in fluorescence lifetime for free fluorophores as not 
significant. Data presented in the box plot was collected from 5 separate 
experiments, with the average of 2 to 3 regions per 35 mm dish (samples in 
technical duplicates) per experiment. The total cells measured for the 
mTurquoise2 was 95, and 87 for both fluorophores. 
C. Western blot representation of transfection efficiency. Anti-vinculin antibody 
was used as a loading control. Anti eIF4A2 antibody detected WT band in all the 
samples. Bands for the fluorophore-tagged eIF4A2 were detected with both anti-
GFP and anti-eIF4A2 antibody below the marker size of 75 kDa. Anti-GFP 
antibody detected bands corresponding to the free fluorophores. In the non-
transfected HeLa cells only the bands corresponding to vinculin and WT eIF4A2 
were observed.  
 
As 1) the detected change in fluorescence lifetime for tagged-eIF4A2 was 
significant and not detected for free fluorophores, 2) the extent of the change 
was similar to what was reported in the literature for in cell interaction (Bertolin 
et al., 2019), and 3) the overexpression of both tagged-eIF4A2 was on a similar 
level, all the gathered data so far were indicative of eIF4A2-eIF4A2 interaction 
in cell. However, a question remained why the change in fluorescence lifetime 
in cell was not as large as the one reported for the tandem construct (Bertolin et 
al., 2019). One of the reasons could be the fact that for the full change the 
donor has to interact specifically with the acceptor. In a situation where two 
donors (or two acceptors, or a donor and a WT) interact with each other the 
change of fluorescence lifetime would not be visible.  
To understand the possible interactions a series of immunoprecipitations (IPs) 
were performed. Briefly, HeLa cells were treated in a similar manner as for the 
FLIM-FRET experiment and IPs were carried out as described in Chapters  2.4.5, 
2.4.6, with use of 1) anti-IgG, 2) anti-eIF4A1, 3) anti-eIF4A2 4) anti-GFP 
antibodies (Figure 3.7-4, panel A, left). Here, the input lanes for non-
transfected HeLa cells only detected WT eIF4A2, whereas the input lanes for all 
the other conditions contained both WT eIF4A2 and fluorophore-eIF4A2. As 
expected, only the WT eIF4A2 was detected in eIF4A2 IP lane for non-
transfected condition. The eIF4A2 IP lanes in all of the transfected conditions 
detected both WT and fluorophore tagged eIF4A2. In the GFP IP lanes in the 
transfected conditions not only the fluorophore tagged eIF4A2 but also the WT 
were detected. This suggested that the tagged eIF4A2 can interact with the WT. 
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Thus, giving a potential explanation why the observed reduction in fluorescence 
lifetime was smaller than the one theoretically expected. Additionally, eIF4A1 IP 
lanes detected only WT eIF4A1, further suggesting, that the interaction is 
specific.  
As the RNA in the tested conditions was intact (Figure 3.7-4, panel A, right), 
another reason for the interaction in cell had to be considered, i.e., the 
observed interaction could stem from binding to the same long mRNA. This time, 
the cells were lysed in presence of RNase 1 to degrade the RNA and treated in 
the same way as described above. Interestingly, the same result was observed in 
the RNase 1 samples (Figure 3.7-4, panel B, left), which suggests that the 
interaction is not only due to the two proteins being bound to the same RNA at 
the same time but through actual protein-protein interaction. Understandably, 
RNase 1 should not digest the RNA completely, which should still permit for the 
RNA fragments that were occupied by the protein, and necessary for the 
oligomerisation to remain untouched. To verify this result, RNA integrity test 
was performed, and clear degradation was observed (Figure 3.7-4, panel B, 
right).  
In all, eIF4A2 is capable of interaction in live cells, the N-terminal tag does not 
inhibit the interaction between the tagged proteins, as well as between the 
tagged protein and WT. Additionally the true extent of oligomerisation, might be 
greater, and it is not mediated by the proteins being bound to the same RNA 
next to each other. The gathered data provide a basis for further investigation of 




Figure 3.7-4 Fluorophore tagged eIF4A2 interacts with WT in cells 
HeLa cells were either non-transfected or transfected with indicated fluorophore-
eIF4A2 and treated in the same manner as for the FLIM-FRET experiments. Single 15 cm2 
dish was used for each condition. After cells collection, each dish was divided in half 
and lysed in presence of either 80 U Ribolock (to block activity of RNases and inhibit 
RNA degradation) or 1000 U RNase 1. After the lysis, protein concentration in each 
sample was measured with the Bradford method. Subsequently, the same amount of 
protein from each sample was used for IPs. RNA samples were collected for each 
condition.  
A. The Western Blot (left) represents samples treated with Ribolock. In the input 
and IP lanes for non-transfected HeLa cells, only the WT eIF4A2 was detected. In 
all other samples the input contained both WT eIF4A2 and tagged-eIF4A2 
(tagged-eIF4A2 can be detected with both anti-eIF4A2 and anti-GFP antibodies). 
IgG lanes in all the tested conditions did not show unspecific 
immunoprecipitation of proteins. In all the tested conditions in the GFP IP a co-
pull down of WT eIF4A2 was observed. In the eIF4A1 IP both the WT and the 
tagged-eIF4A2 was not detected. The RNA remained intact (right).  
B. The Western Blot (left) represents samples treated with RNase 1. The obtained 
IP result is the same as in panel A. Degradation of the RNA (lack of 




3.8. Catalytic activities of oligomeric eIF4A2 
 
In the previous subchapter, interaction of eIF4A2 was demonstrated to exist in 
cells, suggesting that there may be a potential function associated with those 
complexes (Chapter 3.7). Additionally, eIF4A2 was shown to form oligomeric 
complexes on the RNA substrates with double-stranded regions, indicating that 
those complexes can form on single-stranded RNA adjacent to the double-
stranded one (Chapter 3.6). Moreover, different RNA sequences were shown to 
induce oligomerisation to a different extent (Chapters 3.5, 3.6). Finally, as 
observed in the Chapter 3.3 the unwinding activity of eIF4A2 is performed in a 
co-operative manner. Taken together, these data provide the evidence needed 
for further exploration of the activities of the oligomeric eIF4A2.  
To understand how the oligomerised species of eIF4A2 behaves enzymatically, 
and whether the extent of oligomerisation matters in the catalytic capacities of 
eIF4A2, its unwinding and ATPase activities were tested. To achieve the 
oligomerised state, eIF4A2 concentration was kept above the concentration of 
the RNA substrate (see Figure 3.5-1).  
As shown in the Chapters 3.4 and 3.5 (Figures 3.4-1, 3.5-2), the AG-RNA 
induced oligomerisation to the highest extent, and the oligomers did not form as 
readily on the (CAA)6CA RNA. Therefore, the differences in unwinding and 
ATPase on double-stranded substrates, with (AG)10 and (CAA)6CA single-stranded 
regions were investigated (RNA substrates as shown in Figure 3.3-1, panel A). 
The used substrates differed only in the sequence of the single-stranded region.  
Unwinding and ATPase reactions were performed by a titration of eIF4A2 on 
(AG)10 overhang substrate (Figure 3.8-1, panel A and B, respectively) and on a 
(CAA)6CA overhang substrate (Figure 3.8-1, panel C and D, respectively). eIF4A2 
exhibited higher unwinding activity on the RNA substrate containing AG single-
stranded region compared to (CAA)6CA one (Figure 3.8-2, panel A). Additionally, 
the obtained Hill coefficient for (CAA)6CA-containing RNA was smaller than for 
(AG)10 in the unwinding reaction (hCAA = 1.5 ± 0.3 in comparison to hAG = 2.6 ± 
0.3). A similar pattern was observed for eIF4A2 ATPase activity (Figure 3.8-2, 
panel B). Additionally, the ATPase activity on the substrate with AG overhang 
followed a sigmoidal shape with Hill coefficient hAG = 2.5 ± 0.47, whereas this 
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pattern was not observed for the (CAA)6CA RNA where the Hill coefficient was 
found to be only 0.5 ± 0.24. This in turn suggested that the cooperativity in the 
ATPase activity is dependent on the RNA substrate, as no indication of 
cooperativity was observed on the substrate with (CAA)6CA overhang.  
In general, the Hill coefficients for both the ATPase and unwinding activity were 
higher for (AG)10 overhang substrate, which correlated with the higher extent of 
oligomerisation on single-stranded AG-RNA (Figure 3.4-1), as well as on (AG)10 
24BP RNA (Figures 3.6-6, 3.6-9, and Appendix 1 Figure 1-3). This in turn, 
suggested that more readily formed oligomers correlated with greater outcome 
of both the unwinding and the ATPase. However, the dissociation constant for 
both overhangs differed (as presented earlier in Wilczynska et al., 2019), with 
higher affinity towards (AG)10 containing substrate ((AG)10 KD = 0.27 ± 0.03 and 
(CAA)6CA KD = 1.04 ± 0.21). As previously shown, the oligomerisation of eIF4A2 
was not dependent on affinity towards the RNA substrate but on its sequence 
(Figure 3.5-2). However, in this case, the possibility that the activities are 






Figure 3.8-1 Unwinding and ATPase activity of eIF4A2 increases with protein 
concentration 
A. Unwinding activity of eIF4A2 on (AG)10 24BP RNA substrate presented as fraction 
unwound over time with indicated concentrations of eIF4A2. Representative 
graph, n = 4, error bar – SEM from technical duplicate. For more details how the 
reactions were performed please refer to Chapter 2.3.3).  
B. Representation of ATPase activity of indicated concentrations of eIF4A2 on a 
(AG)10 24BP RNA substrate. The raw data were normalised to the respective 
starting value of each dataset. Trend with no error bars is shown. The raw data 
were used for further analysis in this chapter to obtain nM of ATP used per 
second. For more details about the analysis and an example of raw ATPase 
activity data please refer to the Chapter 2.3.4. Representative graph, n = 3. 
C. Unwinding activity of eIF4A2 on (CAA)6CA 24 BP RNA substrate presented as 
fraction unwound over time with indicated concentrations of eIF4A2. Very 
limited unwinding activity was detected for 1 and 3 µM eIF4A2 (error bars for 
those two concentrations removed for clarity of presentation). Representative 
graph, n = 3, error bar – SEM from technical duplicate.  
D. Representation of ATPase activity of indicated concentrations of eIF4A2) on a 
(CAA)6CA 24BP RNA substrate, presented as in the panel B. Representative graph, 





Figure 3.8-2 Unwinding and ATPase activity of eIF4A2 is greater on (AG)10 
overhang substrate than on the (CAA)6CA one  
A. Unwinding activity presented as velocity of unwinding (fraction unwound per 
second) versus eIF4A2 concentration on (AG)10 and (CAA)6CA overhang containing 
RNA substrate. Reactions were started with 1 mM ATP, eIF4A2 was in excess over 
RNA substrate (50 nM). Data collected from 3 individual replicates for (CAA)6CA 
24BP and 4 replicates for (AG)10 24BP, error bar – SEM, fit – Hill equation.  
B. ATPase activity on the same RNA substrates as in the panel A. Reactions were 
performed at the same time as unwinding reactions, in wells supplemented with 
ATPase mix (please see Chapter 2.3.4 for more details). Activity presented as 
velocity of ATPase (nM of ATP used per second) versus eIF4A2 concentration, n = 
















As both the extent of oligomerisation and the different KD for the two tested 
RNA substrates could not be excluded as the main determinant of differences in 
their catalytic activities, further RNA substrates were employed. This time, the 
velocity of unwinding and KD was compared for substrates with 20 nt (AGUG)5, 
(UCUC)5, or (UGUU)5 single-stranded overhangs (Figure 3.8-3, panel A). As 
before, the double-stranded component of the RNA substrate was the same for 
all permutations. The RNA substrate with the greatest sequence similarity to the 
AG-RNA, (AGUG)5, was found to have the lowest measured KD, and the highest 
measured velocity. This further suggests there is a correlation between 
unwinding activity and KD. However, for the other two tested substrates an 
inverse correlation was observed. The unwinding activity on (UGUU)5-containing 
RNA substrate was lower than the one observed on (UCUC)5-containing one. 
However, the measured KD was lower (higher affinity) on (UGUU)5. This result 
suggests the unwinding activity does not correlate with eIF4A2 affinity towards 
the RNA substrate. It should be noted that the differences in the measurements 
of KD were greater than those for the unwinding reaction.  
The next question was whether oligomerisation could instead drive the extent of 
RNA unwinding. For this, pre-formed eIF4A2-RNA complexes were resolved using 
EMSA (Figure 3.8-3, panel B). As expected, oligomeric complexes were formed 
most readily on the similar (AG)10 and (AGUG)5 RNAs (see Figure 3.5-6). All three 
complexes (monomer, dimer, and trimer) were detected on (UGUU)5 RNA, and 
no RNA binding was observed on (UCUC)5. Therefore, the gathered data suggests 
that neither the measured KD, nor the extent of oligomerisation correlated with 
the unwinding activity.  
As the question of what drives the unwinding reaction remains open, there are 
certain possibilities worth considering. Perhaps the differences observed in the 
dimensionless Kratky plot, or the different dimensions of the obtained 
complexes could play a role (Figure 3.6-4, Table 3.6-1). Additionally, as RNA 
unwinding is a dynamic process performed by eIF4A2 only in the presence of 
ATP, a question was posed whether the AMP-PNP RNA bound state could reflect 
what complexes actually take part in the reaction. As shown in Figure 3.8-3, 
panel C, complexes formed in presence of AMP-PNP are more stable than those 
formed in presence of ATP. Moreover, complexes resolved using EMSA are pre-
incubated for an hour before visualisation, whereas the change in fluorescence 
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as measured in the unwinding assays can be observed in the first minutes of the 
reaction (see Figure 3.8-1, panel A and C). The measured AMP-PNP bound state 
allows for measurements of KD excluding the influence of ATPase activity and 
the RNA binding dynamics. However, this could potentially mean that the 
measured AMP-PNP bound state does not reflect possible different kon and koff 
rates of eIF4A2 binding to RNA substrates. Thus, the RNA binding capacity and 
the KD in presence of hydrolysable ATP could be different. To test this, eIF4A2 
RNA binding was measured in presence of either ATP or AMP-PNP (data 
presented in Table 3.8-1). The KD in presence of ATP for (AG)10, (CAA)6CA, and 
(AGUG)5 was found to be greater than the one measured in presence of AMP-
PNP. The trend of affinity for different RNA substrates remained the same. 
Surprisingly, the KD for (UCUC)5 and (UGUU)5 was smaller in presence of ATP 
compared to of AMP-PNP, further suggesting that different RNA sequences can 
employ different binding dynamics.  
In all, eIF4A2 unwinding velocity differs depending on the sequence of the 
single-stranded region proceeding the double-stranded RNA. The unwinding 
activity was greater on substrates containing AG motifs. Similarly, the ATPase 
activity was higher for (AG)10 than for the (CAA)6CA containing RNA. Additionally, 
for RNAs with single-stranded (AG)10, (AGUG)5 as well (CAA)6CA regions the 
unwinding activity correlated with both oligomerisation propensity as well as KD. 
However, for other RNA substrates, i.e., (UCUC)5, (UGUU)5, the unwinding 
activity did not correlate with the oligomerisation nor the KD, suggesting that 










Figure 3.8-3 Unwinding activity does not follow KD nor oligomerisation extent 
A. Unwinding activity does not follow KD. Unwinding activity (velocity) presented on 
left axis, and KD (right axis) of eIF4A2. Unwinding activity was measured for a 
single concentration of eIF4A2 (5 µM) on 50 nM double-stranded RNA substrate, 
differing in the sequence of the single-stranded region: (AGUG)5, (UCUC)5, 
(UGUU)5. KD was measured by titrating eIF4A2 on the single-stranded RNAs, i.e., 
(AGUG)5, (UCUC)5, (UGUU)5, in the presence of AMP-PNP. KD was derived from 
Hill equation. N = 3.  
B. Oligomerisation is dependent on RNA sequence. EMSA representing eIF4A2 (5 µM) 
formed complexes on 1 µM 20 nt single-stranded RNAs, i.e. (AG)10, (CAA)6CA, 
(AGUG)5, (UCUC)5, (UGUU)5
 in presence of AMP-PNP. Free RNAs on the left side of 
the gel. N = 2. Unrelated lanes removed for clarity. Note the surprising 
formation of a monomer and trimer on (CAA)6CA RNA in this experiment.  
C. AMP-PNP formed complexes are more stable than ATP formed one. 
Representative (n = 3) RNA binding over a span of 60000 s. Free FAM-labelled 
RNA has polarisation around 50 and does not change over time (yellow). eIF4A2 
(5 µM) bound to AG-RNA (50 nM) in presence of AMP-PNP is shown in burgundy, 
and in presence of ATP in red.  
 
Table 3.8-1 Dissociation constant (KD) of eIF4A2 to various RNA substrates 
RNA KD (µM) AMP-PNP KD (µM) ATP 
(AG)10 0.75 ± 0.05 3.82 ± 0.42 
(CAA)6CA 3.24 ± 0.32 6.11 ± 0.61 
(AGUG)5 0.53 ± 0.12  2.59 ± 0.31 
(UCUC)5 8.27 ± 1.22 4.43 ± 0.47 
(UGUU)5 5.02 ±1.47 3.10 ± 0.36 
KD from polarisation experiments of eIF4A2 binding to (AG)10, (CAA)6CA, (AGUG)5, (UCUC)5, 
(UGUU)5 in presence of AMP-PNP, measured after 1 hour of pre-incubation, n = 3, and 
immediately after assembling complexes in presence of ATP, n = 1. KD obtained from Hill 
equation fitted to the data. Error = SEM from 3 individual replicates for AMP-PNP, and from 
technical duplicate for ATP. Note that the KD for (AG)10 differs from the one obtained previously 
using a different method (see Figure 3.5-4, panel C). Due to slight differences in the reaction 
conditions (see Chapters 2.3.1.1, 2.3.1.3) the KD for both (AG)10 and (CAA)6CA is different to the 
one reported in Wilczynska et al., 2019. The trend of KD for (CAA)6CA RNA being much higher 
than for (AG)10 one is consisted with what was observed previously for eIF4A1 in Iwasaki, Floor 
and Ingolia, 2016. 
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The sequence of the single-stranded overhang on a double-stranded RNA 
substrate drove the outcomes of unwinding reactions. This led to a question of 
whether the RNA sequence was the main determinant of the outcome. As 
previously reported (Rozen et al., 1990; Rogers, Lima and Merrick, 2001) eIF4A is 
a bi-directional helicase. However, the concept of bi-directionality has not been 
explored for eIF4A2, and the influence of the single-stranded region’s sequence 
on unwinding of substrates from 3’ to 5’ direction is currently not known. 
Additionally, employing RNA substrates that differ only through the positioning 
of the single-stranded region form the substrates used in Figure 3.8-1 and 
Figure 3.8-2 could potentially help to understand the importance of the 
sequence of single-stranded region in the unwinding and ATPase activities.  
As a first step to addressing this, the activity of eIF4A2 on double-stranded RNA 
substrates, differing in the location of the single-stranded overhang was 
assessed. As 1) the outcome of unwinding and ATPase activity, 2) the propensity 
to oligomerise, and 3) the KD differed between substrates with (AG)10 and 
(CAA)6CA 5’-overhangs differed, these single-stranded sequences were explored. 
Thus, unwinding and ATPase assays were performed for 3’(AG)10 or 3’(CAA)6CA 
overhangs RNA substrates (Figure 3.8-4). 
These experiments revealed that eIF4A2 exhibits 3’-to-5’ helicase activity. 
Furthermore, a preference for the 3’overhang sequence was observed, with the 
initial velocity being the largest for 3’(AG)10 RNA (Figure 3.8-5 and Table 
3.8-2). Moreover, the collected data suggests that eIF4A2 prefers 3’ overhang 
substrate over the RNA sequence. However, when comparing only 5’ overhangs 
or only 3’ overhangs to each other, in both cases, (AG)10 sequence was preferred 
by the helicase. As the affinities for the overhangs should remain the same (see 
Table 3.8-1) regardless of the direction, the obtained results unexpectedly point 
to a preference for unwinding in 3’-to-5’ direction.  
Next, the ATPase activity between tested RNA substrates was compared. Since, 
greater unwinding activity on the 5’(AG)10 overhang substrate was associated 
with slightly higher ATPase activity (Figure 3.8-2), a similar outcome was 
expected for substrates with 3’ single-stranded overhang. Surprisingly, the 
ATPase activity of both substrates with 3’ overhang followed very closely the 
same trend (Figure 3.8-5, panel B). In general, despite the observed differences 
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in unwinding activity between RNA substrates with 5’ and 3’ overhangs, the 
ATPase activity was similar (Table 3.8-2, Figure 3.8-5, panel B).  
In sum, the sequence of the single-stranded region on a double-stranded RNA 
substrate seems to be the main determinant of the outcome of the unwinding 
reaction. RNAs containing AG-motifs, i.e., (AG)10 or (AGUG)5 promote unwinding 
to the highest extent. Similarly, for the tested AG-RNAs both eIF4A2 affinity and 
the extent of eIF4A2 oligomerisation was greater than for the other tested RNAs. 
Moreover, this preference towards (AG)10 containing RNA was also visible in the 
RNA substrates with 3’ overhangs. Unexpectedly, the unwinding activity for both 
the (AG)10 and (CAA)6CA 3’overhangs substrates was greater than the ones with 
5’overhangs, suggesting that the unwinding activity can be modulated by the 
positioning of the single-stranded overhang. More broadly, this implicates eIF4A2 
as a predominantly 3’-to-5’ helicase. Finally, despite the clear differences in 
unwinding activity of eIF4A2 on the tested RNA substrates the variation in 
ATPase activity was lower. This suggested that the ATPase activity is less 
dependent on the outcomes of unwinding reaction as well as on the sequence of 




Figure 3.8-4 Oligomerised eIF4A2 performs unwinding and ATPase activities 
on RNA substrates with 3’ single-stranded overhangs 
A. Unwinding activity of eIF4A2 on 3’(AG)10 24 BP RNA substrate presented as 
fraction unwound over time with indicated concentrations of eIF4A2. Data points 
are the mean and error of a technical duplicate. Representative graph, n = 3.  
B. Representation of ATPase activity of selected concentrations of eIF4A2 (0, 1, 3, 
5, 7, 10 µM) on a 3’(AG)10 24 BP RNA substrate, presented in the same way as in 
Figure 3.8-1. Representative graph, n = 3. 
C. Unwinding activity of eIF4A2 on 3’ (CAA)6CA 24 BP RNA substrate presented as 
fraction unwound over time with indicated concentrations of eIF4A2. 
Representative graph, n = 3, error bar – SEM from a technical duplicate.  
D. Representation of ATPase activity of selected concentrations of eIF4A2 (0, 1, 3, 
5, 7, 10 µM) on 3’ (CAA)6CA 24 BP RNA substrate, presented in the same way as 






Figure 3.8-5 Unwinding activity but not ATPase of eIF4A2 is greater on a 
substrate with 3’ overhang single-stranded region.  
A. eIF4A2 unwinding activity presented as velocity of unwinding versus eIF4A2 
concentration on RNA substrates with 5’ and 3’ single-stranded overhang. Hill 
equation was fitted to visualise the trend. N = 3, error = SEM.  
B. ATPase activity performed simultaneously in separate wells on the same RNA 
substrates as in panel A, presented as nM ATP consumed per second versus 
eIF4A2 concentration, fit - Hill equation, n = 3, error = SEM.  
 
Table 3.8-2 Velocity of unwinding and ATPase of 10 µM eIF4A2 on RNA 
substrates with 5’ and 3’ single-stranded overhangs 
24BP RNA substrate overhang V x 10-3 frac. s-1 nM ATP s-1 
5’(AG)10 0.651 ± 0.046 25.570 ± 5.055 
5’(CAA)6CA 0.463 ± 0.039 24.225 ± 2.227 
3’(AG)10 2.295 ± 0.084 33.100 ± 10.227 





3.9. eIF4A2 activity is modulated by natural family of eIF4A 
inhibitors 
High overexpression of eIF4A1 in many types of cancer is driving a growing 
interest in eIF4A inhibitors (Liang et al., 2014; Modelska et al., 2015; 
Cunningham, Chapman and Schatz, 2018; Gao et al., 2020). As eIF4A2 has 90% of 
amino acid sequence identity with eIF4A1, the effect of the inhibitors on eIF4A2 
was further explored. As the data presented so far probed the new and 
unexpected ability of eIF4A2 to oligomerise a major question was to examine the 
effect of inhibitors in the context of oligomerisation.  
Two of the known eIF4A inhibitors have opposite mechanisms of action (see 
Chapter 1.5.3). Silvestrol, a rocaglate derivative, is known to induce tighter 
RNA binding (clamping) with longer half-life of eIF4A on RNA (Iwasaki, Floor and 
Ingolia, 2016; Wilczynska et al., 2019) and hippuristanol, has been shown to 
inhibit the eIF4A RNA binding activity altogether (Cencica and Pelletier, 2016). 
Therefore, the effect of the two inhibitors on eIF4A2 RNA binding activity in 
oligomerised conditions was tested.  
As shown in the Figure 3.9-1 silvestrol stimulated formation of eIF4A2 oligomers 
on both (AG)10 and CAA RNA. In turn, hippuristanol almost completely abolished 
RNA binding of eIF4A2 with most of the substrate remaining unbound and no 
oligomeric complexes detected. Since silvestrol had a direct influence on the 
oligomerisation potential of eIF4A2 its effect was explored further.  
As silvestrol induced formation of trimeric complexes on AG-RNA as well as on 
the less preferred (CAA)6CA one, the question was posed whether it can 
stimulate oligomer formation on less-than-optimal binding interfaces. As 
previously (Chapter 3.5) eIF4A2 was incubated with RNAs of varying length of AG 
repeats and the obtained complexes were resolved using EMSA (Figure 3.9-2, 
panel A). In the presence of silvestrol, a dimer band was detected on the gel 
with the shorter 10 nt long RNA substrate. As 10 nt long RNA comprises single 
binding site for eIF4A, formation of oligomeric complexes on this RNA further 
supports protein-protein interaction mediated oligomerisation. As an additional 
control analytical gel filtration of eIF4A2 complexes formed on 10, 15, 20 nt long 
AG-RNA in presence of silvestrol was performed (Figure 3.9-2, panel B, see also 
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Figure 3.5-4). This technique supported that silvestrol enhances the 
oligomerisation potential of eIF4A2. 
Subsequently, the KD on RNA substrates in presence of silvestrol were quantified 
and compared to the conditions without the inhibitor (Figure 3.9-2, panel C, D 
see also Figure 3.5-4, panel C). Silvestrol improved the binding affinity (reduced 
dissociation constant) of eIF4A2 to each of the tested RNA substrates, however 




Figure 3.9-1 Silvestrol improves RNA binding and oligomerisation status of 
eIF4A2 
EMSAs of 5 µM eIF4A2 in presence of either Dy780 labelled (AG)10 (left panel) or Dy680 
labelled (CAA)6CA (right panel); eIF4A2-RNA in the absence of inhibitors (DMSO), or in 
the presence of silvestrol (100 µM) or hippuristanol (50 µM). The protein was 
simultaneously incubated with 25 nM RNA, binding buffer (100 mM KCl, 2 mM MgCl2, 20 
mM HEPES pH=7.5), 1 mM AMP-PNP and inhibitors for 1 h at room temperature and the 
obtained complexes were subsequently resolved on 7% native acrylamide gel (100 V, 45 




Figure 3.9-2 Silvestrol enhances eIF4A2 RNA binding affinity and induces 
oligomerisation on short RNA substrates  
A. Representative (n = 3) EMSAs of titration eIF4A2 (indicated as the triangles above 
each gel, 0 to 7 µM eIF4A2) on (25 nM) Dy780 labelled RNA substrate containing 
various lengths of AG stretches (10, 15, 20, 50 nt) in presence of silvestrol. 
Samples prepared, resolved, and visualised in the same way as described in 
Figure 3.9-1. Silvestrol induced oligomerisation on shorter RNA substates.  
B. Representative (n = 3) aSEC of 16 µM eIF4A2 and 4 µM AG RNA (10, 15, 20 nt) 
performed in the same way as in Figure 3.5-4, panel A, in presence of silvestrol. 
Silvestrol induces formation of oligomers.  
C. Quantification of RNA binding from EMSAs (n = 3), as presented in panel A. Fit – 
hill equation, error bar – SEM.  
D. Dissociation (KD) constant obtained from fitted Hill equation to the data in panel 
B, compared to the KD from Figure 3.5-4, panel B and C, in DMSO conditions. 
Silvestrol improves the binding affinity of eIF4A2 to polypurine RNA regardless of 




It has been reported previously in a publication by Iwasaki, Floor and Ingolia, 
2016 that eIF4A1 in presence of RocA (rocaglamide inhibitor) binds AG-RNA 
regardless of presence of AMP-PNP. Additionally, it has been shown that eIF4A2 
has a natural preference for AG-RNA and in this aspect behaves like inhibited 
eIF4A1 (Wilczynska et al., 2019). However, whether eIF4A2 can bind the AG-RNA 
without the presence of nucleotide and how the possible outcome influences 
oligomerised eIF4A2 has not been explored.  
To test the influence of nucleotide as well as silvestrol eIF4A2 was pre-incubated 
with either (AG)10, (CAA)6CA, or A20 in presence of either DMSO (control) or 
silvestrol with 1) no nt, 2) 1 mM ADP + Pi, 3) 1 mM AMP-PNP. (AG)10 is the same 
polypurine RNA as used in previous reports (Iwasaki, Floor and Ingolia, 2016) that 
was demonstrated to be bound by eIF4A1 in presence of silvestrol without nt. In 
the same study (CAA)6CA was shown not to promote binding in the same 
conditions. As an additional control A20 was employed, that was shown in this 
thesis to induce formation of oligomers, however the previously measured KD 
was higher than the one for (AG)10 and (CAA)6CA (see Figure 3.5-2).  
The RNA binding capacity was then visualised with an EMSA (Figure 3.9-3, panel 
A). It was observed, that eIF4A2, similarly to eIF4A1 was capable of silvestrol-
induced, ATP-independent binding only to the AG-RNA substrate. However, 
silvestrol enhanced both binding, and oligomerisation on (CAA)6CA and A20 RNA 
substrates in presence of AMP-PNP. This ATP-independent binding to the AG-
RNA, was further proved using an additional technique, fluorescence 
polarisation. eIF4A2, again, bound the AG-RNA, regardless of presence of AMP-
PNP in the silvestrol condition (Figure 3.9-3, panel B).  
In all, this suggests silvestrol influences eIF4A2 binding capacity in a similar 
manner to eIF4A1. The complexes formed on (AG)10 in the -nt and ADP + Pi 
conditions corresponded to at least a dimer. Additionally, silvestrol stimulated 






Figure 3.9-3 Silvestrol induces eIF4A2 RNA binding to polypurine RNA 
regardless of presence of ATP derivatives   
A. Representative (n = 2) EMSAs of eIF4A2 (5 µM) to (25 nM) RNA substrate (D780 
labelled (AG)10, Dy680 labelled (CAA)6CA, Dy780 A20) in presence of DMSO 
(control; top panel) and silvestrol (bottom panel). The use of ATP analogue or 
lack of it is indicated above each lane. eIF4A2 binds RNA only in the presence of 
AMP-PNP in DMSO conditions, silvestrol induces RNA binding regardless of 
presence of nucleotide on polypurine RNA only.  
B. Representative (n = 3) eIF4A2 RNA binding measured by fluorescence polarisation 
to 50 nM FAM-labelled (AG)10 RNA substrate. Samples were prepared in the same 
manner as in panel A. Silvestrol induces polypurine RNA binding of eIF4A2 in 
presence of ADP + Pi and no nucleotide. Error – SEM from technical duplicate, fit 








Both higher oligomerisation and higher affinity of eIF4A2 towards AG-RNA were 
correlated with higher unwinding and ATPase activities (see Figures 3.8-2, 
3.8-3, and Table 3.8-1). As silvestrol improved both the oligomerisation and KD 
of eIF4A2 on AG-RNA a question was asked how it potentially influences eIF4A2 
catalytic capacities (see Figures 3.9-1, 3.9-2). As silvestrol is an inhibitor that 
acts on eIF4A1 the expectation would be that it inhibits eIF4A activities 
especially in the cancer setting.  
Here, eIF4A2 unwinding and ATPase reactions in presence of silvestrol were 
explored. As shown in the Figure 3.9-4, panel A, eIF4A2 unwinding activity was 
greater on both the (AG)10 and (CAA)6CA 5’overhang substrates. Silvestrol 
enhanced not only the amount of unwound substrate but also the velocity with 
which the unwinding was performed for (AG)10 5’overhang RNA (Figure 3.9-4, 
panel B, Table 3.9-1). The same trend was observed for the ATPase activity 
(Figure 3.9-4, panel C and Table 3.9-1).  
As silvestrol is an inhibitor the improvement of activities seemed contra 
intuitive. However, it has been reported previously that another eIF4A inhibitor – 
pateamine A – stimulated eIF4A1 RNA binding, unwinding and ATPase activities 
(Bordeleau et al., 2005). Additionally, the observed earlier improvement of 





Figure 3.9-4 Silvestrol enhances eIF4A2 catalytic activities  
A. Representative (n = 3) unwinding activity of 5 µM eIF4A2 in presence and 
absence of silvestrol on double-stranded RNA substrates containing 5’ single-
stranded overhang consisting of either (AG)10 or (CAA)6CA RNA stretch. The graph 
is presented as relative change in fluorescence (change was measured by 
dividing the measured fluorescence by the starting value – before the start of the 
reaction, and subsequently subtracting the obtained (=1) starting value) over 
time. Silvestrol induces greater unwinding regardless of RNA substrate. Error 
bars – SEM from a technical duplicate. 
B. Comparison of velocity of unwinding for an RNA substrate with (AG)10 single-
stranded 5’overhang over the concentration of eIF4A2 in presence of either 
DMSO (red) or silvestrol (orange). Error bars - SEM, n = 3, fit - Hill equation. 
Silvestrol induces greater velocity for each tested eIF4A2 concentration.  
C. Comparison of ATPase activity presented as velocity of ATPase over eIF4A2 
concentration (0 to 14 µM) in presence of DMSO (red) and silvestrol (orange) on 
RNA substrate containing 5’ single stranded overhang consisting of (AG)10. 




Table 3.9-1 Velocity of unwinding and ATPase of 5 µM eIF4A2 on AG-RNA 
substrates  
5’(AG)10 24BP RNA  V x 10
-3 frac. s-1 nM ATP s-1 
DMSO 0.426 ± 0.004 12.800 ± 2.300 
silvestrol 1.950 ± 0.201 39.966 ± 4.561 
 
In all, the gathered data indicates that both hippuristanol and silvestrol exert 
their function on eIF4A2. Hippuristanol abrogated RNA binding almost 
completely. The further exploration of silvestrol influence on eIF4A2 suggested 
that silvestrol enhances both the RNA binding as well as oligomerisation, even on 
the less optimal RNA substrates. Additionally, similarly as reported in the 
literature (Iwasaki, Floor and Ingolia, 2016), silvestrol induced ATP-independent 
AG-RNA binding. This potentially opens a question on the effect of silvestrol on 
eIF4A2 activities in the cancer setting. Additionally, the catalytic capacities of 
eIF4A2 were enhanced by silvestrol, an induction of activities not unheard of for 




3.10. Unwinding is performed by free and oligomerised 
eIF4A2 
  
Throughout this thesis the formation of oligomeric eIF4A2 was thoroughly 
described. It has been explored what influences oligomerisation of eIF4A2 and 
what enzymatic capacities the oligomeric eIF4A2 has. Additionally, it was 
demonstrated that eIF4A2 may oligomerise in live cells (Figure 3.7-3). However, 
the existence of monomeric eIF4A2 in cells cannot be excluded. Moreover, on 
certain RNAs eIF4A2 formed mostly monomeric complexes (Figures 3.5-2, 
3.5-6). Therefore, the question about the activity of monomeric eIF4A2 remains 
open.  
As described previously eIF4A2 forms oligomers only in the presence of RNA and, 
with the protein being in excess over the RNA substrate (Figure 3.5-1). 
Therefore, by modulating the protein to RNA ratio it should be possible to 
change the oligomerisation status of eIF4A2. The more RNA added should create 
a situation where the protein is in monomeric conditions. To test the monomeric 
eIF4A2 catalytic capacities, the unwinding and ATPase reactions thus should be 
performed with addition of competitor RNA. However, as the unwinding activity 
of eIF4A2 was measured on a fluorescently labelled RNA substrate (see Figure 
3.3-1, panel A) and the use of more labelled RNA would influence the sensitivity 
of the detection, a non-labelled single-stranded RNA would be a better choice as 
a competitor RNA. Additionally, ATP is necessary for unwinding activity, 
therefore certain precautions need to be taken, to assure that eIF4A2 stays 
bound to the unwinding substrate.  
As seen previously, silvestrol induced eIF4A2 binding to AG-RNA without the 
presence of ATP analogue (Figure 3.9-3). This could mean, that silvestrol could 
potentially serve as a tool, where eIF4A2-unwinding substrate complexes can be 
formed before the start of the reaction with ATP. Additionally, complexes 
formed with silvestrol are more stable, as the RNA strand release is much slower 
than in the control condition (Figure 3.10-1).  
To test whether eIF4A2 would remain bound to the RNA substrate in presence of 
competitor RNA, eIF4A2 was first preincubated with Dy780 (AG)10 RNA in 
presence of silvestrol. After the preincubation time has elapsed, increasing 
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amounts of unlabelled competitor RNA (either (AG)10 or (CAA)6CA) and 1mM AMP-
PNP were added to the pre-formed complexes and incubated for equivalent 
amount of time. Subsequently the complexes were resolved using EMSA (Figure 
3.10-2, panel A). As the hypothesis predicted, with increasing concentration of 
competitor RNA oligomerisation status of eIF4A2 has changed, however the 
protein remained fully bound to the labelled RNA.  
Additionally, (AG)10 competitor RNA had greater effect than (CAA)6CA which can 
be explained by higher KD of eIF4A2 on (CAA)6CA (see Table 3.8-1) and possibly 
the different oligomerisation potential.  
 
 
Figure 3.10-1 Silvestrol blocks the RNA strand release of eIF4A2  
(AG)10 RNA (50 nM) release experiment of 5 µM eIF4A2 in presence of DMSO (control) 
and silvestrol (100 µM) in presence of ATP measured by polarisation. The complexes 
were mixed in room temperature and immediately placed in a plate reader to 
observe the change in polarisation. Single, representative, technical replicate 
shown, for clarity of presentation, n = 3. Data normalised to starting value, and RNA 
only sample used as a baseline (0). Silvestrol prohibits RNA release in comparison to 







As it was possible to manipulate the oligomerisation status of eIF4A2, the 
catalytic activity of the scavenged complexes was assessed. Here, eIF4A2 was 
preincubated in presence of silvestrol with RNA substrate containing 5’ single-
stranded (AG)10 overhang, representing the more traditional role of the helicase 
in unwinding from 5’-to-3’ direction. Then the (AG)10 or (CAA)6CA RNA 
competitor was added, and the samples were incubated for the same amount of 
time. Subsequently, the unwinding reactions were started by addition of ATP. 
Addition of (AG)10 competitor RNA almost completely abolished the unwinding 
activity of eIF4A2 (Figure 3.10-2, panel B). The influence of the (CAA)6CA 
competitor RNA was less potent (Figure 3.10-2, panel C). The velocity of 
unwinding (Figure 3.10-2, panel D) was compared between the reactions with 
the two competitor RNAs. The velocity of unwinding decreased to almost 0%, 
however this change was not as consistent for the (CAA)6CA RNA. The difference 
here could stem from the mode of binding, as (CAA)6CA was not bound by eIF4A2 
in presence of silvestrol without nt (see Figure 3.9-3, panel A). Therefore, the 
binding to the (CAA)6CA RNA could only occur in the presence of ATP, which 
would allow for the reaction to start on the already pre-formed complexes on 
the unwinding substrate.  
It should be noted that the resolved complexes in the presence of AMP-PNP may 
not fully reflect what happens in a dynamic reaction in presence of ATP. 
Additionally, the decrease in activity was observed even for the (AG)10 
competitor RNA concentration that did not cause a large change in 
oligomerisation, and eIF4A2 was still in excess. Similar decrease in unwinding 
activity for comparable protein to RNA ratio was previously reported in the 
literature (Rogers, Lima and Merrick, 2001). Potentially, in this situation all of 
the protein is bound to the RNA in oligomeric conditions. A possible explanation 
could be that the unwinding activity is performed by the free eIF4A2 that is 
recruited to the double-stranded region by the already formed oligomer. In the 
case of (CAA)6CA competitor RNA not all of the free protein was scavenged, 
therefore the reduction in the unwinding activity was not as high.  
Additionally, the influence of the competitor RNA on eIF4A2 ATPase activity was 
tested (Figure 3.10-2, panel E). For both of the tested competitor RNAs ATPase 
activity increased with increase of the concentration of competitor, indicating 




Figure 3.10-2 Unwinding activity is performed by excess of free and 
oligomerised eIF4A2  




A. Representative EMSA (n = 3) of (2 µM) eIF4A2 binding to (25 nM) Dy780 (AG)10 
RNA in presence of increasing concentration (0 to 4 µM) of unlabelled competitor 
RNA (AG)10 and (CAA)6CA. Competitor RNA induced change in oligomerisation 
status (more monomer formation) without releasing the RNA substrate. (AG)10 -
competitor RNA induced change in oligomerisation status to a greater extent 
than (CAA)6CA competitor.  
B. Representative (n = 5) unwinding activity of eIF4A2 on RNA substrate with (AG)10 
single-stranded overhang and double-stranded region in presence of varying 
amounts of (AG)10 competitor RNA. Samples prepared in the same way as in the 
panel A, reactions started with ATP (no AMP-PNP in this reaction). Fraction 
unwound by eIF4A2 without competitor was established as 100% fraction 
unwound, the percentage of other conditions was calculated using ratio of the 
unwound fractions to the 100%. eIF4A2 does not unwind double-stranded RNA in 
presence of single-stranded (AG)10 competitor RNA. Error bars - SEM, technical 
duplicate presented.  
C. Representative (n = 3) unwinding activity of eIF4A2 on RNA substrate with (AG)10 
single-stranded overhang and double-stranded region in presence of varying 
amounts of (CAA)6CA competitor RNA. Samples prepared and data analysed in the 
same manner as in panel B. eIF4A2 unwinding activity is reduced in presence of 
(CAA)6CA competitor RNA. Error bars - SEM, technical duplicate presented. 
D. Fraction unwound in presence of competitor RNA. Graph created based on 
unwinding activity as presented in panels B and C. N = 5 for (AG)10 competitor 
and n = 3 for (CAA)6CA competitor, error bar - SEM. Presence of competitor 
reduces unwinding activity of eIF4A2.  
E. ATPase activity of 2 µM eIF4A2 in presence of competitor RNA. Reactions 
performed simultaneously as the unwinding reactions presented in panels B and 
C in reactions supplemented with NADH, PEP and LDH/PK mix. Graph presented 
as fold change of ATPase activity with ATPase activity of eIF4A2 without 
competitor RNA used as a starting value. N = 5 for (AG)10 competitor and n = 3 for 
(CAA)6CA one. Error bars – SEM, fit – Hill equation.  
 
In sum, in the previous subchapter (Chapter 3.8) unwinding activity was 
detected on all of the tested RNA substrates. This activity was observed for high 
excess of eIF4A2 over the RNA, which correlated with formation of oligomeric 
complexes. As shown here, the eIF4A2 oligomerisation status can be modulated 
by changing the concentration of RNA. However, in the tested conditions a fully 
monomerised eIF4A2 was not observed. Perhaps, due to dynamic nature of the 
unwinding reaction the true oligomerisation status could be different. As the 
almost complete abrogation of the unwinding activity was seen for (AG)10 
competitor to eIF4A2 ratio that in other tested conditions could potentially still 
promote oligomerisation (see Figure 3.5-1), the gathered data may indicate 
that the unwinding is performed by a cooperation between the oligomerised, 




3.11. Chapter discussion  
 
This chapter was focused on a thorough biochemical characterisation of DEAD-
box helicase eIF4A2, a highly similar paralogue of eIF4A1. As eIF4A1 is the more 
abundant paralogue it has been studied in a greater detail than eIF4A2 (Nielsen, 
McMaster and Trachsel, 1985; Nielsen and Trachsel, 1988; Galicia-Vazquez et 
al., 2012). eIF4A1 overexpression has been implicated in many types of cancer 
and a mostly opposite correlation has been observed for eIF4A2 (Ji et al., 2003; 
Yan et al., 2011; Lomnytska et al., 2012; Shaoyan et al., 2013; Liang et al., 
2014; Modelska et al., 2015). Therefore, a detailed biochemical characterisation 
of eIF4A2 was imperative to understand the mechanisms of actions governing 
eIF4A2 that could potentially help elucidate the differences between the two 
paralogues and allow for more specialised targeting in the future.  
While investigating the biochemical characteristics of heterologously produced 
highly pure eIF4A2 (Figure 3.2-1) a novel oligomeric version of the helicase was 
discovered (Figure 3.3-1, 3.4-1). The concept of oligomerisation in the context 
of eIF4A2 is unprecedented, however the phenomenon of multimerisation for 
other DEAD-box helicases has been previously observed (Putnam et al., 2015; 
Kim and Myong, 2016; Sharma et al., 2017) (see also Chapter 1.5.1).  
This study explored how eIF4A2 oligomeric complexes are formed and the 
presented data suggest that the eIF4A2 oligomerisation is dependent both on the 
presence of RNA and protein being in excess (Figure 3.5-1). The necessity of 
presence of RNA for eIF4A2 oligomerisation is different to what has been 
previously described for Ded1p (Putnam et al., 2015), suggesting a different 
mechanism involved in formation of those oligomeric complexes. However, the 
crystal structure of DDX3 (human ortholog of Ded1p) presented the oligomer only 
in presence of RNA (Song and Ji, 2019). 
The requirement for eIF4A2 to be in excess over RNA in order to oligomerise has 
potential implication in vivo. eIF4A2 is thought to be less abundant in cells than 
eIF4A1, however its expression depends on the type of the tissue as well as the 
state of the cell (Galicia-Vazquez et al., 2012, 2014). One example is a higher 
expression of eIF4A2 in differentiated cells (Williams-Hill et al., 1997). 
Additionally, the relative abundance of eIF4A2 as quantified in Galicia-Vaquez et 
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al., 2012 is higher than eIF4A1 in foetal brain, heart, kidney and adult brain, 
skeletal muscles, ovaries and leukocytes. Depending on the local concentrations 
and abundance as well as the affinity towards the RNA it is possible that eIF4A2 
oligomers are highly prevalent in vivo.  
The oligomeric complexes were shown to form predominantly on AG-RNA 
(polypurine motifs) (Figure 3.5-2). As eIF4A2 has been shown previously 1) to 
have the same preference to AG-RNA as inhibited eIF4A1, and 2) to exert 
repression through binding to the AG-rich motifs in the 5’UTRs of mRNAs 
(Wilczynska et al., 2019), it is possible that the oligomeric form of eIF4A2 takes 
part in the repression.  
Additional features have been identified in mRNAs associated with eIF4A, i.e., 
long 5’UTRs and high GC content or only C content (Rubio et al., 2014; Wolfe et 
al., 2014; Modelska et al., 2015; Waldron et al., 2019). However, the previous 
studies either focused on eIF4A1 or did not differentiate between the two 
paralogues. Nevertheless, the studies presented in this thesis cannot exclude the 
involvement of eIF4A2 in either monomeric or oligomeric form on RNAs exerting 
the stated above features. The other tested RNA sequences promoted 
oligomerisation to varying extent. In line with the high GC content, (GUGCU)4 
RNA promoted formation of oligomers to a higher extent than (CAA)6CA. 
Additionally, the oligomerisation was shown to not be correlated with eIF4A2 KD 
to the tested RNAs (Figures 3.5-2, 3.5-6). As the long uninterrupted stretches of 
AG motifs are uncommon in native mRNAs, the positioning of AGs within the RNA 
substrates was investigated. This showed that eIF4A2 requires at least four 
purines next to each other and an appropriate positioning of the flanking regions 
to readily oligomerise (Figure 3.5-6).  
Moreover, both the RNA binding site and optimal RNA length for oligomerisation 
was investigated (Figure 3.5-4). The gathered data suggest that the optimal 
binding site increases from 10 to 15 nt, which is in agreement with previous 
studies  (Abramson et al., 1987; Alexandra Z. Andreou and Klostermeier, 2013). 
The available crystal structure presenting eIF4A1 bound to 10 nt long AG-RNA in 
presence of RocA (Iwasaki et al., 2019) shows that eIF4A1 binds fully to the 10 
nt, leaving no flanking regions that would allow for another protein to bind to 
the same RNA. The gathered data showed that silvestrol induced oligomerisation 
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on exactly the same 10 nt AG-RNA, which further supports RNA mediated 
protein-protein interaction dependent oligomerisation (Figure 3.9-2).  
Moreover, in this chapter in-depth structural analysis of eIF4A2 using SAXS was 
presented. SAXS provides a structural information in solution and does not 
require any prior structural information (Tsutakawa et al., 2007). The recently 
predicted eIF4A2 structure (AF-Q14240-F1) with AlphaFold 2.0 (Jumper et al., 
2021) features a similar elongated extension visible in apo-eIF4A2 SAXS envelope 
model (Figure 3.6-3, see also Figure 1.5.1-1). The positioning of the extension 
in the predicted structure differs, however the model of confidence in this 
region is low, which could suggest that the predicted structure resembles the 
envelope model to even higher degree. The gathered data demonstrated that 
RNA bound state is more folded than both the apo and AMP-PNP bound eIF4A2. 
The structural data gathered for the oligomeric eIF4A2 provides a direct 
evidence that eIF4A2 is able to form the oligomeric complexes, and that their 
dimensions differ from the monomeric ones (Figure 3.6-2, Table 3.6-1). The 
calculated Rg for the oligomeric complexes is larger than for the monomeric ones 
indicating larger radius from the centre of gravity in the oligomer, and possible 
different mass distribution. The envelope models of the monomers formed on 
(AG)10, and (CAA)6CA RNAs, show high degree of similarity (Figure 3.6-5). 
However, the differences in the dmax as well as in the dimensionless Kratky plot 
could indicate a minor disparity in how eIF4A2 binds those two RNAs with 
different propensities to induce oligomer formation (Figure 3.6-4, Table 3.6-1).  
Subsequently, both oligomeric and monomeric complexes on RNAs with double-
stranded regions, differing only in length and sequence of 5’overhang were 
investigated. This analysis suggested differences in all paired monomers and 
oligomers with oligomers being less globular and folded (Figure 3.6-7). 
Moreover, (AG)10 24BP oligomer had a more defined and rigid structure than the 
(CAA)6CA 24BP eIF4A2 oligomer. The presence of oligomers on the (AG)5 24BP 
RNA substrate, a 10 nt single-stranded region that did not promote oligomer 
formation without the presence of inhibitor (Figure 3.5-3) suggests that there is 
at least a partial interaction with the double-stranded region. This has been 
suggested previously in the literature (Rogers, Lima and Merrick, 2001), however 
other reports contested this activity (Lorsch and Herschlag, 1998a). The 
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formation of eIF4A2 oligomers on both (AG)5 24BP and (CAA)6CA 24BP (Appendix 
1 Figures 1-5, 1-6) to a lower extent than on (AG)10 24BP RNA further 
emphasises the importance of the optimal binding site and the RNA sequence of 
the single-stranded overhang in oligomerisation. The effect of single-stranded 
RNA on the conformation and activities of eIF4A has been investigated for the 
yeast ortholog (Andreou, Harms and Klostermeier, 2019), further implicating the 
single-stranded RNA as a determinant of eIF4A behaviour. Additionally, the 
dissimilar complexes obtained on different RNAs are in stark contrast and 
provide evidence against the previously described lack of sequence specificity of 
eIF4A (Abramson et al., 1987).  
Furthermore, as the determination of the RNA position and influence in the 
modelled SAXS envelopes cannot be sufficiently distinguished from the protein in 
the formed complexes, a use of a different technique would be advisable. One 
example of a technique to use together with SAXS could be SANS (small-angle 
neutron scattering).   
The potential of eIF4A2 to oligomerise was also investigated in live cells. As for 
the FLIM-FRET technique the protein of interest needs to be tagged with a 
fluorophore the influence of the tag on eIF4A2 oligomerisation was investigated. 
The tests on the tagged-eIF4A2 demonstrated that the tag does not prohibit 
formation of oligomers (Figure 3.7-2). The tagged-eIF4A2 had cytosolic 
localisation, visible in the fluorescence distribution in live cells (Figure 3.7-3), 
which suggested endogenous localisation. The change in fluorescence lifetime, 
i.e., the measurement indicating interaction, was only observed for tagged-
eIF4A2 and not for the free fluorophores, suggesting eIF4A2-eIF4A2 interaction in 
cells. Additional control (Figure 3.7-4) showing co-precipitation of tagged-
eIF4A2 and eIF4A2 WT in RNase 1 conditions indicated direct interactions 
between eIF4A2-eIF4A2. As eIF4A2 can form trimeric complexes, perhaps a use 
of modified FRET could provide additional information about the distribution of 
oligomeric complexes in cells. Methods described in Sun et al., 2010; Hoppe et 
al., 2013 suggest use of three-fluorophore system in which interactions between 
multiple proteins can be measured.  
As shown in Figure 1.3.2-2 eIF4G has two binding sites for eIF4A and although 
eIF4G is not the preferred interaction partner of eIF4A2, it has been shown 
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previously that overexpression of eIF4A2 causes it to associate with eIF4G 
(Wilczynska et al., 2019). Taken together, the possibility of eIF4G-mediated in 
cell interaction between eIF4A2 cannot be excluded. However, the native 
concentrations of both eIF4A1 and eIF4A2 as well as the amount of tagged 
eIF4A2 should far exceed the in-cell concentration of eIF4G (see Bekker-Jensen 
et al., 2017 for quantification of endogenous HeLa cell proteome). This suggests 
that at least part of the observed signal stems from eIF4A2-eIF4A2 eIF4G-
independent interaction. For additional supporting evidence please refer to 
Appendix 3 Figure 3-3. Perhaps, in the future, using the above-mentioned 
three-fluorophore system could provide more evidence for eIF4G-independent 
interaction.  
One of the disadvantages of FLIM-FRET is that it requires overexpression of the 
tagged proteins, which as mentioned-above could potentially change the in-cell 
interactions. However, there is a lack of specific methods that would detect 
homo-interacting proteins without using a tag. Antibody based methods as IP or 
PLA (proximity ligation assay) require a use of tagged proteins to detect homo-
complexes. In this case, the performed Western Blot control demonstrated that 
WT and overexpressed eIF4A2 was on a comparable level (Figure 3.7-3) and the 
signs of cell death were not visible suggesting that overexpression of eIF4A2 was 
not detrimental to the cells and similar to what could be expected naturally.  
As oligomeric complexes were detected on RNA substrates with double-stranded 
region, and co-operativity in the unwinding reaction was observed (Figure 
3.3-1) the catalytic activities of eIF4A2 in conditions stimulating oligomerisation 
were investigated. Both the unwinding and ATPase activities were higher on RNA 
substrate with (AG)10 than (CAA)6CA single-stranded overhang (Figure 3.8-2). 
However, this correlated both with the higher affinity towards the (AG)10 RNA as 
well as the greater oligomerisation induction by this RNA. To determine what 
was the main predictor of the differences in the catalytic capacities of eIF4A2, 
additional RNA substrates were employed (Figure 3.8-3). eIF4A2 activity on the 
substrate with most similarities in its sequence to previously used (AG)10 - 
(AGUG)5 single-stranded overhang, exhibited the greatest unwinding potential. 
This again correlated with both the highest oligomerisation and the lowest KD. 
However, for other tested substrates, this correlation was not observed. The 
difference between apparent KD measured in presence of ATP and KD in AMP-PNP 
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conditions for all the tested RNA substrates indicates possible different binding 
dynamics in presence of ATP (Table 3.8-1). Additional experiments could 
perhaps indicate whether possible differences in the dynamics of RNA binding 
(kon and koff rates) dictate the outcomes of the unwinding. Possibly the 
differences observed in the SAXS data for monomers formed on (AG)10 and 
(CAA)6CA could also indicate different modes of binding to the tested RNA 
substrates. Worth noting is that the RNAs used in the unwinding assay have a 
relatively long double-stranded region (24 base-pairs). As the measured increase 
in fluorescence stems only from the fully unwound RNA substrate, potential 
small steps of unwinding could remain unnoticed. Additionally, there is a chance 
that the long duplex could reanneal, especially if the protein is no longer bound 
to it. Perhaps shorter dissociation rates of eIF4A2 from the RNA substrate could 
be responsible. Previous studies have explored different lengths of the double-
stranded regions and often resolved to shorter stretches (Lorsch and Herschlag, 
1998a; Rogers, Richter and Merrick, 1999; George W. Rogers, Lima and Merrick, 
2001). Perhaps using RNA substrates with shorter double-stranded regions would 
provide a different or more specific result. Nonetheless, as the sequence of the 
double-stranded region is identical in the tested substrates the comparison 
between different RNA overhangs was possible. Finally, the unexpected 3’-to-5’ 
helicase preference of eIF4A2 (Table 3.8-2, Figure 3.8-5), which was not 
observed for eIF4A1 (George W. Rogers, Lima and Merrick, 2001), could 
potentially correlate with roles more specific to eIF4A2.   
The tested small-molecule inhibitor – silvestrol – induced the RNA binding, 
oligomerisation as well as catalytic activities of eIF4A2 (Figures 3.9-1, 3.9-2, 
3.9-4). This induction of eIF4A activities by an inhibitor has been previously 
reported in the literature (Bordeleau et al., 2005). However, the induction of 
those activities does not preclude silvestrol for being a potent in cell inhibitor 
(Jin et al., 2013; Wolfe et al., 2014; Chen et al., 2016; Biedenkopf et al., 2017). 
The described function of inducing RNA clamping (Iwasaki, Floor and Ingolia, 
2016) and creating a potential molecular roadblock for the ribosome still stands 
true in line with the concept of oligomerisation. The long RNA release time in 
presence of silvestrol was also observed (Figure 3.10-1). The imparted by 
silvestrol functions however point to the lack of specificity of the inhibitor 
towards one paralogue.  
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Finally, the potential differential roles of monomers were explored. Addition of 
competitor RNA induced change in oligomerisation status however full 
monomerisation was not observed (Figure 3.10-2). Another study in a similar 
manner has used competitor RNA to explore the capacities of a monomer, 
however a control of the conditions was not presented (Putnam et al., 2015). 
Nonetheless, addition of (AG)10 competitor RNA obliterated eIF4A2 unwinding 
activity. The change in activity was visible for a competitor concentration that 
did not induce change in oligomerisation. Similar change in activity was 
previously reported without investigation of the eIF4A complexes (G. W. Rogers, 
Lima and Merrick, 2001). The result differed for (CAA)6CA RNA, which did not 
induce oligomerisation to the same extent as (AG)10 RNA, suggesting that the 
unwinding is potentially performed by a free protein recruited by the already 
bound oligomer. Perhaps, additional studies, exploring the regions of eIF4A2 
responsible for oligomerisation could bring more answers.  
In sum, this chapter provided detailed description of molecular functions of 
eIF4A2 and on the basis of this further studies into the wider implication of 
oligomerisation could be produced. Perhaps the eIF4A2 oligomerisation and 
unwinding activities could be part of uORF translation (Wilczynska et al., 2019) 
(see also Chapter 1.5.2). Or maybe the recently found role of eIF4A in 
unwinding RNA secondary structures in stress granules (Tauber et al., 2020), 





4. Interaction partners influence activities of eIF4A2  
4.1. Chapter introduction 
 
The previous chapter focused on the activities of eIF4A2 without its auxiliary 
factors. However, the busy cellular environment provides multitude of 
opportunities for proteins to interact with one another.  
Since eIF4A2 and eIF4A1 have been implicated in distinct translational processes 
(Meijer et al., 2013) with eIF4A1 being the more abundant paralogue in many 
tissues (Nielsen and Trachsel, 1988; Galicia-Vazquez et al., 2012) and the one 
most often recognised as responsible for cancer development and progression (Ji 
et al., 2003; Yan et al., 2011; Lomnytska et al., 2012; Liang et al., 2014; 
Modelska et al., 2015; Tillotson et al., 2017; Gao et al., 2020) it has been 
studied in greater detail. In contrast, the enzymatic activities of eIF4A2 have 
rarely been explored and knowledge about regulation by its interaction partners 
is missing. Moreover, what the implications of this novel, oligomerisation 
potential of eIF4A2 on the interactions with auxiliary proteins remains 
uncovered.  
Here, eIF4A2 activities were explored in presence of the canonical interaction 
partners of eIF4A1 (see also Chapters 1.3.2, 1.4): 1) the small auxiliary protein 
eIF4H, implicated in enhancing the activities of eIF4A1 (Richter-Cook et al., 
1998; Richter et al., 1999; Rogers, Richter and Merrick, 1999; Özeş et al., 2011), 
2) eIF4G1, the scaffold protein of eIF4F complex (Grifo et al., 1983), and 3) 
PDCD4, the mTOR-regulated eIF4A inhibitor (Yang et al., 2002; Suzuki et al., 
2008; Loh et al., 2009; Dennis, Jefferson and Kimball, 2012).  
Additionally, as eIF4A2 but not eIF4A1 is thought to interact with CNOT1, the 
scaffold protein of CCR4-NOT complex (Meijer et al., 2013, 2019; Wilczynska et 
al., 2019), (see also Chapter 1.3.6), the possible influence of short CNOT1 
constructs on eIF4A2 activities was investigated.  
To uncover possible interactions between eIF4A2 and eIF4G1, PDCD4, or CNOT1, 
both in cell and in vitro co-immunoprecipitations were employed in this chapter 
(see also Chapters 2.3.7, 2.4.5).  
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Moreover, as this chapter was focused on the influence of interaction partners 
on enzymatic activities of eIF4A2, pivotal to this study was the purification of 
high-quality recombinant proteins. Next, using biochemical methods described 
and used throughout the previous chapter (Chapter 3), the influence of the 
auxiliary proteins on eIF4A2 unwinding and ATPase activities as well as on RNA 
binding and release was assessed.  
Finally, as eIF4A2 has been shown to inhibit CNOT7 deadenylation activity on 
RNA substrates containing polyA tails in presence of longer CNOT1 constructs 
(Meijer et al., 2019), the effect of eIF4A2 on CNOT7 in presence of shorter 
CNOT1 constructs was tested (see Chapter 2.3.6). Additionally, as DDX6 has 
been shown to interact strongly with CNOT1 (Chen et al., 2014), it has been 
employed as a control for determination of CNOT1 imposed activities.  
In all, this chapter focuses on the influence of potential auxiliary proteins on 

















4.2. eIF4H stimulates unwinding activity of eIF4A2 
 
eIF4H is found ubiquitously in human tissues, with varying degrees of mRNA as 
well as protein expression. Both the eIF4H mRNA and protein levels are high in 
skeletal muscle and brain (Richter et al., 1999, Human Protein Atlas), tissues 
previously shown to have high eIF4A2 expression (Galicia-Vazquez et al., 2012). 
Intriguingly, the expression of eIF4B, an initiation factor described to have 
similar, although more potent role than eIF4H in vitro (Özeş et al., 2011), was 
lower in the brain (Richter et al., 1999, Human Protein Atlas). Therefore, a 
question remains open whether the similar expression pattern of eIF4A2 and 
eIF4H could mean that the two proteins specifically interact with each other.  
As previous studies described the enhancement of eIF4A1 helicase and ATPase 
activities by eIF4H without focusing on how it affects eIF4A2 a further scrutiny 
was needed.  
First, to examine the influence of eIF4H on the catalytic capacities of eIF4A2, 
eIF4H was heterologously expressed. A previously cloned full length eIF4H 
construct containing a His-SUMO tag was expressed in E. coli strain BL21 DE3 RP 
codon+. Bacterial cells were grown, induced, harvested, and lysed as described 
above for eIF4A2 (Chapter 3.2). The cleared lysate was then applied to a Ni2+ 
column and the bound protein eluted in a linear imidazole gradient (Figure 
4.2-1, panel A). Next, the pooled peak fractions were applied to ion exchange 
chromatography. As eIF4H has a calculated pI = 6.66 and is an RNA binding 
protein, a cation exchange column was used (Figure 4.2-1, panel B). Pooled 
peak fractions were subsequently applied on a size exclusion chromatography 
column (Figure 4.2-1, panel C). The eluted protein was concentrated, its 
concentration measured using a UV-VIS spectrometer and the purity was 
estimated through SDS-PAGE (Figure 4.2-1, panel D). In all, eIF4H was deemed 







Figure 4.2-1 eIF4H purification 
A. Representative chromatogram of an elution profile of His-SUMO eIF4H on a 
HisTrap HP column.  
B. Representative chromatogram of an elution profile of pooled fractions containing 
eIF4H after tag cleavage using a HiTrap Heparin column.  
C. Representative size exclusion chromatography elution profile. Purified eIF4H 
elutes at around 90 – 95 mL on a Superdex S200 HiLoad 16/600 column.  
D. Representative Coomassie stained SDS-PAGE of purified, full length, tag free 27 
kDa eIF4H. The numbers on the left of the gel indicate sizes of the protein 











Next, the influence of eIF4H on the unwinding and ATPase activity of eIF4A2 was 
tested. Here, the 5’(AG)10 overhang RNA substrate was used for assays 
established in the previous chapter (Chapter 3.8). This revealed that eIF4H 
greatly stimulated eIF4A2 unwinding activity (Figure 4.2-2, panel A, Table 
4.2-1). The mean unwinding velocity of 5 µM eIF4A2 was 11-fold greater in 
presence of eIF4H. Additionally, eIF4H stimulated eIF4A2 unwinding activity in a 
concentration dependent manner. Curiously, when the Hill equation was fitted 
to the data, it was found that eIF4H reduced the co-operativity between 
different eIF4A2 subunits in the oligomer in the unwinding reaction (Figure 
4.2-2, panel B). This suggests that a functional sub-oligomeric eIF4A2 complex 
may exist when interacting with eIF4H.  
In contrast to earlier reports (Richter-Cook et al., 1998) eIF4H enhanced eIF4A2 
ATPase activity only slightly in presence of both 0.5 µM and 5 µM eIF4H (Figure 
4.2-2, panel C, Table 4.2-1).     
 
 
Figure 4.2-2 eIF4H enhances unwinding activity of eIF4A2 without increasing 
the ATPase activity  
A. Velocity of unwinding of indicated concentrations of eIF4A2 alone (red, n = 4), 
and in presence of 0.5 µM eIF4H (light green, n = 2), 5 µM eIF4H (dark green, n = 
4). Error = SEM, fit – Hill equation. eIF4H enhances eIF4A2 unwinding activity to a 
higher degree than silvestrol.  
B. Hill coefficient of obtained from the fit in panel A. eIF4H reduces the 
cooperativity between eIF4A2. 
C. ATPase activity of 5 µM eIF4A2 concentration in presence of indicated eIF4H 
concentration. Colour scheme of samples, n and error as in panel A. eIF4H only 
slightly increases ATPase activity of 5 µM eIF4A2.  
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Next, as eIF4A2 showed a preference in the directionality of unwinding (see 
Figure 3.8-5), it was investigated if the presence of eIF4H affects directional 
specificity. Unwinding assays for double-stranded RNA with 5’ or 3’ single-
stranded overhangs were performed as before (see Figure 3.8-4). The results 
show that eIF4A2 maintains its preference for unwinding in the 3’-to-5’ direction 
also in presence of eIF4H on RNA substrates with AG-overhang (Figure 4.2-3, 
panel A, Table 4.2-1). However, the difference is not as large as for the free 
eIF4A2 (5 µM eIF4A2 with 0.5 µM eIF4H V5’ 4.75 ± 0.39 in comparison to V’3 = 5.53 
± 0.63). Moreover, the activity of free eIF4A2 was enhanced by the presence of 
eIF4H on both 3’(AG)10 and 3’(CAA)6CA overhang substrates. The unwinding 
velocity increased 5-fold in presence of eIF4H for 5 µM eIF4A2 on 3’(CAA)6CA. 
Similarly, to what was shown in Figure 3.8-5, the activation on 3’(AG)10 RNA was 
greater than on 3’(CAA)6CA (Figure 4.2-3, panel B). However, this time, the 
unwinding activity in presence of eIF4H was greater on both the 5’- and 3’(AG)10 
overhang substrates than on the 3’(CAA)6CA (see Figure 3.8-5, Table 4.2-1).  
Next, the contribution of eIF4H to eIF4A2 ATPase activity was tested. A slight 
reduction in the ATPase activity was detected when comparing ATPase of free 
eIF4A2 and in presence of eIF4H on both tested 3’overhang substrates (Figure 










Figure 4.2-3 eIF4H enhances eIF4A2 unwinding activity on a substrate with 
3’overhang to a greater extent than on the one with 5’overhang  
A. Unwinding activity of eIF4A2 in presence of 0.5 µM eIF4H presented as velocity of 
unwinding versus eIF4A2 concentration. eIF4H enhances eIF4A2 unwinding 
activity on substrate with 3’(AG)10 overhang (light turquoise, n = 3) more than on 
5’(AG)10 overhang (green, n = 2). Error = SEM, fit – Hill equation.  
B. Unwinding activity of eIF4A2 presented as in panel A on 3’(AG)10 overhang 
substrate without (light orange) and with 0.5 µM eIF4AH (light turquoise) and on 
3’(CAA)6CA overhang substrate without (light pink) and with 0.5 µM eIF4AH 
(green). eIF4H enhances eIF4A2 activity on both substrates. N = 3, error = SEM, 
fit – Hill equation.  
C. ATPase activity versus eIF4A2 concentration on the same RNA substrates as in 
panel B, colour scheme the same as in panel B. eIF4H slightly reduces the 













As 1) eIF4H stimulated unwinding activity of eIF4A2 to a greater extent on both 
3’ and 5’(AG)10 than on 3’(CAA)6CA overhang RNA, and 2) in the previous chapter 
(Chapter 3.8), eIF4A2 was shown to have a greater preference to unwind RNA 
substrates in 3’-to-5’ direction regardless of the overhang sequence of the 
tested RNA, a question was posed whether eIF4H itself could have a preference 
for the AG-RNA. It has been shown that eIF4H has an RNA recognition motif 
(RRM) (Richter et al., 1999; Rogers et al., 2001); however, as it has been 
reported previously, it is considered to only weakly bind to RNA (Richter-Cook et 
al., 1998; Rozovsky, Butterworth and Moore, 2008). To explore whether eIF4H 
binds AG-RNA, polarisation-based RNA binding experiments were performed, and 
the binding affinity was quantified as KD (Figure 4.2-4). Surprisingly, eIF4H 
showed a higher affinity for (AG)10 RNA than eIF4A2 (KD, eIF4H < KD, eIF4A2). This 
could potentially lead to a possible mechanism for eIF4H-induced eIF4A2 
unwinding activation. It has been shown in the literature that eIF4H improves 
RNA binding of eIF4A1 and that this induction happens through possible protein-
protein interaction (Richter et al., 1999; Rozovsky, Butterworth and Moore, 
2008). Perhaps, here the stronger enhancement of eIF4A2 activity on 5’(AG)10 
than 3’(CAA)6CA could stem from the eIF4H binding itself to the AG-RNA. As the 
eIF4H reduced co-operativity between different eIF4A2 subunits in the oligomer, 
a possible explanation could be that eIF4H binds to the RNA and recruits eIF4A2, 








Figure 4.2-4 eIF4H binds AG-RNA with stronger affinity than eIF4A2  
A. Representative binding of eIF4H (green) and eIF4A2 (red) to (AG)10 RNA measured 
by polarisation. Values were normalised to the polarisation of free RNA, then 
baseline was removed (-1). N = 3, error = SEM from technical duplicate, fit – Hill 
equation.  
B. Comparison of KD obtained from Hill equation fitting of 3 replicates of 
polarisation experiment as presented in panel A. Each dot represents the KD 
obtained from an individual replicate.  
 
 
Table 4.2-1 Comparison of velocity of unwinding and ATPase of 5 µM eIF4A2 
in presence of eIF4H 
24BP RNA overhang eIF4H (µM) V x 10-3 frac. s-1 nM ATP s-1 
5’(AG)10 0 0.43 ± 0.00 12.80 ± 2.30 
5’(AG)10  0.5 4.75 ± 0.39 17.33 ± 4.43 
3’(AG)10 0 1.43 ± 0.56 17.10 ± 2.61 
3’(AG)10 0.5 5.53 ± 0.63 11.83 ± 1.17  
3’(CAA)6CA 0 0.54 ± 0.32 16.78 ± 3.21 










In sum, this chapter described the influence of eIF4H on the catalytic activities 
of eIF4A2 in oligomerisation-inducing conditions. eIF4H stimulated the unwinding 
activity of eIF4A2. However, a decrease of co-operativity between eIF4A2 
protomers in unwinding reaction in the presence of eIF4H was observed. This 
indicates possible different mechanism of unwinding in presence of eIF4H, where 
eIF4A2 relies more on the interaction with eIF4H than between protomers. 
Moreover, eIF4H-stimulated unwinding has a bidirectional nature. However, 
unlike for eIF4A2 alone (see Figure 3.8-5), the presence of eIF4H correlated 
with stronger activity on (AG)10 RNA regardless of the position of single-stranded 
region. This could be perhaps further explained through the surprisingly high 
affinity of eIF4H towards (AG)10 RNA (KD = 0.34 ± 0.08), however eIF4H RNA 
binding to (CAA)6CA as well as eIF4A2 binding in presence of eIF4H should be 
evaluated to reach conclusion.  
Finally, the assessment of the eIF4A2 ATPase activity indicated that the changes 
induced by eIF4H are less potent than its influence on unwinding activity. A 
slight increase was observed for the 5’(AG)10 overhang substrate, however the 
opposite was observed for substrates with a 3’overhang. This suggested that the 

















4.3. eIF4G does not synergistically activate eIF4A2 in 
presence of eIF4H  
 
eIF4G has been shown not to be the main interaction partner of eIF4A2 (Meijer 
et al., 2013, 2019; Wilczynska et al., 2019). However, none of the above-
mentioned publications contested the eIF4A2-eIF4G interaction. In fact, in 
Wilczynska et al., 2019 under the high overexpression of eIF4A2 a large increase 
of interaction with eIF4G was observed. This significant increase was not 
observed for overexpressed eIF4A1. Moreover, as presented in Wilczynska et al., 
2019 the regions responsible for interaction with eIF4G are highly identical 
between eIF4A1 and eIF4A2, with only one amino acid difference between them. 
Additionally, as presented in Meijer et al., 2019 in fractions of cytoplasmic HeLa 
lysate containing eIF4A2, both the presence of CNOT1 and eIF4G was detected. 
Moreover, a more recent report (Robert et al., 2020) has described existence of 
different variations of eIF4F complex, some of them containing eIF4A2. In all, 
the interaction between eIF4A2 and eIF4G cannot be dismissed. Perhaps, in cells 
with high eIF4A2 overexpression, or tissues in which eIF4A2 is the dominant 
paralogue it is the eIF4A2 that preferentially interacts with eIF4G.  
First, to support the previous reports, immunoprecipitations of eIF4A1 and 
eIF4A2 were performed in HeLa cells lysed either in presence of Ribolock, to 
preserve RNA integrity, or RNase 1, to degrade the RNA (Figure 4.3-1). eIF4G1 
co-precipitated strongly with eIF4A1, however in both RNA stabilising and RNA 
degrading conditions, a small fraction of eIF4G1 co-precipitated with eIF4A2 
suggesting that at least a small fraction of eIF4A2 in non-overexpressing 






Figure 4.3-1 eIF4A2 interacts with eIF4G1 
Co-immunoprecipitations of IgG, eIF4A1 and eIF4A2 in HeLa cells lysed in presence of 
Ribolock (left) and RNase 1 (right), probed with anti-eIF4G1 and anti-eIF4A2, and anti-
eIF4A1 antibodies. eIF4G1 interacts strongly with eIF4A1, however co-precipitation of 
eIF4G1 with eIF4A2 is also visible. No unspecific bands were detected in IgG IP lane. 
Asterisk indicates denatured antibody chains.  
 
As both the previous reports and data presented in Figure 4.3-1 showed that 
eIF4A2 can interact with eIF4G1, the influence of eIF4G1 on catalytic activities 
of eIF4A2 was investigated. First, an N-terminally truncated eIF4G1 (amino acids 
674 – 1599), called eIF4G-MC, previously cloned into petSUMO vector was 
expressed in a similar manner as described in Chapter 4.2. The lysate containing 
His-SUMO-eIF4G-MC was subjected to affinity chromatography and eluted in a 
linear imidazole gradient (Figure 4.3-2, panel A). Subsequently, the fractions 
containing the protein were pooled together and cleaved with ULP1 to remove 
His-SUMO tag. Next, the sample was applied onto cation exchange column, as 
the pI of eIF4G-MC is 7.89 (Figure 4.3-2, panel B, see also Chapter 2.2). The 
eluted peak was then subjected to size exclusion chromatography (Figure 4.3-2, 
panel C), and fractions eluted at around 70 mL were collected and 
concentrated. The purity of the obtained protein was investigated by SDS-PAGE 
(Figure 4.3-2, panel D) and UV-VIS spectrum indicated no nucleic acid 
contamination. In sum, eIF4G-MC was deemed to be of good purity level for use 




Figure 4.3-2 eIF4G-MC purification 
A. Affinity chromatography elution profile on 5 mL HisTrap HP column (Ni2+ resin). 
eIF4G-MC elutes in a linear imidazole gradient.  
B. Ion exchange chromatography – eIF4G-MC after ULP1 cleavage elutes in a linear 
gradient of KCl on cation exchange column (HiTrap Heparin column).  
C. SEC chromatogram of peak collected from heparin column in panel C. eIF4G-MC 
elutes at around 70 mL Superdex S200 HiLoad 16/600 column.  
D. Coomassie stained SDS-PAGE gel presenting purified eIF4G-MC (104 kDa). Protein 
marker sizes in kDa indicated on the left.  
 
 
As the N-terminal truncation of eIF4G1 – eIF4G-MC contains both eIF4A binding 
sites but lacks the eIF4E binding site, rendering it eIF4E independent and 
functionally active (Feoktistova et al., 2013), this construct can be used in 
assays without additional co-factors.    
First the influence of eIF4G-MC was investigated on eIF4A2 unwinding and 
ATPase activity on 5’(AG)10 overhang RNA substrate (Figure 4.3-3, panel A and B 
respectively). Similarly to what was described in the literature for eIF4A1 
(Rogers et al., 2001; Korneeva et al., 2005; Nielsen et al., 2011; Özeş et al., 
2011), a slight increase in the tested activities was detected. However, the 
observed change was less than previously described 2-fold increase.  
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As 1) eIF4G-MC stimulated eIF4A2 activity only weakly, 2) previous studies 
indicated synergistic activation of eIF4A(1) by eIF4G and eIF4B (Abramson, Dever 
and Merrick, 1988; Nielsen et al., 2011), and 3) eIF4H was found to be 
functionally similar to eIF4B in vitro (Rogers et al., 2001), a question was posed 
whether eIF4A2 could be synergistically activated by eIF4H and eIF4G-MC.  
This time, unwinding reactions were performed on 5’(AG)10 RNA substrate with 
0.5 µM eIF4G-MC and either 0.5 or 5 µM eIF4H (Figure 4.3-3, panel C, Table 
4.3-1). Surprisingly, the enhanced velocity of unwinding of eIF4A2 induced by 
eIF4H was reduced in presence of eIF4G-MC at higher eIF4A2 concentrations. 
Intriguingly, this reduction in velocity was eIF4H concentration dependent, i.e., 
higher concentration of eIF4H correlated with higher unwinding activity. eIF4G-
MC, similarly as eIF4H reduced cooperativity between eIF4A2 protomers, 
however to a lesser extent (Table 4.3-2). The cooperativity of eIF4A2 in 
presence of both eIF4H and eIF4G-MC cannot be determined as calculated error 
of the Hill coefficient was too high. Moreover, the functional binding affinity 
(presented as KD) of eIF4A2 to RNA substrate decreased in presence of eIF4G-MC, 
whereas in presence of eIF4H KD changed only slightly (Table 4.3-2). 
Interestingly, presence of both eIF4G-MC and eIF4H increased the affinity. As the 
functional binding of eIF4A2 was greater (lower KD) in presence of both tested 
co-factors but the velocity was lower than the one in presence of eIF4H alone, 
the data might indicate a possible competition between eIF4H and eIF4G-MC for 
eIF4A2. Additional indication for the possible competition can stem from slight 
increase in activity in presence of both interaction partners for lower 
concentration of eIF4A2 (3 µM) in comparison to 0.5 µM eIF4H only.  
Interestingly, the opposite effect was observed for eIF4A2 ATPase activity 
(Figure 4.3-3, panel D, Table 4.3-1). Presence of eIF4H in the reaction reduced 
the ATPase activity of eIF4A2 in eIF4H concentration dependent manner, visible 
at high eIF4A2 concentrations. In all, the presence of eIF4G-MC in the reaction 
changed the activity of eIF4A2, suggesting eIF4H and eIF4G-MC seemed to exert 






Figure 4.3-3 eIF4G does not strongly stimulate eIF4A2 catalytic activities and 
reduces the influence of eIF4H on unwinding activity 
A. Unwinding activity of eIF4A2 presented as velocity of unwinding of 5 µM eIF4A2 
on 5’(AG)10 overhang substrate (red) and in presence of 0.5 µM eIF4G-MC 
(burgundy). Activity of eIF4A2 alone and in presence of eIF4G-MC is highly 
similar. N = 4, error = SEM.  
B. ATPase activity of 5 µM eIF4A2 on (AG)10 overhang RNA (red) and in presence of 
0.5 µM eIF4G-MC (burgundy). ATPase with and without eIF4G-MC is similar. N = 
4, error = SEM. 
C. Velocity of unwinding versus eIF4A2 concentration on 5’(AG)10 overhang RNA 
substrate in presence of: 1) 0.5 µM eIF4H (bright green), n = 2, 2) 5 µM eIF4H 
(dark green), n = 4, 3) 0.5 µM eIF4G-MC and 0.5 µM eIF4H (bright green with 
burgundy border), n = 3, 4) 0.5 µM eIF4G-MC and 5 µM eIF4H (dark green with 
burgundy border) n =3. Addition of eIF4G-MC reduces the increase in eIF4A2 
unwinding activity exerted by presence of eIF4H. Error = SEM.  
D. ATPase activity for indicated eIF4A2 concentrations on 5’(AG)10 overhang RNA in 
presence of 1) eIF4G (burgundy) n = 4, 2) 0.5 µM eIF4G-MC and 0.5 µM eIF4H 
(bright green with burgundy border), n = 3, 3) 0.5 µM eIF4G-MC and 5 µM eIF4H 
(dark green with burgundy border) n =3. Error = SEM. A reduction of ATPase 
activity in presence of eIF4H is visible.  
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eIF4G-MC seemed to stimulate eIF4A2 unwinding activity on 5’(AG)10 overhang 
RNA only to a low extent. However, eIF4A2 showed a preference in unwinding 
from 3’-to-5’ direction (see Figure 3.8-5), therefore the next step was to 
determine the effect of eIF4G-MC on 3’(AG)10 overhang RNA. A very limited 
increase of eIF4A2 activity in presence of eIF4G-MC was detected in the 3’-to-5’ 
unwinding direction (Figure 4.3-4, panel A). Additionally, the unwinding activity 
was lower than for the free eIF4A2 (compare Table 4.2-1 and 4.3-1). Moreover, 
the ATPase activity on the 3’overhang RNA was reduced in comparison to 
5’overhang, similarly as in the case of eIF4H (Figure 4.3-4, panel B, see also 
Table 4.2-1).  
 
 
Figure 4.3-4 eIF4G reduces eIF4A2 activity on 3’overhang RNA substrate 
A. Comparison of unwinding velocity versus eIF4A2 concentration for eIF4A2 activity 
in presence of 0.5 µM eIF4G-MC on RNA substrates with (AG)10 5’- (burgundy, n = 
4) and 3’- (orange, n = 3) overhangs. Activity on 3’(AG)10 is only marginally 
increased in comparison to 5’overhang. Error = SEM.  
B. Comparison of ATPase activity versus eIF4A2 concentration in presence of 0.5 µM 
eIF4G-MC. Colour scheme, n, and error as in panel A.  
 
 
Table 4.3-1 Comparison of velocity of unwinding and ATPase of 5 µM eIF4A2 
in presence of eIF4G-MC 
24BP RNA 
overhang 
eIF4H (µM) eIF4G-MC (µM) V x 10-3 frac. s-1 nM ATP s-1 
5’(AG)10 0 0.5 0.69 ± 0.17 15.96 ± 2.61 
5’(AG)10  0.5 0.5 4.52 ± 1.27 12.53 ± 1.56 
5’(AG)10  5 0.5 7.08 ± 1.22 8.32 ± 1.75 





Table 4.3-2 Functional binding affinity and Hill coefficient of eIF4A2 for 
unwinding reactions in presence of interaction partners  
24BP RNA 
overhang 
eIF4H (µM) eIF4G-MC (µM) functional KD (µM) Hill 
coefficient 
5’(AG)10 0 0 4.9 ± 0.5 2.6 ± 0.3 
5’(AG)10 0.5 0 3.9 ± 0.6 1.6 ± 0.4 
5’(AG)10  5 0 5.3 ± 0.2 1.1 ± 0.3 
5’(AG)10  0 0.5 8.4 ± 0.7  1.9 ± 0.3 
5’(AG)10 0.5 0.5 1.9 ± 0.8 2.7 ± 1.9 
5’(AG)10 5 0.5 3.5 ± 0.3 2.6 ± 0.8 
 
 
In sum, eIF4G1 can interact with eIF4A2, and similarly, as in the case of eIF4A1 
(Rogers et al., 2001; Korneeva et al., 2005; Nielsen et al., 2011; Özeş et al., 
2011), eIF4G-MC enhanced the catalytic activities of eIF4A2, however to a lower 
extent. Moreover, both eIF4G-MC and eIF4H seem to reduce the cooperativity 
between the eIF4A2 protomers, while exerting different outcomes on eIF4A2 
activity. Additionally, the functional binding affinity of eIF4A2 was reduced in 
presence of eIF4G-MC. However, an increase of the functional binding affinity 
was observed when both eIF4G-MC and eIF4H were present in the reaction. In 
presence of both interaction partners eIF4A2 unwinding activity was greater than 
for the free eIF4A2, however the velocity was lower than in presence of eIF4H 
alone. However, the presence of eIF4H reduced the ATPase activity of eIF4A2-
eIF4G-MC. This potentially suggest, a competition between the eIF4G-MC and 
eIF4H for eIF4A2. Finally, the tested activities in presence of eIF4G-MC showed a 
slight increase of unwinding and decrease in ATPase on 3’(AG)10 in comparison to 
5’(AG)10 RNA substrate. Moreover, the activities of free eIF4A2 on 3’(AG)10 RNA 









4.4. PDCD4 inhibits eIF4A2 catalytic activities  
 
PDCD4 is thought to be a tumour suppressor that acts upon eIF4A helicase (Yang 
et al., 2002, 2004; Chen et al., 2003; LaRonde-LeBlanc et al., 2006; Chang et 
al., 2009; Loh et al., 2009). Interestingly, despite the functional differences in 
protein translation between eIF4A1 and eIF4A2 (Meijer et al., 2013), PDCD4 has 
been shown to interact with eIF4A2 (Yang et al., 2002). Moreover, as eIF4A2 
expression in the brain is higher than that of eIF4A1 (Galicia-Vázquez et al., 
2012), PDCD4 has been demonstrated to interact more preferentially with eIF4A2 
in this organ (Yang et al., 2002). Despite this interaction, previous studies 
exploring enzymatic activities in presence of PDCD4 have been focused solely on 
eIF4A1 and its co-factors (Yang et al., 2002).  
Moreover, in the study that explored in vitro inhibition of eIF4A1 by PDCD4, 
PDCD4 has been shown to inhibit eIF4A1 activation by eIF4B (Yang et al., 2002). 
As 1) PDCD4 and eIF4G1 share MA3 domain similarities (Suzuki et al., 2008), 2) 
PDCD4 has been shown to displace eIF4G from eIF4A (Suzuki et al., 2008; Chang 
et al., 2009), but 3) no additive effect was observed between eIF4H and eIF4G-
MC on eIF4A2 activity, (see Figure 4.3-3, panels C, D), a question whether eIF4H 
could still exert its function upon eIF4A2 in presence of PDCD4 was posed.  
First, the interaction of eIF4A2 and PDCD4 was assessed by co-
immunoprecipitation in HeLa cells (Figure 4.4-1, panel A). PDCD4 co-
precipitated in both eIF4A1 and eIF4A2 lanes and not in IgG IP lane, indicating an 
association of eIF4A2 with PDCD4. 
Therefore, the effect of PDCD4 on catalytic activities of eIF4A2 was assessed. 
First, full length PDCD4 cloned into petSUMO vector was expressed in E. coli as 
described previously (see Chapters 2.2, 3.2, 4.2). The cleared lysate was 
applied on a HisTrap HP column and fractions containing bound proteins were 
eluted in a linear imidazole gradient (Figure 4.4-1, panel B). Next, the His-
SUMO tag was cleaved off with ULP1 and the sample was subjected to anion 
exchange chromatography as calculated pI of PDCD4 is 5.07 (Figure 4.4-1, panel 
C). PDCD4 eluted in linear KCl gradient and the pooled fractions containing the 
protein were applied to size exclusion chromatography (Figure 4.4-1, panel D). 
PDCD4 eluted around 85 mL on Superdex S200 HiLoad 16/600 column. The 
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concentration of protein was determined using UV-VIS spectrum and calculated 
extinction coefficient and the purity was estimated by SDS-PAGE (Figure 4.4-1, 
panel D, left). In all, the obtained PDCD4 protein was assessed to be of good 




Figure 4.4-1 PDCD4 purification  
A. Co-immunoprecipitations of IgG, eIF4A1 and eIF4A2 in HeLa cells, probed with 
anti-PDCD4 and anti-eIF4A2 antibodies. PDCD4 co-precipitated in both eIF4A1 
and eIF4A2 IP lanes. No unspecific bands were detected.  
B. Representative elution profile of PDCD4 in a linear imidazole gradient on a 
HisTrap HP column. 
C. Representative chromatogram of PDCD4 protein sample after ULP1 treatment. 
PDCD4 elutes in a linear KCl gradient on a ResourceQ column. 
D. Representative size exclusion chromatography column of PDCD4. PDCD4 elutes 
around 85 mL on a Superdex S200 HiLoad 16/600 column.  
E. Coomassie stained SDS-PAGE gel presenting purified PDCD4 (52 kDa). Protein 








Next, the effect of PDCD4 on eIF4A2 unwinding and ATPase activities was tested 
on 5’(AG)10 overhang RNA. Similarly, as what was previously described for eIF4A1 
(Yang et al., 2002), PDCD4 inhibited eIF4A2 unwinding activity in a 
concentration dependent manner (Figure 4.4-2, panel A); here even a 4-fold 
excess of PDCD4 did not inhibit fully the unwinding activity of 5 µM eIF4A2. 
However, as this reaction was performed in presence of eIF4H, its influence on 
the inhibition could not be excluded. Contrary to what was reported for eIF4A1, 
eIF4B and PDCD4 (Yang et al., 2002), eIF4H in presence of equimolar PDCD4 and 
eIF4A2 concentrations still stimulated eIF4A2 unwinding activity (Figure 4.4-2, 
panel B, left). To exclude possible batch issues, this experiment was replicated 
with PDCD4 from a new protein purification. The obtained results were identical 
(± SEM), suggesting that eIF4H can stimulate eIF4A2 in presence of PDCD4. To 
exclude a role of eIF4H in prevention of eIF4A2 inhibition by PDCD4, the same 
experiments were performed in absence of eIF4H (Figure 4.4-2, panel B, left). 
Note, that the reaction performed with free eIF4A2 is only a technical duplicate. 
Similarly, as in the presence of eIF4H, equimolar concentration of PDCD4 did not 
fully inhibit eIF4A2 activity (Figure 4.4-2, panel B, left). Since the activity of 
eIF4A2 is a lot lower than in presence of eIF4H a direct comparison is difficult to 
make. Therefore, the obtained results were normalised to the respective 
starting value with 0 µM PDCD4 (Figure 4.4-2, panel B, right). The PDCD4 
inhibition followed a similar trend both in presence and absence of eIF4H. 
Additionally, PDCD4 inhibition of eIF4A2 ATPase activity was correlated with the 
inhibition of unwinding (Figure 4.4-2, panel C).  
In all, PDCD4 interacts with eIF4A2 even in cells in which eIF4A2 is not the 
dominant paralogue. Moreover, PDCD4 inhibits eIF4A2 in concentration 
dependent manner, however a full inhibition of both unwinding and ATPase 
activity requires excess of PDCD4. Additionally, eIF4H stimulates eIF4A2 
unwinding activity even in equimolar PDCD4 to eIF4A2 ratio. Finally, the 






Figure 4.4-2 PDCD4 completely inhibits eIF4A2 unwinding and ATPase 
activities when in excess over eIF4A2 
A. Unwinding activity of 5 µM eIF4A2 in presence of 0.5 µM eIF4H and indicated 
concentration of PDCD4, presented as fraction unwound over time. Activity of 
eIF4A2 decreases with increase of PDCD4 concentration. N = 6, error bar – SEM.  
B. Left: eIF4A2 velocity of unwinding versus PDCD4 concentration for 5 µM eIF4A2 
(light purple, n = 1), and in presence of 0.5 µM eIF4H (dark purple, n = 6). Right: 
Normalisation of unwinding from the graph on the left to the result obtained for 
0 µM PDCD4 concentration. The influence of PDCD4 on eIF4A2 activity is the 
same both with and without presence of eIF4H. Error – SEM.  
C. ATPase activity of 5 µM eIF4A2 alone (light purple = 1) and in presence of 0.5 µM 












4.5. CNOT1 reduces eIF4A2 affinity for RNA  
 
Recent reports have shown that eIF4A2 plays a role in translational repression, 
through association with CNOT1, a large scaffold protein of CCR4-NOT complex 
(Meijer et al., 2013, 2019; Wilczynska et al., 2019). However, this interaction 
has also been contested (Chen et al., 2014). This subchapter’s aim was to 
explore the potential interaction and what could modulate it, as well as to test 
the previously unexplored possible influence of CNOT1 on eIF4A2 enzymatic 
activities.  
As purification of a longer construct of CNOT1 spanning both MA3 and MIF 
domains turned out to be problematic (see selected examples Appendix 2 




Figure 4.5-1 CNOT1 constructs 
CNOT1 constructs used in this thesis. Numbers indicate start and end residues of the 











First His-SUMO-CNOT1-MIF4G construct (further called as MIF – amino acids 1093 
– 1317; generated by Dr Tobias Schmidt) was expressed in E. coli strain BL21 DE3 
RP codon+. The precleared bacterial lysate was treated in the same manner as 
for the other proteins in this chapter (see also Chapter 2.2). First, His-SUMO-MIF 
was eluted in a linear imidazole gradient from HisTrap HP affinity column 
(Figure 4.5-2, panel A, top left), next after ULP1 cleavage the fractions 
containing MIF protein were applied to a ResourceQ column (Figure 4.5-2, panel 
A, top right; see SDS-PAGE bottom right). Even though the calculated pI of MIF 
was 6.62 the protein did not bound to the anion exchange column in pH 7.5. 
Therefore, flow through (FT) was collected, concentrated, and applied on a 
Superdex S200 HiLoad 16/600 size exclusion column (Figure 4.5-2, panel A, 
bottom left). The fractions containing proteins that eluted at around 100 mL 
retention volume were collected and resolved on an SDS-PAGE (Figure 4.5-2, 
panel A, bottom right). This time, contaminants were visible in the sample and 
additional purification steps were performed. As most of the contaminants 
visible on a Coomassie stained gel corresponded in size to His-SUMO tag a 
reverse affinity chromatography was performed (Figure 4.5-2, panel B, top). 
This time, flow through from the HisTrap HP column contained MIF protein and 
contaminants were eluted in a linear imidazole gradient (Figure 4.5-2, panel B, 
bottom left). Finally, the flow through from reverse affinity chromatography was 
concentrated and applied again on a Superdex S200 HiLoad 16/600 column. This 
time, the sample did not contain contaminants, and MIF eluted in earlier 
fractions - 95 mL (Figure 4.5-2, panel B, bottom right). Finally, the 
concentration of MIF was determined by measuring its absorbance and the purity 
was assessed using SDS-PAGE (Figure 4.5-2, panel B, bottom right). In all, MIF 





Figure 4.5-2 CNOT1 MIF domain purification  
A. Purification of CNOT1 MIF domain (amino acids 1093-1317). Representative 
chromatograms. MIF elution in imidazole gradient on HisTrap HP (affinity 
chromatography) – top left. ULP1 treated MIF did not bound to anion exchange 
column (ResQ), the flow through was collected and concentrated – top right 
panel. The 26 kDa MIF eluted at around 100 mL on Superdex S200 HiLoad 16/600 
column – bottom left panel. Coomassie stained gels from MIF purification – 
bottom right, fractions presented on the gels indicated above each lane, marker 
sizes in kDa indicated on the side. FT – flow through. MIF construct was deemed 
not pure enough (contamination of cleaved tag and other proteins visible).  
B. Further purification of pooled fractions from size exclusion chromatography 
visible in panel A. The pooled fractions were of large volume, therefore double 
application on HisTrap HP column was needed – top panels. Collected flow 
through (FT) from HisTrap HP resolved on Coomassie stained gel visible in the 
bottom left panel – samples indicated on the top of the gel, marker sizes in kDa 
indicated on the side. Size exclusion chromatography of concentrated FT 
fractions from reverse affinity (Superdex S200 HiLoad 16/600 column), with 
Coomassie stained gel indicating final product (bottom right).  
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Next, CNOT1 MA3 domain (amino acids 800 - 999; cloned by Dr Lori Buetow) in 
petSUMO vector was expressed in E. coli strain BL21 DE3 RP codon+. It should be 
noted that there are 93 amino acids uncovered between both MIF and MA3 
constructs, however purification of longer MA3 domain, including linker was 
unsuccessful (see Appendix 2 Figure 2-3). First, pre-cleared lysate was applied 
to a HisTrap HP column, and the bound protein eluted in a linear imidazole 
gradient (Figure 4.5-3, panel A). Next, a protocol described in Fabian et al., 
2013 was followed. However, the construct did not bind to an anion exchange 
column both in the pH conditions described previously (Fabian et al., 2013) as 
well as in increased pH of the buffer (Figure 4.5-3, panel B, left). As the 
collected flow-through contained both the MA3 domain and the cleaved His-
SUMO tag (Figure 4.5-3, panel B, middle), reverse affinity chromatography was 
performed using a peristaltic pump. The absorbance of collected FT was 
measured and the final product purity was determined based on Coomassie 
stained gel (Figure 4.5-3, panel B, right). In sum, the MA3 domain was deemed 
to be of good quality to be used in further studies.  
In this subchapter CNOT1 constructs are referred to as MIF (amino acids 1093 – 
1317), MA3 (amino acids 800 - 999), MIF + MA3, when used together. 
Additionally, longer construct spanning both domains (amino acids 800 – 1312) 
was gifted by Dr Lori Buetow and is referred to as MA3-MIF (see Appendix 2 
Figure 2-4). It should be noted that the longer MA3-MIF construct was limited in 
both concentration (due to aggregation issues) and amount therefore it could 





Figure 4.5-3 CNOT1 MA3 domain purification  
A. Elution profile of CNOT1 MA3 (amino acids 800 – 999) in a linear imidazole 
gradient on HisTrap HP column – left, and a Coomassie stained gel representing 
fractions from this step of purification (marker sizes in kDa indicated on the side 
of the gel). Flow through – FT.  
B. MA3 elution profile on a heparin column in increasing concentration of KCl in pH 
= 7.5 (left) and collected flow through (FT) applied again in pH = 8.5 (middle). 
Coomassie stained gels from purification (right), with marker size indicated on 
the side of the gel. Each time, MA3 fraction was found in FT. Gel on the right 
indicates additional purification steps – reverse affinity chromatography – done 
with a peristaltic pump – FT fractions contained clean protein.  
 
 
Next, the interactions between the purified CNOT1 constructs and eIF4A2 were 
examined through immunoprecipitations of recombinant proteins (see also 
Chapter 2.3.7). As interaction between MIF domain and DDX6 has been 
previously described (Chen et al., 2014), DDX6 was used as a control. For DDX6 
purification see Appendix 2 Figure 2-5. The proteins for IPs were mixed in 
equimolar concentrations in binding buffer supplemented with IGEPAL CA-630 
(see Chapter 2.3.7). MIF domain precipitated weakly with eIF4A2, however the 
precipitation with DDX6 was only 1.5-fold stronger, quantified as signal intensity 
from the gel (Figure 4.5-4, panel A). No interaction between eIF4A2 and MA3 
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was detected in the tested conditions, and 10-fold lower interaction was 
observed for MA3 and DDX6 than for MIF and DDX6.  
As it has been described that 1) CNOT1 stimulates ATPase activity of DDX6 and 
modulates its conformation, with the structure indicating that bound DDX6 is 
ATPase competent (Mathys et al., 2014), 2) the ATPase competent conformation 
of DDX6 is similar to the one observed for yeast eIF4A in presence of eIF4G 
(Schutz et al., 2008), 3) eIF4A undergoes conformational changes during ATP 
conversion and RNA binding (Lorsch and Herschlag, 1998b), the interaction 
between eIF4A2 and MIF was explored in presence of RNA and three stages of 
ATP conversion, i.e., AMP, ADP + Pi, AMPPNP (Figure 4.5-4, panel B). Indeed, 
presence of RNA and different adenosine phosphates influenced the interaction. 
The strongest, albeit still rather weak, interaction between eIF4A2 and MIF was 
observed in presence of ADP + Pi. Free proteins interacted to lower extent, and 
a low intensity band was detected for AMP condition.  
As presence of ATP derivatives and RNA seemed to change the interaction 
between MIF and eIF4A2, it was tested whether both MIF and MA3 could co-
precipitate in AMP and ADP + Pi conditions (Figure 4.5-4, panel C). MIF domain 
again coprecipitated with eIF4A2 in the tested conditions, however this time MIF 
domain interacted with eIF4A2 the strongest when both MIF and MA3 were 
present in ADP + Pi conditions. Moreover, a co-precipitation of MA3 was observed 
in ADP + Pi condition.  
In all, both MIF and MA3 domains can interact with eIF4A2 to a low extent. 
Moreover, this interaction can be modulated by presence of RNA and different 






Figure 4.5-4 MIF domain of CNOT1 interacts with eIF4A2 more strongly than 
MA3 domain  
A. Coomassie stained gel of IPs on recombinant proteins representing interactions 
of eIF4A2 and DDX6 with MIF and MA3 domains. Both MIF and MA3 domains co-
precipitated with DDX6, MA3 to a lower extent. Only MIF domain of CNOT1 co-
precipitated with eIF4A2. 100 µL of 5 µM of each protein was used per IP.  
B. Coomassie stained gel of IP on recombinant proteins representing co-
precipitation of CNOT1 MIF domain and eIF4A2 in 4 conditions: 1) free proteins, 
2) 1 µM (AG)10 RNA and 1 µM AMP, 3) 1 µM (AG)10 RNA and 1 µM ADP + Pi, 4) 1 µM 
(AG)10 RNA and 1 µM AMP-PNP. 100 µL of 5 µM of each protein was used per IP. 
eIF4A2 precipitated in eIF4A2 IP in all conditions, MIF co-precipitation visible in 
all conditions except the AMP-PNP one.  
C. Coomassie stained gel of IP on recombinant proteins representing co-
precipitation of CNOT1 MIF and MA3 domains and eIF4A2 in 1 µM (AG)10 RNA and 
1 µM AMP and 1 µM (AG)10 RNA and 1 µM ADP + Pi conditions. 100 µL of 5 µM of 
each protein was used per IP. Lanes with conditions unrelated to this experiment 
were removed. MIF domain co-precipitated with eIF4A2 in all tested conditions, 
weak co-precipitation of MA3 domain is visible only in ADP + Pi condition with all 
the tested proteins present.  
 
 
Next, as the interaction between MIF, MA3 and eIF4A2 was established, the 
influence of both domains on eIF4A2 RNA unwinding was investigated. Here, free 
eIF4A2 unwinding activity was set as 100% and the activity in presence of MA3, 
MIF, and MA3-MIF was normalised to this value (Figure 4.5-5, panel A). None of 
the tested domains influenced significantly eIF4A2 activity. A small reduction 




As the influence on eIF4A2 unwinding activity was not striking, the same CNOT1 
constructs were tested with DDX6 (Figure 4.5-5, panel B). As MIF domain 
induced DDX6 unwinding to a high extent, the unwinding activity of free DDX6 
and in presence of other CNOT1 constructs was normalised to this value, 
similarly as in Figure 4.5-5, panel A. DDX6 unwinding activity was undetectable, 
and MA3 did not activate DDX6 unwinding activity. MA3-MIF activated DDX6 
however to about 30% of the activation observed in presence of MIF. It should be 
noted however, that previous experiments in the Bushell lab, indicated a greater 
activation of DDX6 unwinding in presence of a longer construct (amino acids 842 
– 1317). This could possibly indicate, 1) that the longer construct used in this 
experiment (amino acids MA3-MIF 800 – 1312) acts differently than the one 
previously used in the Bushell lab (amino acids 842 – 1317), 2) the gifted MA3-
MIF is a mixture of both active and inactive protein, 3) small amounts of 
contaminants present in MA3-MIF sample led to inaccurate determination of 
concentration. However, the constructs were active, and used in the further 
studies.  
As eIF4G and CNOT1 share sequence similarities (Rouya et al., 2014), and eIF4G-
MC reduced functional affinity of eIF4A2 (see Table 4.3-2), it was tested 
whether CNOT1 constructs could influence eIF4A2 RNA binding affinity. 
Interestingly, all of the tested CNOT1 constructs reduced eIF4A2 binding affinity 
(Figure 4.5-5, panel C). Intriguingly, only the affinity towards the AG-motifs 
RNAs, i.e., (AG)10, (AGUG)5 could be measured, as either no binding or not well 
quantifiable affinity (above 20 µM and unreliable) was detected for (CAA)6CA, 
(UCUC)5, (UGUU)5. Additionally, as only MA3-MIF was shown to exert any RNA 
binding on its own, and only towards (AG)10 and (AGUG)10 (Figure 4.5-5, panel 
D), the observed decrease in affinity possibly stems from protein-protein 
interaction and not competition for RNA binding.  
Next, as a reduction of eIF4A2 affinity was observed in presence of CNOT1 
constructs, it was examined whether RNA release by eIF4A2 could also be 
influenced. Since MIF and MA3 did not bind RNA, the signal observed in RNA 
release experiment stems from eIF4A2 activity (Figure 4.5-5, panel E). Despite 






Figure 4.5-5 CNOT1 reduces eIF4A2 binding affinity  
A. Unwinding activity of eIF4A2 alone (red) and in presence of 0.5 µM CNOT1 
constructs: MIF (purple), MA3 (light pink), and the longer MA3-MIF (yellow). 
Representative graph (n = 3), normalisation to the activity of 5 µM eIF4A2 – set 
as 100 %, error – STD from technical duplicate. MIF and MA3 constructs do not 
change eIF4A2 unwinding activity. Slight reduction of unwinding activity visible 
in MA3-MIF.  
B. Unwinding activity of 5 µM DDX6 alone (blue) and in presence of 0.5 µM MIF 
(black) and 0.5 µM MA3-MIF (purple). Normalisation to the unwinding activity of 
5 µM DDX6 in presence of 0.5 µM MIF – set as 100 %. MA3 did not change the 
unwinding activity of DDX6 (points omitted for clarity). MIF strongly enhanced 
the activity of DDX6. The longer construct induced unwinding to only about 30 % 
of what was observed for MIF. Error – STD from technical duplicate, n = 2.  
C. KD of eIF4A2 measured by polarisation for eIF4A2 alone (red, n = 4) and in 
presence of 0.5 µM MIF (pink, n =2), 0.5 µM MA3 (purple, n = 2) and 0.5 µM MA3-
MIF (yellow, n = 3) for (AG)10 and (AGUG)5 RNAs. KD of eIF4A2 increases in 
presence of all tested CNOT1 constructs. Error – SEM, measured in presence of 
AMP-PNP, RNA concentration 50 nM. 
 




D. RNA binding of 0.5 µM of each MIF (pink, n =3), MA3 (purple, n = 3), MA3-MIF 
(yellow, n = 3). Relative polarisation for each free RNA (black), polarisation 
measured for each construct divided by polarisation of free RNA. Only visible 
change for (AG)10 and (AGUG)5 RNA for longer construct MA3-MIF, indicates RNA 
sequence specific binding. Error – SEM. 
E. (AG)10 RNA release of 5 µM eIF4A2 (red) in presence of 0.5 µM MIF (orange), 0.5 
µM MA3 (black). The tested domains do not influence RNA release. Technical 




So far, the only influence of the tested CNOT1 constructs on eIF4A2 was 
observed in the RNA binding affinity. As CNOT1 interacts with deadenylases 
CNOT6 and CNOT7, and eIF4A2 has been shown to inhibit CNOT7 deadenylation 
activity through interaction with longer CNOT1 construct (Meijer et al., 2019), it 
was explored whether similar activity can be observed for shorter (MIF and MA3) 
constructs. For purification of CNOT7 see Appendix 2 Figure 2-6.  
Here, no deadenylation activity of CNOT7 was observed in presence of eIF4A2 
and MIF, MA3, or both MIF + MA3 (Figure 4.5-6 top). In contrast, strong 
deadenylation was observed in presence of DDX6 and MIF or both MIF + MA3 
(Figure 4.5-6 middle). However, no deadenylation was detected in presence of 
MA3 and DDX6, indicating that what was previously observed for the longer 
CNOT1 construct (Meijer et al., 2019), was mediated through MIF domain. 
Additionally, no deadenylation activity was detected for either CNOT7 alone, or 
in presence of MIF, MA3, both MIF + MA3 without DDX6. As deadenylation activity 
has been observed for longer construct of CNOT1 and CNOT7 in absence of the 
helicases (Meijer et al., 2019), the lack of deadenylation in presence of MIF 









Figure 4.5-6 eIF4A2 do not influence deadenylation activity of CNOT7 in 
presence of short CNOT1 constructs 
Deadenylation activity of 0.5 µM CNOT7 with 3 µM of indicated proteins on 1 µM 
deadenylation substrate in presence of 1 mM AMP-PNP. Timepoints indicated as numbers 
above the lanes in minutes, sample at timepoint 0 contains no CNOT7. M stands for fully 
deadenylated marker. Short constructs of CNOT1 do not induce deadenylation activity 
of CNOT7. DDX6 enhances deadenylation only in presence of MIF domain or both MIF and 















In summary, eIF4A2 was shown to interact with MIF and MA3 CNOT1 constructs in 
vitro, and this interaction was modulated by presence of RNA and ATP 
derivatives. MIF interacted with eIF4A2 to a greater extent than MA3, which 
interaction was detected only when both MIF and MA3 were present in the 
reaction. Moreover, ADP + Pi bound state of eIF4A2 seemed to be the most 
favourable for the interaction with the tested constructs. In contrast to DDX6, 
the CNOT1 constructs did not greatly change eIF4A2 unwinding activity, and the 
largest effect was observed on RNA binding affinity of eIF4A2. All of the tested 
constructs reduced eIF4A2 binding affinity for RNAs, with only detectable 
binding for the AG-motifs. Furthermore, this reduced affinity possibly did not 
stem from competition for RNA substrate as only MA3-MIF had a measurable 
binding to (AG)10 and (AGUG)5 RNAs. The reduced binding affinity however did 
not correlate with faster or changed RNA release by eIF4A2. Finally, eIF4A2 did 
not influence deadenylation of CNOT7 in presence of MIF and MA3, while 

















4.6. Chapter discussion  
 
In this chapter the influence of potential interaction partners on activities of 
eIF4A2 was explored. As previous studies have focused on the effect of 
interaction partners exerted on eIF4A1, and none of the previous reports 
investigated their influence on the novel, oligomerised eIF4A, a thorough 
examination of eIF4A2 in presence of auxiliary proteins was necessary.  
First, the effect of eIF4H on eIF4A2 was investigated. Both the unwinding and 
ATPase activities of eIF4A2 on 5’(AG)10 overhang RNA were stimulated (Figure 
4.2-2). However, the increase in ATPase activity, contradictory to previous 
reports on the effect on eIF4A1, was minimal (Richter-Cook et al., 1998). 
Moreover, eIF4H seemed to reduce the cooperativity between eIF4A2 protomers 
in the unwinding reaction in concentration dependent manner. This could 
potentially indicate, that eIF4A2 achieves the enhanced activity by either 
creating sub-oligomeric complexes or by each individual protomer interacting 
more with eIF4H than with another eIF4A2.  
Moreover, the unwinding activity in 3’-to-5’ direction in presence of eIF4H was 
investigated (Figure 4.2-3). Contrary to what was previously reported for eIF4A1 
(Rogers et al., 2001), the activity on 3’-to-5’ direction was further stimulated, 
albeit not to a high extent. This time, a stronger preference towards AG-RNA 
was observed in both direction than to 3’(CAA)6CA overhang as was detected for 
free eIF4A2 (Figure 4.2-3). Additionally, a slight decrease in ATPase activity was 
observed on 3’overhang RNA substrates (Table 4.2-1). This suggests that eIF4A2 
unwinding activity in presence of eIF4H on 3’overhang RNA is more productive 
per unit of ATP.  
Next, to understand what could drive the stronger preference of eIF4A2 in 
presence of eIF4H towards AG-RNA than to the position of the overhang itself, 
eIF4H binding affinity towards (AG)10 was investigated. Conversely to what has 
been described in the literature (Richter-Cook et al., 1998; Rozovsky, 
Butterworth and Moore, 2008), eIF4H bound to (AG)10 with higher affinity than 
eIF4A2. Perhaps eIF4H could enhance the affinity of eIF4A2 itself in the reaction, 
however a strong increase (KD reduction) in functional binding affinity was not 
observed (Table 4.3-2). Another reason for this AG-specific stimulation could 
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stem from both the decrease in cooperativity between eIF4A2 protomers and the 
affinity of eIF4H towards (AG)10. Possibly eIF4H binds strongly to the AG-RNA and 
recruits eIF4A2 forming a distinct oligomeric complex. Additional explanation 
could be what was speculated before (Assen Marintchev et al., 2009), that eIF4H 
could stabilise the single-stranded RNA region and prevent duplex reannealing. 
Perhaps additional tests for eIF4H binding to the duplex region, or the single-
stranded region created after strand dissociation and to other RNA substrate 
sequences could yield more answers.  
Next, the influence of eIF4G1 was investigated. As eIF4G1 has been shown to not 
be the main interaction partner of eIF4A2 (Meijer et al., 2019; Wilczynska et al., 
2019), the interaction of the two proteins was investigated in HeLa cells. In HeLa 
cells, where eIF4A2 is not the dominant paralogue (Roger Duncan and Hershey, 
1983; Bekker-Jensen et al., 2017), an interaction was observed (Figure 4.3-1).  
Therefore next, constitutively active eIF4G-MC (amino acids 674 – 1599) was 
purified (Feoktistova et al., 2013). Here, in contrast to eIF4A1 (Rogers et al., 
2001; Korneeva et al., 2005; Nielsen et al., 2011; Özeş et al., 2011) a 
stimulation of the eIF4A2 unwinding and ATPase activities in presence of eIF4G-
MC was limited (Figure 4.3-3). This in turn could suggest a different interaction 
mechanism between eIF4G-MC and eIF4A1 or eIF4A2. Next, whether eIF4H and 
eIF4G-MC can impart synergistic effect on eIF4A2, similarly to what has been 
shown for eIF4A1, eIF4G and eIF4B was investigated (Abramson, Dever and 
Merrick, 1988; Nielsen et al., 2011). Again, a dissimilar effect to the one 
described for eIF4A1 was observed, further suggesting that eIF4G-MC acts 
differently upon eIF4A2 (Figure 4.3-3). Moreover, a reduction in eIF4H 
stimulation was observed in the unwinding reaction. This reduction however was 
not due to competition for RNA binding or lack of eIF4G-eIF4A2 interaction. In 
fact, eIF4G-MC reduced eIF4A2 functional binding affinity for RNA substrate 
(Table 4.3-2), however presence of both cofactors increased the affinity of 
eIF4A2 for RNA. This indicates, that despite lower activity detected for eIF4A2 in 
presence of both interaction partners than just eIF4H, eIF4A2 bound tighter to 
the RNA substrate. Moreover, eIF4G-MC, similarly as eIF4H reduced cooperativity 
between eIF4A2 protomers however to a lower extent, suggesting that in the 




In the ATPase reaction, the opposite effect to what was observed in unwinding 
was detected. With addition of eIF4H the ATPase activity decreased in eIF4H 
concentration-dependent manner in comparison to ATPase of eIF4A2 and eIF4G-
MC complex (Figure 4.3-3). This indicates, that both cofactors exert different 
effect on eIF4A2 and in fact do not act in a synergistic manner. Additionally, a 
similar reduction in ATPase activity was observed for eIF4G-MC eIF4A2 on RNA 
substrate with 3’(AG)10 (Figure 4.3-4). Moreover, regardless of the slight 
increase in the eIF4A2 unwinding activity in presence of eIF4G-MC in 3’-to-5’ 
direction versus 5’-to-3’, the observed activity was lower than for eIF4A2 alone 
(compare Table 4.2-1 and Table 4.3-1). This could potentially suggest that 
eIF4A2 while bound to eIF4G-MC loses its 3’-to-5’ directional preference. 
Perhaps, a competition experiments on a substrate with single-stranded region 
in the middle, and two differently labelled double stranded region would provide 
more information about the eIF4A2 preference when faced with a choice of 
direction, especially in presence of auxiliary proteins.  
Last of the canonical interaction partners of eIF4A tested on eIF4A2 was the 
tumour suppressor, mTOR-regulated eIF4A inhibitor – PDCD4 (Yang et al., 2002, 
2004; Chen et al., 2003; Dennis, Jefferson and Kimball, 2012; Jin et al., 2013; 
Modelska et al., 2015). Despite the previously reported interaction between 
eIF4A2 and PDCD4 (Yang et al., 2002), this interaction was re-examined in HeLa 
cells. Indeed, even in cells preferentially overexpressing eIF4A1 (Duncan and 
Hershey, 1983), interaction between the two proteins was observed (Figure 
4.4-1).  
Next, the PDCD4 imposed inhibition of RNA unwinding and ATPase activity was 
tested in vitro (Figure 4.4-2). PDCD4, in agreement to previous reports on 
eIF4A1 (Yang et al., 2002) inhibited eIF4A2 in concentration dependent manner. 
Similarly, a full inhibition was not observed for equimolar concentrations of both 
proteins. This however, is in contrast with the available crystal structures of 
PDCD4 in complex with eIF4A1 (Chang et al., 2009; Loh et al., 2009), where a 
1:2 interaction of PDCD4 to eIF4A1 was suggested, which could be interpreted as 
PDCD4 binding an oligomeric version of eIF4A. However, the full inhibition of 
both eIF4A2 activities was not observed for PDCD4 concentrations exceeding 
eIF4A2 concentration. Additionally, the previously observed low protein levels of 
PDCD4 in cells would not be sufficient to inhibit all of the free eIF4A (Vikhreva, 
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Kalinichenko and Korobko, 2017). Perhaps, the suggested previously mechanism 
of translation inhibition in which PDCD4 directly binds to mRNAs in the nucleus 
(Singh et al., 2011; Vikhreva, Kalinichenko and Korobko, 2017), could be the 
main explanation for the reduction of translation in cells. Possibly, because the 
experiments performed in this chapter were started by preincubation of the 
proteins before adding the RNA substrate, the full inhibition was not observed. 
Another speculation about PDCD4 mediated translational inhibition could be 
recruitment of eIF4A2 to already bound by PDCD4 mRNA, and subsequently 
recruitment of CCR4-NOT complex.  
Additionally, PDCD4 in conducted experiments did not inhibit stimulation 
imposed by eIF4H, which again could potentially indicate different modes of 
actions of on eIF4A2.  
Finally, the influence of CNOT1 on eIF4A2 was investigated. For this short 
constructs of CNOT1 spanning 800 – 999 amino acids (MA3), and 1093 – 1317 
amino acids (MIF) were purified. As the purification of a longer CNOT1 construct 
was problematic (see Appendix 2 Figures 2-1, 2-2, 2-3) due to aggregation and 
contaminants, only a small amount of longer construct spanning 800 – 1312 
amino acids (MA3-MIF) was obtained as a gift and used in this study.  
Contrary to the contested interaction between eIF4A2 and CNOT1 (MIF) (Chen et 
al., 2014), an interaction between eIF4A2 and MIF was observed (Figure 4.5-4). 
Additionally, both MIF and MA3 co-precipitated with eIF4A2 in presence of ADP + 
Pi indicating that this interaction, similarly to what was described for both 
CNOT1 and DDX6 (Mathys et al., 2014), as well as yeast eIF4A and eIF4G (Schutz 
et al., 2008), could be dependent on conformational change of eIF4A2.  
Next, the influence of CNOT1 on eIF4A2 was tested. Despite the strong 
stimulation of DDX6 unwinding activity by both MIF and MA3-MIF constructs, 
almost no change in eIF4A2 unwinding activity was detected (Figure 4.5-5).  
Interestingly, eIF4A2 binding affinity was decreased in presence of all of the 
tested CNOT1 constructs (Figure 4.5-5). Additionally, the binding affinity was 
only observed for the AG-RNAs, i.e., (AG)10 and (AGUG)5 as for the other tested 
sequences either no binding or unreliable KD values were measured. This 
increase in KD is similar to what was observed for functional binding in presence 
of eIF4G-MC (Table 4.3-2), suggesting a possible similar mechanism imposed by 
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the two proteins. However, when interpreting the lack of eIF4A2 binding to 
certain RNA sequences in presence of CNOT1, caution need to be taken as 1) 
those binding affinities were measured in presence of AMP-PNP, and 2) for some 
of the tested sequences, i.e., (UCUC)5, (UGUU)5 eIF4A2 had higher affinity in 
presence of ATP (see Table 3.8-1). Furthermore, the change in binding affinity 
in presence of MIF and MA3 did not reflect the RNA release, as no change was 
detected on (AG)10 RNA (Figure 4.5-5). Perhaps, investigating different RNA 
sequences and using the longer MA3-MIF construct would yield a different 
outcome.  
More importantly, RNA binding to AG-motifs was detected for the longer 
construct, which has not been previously shown. Only in Baltz et al., 2012, 
CNOT1 was indicated as possible mRNA binder with 50 % confidence. As both MIF 
and MA3 alone did not exhibit RNA binding, possibly the linker between two 
domains (between 1000 and 1092 amino acids) or a change in conformation is 
responsible for binding to mRNA.  
Lastly, influence of eIF4A2 on CNOT7 deadenylation activities was examined in 
presence of MIF and MA3 domains (Figure 4.5-6). In contrast to DDX6, which 
induced deadenylation in presence of MIF, no induction of this activity was 
observed in presence of eIF4A2. Previously eIF4A2 was implicated in inhibition of 
CNOT7 deadenylation activity (Meijer et al., 2019), however as this time as MIF 
domain did not induce CNOT7 deadenylation on its own, it cannot be concluded 
whether it was lack of activity or its inhibition. Furthermore, with the tested 
deadenylation substrate, i.e., (CAA)6CA-C20-A20 in presence of MIF and AMP-PNP 
no binding by eIF4A2 should be expected. However, as shown in Meijer et al., 
2019, the inhibition of CNOT7 deadenylation was independent of eIF4A2 RNA 
binding capacity. Moreover, the greater interaction between eIF4A2 and MIF was 
observed in presence of ADP + Pi (Figure 4.5-4), however how that could be 
affected by addition of CNOT7 was not investigated. Perhaps, additional studies 
into different deadenylation RNA substrates, and different ATP analogues could 
potentially provide more information about the role of eIF4A2 in this process.  
In all, in this chapter interactions of eIF4A2 with both the canonical eIF4A1 
interaction partners as well as the CNOT1 from the translational repression 
complex was demonstrated. Moreover, the influence of eIF4G-MC was dissimilar 
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to the one previously described for eIF4A1. Perhaps, eIF4A2 exerts a dual 
activity, one in initiating translation (and possibly pro-tumourigenic), and the 
other in translational repression. After all, in Wilczynska et al., 2019, mRNAs 
bound by both eIF4A1 and eIF4A2 were not shifted more towards the translating 
polysomal fractions, nor towards the repressed subpolysomal fractions. This in 
turn, may indicate that eIF4A2 behaviour is modulated by its interaction 




5. The eIF4A paralogues and cross-species comparison  
5.1. Chapter introduction 
 
The differences on the effect on protein translation exerted by the highly 
identical eIF4A1 and eIF4A2 in the cellular and tumour environment are 
supported by the growing body of research (Galicia-Vazquez et al., 2012; Meijer 
et al., 2013; Modelska et al., 2015; Wilczynska et al., 2019; Gao et al., 2020), 
(see also Chapters 1.3, 1.5). However, how these different activities are 
achieved remains largely unknown. Therefore, the aim of the final results 
chapter of this thesis was to elucidate potential molecular differences between 
eIF4A1 and eIF4A2. 
For this, different properties of eIF4A1 and eIF4A2 were compared including 
oligomerisation, unwinding, ATPase activity, and RNA binding. In particular, the 
effect of cofactors eIF4H and eIF4G on eIF4A1 and eIF4A2 was compared, as 
earlier reports about eIF4A1 (Abramson, Dever and Merrick, 1988; Nielsen et al., 
2011) and findings about eIF4A2 from this study (Chapters 4.2, 4.3) indicated 
distinct cofactor activity upon the eIF4A paralogues. 
As one of the major differences between the paralogues was observed in their 
RNA binding sequence-selectivity in a previous study from the Bushell lab 
(Wilczynska et al., 2019), this was further explored. Identification of the 
responsible region for eIF4A2’s strong binding sequence-selectivity could support 
determining the molecular differences between the paralogues and help our 
understanding how eIF4A1 and eIF4A2 establish their biological functions. 
Moreover, as the eIF4A2 binding-selectivity was implicated in translational 
repression, further understanding of which regions of those highly identical 
paralogues are responsible for this activity could potentially lead to targeting 
specific regions of the helicases in the future. Here, to identify regions 
responsible for this molecular divergence, a mutational analysis of the 
paralogues was performed.  
As an additional approach to understand how differences between eIF4As can 
result in divergent functions, the Saccharomyces cerevisiae eIF4A (Sc eIF4A) was 
examined. Many previous studies exploring the activities of eIF4A were 
performed in yeast (Caruthers, Johnson and McKay, 2000; Schutz et al., 2008;   
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Andreou and Klostermeier, 2013; 2014; Andreou, Harms and Klostermeier, 2019). 
However, it is not known whether the Sc eIF4A can oligomerise or has activities 
similar to one or both of the human eIF4A paralogues. Often yeast and human 
proteins exhibit striking similarities, i.e., synergistic stimulation of yeast eIF4A 
by their interaction partners (Andreou and Klostermeier, 2014). However, eIF4A2 
activity was often in contrast with the literature. Moreover, yeast eIF4G, in 
contrast to human orthologue, has only one eIF4A binding site (Schutz et al., 
2008). Therefore here, the main focus was on the RNA binding capacity of 
Saccharomyces cerevisiae eIF4A, and the possible differences in KD for different 
RNA sequences both alone and in presence of S. cerevisiae eIF4G.  
In all, this chapter is focused on bringing together the data describing the 
activity of eIF4A2 alone (Chapter 3), and in presence of its interaction partners 
(Chapter 4) and comparing it to its highly identical paralogue eIF4A1, and 

















5.2. eIF4A1 is a less efficient helicase than eIF4A2 in vitro 
 
As a previous study from the Bushell lab (Wilczynska et al., 2019) identified 
differences in the binding preferences of the two paralogues, with eIF4A2 
preferentially binding AG-RNA, a question was posed how additional activities of 
both paralogues can be affected by this RNA in light of the newly described 
oligomerisation potential of eIF4A2 (Chapter 3).  
To compare eIF4A1 and eIF4A2 activities in vitro, first full length eIF4A1 was 
heterologously produced and purified (see Chapter 2.2). Briefly, a previously 
cloned full length His-SUMO-eIF4A1 protein construct was produced in E. coli 
strain BL21 DE3 RP codon+. The prepared bacterial lysate was applied to a 
HisTrap column (Figure 5.2-1, panel A), and the bound protein was eluted in a 
linear imidazole gradient. Next, the pooled fractions containing His-SUMO-eIF4A1 
were subjected to SUMO-tag cleavage with ULP1 and applied to a Resource Q 
column (Figure 5.2-1, panel B), (eIF4A1 pI = 5.32). The peak fractions were 
combined and applied on a size exclusion chromatography column (Figure 5.2-1, 
panel C). The eluted protein was concentrated, and its purity was assessed by 
SDS-PAGE (Figure 5.2-1, panel C) and UV-VIS spectrum. In sum, eIF4A1 was 












Figure 5.2-1 eIF4A1 purification 
A. Representative chromatogram of His-SUMO eIF4A1 elution in a linear imidazole 
gradient on a HisTrap HP column.  
B. Representative elution profile of eIF4A1 after ULP1 cleavage on a ResourceQ 
anion exchange column.  
C. Representative chromatogram of eIF4A1 on a Superdex S200 HiLoad 16/600 
column. eIF4A1 elutes around 80-85 mL.  
D. Coomassie stained gel of purified full length, 46 kDa eIF4A1. Numbers on the left 




As the novel propensity of eIF4A2 to form oligomeric complexes has not been 
characterised for the paralogue eIF4A1, therefore its oligomerisation potential 
was tested utilising the same methods as used for eIF4A2, i.e., EMSAs and aSEC 
(see Chapter 3.5). Since 1) eIF4A2 formed oligomers due to protein-protein 
interactions, and 2) silvestrol, a small molecule eIF4A inhibitor (Bordeleau et 
al., 2008), stimulated oligomer formation even on a short RNA substrate (see 
Figure 3.9-2), eIF4A1 oligomerisation potential was tested on RNA substrates 
with varying length of AG-repeats in presence and absence of silvestrol (Figure 
5.2-2, panel A). eIF4A1, similarly to eIF4A2, formed trimeric complexes only on 
20 nt AG-RNA. Moreover, silvestrol induced oligomerisation of eIF4A1, and 
stimulated oligomer formation on 10 nt AG-RNA. This suggest, that both 
paralogues can form oligomers, and oligomer formation is supported through 
protein-protein interactions.  
To visualise eIF4A1 oligomerisation side by side with eIF4A2 EMSA was used 
(Figure 5.2-2, panel B, see also Chapter 2.3.1.1). Here, eIF4A2 seemed to 
exhibit greater oligomerisation potential in vitro than eIF4A1. Moreover, 
silvestrol enhanced oligomerisation of both paralogues on AG-RNA (Figure 5.2-2, 
panel C). However, in contrast to eIF4A2, eIF4A1 failed to support 
oligomerisation on (CAA)6CA RNA in this assay. This suggests that eIF4A1 is more 
selective in its preference for oligomerisation-inducing RNA sequence.  
Next, the KD of eIF4A1 binding to different lengths of AG-RNA was quantified in 
the same way as for eIF4A2 (see Figure 3.5-4 and Figure 5.2-2, panel B). In 
contrast to eIF4A2, eIF4A1 demonstrated the highest affinity (lowest KD) to 20 nt 
AG-RNA (Figure 5.2-2, panel D, left). The same was observed in presence of 
silvestrol, which increased the affinity of both paralogues for AG-RNA (Figure 
5.2-2, panel D, right). Similar silvestrol-induced increase of affinity was 
previously described in literature (Iwasaki, Floor and Ingolia, 2016; Wilczynska et 
al., 2019). The difference in observed minimal KD of both paralogues (20 nt for 
eIFA1, 15 nt for eIF4A2), indicates that eIF4A2 binds more strongly to shorter 
RNA substrates. That suggests that eIF4A2’s mechanism of RNA binding is distinct 
to eIF4A1. Additionally, the KD of eIF4A2 in DMSO conditions is lower for each 
RNA length than the KD of eIF4A1 showing that eIF4A2 binds more strongly to AG-
RNA than eIF4A1 (Figure 5.2-2, panel D, left).  
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Additionally, eIF4A1, similarly to eIF4A2, was observed to oligomerise in live 
cells using FLIM-FRET (Appendix 3 Figure 3-1). Moreover, eIF4A1 
oligomerisation was eIF4G independent in cells (Appendix 3 Figures 3-2, 3-3, 
3-4) and there was no requirement for all of the protomers in the oligomer to 
have RNA binding capacity (Appendix 3 Figure 3-1).  
In all, both paralogues can form oligomeric complexes, with eIF4A2 having 
greater propensity to oligomerise in vitro, and being less selective to 












Figure 5.2-2 eIF4A2 has better oligomerisation potential than eIF4A1 in vitro 
A. Representative chromatograms of eIF4A1 (left) and eIF4A2 (right) complexes 
formed on AG-RNA (10, 15, 20 nt) in presence of DMSO (full line) or silvestrol 
(dashed line). Both paralogues form oligomeric complexes, and silvestrol induces 
oligomerisation. N = 3.  
B. Representative EMSA of eIF4A2 and eIF4A1 binding to (AG)10 RNA in DMSO 
conditions at indicated protein concentrations. eIF4A2 forms oligomers more 
readily than eIF4A1. N = 3.  
C. Representative EMSA of 5 µM eIF4A1 and eIF4A2 binding to (AG)10 (left) and 
(CAA)6CA (right) in presence of silvestrol. Both proteins bind to (AG)10 as 
oligomers, however only eIF4A2 oligomers are detected in the tested conditions 
on (CAA)6CA RNA. N = 3.  
D. KD of eIF4A1 and eIF4A2 in DMSO (left) and silvestrol (right) conditions. 
Quantification from measured fraction bound on from individual EMSAs (n = 3 for 
each condition), Hill equation applied to the data. eIF4A1 has lower affinity than 




Furthermore, as 1) eIF4A1 was shown to oligomerise (Figure 5.2-2), and 2) 
similarly to eIF4A2, eIF4A1 did not exhibit unwinding activity in monomerisation-
inducing conditions (Appendix 3 Figure 3-5), the catalytic capacities of both 
paralogues under oligomerisation-inducing conditions were assessed.  
As both of the helicases had a preference to AG-RNA (see Table 3.8-2, and 
Iwasaki, Floor and Ingolia, 2016; Wilczynska et al., 2019), and previous studies 
of eIF4A1 have focused mostly on the canonical 5’-to-3’ unwinding activity, the 
data presented in Figure 5.2-3 correspond to experiments performed on 
5’(AG)10 overhang RNA.  
Here, the activity of eIF4A1 was compared to the activity of eIF4A2 in the same 
conditions (Figure 5.2-3, panel A). eIF4A2 had higher unwinding activity than 
eIF4A1, both alone and in the presence of eIF4G-MC. Since the increase in 
eIF4A2 activity caused by eIF4G-MC was only minimal (see Figure 4.3-3), the 
higher activity of eIF4A2 than eIF4A1 in presence of eIF4G-MC was possibly due 
to the higher activity of eIF4A2 itself. Both the activity of eIF4A2 in presence of 
eIF4H alone, and eIF4H with eIF4G-MC seemed to be greater than the unwinding 
activity of eIF4A1 in those conditions. However, caution needs to be taken when 
interpreting these data as the error bars for eIF4A2 activity is high. 
Nevertheless, eIF4A1 unwinding activity in presence of both eIF4H and eIF4G-MC 
seems to be closer to the activity of eIF4A2, supporting the previously described 
synergistic activation of eIF4A1 (Abramson, Dever and Merrick, 1988; Nielsen et 
al., 2011).  
Next, to better compare the effect of the cofactors on eIF4A1 and eIF4A2 
unwinding activity was assessed (Figure 5.2-3, panel B). For this, the unwinding 
activity of 5 µM eIF4A1 or eIF4A2 in absence of cofactors was used as a baseline. 
eIF4A1 unwinding activity was enhanced to a greater extent by the presence of 
cofactors than eIF4A2. Moreover, for eIF4A1 an additive activation by eIF4H and 
eIF4G-MC was observed, which was not observed for eIF4A2 (see also Figure 
4.3-3).  
To further understand the additive activation of eIF4A1 by eIF4H and eIF4G-MC 
and compare it to the observed apparent lack of synergy in case of eIF4A2, a 
titration of eIF4G-MC in the unwinding reaction was performed (Figure 5.2-3, 
panel C). Here, a lower concentration of the helicases was used (2 µM) and an 
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equimolar concentration of eIF4H. The collected data were normalised to the 
activity of the respective helicase in absence of eIF4G-MC. At concentrations of 
eIF4G-MC lower than eIF4A1-eIF4H (<2 µM) eIF4A1 was activated. However, at 
equimolar concentration of all proteins in the reaction (2 µM) a slight decrease 
in the velocity of unwinding was observed, which further decreased at higher 
eIF4G-MC concentrations. It should be noted that eIF4A2 activity was only 
measured in single replicate. Nonetheless, the obtained result indicates that an 
increase in activity as observed for eIF4A1 may not be apparent. This is further 
supported by data presented in (Figure 4.3-3, panel C and Figure 5.2-3, panel 
A). Similarly, as was observed for eIF4A1, at high concentrations of eIF4G-MC, 
eIF4A2 activity became inhibited. In all, this suggests that the cofactor 
concentrations play a crucial role in the activation, possibly indicating that 
eIF4A2 has different optimum for cofactor activation than eIF4A1. Moreover, as 
previously mentioned eIF4G has two binding sites for eIF4A (see also Figure 
1.3.2-2), the sub-molar optimum of eIF4G concentration for eIF4A1 activation 
indicates that when a single eIF4A1 is bound to eIF4G its main function could be 
different to RNA unwinding.  
Lastly, the ATPase activity of both helicases in presence of interaction partners 
was compared to the activity of free eIF4A1 and eIF4A2, respectively (Figure 
5.2-3, panel D). The activity of eIF4A2 was less subjected to change in presence 
of interaction partners, than the activity of eIF4A1 in the tested conditions. 
Surprisingly, in stark contrast to what was previously observed in the literature 
(Rogers et al., 2001; Korneeva et al., 2005; Nielsen et al., 2011; Özeş et al., 
2011), the ATPase activity of eIF4A1 seemed to decrease in conditions containing 






Figure 5.2-3 eIF4A2 is a faster helicase than eIF4A1 
A. Fold change of velocity of unwinding normalised to eIF4A2 activity in each 
category. Helicases at 5 µM, interaction partners at 0.5 µM. All samples n = 3, 
apart from eIF4A2 and eIF4A2 with eIF4G n = 4, eIF4A2 with eIF4H n = 2. Error – 
SEM. eIF4G label corresponds to construct used in a previous chapter – eIF4G-MC. 
eIF4A2 activity seems to be higher than the one of eIF4A in all tested conditions, 
however error for eIF4A2 activity in presence of eIF4H and both eIF4H and eIF4G-
MC is high, therefore accurate determination of change between eIF4A2 and 
eIF4A1 is not possible in those conditions. 
B. Fold change of velocity of unwinding on 5’(AG)10 overhang RNA in presence of 
cofactors normalised to activity of 5 µM eIF4A1 (left, blue) and 5 µM eIF4A2 
(right, red). Replicate number, error, RNA, the proteins used and their 
concentrations as in panel A. All of the interaction partners enhance eIF4A1 
activity to a greater extent than the one of eIF4A2. Synergistic effect of eIF4H 
and eIF4G is visible in the case of eIF4A1.  
C. Fold change of unwinding velocity on 5’(AG)10 overhang RNA of 2µM eIF4A1 (blue) 
and 2µM eIF4A2 (red) in presence of 2µM eIF4H and indicated concentrations of 
eIF4G-MC, normalised to the activity at 0 µM eIF4G-MC. eIF4A1 n = 3, eIF4A2 n = 
1. eIF4A1 is synergistically activated by eIF4H and eIF4G-MC at sub-molar eIF4G-
MC concentrations. This effect is not as pronounced for eIF4A2.  
D. Fold change of ATPase activity (VATPase = nM ATP x s
-1) on 5’(AG)10 overhang RNA 
for eIF4A1 (blue) and eIF4A2 (red) in presence of indicated co-factors, 
normalised to the activity of the respective free helicase. Replicate number, 
error, the proteins used and their concentrations as in panel A. 
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To sum up, both eIF4A1 and eIF4A2 can oligomerise in cells and in vitro 
(Appendix 3 Figure 3-1 and Figures 3.7-3, 5.2-2). Additionally, the 
oligomerisation of both paralogues can be further enhanced by silvestrol. One of 
the most noticeable differences was the preferred AG-RNA length. eIF4A2 
exhibited greater affinity towards shorter RNA substrates than eIF4A1, 
suggesting preference of eIF4A2 for shorter RNA substrates. Moreover, this 
difference in the preferred RNA length could potentially indicate that the two 
paralogues have different RNA binding interface. Another striking difference 
between the helicases was the lack of eIF4A1 oligomers on (CAA)6CA RNA in the 
tested conditions, indicating that eIF4A1 is potentially more selective then 
eIF4A2 when it comes to the oligomerisation-promoting RNA sequence.  
Furthermore, eIF4A2 showed a trend to unwind RNA substrates with greater 
velocity then eIF4A1 in the tested conditions (Figure 5.2-3). Interestingly, 
cofactors eIF4G and eIF4H stimulated the activity of eIF4A1 more than eIF4A2. 
Additionally, eIF4A1 was synergistically activated by eIF4H and eIF4G-MC, while 
this was not observed for eIF4A2. This suggest a different role of eIF4A1 and 
eIF4A2 when in complex with the tested co-factors, in which eIF4A2 unwinding 
activity is not stimulated. Finally, the ATPase activity of eIF4A2 was relatively 
unchanged in all of the tested conditions, while eIF4A1 activity decreased in 
presence of eIF4G-MC. In all, the influence of the co-factors on the helicases 
activity on different RNA substrates could potentially yield more information 











5.3. Mutational analysis of the paralogues identifies regions 
responsible for lack of sequence-specific binding 
selectivity of eIF4A1 
 
The investigations presented in the previous subchapter elucidated disparities 
between the highly identical paralogues eIF4A1 and eIF4A2, thus the next 
question was what drives those differences. To identify which divergent regions 
in the amino acid sequence of the two paralogues play a role in the different 
behaviour of eIF4A1 and eIF4A2, mutations were introduced into the two 
paralogues. 
Previously, several eIF4A mutants were generated to elucidate the difference 
between the paralogues in cells (Wilczynska et al., 2019). However, it is not 
clear how these mutations change the biochemical properties of both helicases. 
These mutants include: 1) eIF4A1 1-18 A2; an eIF4A1 mutant with the first 18 
amino acids exchanged for those from eIF4A2, 2) eIF4A2 1-18 A1; an eIF4A2 
mutant with the first 18 amino acids exchanged for those from eIF4A1, 3) eIF4A1 
Δ N-20; eIF4A1 with a 20 amino acids N-terminal truncation, 4) eIF4A2 Δ N-21; 
eIF4A2 with a 21 amino acids N-terminal truncation, 5) eIF4A2-7-mut; eIF4A2 
with 7 mutations exchanging residues for the corresponding amino acids in 
eIF4A1: N34S K41S E101A N143A A150M S207N I208T (Figure 5.3-1). The eIF4A2-
7-mut was previously shown to switch off the eIF4A2 translation repressive 









Figure 5.3-1 Schematic of eIF4A1 and eIF4A2 mutants  
Schematic of mutants used in this study: 1) eIF4A2 with exchanged first 18 amino acids 
with eIF4A1 (top left), 2) eIF4A1 with exchanged first 18 amino acids with eIF4A2 (top 
right), 3) eIF4A2 with N-terminal truncation (middle left), 4) eIF4A1 with N-terminal 
truncation (middle right), 5) eIF4A2 with 7 mutations exchanging residues for the ones 
corresponding to eIF4A1 (bottom).  
 
First, the eIF4A mutants constructs were cloned into petSUMO vector for 
expression in E. coli BL21 DE3 RP codon+. The bacteria were treated in the same 
way as described previously (see Chapter 2.2). Next, the precleared bacterial 
lysates were applied on HisTrap HP columns, and the bound proteins were eluted 
in a linear imidazole gradient (Figure 5.3-2, left in panels A-D, see figure 
legend for each mutant). Next, the pooled fractions were treated with ULP1 to 
cleave off the His-SUMO tag. As the pI of the mutants did not differ greatly from 
WT proteins, the samples were applied on anion exchange chromatography 
(Figure 5.3-2, middle left in all panels). Fractions corresponding to main peaks 
were subsequently subjected to size exclusion chromatography (Figure 5.3-2, 
middle right in all panels). All of the mutants eluted at a similar retention 
volume as WT eIF4A1 and eIF4A2, suggesting that the expressed proteins are 
correctly folded. The purified proteins were visualised using SDS-PAGE (Figure 
5.3-2, right in all panels), and their UV-VIS spectrum was measured. In all, the 
quality of the purified proteins was deemed to be high, and all the purified 
eIF4A mutants could be used in subsequent experiments.  
Additionally, used in this study, eIF4A1 Δ N-20 protein, was obtained as a gift 





Figure 5.3-2 Purification of eIF4A1 and eIF4A2 mutants 
Purification of eIF4A1 and eIF4A2 mutants: 1) affinity chromatography on HisTrap HP 
column – left, 2) anion exchange chromatography on Resource Q column after ULP1 
cleavage – middle left, 3) size exclusion chromatography on Superdex S200 HiLoad 
16/600 column – middle right, 4) Coomassie stained gels of final purification products 
with schematic of mutations; protein marker sizes in kDa indicated on the left of the 
gel; unrelated lanes removed from gels – right. Amino acid – aa.  
A. eIF4A1 with exchanged 1 - 18 aa for eIF4A2 (labelled eIF4A1 1-18 A2),  
B. eIF4A2 with exchanged 1 - 18 aa for eIF4A1 (labelled eIF4A2 1-18 A1), 
C. eIF4A2 with removed first 21 aa (labelled eIF4A2 Δ N-21),  
D. eIF4A2 with 7 mutations for eIF4A1 residues: N34S K41S E101A N143A A150M 
S207N I208T (labelled eIF4A2-7-mut). Chromatograms for eIF4A2-7-mut traced 







One of the interesting differences between eIF4A1 and eIF4A2 was the previously 
described RNA sequence specificity (Wilczynska et al., 2019). The authors of 
that work have observed that eIF4A2, unlike eIF4A1, exhibits a preference 
towards AG-RNA under competitive conditions. Most intriguingly, this activity 
could be artificially induced in eIF4A1 by silvestrol. The authors speculated that 
this selectivity of eIF4A2 drives its role in translational repression through the 
AG-motifs on a given mRNA.  
As the nature of this observation has implications in the outcome of protein 
translation, the question of what drives the natural selectivity of eIF4A2 was 
explored. First, the selectivity experiment was replicated and expanded by 
utilisation of eIF4A1 and eIF4A2 mutants (Figure 5.3-3, panel A, note the 
different scale of Y axis in the top and bottom panels). Similarly to what was 
observed previously (Wilczynska et al., 2019), eIF4A2, in contrast to eIF4A1, did 
not change the affinity towards AG-RNA even in the presence of large excess 
(50-fold) of competitor RNA. The exact numbers are slightly different than in the 
published work (Wilczynska et al., 2019) as eIF4A1 did not exhibit an increase in 
KD for (AG)10 in presence of equimolar competitor RNA (2 out of 3 replicates). 
However, the overall trend remained unchanged. Strikingly, data collected for 
the N-terminal eIF4A1 mutants (eIF4A1 1-18 A2 and eIF4A1 Δ N-20) suggest that 
this is the region responsible for lack of selectivity in eIF4A1. Both the 
truncation, and the exchange of amino acids with those from eIF4A2, caused 
eIF4A1 to behave in a selective manner, akin to eIF4A2. Intriguingly, the eIF4A2 
Δ N-21 mutant exhibited similar preference to AG-RNA as WT eIF4A2, suggesting 
that eIF4A2 N terminus is not responsible for eIF4A2 selectivity. Conversely, the 
eIF4A2 1-18 A1 affinity to AG-RNA was reduced, albeit the competitor 
concentration dependent increase of KD was not observed. The last mutant 
tested in these conditions, i.e., eIF4A2-7mut, was observed to have an increased 
KD in the presence of 10-fold competitor RNA. However, due to high discrepancy 
between the calculated KD of eIF4A2-7-mut for each replicate in the 50-fold 
excess of competitor RNA condition, whether the selectivity of eIF4A2 was 
completely lost could not be determined. In all, these data suggest that it is the 
N-terminal region of eIF4A1 that is responsible for lack of RNA binding 
selectivity. However, the data suggest that another region within eIF4A2 is 
responsible for its RNA sequence preferences. Perhaps, combining eIF4A2 1-18 
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A2 and eIF4A2-7-mut mutations could lead to complete loss of selectivity 
associated with eIF4A2.  
As a striking difference was observed for eIF4A1 N-terminal truncation and 
substitution in comparison to eIF4A1 WT in RNA binding selectivity, next 
question was to understand whether those regions could influence how the two 
paralogues bind and release the RNA. For this RNA release experiments in non-
competitive conditions, employing eIF4A mutants were performed (Figure 5.3-3, 
panel B). Here, a distinct behaviour of both eIF4A1 Δ N-20 and eIF4A2 Δ N-21 
compared to WT of both paralogues was observed. Both mutants exhibited 
longer duration of the RNA-bound state compared to wild type on both (AG)10 
and (CAA)6CA RNA. Additionally, the fractions bound for both N-terminally 
truncated mutants were greater than for the WT paralogues. The biggest 
difference was observed for eIF4A1 Δ N-20 on (AG)10 RNA. Its RNA-bound state 
half-life doubled, and the (AG)10 release was only minimal, equating to the 
starting points of eIF4A1 WT. The eIF4A1 1-18 A2 and eIF4A2 1-18 A1 followed a 
similar trend to WT proteins in the first 20 * 103 s of reaction, with greater RNA 
release at further time points. Moreover, the half-lives of both N-terminally 
exchanged mutants decreased in comparison to WT. The half-life for eIF4A1 1-18 
A2 was 62% and 74% of eIF4A1 WT on (AG)10 and (CAA)6CA RNAs, respectively; for 
eIF4A2 1-18 A1 these values were 76% and 51% of eIF4A2 WT. Interestingly, 
eIF4A2-7-mut, released RNA the most with half-lives 46% and 43% of the WT on 
(AG)10 and (CAA)6CA RNAs, respectively. Intriguingly, those numbers for eIF4A2-
7-mut were 45% and 55% in comparison to eIF4A1 WT, implying that this mutant 
has a shorter RNA-bound state than both WT paralogues. Although these data 
cannot be directly compared to the selectivity experiment (Figure 5.3-3, panel 
A) due to lack of the competitor RNA and use of hydrolysable ATP, it can be 
concluded that RNA release does not influence RNA binding selectivity. Hence 
these studies brought insights into which regions are responsible for distinct 






Figure 5.3-3 eIF4A2 has a distinct preference to AG-RNA  
A. Comparison of KD measurements of eIF4A2 and its mutants (top) and eIF4A1 and 
its mutants (bottom) in presence of excess of (CAA)6CA RNA. All measurements n 
= 3, eIF4A2 7-mut n = 4. KD values obtained from fitting Hill equation to the 
helicase titration experiments.  
B. RNA release – (AG)10 (top) and (CAA)6CA (bottom) in presence of ATP in non-
competitive conditions. Decrease of signal correlates with RNA release up to the 
signal of free RNA. eIF4A1, eIF4A2 n = 3, mutants n = 2. Fit – exponential decay. 
N-terminally truncated mutants follow a different pattern to the WT.  
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Next to address a question whether oligomerisation could influence the distinct 
RNA binding preferences of the paralogues, the influence of the mutations on 
the oligomerisation potential of eIF4A1 and eIF4A2 was explored. As described in 
the previous subchapter (see Figure 5.2-2, panel D), eIF4A1 formed oligomeric 
complexes more specifically on AG-RNA. Therefore, this time an EMSA was 
performed on the different eIF4A paralogues and mutants on a single gel, 
exploring oligomerisation potential on (AG)10 and (CAA)6CA RNA (Figure 5.3-4). 
This time, a distinct higher species was detected on (CAA)6CA for eIF4A1 and not 
observed for eIF4A2. These higher order species were occasionally observed on 
different EMSAs; however, its presence was not consistent, suggesting possible 
lower stability of this complex. Moreover, the elution profiles of both eIF4A1 and 
eIF4A2 on AG-RNA in presence of silvestrol could potentially indicate a formation 
of an even higher order species (see Figure 5.2-2, panel A), indicating that 
depending on the conditions both paralogues could potentially form complexes 
greater than trimeric. These higher complexes were detected on (CAA)6CA RNA 
for both eIF4A1 1-18 A2 and eIF4A2 1-18 A1 (Figure 5.3-4), suggesting that the 
N-terminal region of eIF4A1 is sufficient to induce this activity in eIF4A2. 
However, exchange of this region in eIF4A1 is not enough to deplete eIF4A1 of 
this capacity. Moreover, both N-terminally exchanged mutants behaved more 
similar to eIF4A1 than eIF4A2 on AG-RNA. Next, the N-terminally truncated 
eIF4A2, i.e., eIF4A2 Δ N-21 exhibited similar activity to eIF4A2 WT on (CAA)6CA 
RNA, however it had a greater oligomerisation potential on (AG)10 RNA, 
indicating that lack of N-terminal region promotes oligomerisation of eIF4A2. 
Lastly, eIF4A2-7-mut displayed similar oligomerisation potential to eIF4A2 WT, 
with slightly greater ratio of trimeric to monomeric complex on (AG)10. 
Additionally, half of each sample applied on an EMSA was resolved on SDS PAGE 






Figure 5.3-4 eIF4A mutants have distinct oligomerisation potential 
Representative (n = 2) EMSA of Dy780 (AG)10 and Dy680 (CAA)6CA binding to 5 µM eIF4A1, 
eIF4A2, eIF4A1 1 – 18 aa eIF4A2, eIF4A2 1 – 18 aa eIF4A1, eIF4A2 Δ N-21, eIF4A2 7-mut 
(top), and a Coomassie stained gel of the same samples as in the top panel, 
representing loaded proteins (bottom). Numbers on the side indicate protein marker 
sizes in kDa. Both eIF4A1 and eIF4A2 with swapped 18 aa behave similarly to eIF4A1 WT. 
Both eIF4A2 Δ N-21 and eIF4A2 7-mut behave similarly to eIF4A2, however the mutants 












In sum, the previously described distinct RNA sequence selectivity of eIF4A1 and 
eIF4A2 (Wilczynska et al., 2019) was replicated (Figure 5.3-3, panel A). 
Moreover, the collected data suggested that it is the N-terminal region of eIF4A1 
that is responsible for lack of binding selectivity towards the AG-RNA. In 
contrast, the truncation of eIF4A2 N-terminal region did not change its 
propensity to selectively bind AG-RNA. Moreover, the eIF4A2 1-18 A1 mutant 
similarly did not exhibit loss of AG-RNA selectivity, albeit its KD to AG-RNA even 
in non-competitive conditions was increased in comparison to WT. The most 
visible loss of eIF4A2 selectivity was observed in the eIF4A2-7-mut mutant; 
however, due to high error in the measured KD in the presence of 50-fold excess 
of competitor RNA, a strong conclusion cannot be made. Moreover, this mutant 
exhibited the greatest RNA release from all the tested proteins (Figure 5.3-3, 
panel B). However, as 1) loss of selectivity was not observed for eIF4A2 1-18 A1, 
2) the eIF4A1 1-18 A2 mutant gained the selective behaviour, and 3) the RNA-
bound state half-lives of the N-terminally exchanged mutants were decreased, 
the selectivity might not be related to RNA release. An interesting observation 
was made for the N-terminally truncated mutants, especially eIF4A1 Δ N-20, 
which almost completely lost the ability to release (AG)10 RNA. However, as 
mentioned above, the direct comparison between the RNA release and 
selectivity experiments cannot be made due to the differences in the tested 
conditions. Finally, the oligomerisation potential of the mutants was explored 
(Figure 5.3-4). Here, a higher oligomeric species than previously detected was 
observed for eIF4A1 bound to (CAA)6CA RNA. Moreover, similar oligomerisation 
potential was observed for eIF4A1 1-18 A2 and eIF4A2 1-18 A1. Additionally, 
eIF4A2-7-mut exhibited almost identical oligomerisation as the eIF4A2 WT, 
whereas eIF4A2 Δ N-21 oligomerised to a greater extent on (AG)10 RNA. In all, 
both the similarities in the oligomerisation potential, i.e., between the N-
terminally exchanged mutants and eIF4A1, as well as dissimilarities, i.e., eIF4A2 
and eIF4A2 Δ N-21 do not explain the differences observed in selectivity 
experiment, suggesting that eIF4A2 selectivity, and its gain in the case of eIF4A1 






5.4. Yeast eIF4A is distinct from both eIF4A1 and eIF4A2 
 
The previous two subchapters elucidated some substantial differences between 
the two closely related eIF4A paralogues. However, in the literature there is a 
plethora of data regarding yeast eIF4A, but there is a lack of direct comparisons 
between the activity of yeast and human eIF4As. Therefore, the final aspect of 
this thesis was to uncover potential discrepancies in the activities of human and 
yeast eIF4As. 
First, a sequence alignment of human eIF4A1, eIF4A2 and Saccharomyces 
cerevisiae eIF4A (Sc eIF4A) was performed using an online software PRALINE 
(Simossis and Heringa, 2003, 2005) (Figure 5.4-1). Overall, similarities were 
identified between all three helicases, with 66% identity between eIF4A1 and Sc 
eIF4A, and 65% identity between eIF4A2 and Sc eIF4A. Additionally, a large 
proportion of non-identical residues had a high degree of similarity (score 7 or 
higher in Figure 5.4-1). However, significant differences in key conserved motifs 
of the DEAD-box helicases (see Figure 1.5.1-1) were also observed, i.e., 1) the 
substitution of basic lysine in human paralogues for acidic glutamic acid in the Q 
motif responsible for ATP binding and hydrolysis, 2) substitution of hydrophobic, 
branched isoleucine and leucin in eIF4A1 and eIF4A2 for the thiol side chain 
bearing cysteine in the Motif IV responsible for RNA binding. In all, differences 
between the human and yeast orthologues, especially in the conserved motifs, 






Figure 5.4-1 Alignment of human eIF4A1, eIF4A2, and Saccharomyces 
cerevisiae eIF4A 
Alignment of an amino acid sequence between human eIF4A1, eIF4A2 and S. cerevisiae 
eIF4A performed using online software PRALINE (PRALINE, Centre for Integrative 
Bioinformatics VU) (Simossis and Heringa, 2003, 2005). Identical residues – not coloured 
and labelled with an asterisk, most similar residues indicated by red colour and higher 
number, least similar aa in blue and presented with the lowest score (number). DEAD-




As assessment of the sequences of the helicases elucidated key differences 
despite large overall similarity, the next step was to compare the activities of 
eIF4A orthologues in vitro. For this, recombinant full length Saccharomyces 
cerevisiae eIF4A was obtained as a gift from Dr Tobias Schmidt. Moreover, as 
previously the activities of both human eIF4A paralogues were explored in 
presence of its interaction partners, this time the influence of yeast eIF4G was 
also assessed.  
For this, plasmid containing full length S. cerevisiae eIF4G1 was purchased from 
Addgene (Mitchell et al., 2010). Next, two constructs of Sc eIF4G1 were cloned 
into pet-SUMO vector, i.e., Sc eIF4G-M (amino acids 572 -853) and Sc eIF4G-MC 
(amino acids 572 - 952). Selection of the regions was based on the previously 
published data on yeast eIF4F complex (Andreou and Klostermeier, 2014). Next, 
the Sc eIF4G constructs were expressed in E. coli strain BL21 DE3 RP codon+ and 
treated in the same manner as other proteins in this thesis (see Chapter 2.2). 
The precleared bacterial lysates were applied on affinity chromatography 
column and the fractions containing bound proteins were eluted in a linear 
imidazole gradient (Figure 5.4-2, panel A, B, left). Next, the His-SUMO tag was 
cleaved using ULP1, and the samples were applied again on the HisTrap column 
(Figure 5.4-2, panel A, B, middle). As the proteins were subjected to ULP1 
activity, only the free tag and possible uncleaved fraction bound the column. 
Subsequently, the FT from reverse affinity chromatography was concentrated 
and samples were applied to a size exclusion column (Figure 5.4-2, panel A, B, 
right). The shorter Sc eIF4G-M (32 kDa) eluted at around 90 mL retention volume 
on the Superdex S200 HiLoad 16/600 column, and the longer Sc eIF4G-MC (43 
kDa) at around 85 mL. After concentration, the purity of the proteins was 
estimated by SDS-PAGE (Figure 5.4-2, panel C), and UV-VIS spectrum 
measurement. In all, the proteins were assessed to be of good quality to use in 





Figure 5.4-2 Purification of S. cerevisiae eIF4G domains  
A., B. Purification of Saccharomyces cerevisiae short eIF4G constructs: Sc eIF4G-M 
(amino acids 572 -853) – panel A, and Sc eIF4G-MC (amino acids 572 - 952) – panel B. 
Affinity chromatography chromatogram on the left on a HisTrap HP column, reverse 
affinity chromatography after ULP1 cleavage on a HisTrap HP column – middle, size 
exclusion chromatography of flow through samples from a reverse affinity 
chromatography on a Superdex S200 HiLoad 16/600 column – right. 
C. Coomassie stained gel of purified eIF4G-M and eIF4G-MC. Unrelated lanes removed 
from the gel. Numbers on the left indicate sizes of protein marker in kDa, arrows 

















As the novel oligomerisation potential described here for eIF4A1 and eIF4A2 was 
not previously observed for the Sc eIF4A, first this aspect was explored. The RNA 
binding capacity of Sc eIF4A was investigated using EMSA (Figure 5.4-3, panel 
A). In contrast to the previous experiments on eIF4A1 and eIF4A2 (see Chapters 
3.3, 3.5, 5.2) no binding to RNA was detected in presence of the non-
hydrolysable ATP analogue, AMP-PNP (Figure 5.4-3, panel A, left). Therefore, 
following the previous studies (Andreou, Harms and Klostermeier, 2019) Sc 
binding was investigated in presence of ATP. Here, only weak binding to AG-RNA 
was observed and no oligomeric complexes were apparent (Figure 5.4-3, panel 
A, middle), which indicated a major difference between the human and yeast 
orthologues. However, the same image of an EMSA with increased contrast, 
suggested possible weak dimer formation (Appendix 3 Figure 3-6). Moreover, 
use of silvestrol stimulated oligomerisation of Sc eIF4A (Figure 5.4-3, panel A, 
right). This suggested that the yeast eIF4A has the capacity and amino acid 
residues responsible for potential oligomerisation, however the extent of the 
oligomerisation is greatly diminished in comparison to the human eIF4As.  
Next, the Sc eIF4A binding affinity for different RNA substrates was measured 
and compared to the human eIF4As (Figure 5.4-3, panel B). As the Sc eIF4A did 
not exhibit binding in presence of AMP-PNP, the experiments were performed 
with use of ATP. Yeast eIF4A exhibited higher KD than the human orthologues for 
(AG)10, (CAA)6CA, (AGUG)5 and lower for the (UCUC)5 and (UGUG)5. Interestingly, 
the last two sequences, were the ones for which eIF4A2 displayed lower KD in 
presence of ATP than AMP-PNP (see Table 3.8-1). Similarly, as the human eIF4A, 
the yeast eIF4A showed highest affinity (lowest KD) for AG-motif RNAs, i.e., 
(AG)10 and (AGUG)5. This suggested that the high affinity for AG-RNA could 
potentially be universal of eIF4A regardless of the species.  
Next, as 1) eIF4G-MC reduced the functional binding affinity of eIF4A2 to RNA 
substrate in the unwinding reaction (see Table 4.3-2), and 2) all of the tested 
CNOT1 constructs had a similar effect in the binding experiments (see Figure 
4.5-5, Table 5.4-1), whether Sc eIF4G could exert similar effect on Sc eIF4A was 
explored (Figure 5.4-3). Intriguingly, both the shorter Sc eIF4G-M and longer Sc 
eIF4G-MC increased Sc eIF4A affinity towards the tested RNAs, with the most 
striking difference observed for AG-motif RNAs (10-fold affinity increase, see 
Table 5.4-1). As this was in contrast with what was observed for eIF4A2, next 
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the question of what influence eIF4G-MC has on eIF4A1 binding affinity was 
posed (Figure 5.4-3, panel D). eIF4A1 binding affinity was greatly reduced 
(increase of KD) in presence of eIF4G-MC. These data suggest a potential 
different mechanism of Sc eIF4A activation by Sc eIF4G. Last, the RNA binding 
capacity of Sc eIF4G constructs was explored. Similarly, as in the case of CNOT1 
(see Figure 4.5-5), which contains MIF4G domain as eIF4G, only the longer 












Figure 5.4-3 Sc eIF4A affinity is improved by Sc eIF4G constructs  
Sc eIF4A – yeast eIF4A; eIF4A1, eIF4A2 – human paralogues; Sc eIF4G-MC, Sc eIF4G-M 
yeast eIF4G constructs; eIF4G-MC – human eIF4G construct  
A. EMSAs of S. cerevisiae eIF4A binding to Dy780 (AG)10 RNA in presence of AMP-
PNP, left (n = 2), ATP, middle (n = 1), silvestrol (silv) right (n = 2). Almost no 
binding detected in the presence of AMP-PNP, monomeric band visible in the ATP 
conditions, silvestrol induced oligomer formation.  
B. KD of Sc eIF4A, eIF4A1 and eIF4A2 for indicated RNA sequences. Measurements 
for eIF4A1 and eIF4A2 done in presence of AMP-PNP, and for Sc eIF4A in presence 
of ATP. N = 3. KD measurements for eIF4A1 performed by Dr Tobias Schmidt. KD 
values obtained from fitting Hill equation to the titration data.  
C. Comparison of KD measurements of Sc eIF4A and Sc eIF4A in presence of 0.5 µM 
of eIF4G constructs and ATP. KD values obtained from fitting Hill equation to the 
titration data. N = 3. Yeast eIF4G improves the binding affinity of eIF4A.  
D. Comparison of KD measurements of eIF4A1 and eIF4A1 in presence of 0.5 µM of 
human eIF4G-MC and AMP-PNP. N = 3. Measurements performed by Dr Tobias 
Schmidt. Human eIF4G decreases eIF4A1 affinity (increase KD) to RNA.  
E. Relative polarisation change of yeast 0.5 µM eIF4G-MC and yeast eIF4G-M. Slight 
increase in (AG)10 polarisation for eIF4G-MC in comparison to free RNA may 
indicate RNA binding. N = 3 for eIF4G-MC and n = 2 for eIF4G-M.  
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Table 5.4-1 KD (µM) of eIF4A1, eIF4A2 and Sc eIF4A alone and in presence of 
interaction partners on various RNA sequences  
Protein (AG)10 (CAA)6CA (AGUG)5 (UCUC)5 (UGUU)5 
eIF4A1  
0.32 ± 0.03 1.63 ± 0.35 0.33 ± 0.05 17.77 ± 6.65 2.66 ± 0.63 
eIF4A1 + 
eIF4G-MC  10.76 ± 0.76 8.86 ± 1.08 15.29 ± 8.85 12.69 ± 1.70 24.62 ± 13.43 
eIF4A2  
0.75 ± 0.05 3.24 ± 0.32 0.53 ± 0.12 8.27 ± 1.22 5.02 ± 1.47 
eIF4A2 + 
CNOT1 MA3-MIF  
1.08 ± 0.21 n.d. 1.29 ± 0.35 n.d. 10.73 ± 4.56 
Sc eIF4A  
3.36 ± 0.61 4.34 ± 0.71 2.16 ± 0.21 5.31 ± 1.21 3.82 ± 0.40 
Sc eIF4A + 
Sc eIF4G-MC 0.31 ± 0.04 3.33 ± 0.59 0.23 ± 0.02 2.78 ± 0.84 2.80 ± 1.39 
n.d. – not determined  
 
In all, this subchapter elucidated that despite above 60% identity between 
human and yeast eIF4A (Figure 5.4-1), the propensity of Sc eIF4A to bind RNA 
and oligomerise is in stark contrast to what was observed for human paralogues 
(Figure 5.4-3, panels A, B). The gathered data suggest, that Sc eIF4A potentially 
exist mostly in the monomeric form, however the ability to oligomerise is not 
absent (Appendix 3 Figure 3-6). Furthermore, Sc eIF4A exhibits lower affinity 
for (AG)10, (CAA)6CA, and (AGUG)5 RNAs than the human helicases. Albeit, out of 
the tested RNAs, Sc eIF4A similarly to human eIF4As has greatest affinity for AG-
motif RNAs. Intriguingly, the stark difference was observed in presence of eIF4G 
constructs. While the human eIF4G-MC reduced eIF4A1’s affinity (30-fold for AG-
RNA) as well as eIF4A2’s apparent affinity, the yeast eIF4G orthologue increased 
the affinity of Sc eIF4A to RNA (Figure 5.4-3, panel C, see also Tables 4.3-2, 
5.4-1). The large decrease of affinity of eIF4A1 in presence of eIF4G-MC puts in 
perspective the only 2-fold affinity decrease of eIF4A2 in presence of CNOT1 
MA3-MIF, suggesting that possibly eIF4A2 activity in presence of CNOT1 could be 
more akin to the activity of the yeast eIF4A. Taken together, this subchapter 
elucidated major differences between the eIF4A orthologues, with potential 
implication of how the data obtained for yeast complexes may not be related to 





5.5. Chapter discussion  
 
This chapter was focused on biochemical comparison of the human eIF4A1 and 
eIF4A2 and their yeast orthologue eIF4A to elucidate potential differences. 
First the oligomerisation potential of eIF4A1 was explored. Similarly, to what 
was discovered for eIF4A2 (see Chapter 3.5), eIF4A1 was found to oligomerise in 
vitro (Figure 5.2-2, panels A, B). However, its potential to oligomerise was 
lower than that of eIF4A2, revealing a major distinction between the two 
paralogues. Further dissimilarities were found for binding affinities, where 
eIF4A1 binding affinity was the highest for 20 nt RNA, supporting the full 
oligomerisation inducing interface (Figure 5.2-2, panels A, D). This finding is in 
contrast to what is described in the literature, where the binding interface of 
both human and yeast eIF4A was shown to be around 15 nt (Abramson et al., 
1987; A. Z Andreou and Klostermeier, 2013).  
Furthermore, eIF4A1 oligomerisation was shown to exist in cells (Appendix 3 
Figure 3-1). As human eIF4G1 has 2 eIF4A binding sites and was previously 
described to bind two eIF4A molecules (Korneeva et al., 2001; Imataka and 
Sonenberg, 2015) the possibility of the eIF4G-induced eIF4A oligomerisation had 
to be examined. For this eIF4G-binding-deficient eIF4A1 mutants were utilised 
(mutations based on Oberer, Marintchev and Wagner, 2005), which contested 
the idea of eIF4G-induced interaction (Appendix 3 Figure 3-2, 3-3, 3-4). 
However, it should be noted that the cellular localisation of this mutant was not 
restricted to cytoplasm. As endogenous eIF4A1 is in far excess of endogenous 
eIF4G and is exclusively cytoplasmic, this change in not likely due to the loss of 
eIF4G binding and instead suggests that this mutant causes localisation defect. 
Importantly, the in vitro assays show that this mutant is capable of RNA binding, 
similar to WT eIF4A1. Additional use of RNA binding deficient eIF4A1 mutant 
supported the described model for eIF4A2 (see Chapters  3.5, 3.9), in which 
oligomerisation happens through protein-protein interactions and the RNA 
contact is not required for all of the protomers in the oligomer (Appendix 3 
Figure 3-1).   
Next, the catalytic activities of eIF4A1 and eIF4A2 alone and in presence of 
interaction partners were compared. The activity of eIF4A2 in comparison to 
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eIF4A1 in all the tested conditions, both alone and with interaction partners, 
was higher (Figure 5.2-3, panel A). However, the enhancement of unwinding 
activity by eIF4H and eIF4G-MC was greater for eIF4A1 than eIF4A2 (Figure 
5.2-3, panel B). Albeit the absolute effect was still greater for eIF4A2, which 
could be due to a higher activity of free oligomeric eIF4A2 than eIF4A1, as 
eIF4G-MC enhanced eIF4A2 activity only about 1.5-fold (see Figure 4.3-3). The 
observed stimulation for eIF4A1 unwinding activity is in agreement with the 
literature (Rogers, Richter and Merrick, 1999; Korneeva et al., 2005; Nielsen et 
al., 2011; Özeş et al., 2011).  
Intriguingly, eIF4A1 unwinding activity was synergistically stimulated by eIF4H 
and eIF4G similarly to the published data for human and yeast eIF4A (Abramson, 
Dever and Merrick, 1988; Nielsen et al., 2011; Andreou and Klostermeier, 2014). 
Contrary to this observation, the additive effect on eIF4A2 activity was not as 
strong (Figure 5.2-3, panel C, see also Figure 4.3-3). Interestingly, there is only 
one amino acid difference between the two paralogues in the canonical region 
responsible for eIF4G binding. However, as eIF4A2 does not preferentially 
interact with eIF4G1 in cells (Meijer et al., 2013, 2019; Wilczynska et al., 2019) 
a possibility of different regions responsible for full eIF4G-eIF4A interaction 
could explain observed differences. In additional experiments, these data could 
be further expanded through the use of the eIF4A2-7-mut mutant described in 
this chapter, which was previously shown to restore the full interaction with 
eIF4G1 in cells (Wilczynska et al., 2019). Potentially, experiments employing 
eIF4A2-7-mut could explain the lack of strong synergistic activation of eIF4A2 by 
eIF4H and eIF4G.  
Moreover, a surprising decrease in eIF4A1 ATPase activity in presence of eIF4G-
MC, and subsequent decrease in presence of both eIF4G-MC and eIF4H was 
observed (Figure 5.2-3, panel D). This observation is in stark contrast to what 
was described previously in the literature (Nielsen et al., 2011). However, it 
should be noted that the previous observations included RNA substrates of 
different lengths of both single- and double-stranded regions, as well as 
different sequences. Moreover, a relation between the RNA length and ATPase 
activity was previously observed for yeast eIF4A (Andreou, Harms and 
Klostermeier, 2019). Perhaps, testing the eIF4A1 ATPase activity on different 
RNA substrates could explain the observed discrepancy. In contrast, eIF4A2 
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ATPase activity was not subjected to great change regardless of presence of the 
interaction partners. Albeit a slight decrease of eIF4A2 ATPase activity was 
detected in presence of both eIF4G-MC and eIF4H (Figure 5.2-3, panel D, see 
also Figure 4.3-3, panel D). This was also visible when comparing eIF4A1 ATPase 
in presence of eIF4G-MC and both eIF4G-MC and eIF4H, indicating that eIF4H in a 
reaction containing eIF4A-eIF4G complexes could potentially decrease the ATP 
turnover of eIF4A.  
As differences in both oligomerisation potential and the catalytic activities 
between the two paralogues were observed, next part of this chapter focused on 
additional dissimilarities previously described in the literature (Wilczynska et 
al., 2019). Here, the previous work showing selective binding of eIF4A2 to AG-
RNA in the presence of a competitor RNA and the lack of this activity in eIF4A1 
was expanded by use of eIF4A mutants. The goal was to uncover what potential 
regions of eIF4A are responsible for this distinct binding preference of the two 
helicases. The gathered data suggest that the N-terminal region of eIF4A1 drives 
the lack of selectivity (Figure 5.3-3, panel A). Intriguingly, for eIF4A2, loss or 
exchange of N-terminal region with eIF4A1, did not cause the loss of selectivity. 
This suggested that for eIF4A2, additional regions are responsible for its 
selective behaviour. The eIF4A2-7-mut mutant exhibited the largest change, 
resembling the activity of WT eIF4A1; however, the extent of this change was 
lower, and due to a large error between the replicates, strong conclusions could 
not be made. Taken together, these data suggest that the divergent N-terminal 
region of eIF4A1 is the primary driver of the differences in RNA binding between 
the paralogues. Moreover, additional regions in eIF4A2 make it distinct to 
eIF4A1, and resistant to the loss of its natural activity. These discoveries about 
the role of the divergent N-terminal region, and the previously described 
translational repression by eIF4A2 related to its selective behaviour (Wilczynska 
et al., 2019), could aid in future developments into targeting the specific 
paralogue and its activity in a cancer setting.  
Next, RNA release from WT and mutants of eIF4A1 was tested (Figure 5.3-3, 
panel B). Although a direct comparison between the experiments presented in 
this thesis and the ones described in Wilczynska et al., 2019 could not be made 
due to uncompetitive nature of the RNA release experiments presented here 
certain conclusions could be drawn. The excess of competitor RNA used in the 
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previous study induced a faster RNA strand release, with both eIF4A1 and eIF4A2 
exchanging labelled for non-labelled AG-RNA, whereas only eIF4A2 readily 
exchanged labelled (CAA)6CA for unlabelled (AG)10. Here, in the non-competitive 
conditions both paralogues released the (CAA)6CA RNA in a similar manner, even 
in the starting phase of the reaction. The discrepancy between the data 
presented here and the previously published can additionally stem from the use 
of hydrolysable ATP in Figure 5.3-3, panel B, as AMP-PNP is thought to lock the 
proteins onto RNA. Moreover, eIF4A2 exhibited a longer duration in an RNA-
bound state on AG-RNA in contrast to eIF4A1, eIF4A2-7-mut, eIF4A2 1-18 A1 and 
eIF4A1 1-18 A2. Interestingly, the N-terminally truncated mutants of both 
paralogues exhibited the longest half-lives, with eIF4A1 Δ N-20 showing almost 
no AG-RNA release in the tested conditions. These data further emphasise the 
differences between the paralogues and indicates that the RNA release is at 
least partially mediated through the N-terminal region. As an important aside, 
this discovery indicates that caution needs to be taken with interpretation of 
experiments that use N-terminally tagged or truncated eIF4A. Additionally, as 
the previously solved RNA-bound crystal structure of eIF4A1 represents N-
terminal truncation of eIF4A1 (Iwasaki et al., 2019), the findings presented here 
invoke a new question whether a more accurate structure of RNA-bound eIF4A1 
should be determined with the full N-terminus present.   
Moreover, distinct oligomerisation potential was observed for the two paralogues 
and their mutants (Figure 5.3-4). However, the oligomerisation and the 
preference to form larger oligomeric species on specific RNA sequences was not 
correlated with the RNA sequence selective binding. This suggested that the RNA 
binding selectivity might be independent of which species, i.e., monomeric, or 
oligomeric, are bound to the RNA substrate.  
The final aspect of this chapter was the comparison of the human eIF4A 
paralogues and the yeast eIF4A. As Saccharomyces cerevisiae shares above 60% 
sequence identity with both eIF4A1 and eIF4A2 (Figure 5.4-1) the functions of 
exerted by Sc eIF4A are often thought to be similar for its orthologues.  
The data presented here elucidated some large differences between the yeast 
and human eIF4A helicases. The biggest difference was observed in how Sc eIF4A 
binds RNA, with almost no RNA-binding activity detected in presence of AMP-PNP 
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and weak binding in presence of ATP (Figure 5.4-3, panel A). Moreover, almost 
no oligomeric species were detected for yeast eIF4A. Although Sc eIF4A has the 
potential to form oligomers, as silvestrol was shown to induce this activity 
(Figure 5.4-3, panel A).  
Moreover, Sc eIF4A KD for (AG)10, (CAA)6CA, (AGUG)5 is larger than the one 
observed with human paralogues (Figure 5.4-3, panel B). However, this 
difference could potentially stem from the KD measurements of Sc eIF4A in 
presence of hydrolysable ATP. This means that Sc eIF4A ATPase activity could 
influence the measured KD. Additionally, as observed in Table 3.8-1 eIF4A2 
exhibited higher KD values for the same RNAs in presence of ATP than AMP-PNP. 
Next, 1) as CNOT1 fragments decreased eIF4A2 affinity for all tested RNA 
sequences (see Figure 4.5-5, Table 5.4-1), and 2) eIF4G-MC decreased the 
functional binding affinity of eIF4A2 for 5’(AG)10 overhang RNA (see Table 
4.3-2), therefore a question was posed what influence the truncated fragments 
of Sc eIF4G have on Sc eIF4A binding affinities. Interestingly an opposite effect 
was observed for Sc eIF4A (Figure 5.4-3 panel, Table 5.4-1). Here, both tested 
Sc eIF4G constructs increased affinity of Sc eIF4A to all tested RNA substrates, 
with the largest difference visible for AG-motif RNAs. Next, this data were 
compared to the affinities of eIF4A1 with and without eIF4G-MC (Figure 5.4-3, 
panel D, Table 5.4-1). Human eIF4G-MC caused above 30-fold increase in the KD 
of eIF4A1 for (AG)10 and (AGUG)5 RNAs. This large difference puts in perspective 
the only 2-fold increase of KD exerted by CNOT1 MA3-MIF on eIF4A2. This 
potentially indicates that eIF4A2 in presence of CNOT1 behaves in a more similar 
manner to the yeast orthologues than eIF4A1. The RNA binding capacity of yeast 
eIF4G constructs was examined (Figure 5.4-3, panel E) as human eIF4G-MC 
fragment was previously shown to bind RNA (Nielsen et al., 2011), and a weak 
binding to AG-motif RNAs was observed for CNOT1 MA3-MIF fragment (Figure 
4.5-4, panel D). Here a very weak binding of Sc eIF4G-MC to AG-RNA was 
detected which might relate to the previously identified three RNA binding 
regions on yeast eIF4G (Berset et al., 2003). Moreover, only the longer Sc eIF4G-
MC contains one of the RNA binding regions and for full binding activity all three 
regions need to be present. This could possibly indicate greater similarities 
between Sc eIF4A and eIF4A2 in presence of their main interaction partners. 
Additional similarity between eIF4A2 and CNOT1 interaction and the one 
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between Sc eIF4A and Sc eIF4G could potentially be drawn from the nature of 
the interaction. Sc eIF4G has been shown to modulate conformational change of 
Sc eIF4A (Andreou and Klostermeier, 2014). Additionally, the crystal structure of 
Sc eIF4A in complex with Sc eIF4G has been shown to resolve with the greatest 
quality, with less variation in the sample, in presence of both AMP and ADP 
(Schutz et al., 2008). This could possibly be related to the greater co-
immunoprecipitation of MIF and both MIF and MA3 domains of CNOT1 with eIF4A2 
in presence of AMP and ADP + Pi (see Figure 4.5-4). Perhaps, further studies 
could focus on use of different stages of ATP hydrolysis to elucidate the inner 
workings of the formed complexes.  
In all, this chapter emphasised the molecular differences between the highly 
identical human eIF4A paralogues, and highlighted the need for further studies, 
that could dissect the activities of eIF4A1 and eIF4A2. Moreover, the data 
presented here stressed the importance of studying human proteins for further 
progress in medical studies, as despite certain similarities between the 




6. Thesis discussion and future prospects  
 
The high identity between eIF4A1 and eIF4A2 has led many scientists to believe 
that the two paralogues are functionally redundant, therefore most previous 
studies focused solely on exploration of the mechanisms of eIF4A1. However, the 
observation that upon knock out of eIF4A1, eIF4A2 is overexpressed without 
rescuing eIF4A1 role in translation initiation (Galicia-Vazquez et al., 2012) has 
put eIF4A2 on the scientific map. The recent discoveries implicating eIF4A2 in a 
translationally repressive role (Meijer et al., 2013, 2019; Wilczynska et al., 
2019) brought to light the need to investigate this molecularly unexplored eIF4A 
paralogue.  
In this thesis, biochemical, structural, and imaging methods were used to 
uncover the molecular mechanisms that drive eIF4A2. Moreover, the activities 
conferred through the interaction partners were explored and the divergent 
functions between eIF4A1 and eIF4A2 were compared on a biochemical level. 
These findings led to creation of a model which could explain the new activities 
of the paralogues (Figure 6-1). This chapter brings together the most important 
discoveries described in this thesis and proposes future directions.  
The discovery that both eIF4A1 and eIF4A2 can form oligomers in vitro and in 
cells (Figures 3.4-1, 3.7-3, 5.2-2, and Appendix 3 Figure 3-1) can have 
broader implications for our understanding of how protein translation is 
regulated. Both paralogues oligomerised preferentially on RNAs with AG-motifs 
(Figures 3.5-2, 5.2-2), however eIF4A2 displayed more flexibility in this aspect, 
oligomerising on different sequences. Although it could not be determined 
whether the higher unwinding activity of eIF4A2 was correlated with 
oligomerisation potential or its affinity for specific RNA sequence (Figure 3.8-3), 
both eIF4A2 and eIF4A1 did not display RNA unwinding when oligomerisation 
potential and free exchange of protomers in the oligomer were abrogated 
(Figure 3.10-2 and Appendix 3 Figure 3-5). Interestingly, independent 
investigation in the Bushell lab, has shown that the unwinding activity of eIF4A1 
is the highest on AG-RNA, and translation of structured RNAs in reticulocyte 
assays is greater when the AG-motifs are present in a reporter mRNA. It is well 
known that efficient translation of mRNAs with highly structured 5’UTRs requires 
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helicase activity. In fact, depletions of helicases such as DDX3 or DHX36 have 
been shown to reduce translation of mRNAs with highly structured 5’UTRs 
(Pisareva et al., 2008; Calviello et al., 2021). Similar observations were made 
for inhibition of eIF4A (Rubio et al., 2014; Waldron, Raza and Le Quesne, 2018; 
Waldron et al., 2019); however, the interpretation of eIF4A inhibition could be 
more complicated, due to its unwinding-independent activity in mRNA loading 
onto the 43S ribosomal subunit (Sokabe and Fraser, 2017). Interestingly, the gain 
of function inhibitor, silvestrol used in this thesis induced oligomerisation of 
both paralogues as well as their unwinding activity (Figures 3.9-1, 3.9-4, 
5.2-2). However, despite the observed gain of function, other studies using 
silvestrol have reported translational inhibition (Kogure et al., 2013; Wolfe et 
al., 2014; Chen et al., 2016; Biedenkopf et al., 2017). This could be due to the 
previously described (Iwasaki, Floor and Ingolia, 2016) and observed here 
(Figure 3.10-1) clamping mechanism, which leaves eIF4A locked onto the RNA. 
As explained in the publication from Ingolia lab (Iwasaki, Floor and Ingolia, 
2016), the presence of eIF4A bound to the mRNA could physically disturb the 
scanning mechanism of the 40S ribosomal subunit. Alternatively, all available 
eIF4A could be scavenged by clamping it in monomeric form to the RNA, leaving 
no free eIF4A to perform other functions.  
Curiously, the eIF4G-MC, containing both eIF4A binding sites, reduced the 
apparent affinity of eIF4A2 for RNA substrate in the unwinding reaction, as well 
as the cooperativity between the protomers in the oligomer (Table 4.3-2). A 
similar observation was made for eIF4A1, which displayed reduced binding 
affinity in presence of eIF4G-MC (Table 5.4-1). Importantly, eIF4G-MC greatly 
reduced the unwinding activity of both eIF4A1 and eIF4A2 when present in equal 
or greater molar concentration than the helicases (Figure 5.2-3). Moreover, an 
eIF4A1 mutant incapable of binding eIF4G, oligomerised both in vitro and in cells 
(Appendix 3 Figures 3-2, 3-3, 3-4). Of special importance was also the 
observed lack of synergistic activation of eIF4A2 by eIF4H and eIF4G-MC (Figure 
5.2-3), suggesting that eIF4A2, forms complexes of distinct activity. Taken 
together, this indicates that the main function of both eIF4As when in complex 
with eIF4G is independent of unwinding activity. Therefore, it could be proposed 
that in cells the unwinding activity is performed by a population of the non-
eIF4F-associated, free, oligomerised eIF4A. In fact, there are more molecules of 
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eIF4A than ribosomes present in cell, with a 3 to 1 ratio of the helicase to the 
ribosome (Roger Duncan and Hershey, 1983). Intriguingly, a recent landmark 
publication further supports the concept that there may be two pools of eIF4A in 
the cell. An atomic resolution structure of the entire 48S ribosomal initiation 
complex solved by CryoEM from the Ramakrishnan lab (Querido et al., 2020) 
presented single eIF4A in the eIF4F complex at the 40S ribosomal subunit mRNA 
exit channel. This suggested that the canonical role of eIF4A in the eIF4F 
complex could be in the mRNA loading and supported the ‘ratchet’ model of 
translation initiation (as described in Chapter 1.3.2). However, the authors of 
that work did not exclude the possibility of additional, separate population of 
eIF4A existing outside of the eIF4F complex at the 40S mRNA entry channel, 
where it could perform the unwinding activity. Perhaps, the eIF4A2 preference 
to unwind RNA substrates in 3’-to-5’ direction (Figure 3.8-5, Table 3.8-2) could 
play a role here. Moreover, investigation of the conditions in which the 48S was 
assembled (Querido et al., 2020), suggests that the authors would not be able to 
obtain oligomeric eIF4A, as 1 to 2 eIF4G to eIF4A ratio was used. Additionally, 
the authors  (Querido et al., 2020) used ATP analogue, ATP-γ-S, which has been 
previously shown to be hydrolysed by eIF4A (Peck and Herschlag, 2003). 
Implication of that is that eIF4A could shift through conformational cycle, and it 
is currently unknown how transient are the oligomeric complexes.  
Importantly, data collected for the Sc eIF4A additionally support a model in 
which oligomerised eIF4A is needed for unwinding activity. Sc eIF4A was 
demonstrated to mostly exist in monomeric form, however the potential to 
oligomerise was not absent (Figure 5.4-3 and Appendix 3 Figure 3-6). 
Interestingly, the yeast mRNAs have  significantly shorter and less structured 
5’UTRs than human mRNAs (Leppek, Das and Barna, 2018). Furthermore, Sc 
eIF4A has been also shown to have unwinding-independent activity in mRNA 
loading on the 43S (Yourik et al., 2017). That indicates, that Sc eIF4A role could 
be predominantly unwinding-independent, which correlates with its weaker 
oligomerisation potential.  
However, to understand the exact role of oligomeric eIF4A, further 
investigations are necessary. The exact residues responsible for oligomerisation 
of eIF4A1 and eIF4A2 should be determined, either through crystallisation of 
oligomeric complexes, hydrogen-deuterium exchange (HDX), or mutational 
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analysis. The latter two have their limitations. In HDX, hydrogen atoms that are 
accessible to the solution are exchanged for deuterium. Therefore, using two 
separate samples of monomeric and oligomeric eIF4A, one can determine the 
regions which are accessible in monomeric complex and no longer available for 
the exchange in the oligomer. However, this kind of experiment, provides only 
broad regions that could be involved in oligomer formation. The mutational 
analysis requires prior knowledge, therefore can be coupled with HDX. Albeit 
creation of multiple mutations and testing them both in vitro and in cells can be 
time consuming. Therefore, obtaining exact atomic resolutions of oligomeric 
eIF4A is critical. However, crystallisation of the oligomeric complexes could be 
in itself a rather daunting task. As eIF4A oligomerisation is dependent on two 
factors: presence of RNA and protein being in excess over RNA (Figure 3.5-1), 
this often leads to formation of multiple species in one sample. In fact, crystal 
structure of eIF4A1 in presence of AG-RNA and RocA (Iwasaki et al., 2019), was 
obtained in 3 to 1 excess of RNA over the protein. This ratio was perhaps chosen, 
to avoid mixed population in the sample with free and RNA-bound eIF4A. 
However, such a ratio would never lead to obtaining oligomeric complexes. 
Perhaps, deriving from another approach, that has been used in this thesis is 
needed. In the SAXS experiments (Chapter 3.6) the complexes were subjected 
to size exclusion chromatography and then exposed to X-ray radiation. This way, 
analysis of separate complexes was possible. Crystallisation of separate 
complexes eluted from size exclusion column would yield the most homogenous 
samples. As another approach, CryoEM could be used to obtain a more native 
state of the complexes at atomic resolution without the requirement for crystal 
formation.  
Further, the impact of abrogation of oligomerisation should be assessed in cells, 
or mouse models. As overexpression of eIF4A1 and occasionally eIF4A2 is 
associated with poor prognosis for cancer patients (see Table 1.5.1-1) and many 
oncogenic proteins have highly structured 5’UTRs, the correlation between 
oligomerisation and cancer is rather alluring. However, testing whether lack of 
oligomerisation could be detrimental to normal cells should be a priority. 
Moreover, the next step should be to understand which mRNAs are dependent on 
the eIF4A oligomeric state, and to determine whether the disruption of 
oligomerisation of eIF4A reduces proliferation of cancer cells. If that is the case, 
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finding small molecule inhibitors that could disrupt the oligomerisation should be 
a priority. However, as eIF4A2 has been implicated in miRNA-mediated 
translational repression (Meijer et al., 2013), and sometimes overexpression of 
eIF4A2 is beneficial for cancer patients (see Table 1.5.1-1), finding inhibitors 
that target the specific paralogue is of utmost importance.  
Moreover, understanding in which form, oligomeric or monomeric, eIF4A2 exists 
in complex with CNOT1, and therefore performs its repressive function is 
needed. However, as described in this thesis (Chapter 4.5 and Appendix 2), 
obtaining large quantities of pure, non-aggregated longer construct of CNOT1 is 
problematic. In fact, the difficult linker region between MA3 and MIF domains of 
CNOT1 is highly post-translationally modified through phosphorylation, 
acetylation and most importantly glycosylation (PhosphoSite, Hornbeck et al., 
2015). Perhaps, changing from the favoured by many biochemists bacterial 
protein expression system into the mammalian one would be beneficial. In fact, 
understanding what influence the post-translational modifications can have on 
the catalytical properties of eIF4A1 and eIF4A2 could be the next step. 
Advantageously, none of the possible post-translational modifications have an 
effect on eIF4A oligomerisation, as FLIM-FRET assays were performed in human 
HeLa cells (Chapter 3.6 and Appendix 3).  
Interestingly, virtually no RNA binding of eIF4A2 was observed for sequences 
without AG-motifs in presence of CNOT1, indicating that CNOT1 confers even 
more selectivity on eIF4A2 (Figure 4.5-5 and Table 5.4-1). This discovery is in 
agreement with previous work from the Bushell lab (Wilczynska et al., 2019), in 
which eIF4A2 induced repression through the AG-motifs in RNA. Perhaps the 
selective high unwinding of eIF4A1 in presence of AG-motifs, and the repression 
exerted by eIF4A2 through the same motifs act as a sort of a feedback loop to 
keep the translational control. Moreover, this enhanced RNA sequence 
preference, despite the slight increase in KD for AG-motifs, was imparted by 
CNOT1, regardless of its own RNA binding properties (Figure 4.5-5). In fact, 
while investigating the influence of CNOT1 on eIF4A2, a discovery about CNOT1 
RNA binding potential was made. As neither MA3 nor MIF domains themselves 
exhibited RNA binding (Figure 4.5-5), the AG-motif RNA binding of CNOT1 has to 
be attributed to the disordered linker between the two domains. This could have 
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possible implications on different studies, in which constructs lacking RNA 
binding functions were used.  
Furthermore, despite the previously disputed eIF4A2-CNOT1 association (Chen et 
al., 2014), both eIF4A2 and DDX6 interacted with CNOT1 MIF construct (Figure 
4.5-4). Interestingly, the authors (Chen et al., 2014) who contested eIF4A2-
CNOT1 interaction and observed eIF4A2-eIF4G association used non-native levels 
of eIF4A2. As has been shown previously (Wilczynska et al., 2019) overexpression 
of eIF4A2 causes its preferential association with eIF4G. Here, equimolar 
concentrations of recombinant eIF4A2 and CNOT1 constructs were used. 
Moreover, in this thesis the activation of CNOT7 deadenylation activity through 
association with CNOT1 MIF was only observed for DDX6 and not eIF4A2 (Figure 
4.5-6). This supports the previously observed inhibition of CNOT7 deadenylation 
in presence of eIF4A2 (Meijer et al., 2019). The lack of deadenylation in 
presence of eIF4A2 verifies a model in which eIF4A2 bound mRNAs can be 
translationally repressed but not degraded. The implication of that could be that 
the eIF4A2 bound messages targeted for repression are stored.  
Interestingly, eIF4A2-mediated mRNA storage could fit into a model proposed by 
the Parker lab (Tauber et al., 2020), in which eIF4A1 modulated RNA 
condensates. Interestingly, in that publication concentration of eIF4A1 which 
would support oligomerisation was used. Moreover, ATP-dependent dissolving of 
RNA condensates induced by eIF4A1 was observed. Possibly, the unwinding 
activity of oligomerised eIF4A1 played a role in this observation. Perhaps 
expanding that study (Tauber et al., 2020) by use of eIF4A2 and different 
concentrations of both paralogues to obtain both monomeric and oligomeric 
conditions, would yield more definite answer about the role of eIF4A in phase 
separation. Interestingly another landmark study (Hondele et al., 2019) which 
explored roles of DEAD-box helicases in phase separation postulated that eIF4A 
does not form RNA condensates. The condensation was suggested to happen 
mostly through low-complexity regions in the structures of DEAD-box proteins, 
which both eIF4A1 and eIF4A2 lack (Hondele et al., 2019). However, an example 
of condensate-localised DDX39B (UAP56), which lacks low complexity domains 
was presented (Hondele et al., 2019). Moreover, only the yeast eIF4A was 
explored in the aspect of phase-separation in that publication. Taken together, 
this captivating avenue of additional regulatory roles of eIF4As in protein 
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translation should be explored in context of both monomeric and oligomeric 
versions of eIF4A1 and eIF4A2.  
Overall, this study provided in-depth investigation of both paralogues, however 
many more aspects of eIF4As’ activities remain to be determined. Finally, out of 
the scope of this thesis, the possibility of eIF4A1 and eIF4A2 to form hetero 
oligomers was identified. As shown in Wilczynska et al., 2019 there is a large 
group of mRNAs bound by both eIF4A1 and eIF4A2. Perhaps future investigations 
into exact roles of hetero oligomers could explain why in certain cancers eIF4A2 











Figure 6-1 Oligomerisation-dependent model of translational control  
A. Monomeric (or two independent eIF4A1) associate with eIF4F through eIF4G and 
perform function in mRNA loading onto the 40S ribosomal subunit. eIF4F-
independent eIF4A1 unwinding secondary structures in the 5’UTR through 
oligomerisation at AG-motifs.  
B. eIF4A2 in complex with CCR4-NOT represses translation through AG-motifs 
without mRNA degradation, possible role in mRNA storage. DDX6 in CCR4-NOT 
enhances CNOT7 deadenylation activities.  
C. eIF4A2 if in excess of CNOT1 and possibly eIF4G can oligomerise on its own and 







Appendix 1 Figure 1-1 AMP-PNP bound eIF4A2 remains monomeric in solution 
A. Size exclusion chromatography (Superdex 200 increase 3.2) of the sample 
containing 100 µM eIF4A2 and 1 mM AMPPNP in binding buffer (20 mM HEPES pH 
7.5, 100 mM KCl, 2 mM MgCl2, 1 mM DTT) run at the Diamond Light Source 
(Oxford, UK) before the sample was subjected to X-ray radiation, frame 
corresponds to fraction collected during SAXS. Monomeric peak is visible, eluting 
around 470 frames. Grey region corresponds to buffer subtracted as background.  
B. Intensity plot of the sample presented in panel A. Frames with most constant Rg 
(red dots) selected for further analysis (marked in light pink). 
C. Guinier region fitting (top) with residuals (bottom) of the sample from panel A, 
presenting linearisation of scattering data in the region close to 0 for the 




Appendix 1 Figure 1-2 eIF4A2 bound to equimolar amounts of (AG)10 RNA 
remains predominantly monomeric 
A. Size exclusion chromatography (Superdex 200 increase 3.2) of the sample 
containing 90 µM eIF4A2, 90 µM (AG)10 RNA, and 1 mM AMPPNP in binding buffer 
(20 mM HEPES pH 7.5, 100 mM KCl, 2 mM MgCl2, 1 mM DTT) run at the Diamond 
Light Source (Oxford, UK) before the sample was subjected to X-ray radiation, 
frame corresponds to frames collected during SAXS. A main peak detected at 450 
frames and a small peak at 400 frames are detected corresponding to eIF4A2 
monomer and dimer, respectively. The grey region corresponds to buffer 
subtracted as background.  
B. Intensity plot of the sample presented in panel A. Frames with most constant Rg 
(red dots), corresponding to the monomer, selected for further analysis (marked 
in light pink). 




Appendix 1 Figure 1-3 eIF4A2 forms oligomers on polypurine RNA when in 
excess over RNA substrate 
A. Size exclusion chromatography of the sample containing 90 µM eIF4A2, 30 µM 
(AG)10 RNA, and 1 mM AMPPNP in binding buffer (20 mM HEPES pH 7.5, 100 mM 
KCl, 2 mM MgCl2, 1 mM DTT) run at the Diamond Light Source (Oxford, UK) 
before the sample was subjected to X-ray radiation, frame corresponds to 
frames collected during SAXS. Three peaks are visible, monomer at 450 frames, 
and a small peak for oligomer (dimer) at 400 frames and oligomer (timer) at 360 
frames. Grey region corresponds to buffer subtracted as background. 
B. Intensity plot of the sample presented in panel A. Frames with most constant Rg 
(red dots), corresponding to the oligomer (dimer), selected for further analysis 
(marked in light pink). Not enough data was collected for frames corresponding 
to the peak around 360 frames.  




Appendix 1 Figure 1-4 eIF4A2 in presence of equimolar amounts of (CAA)6CA 
RNA remains mostly monomeric  
A. Size exclusion chromatography of the sample containing 90 µM eIF4A2, 90 µM 
(CAA)6CA RNA, and 1 mM AMPPNP in binding buffer (20 mM HEPES pH 7.5, 100 mM 
KCl, 2 mM MgCl2, 1 mM DTT) run at the Diamond Light Source (Oxford, UK) 
before the sample was subjected to X-ray radiation, frame corresponds to 
frames collected during SAXS. Two peaks are visible, monomer at 450 frames, 
and a small peak for oligomer (dimer) at 400 frames. Grey region corresponds to 
buffer subtracted as background. 
B. Intensity plot of the sample presented in panel A. Frames with most constant Rg 
(red dots), corresponding to the monomer, selected for further analysis (marked 
in light pink). 




Appendix 1 Figure 1-5 Shorter single stranded region on an RNA substrate 
with double stranded region induces oligomerisation to a lower extent  
A. Size exclusion chromatography of the sample containing 90 µM eIF4A2, 30 µM 
(AG)5 24BP RNA, and 1 mM AMPPNP in binding buffer (20 mM HEPES pH 7.5, 100 
mM KCl, 2 mM MgCl2, 1 mM DTT) run at the Diamond Light Source (Oxford, UK) 
before the sample was subjected to X-ray radiation, frame corresponds to 
frames collected during SAXS. Two peaks are visible, spanning, monomer at 450 
and oligomer (dimer) at 400 frames. Grey region corresponds to buffer 
subtracted as background. 
B. Intensity plot of the sample presented in panel A. Frames with most constant Rg 
(red dots), corresponding to the monomer, and oligomer, selected for further 
analysis (marked in light pink). 
C. Guinier region fitting (top) with residuals (bottom) of the samples from panel A, 




Appendix 1 Figure 1-6 (CAA)6CA 24BP RNA substrate supports formation of 
oligomeric complexes 
A. Size exclusion chromatography of the sample containing 90 µM eIF4A2, 30 µM 
(CAA)6CA 24BP RNA, and 1 mM AMPPNP in binding buffer (20 mM HEPES pH 7.5, 
100 mM KCl, 2 mM MgCl2, 1 mM DTT) run at the Diamond Light Source (Oxford, 
UK) before the sample was subjected to X-ray radiation, frame corresponds to 
frames collected during SAXS. Two peaks are visible, spanning from 350 to 450 
frames. Grey region corresponds to buffer subtracted as background. 
B. Intensity plot of the sample presented in panel A. Frames with most constant Rg 
(red dots), corresponding to the monomer, and oligomer, selected for further 
analysis (marked in light pink). 
C. Guinier region fitting (top) with residuals (bottom) of the samples from panel A, 





Appendix 1 Figure 1-7 eIF4A2 adopts different conformation based on RNA 
substrate and oligomerisation status 
Envelope models (dummy atom model fitting using DAMMIF and DAMAVER 
packages from ATSAS 3.0.3) – for more information about analysis please refer to 
Chapter 2.3.5 section.  
A. Envelope models formed on (AG)10 24 BP RNA substrate: oligomer on the left 
(deep purple) and monomer on the right (cyan).  
B. Envelope models formed on (AG)5 24 BP RNA substrate: oligomer on the left 
(navy blue) and monomer on the right (blue).  
C. Envelope models formed on (CAA)6CA 24 BP RNA substrate: oligomer on the left 






Appendix 2 Figure 2-1 Purification of MA3-MIF 842-1317 aa CNOT1 constructs 
Protein marker sizes in kDa indicated on the left of the gel; aa – amino acid  
A. Coomassie stained gel from an example of purification. Here purification was 
performed with addition of CHAPS (Thermo Scientific 28299) in the lysis buffer (5 
g per 200 mL of buffer). Protein of interest found throughout all peaks in the 
elution profile from size exclusion column (from 50 to 120 mL on Superdex S200 
HiLoad 16/600), indicating either elution in complexes with other proteins (as 
visible on the gel) and/or the protein of interest was additionally misfolded. 
Samples show signs of aggregation, as well as presence of additional 
contaminants.  
B. Final products of purifications of individual batches of CNOT1 MA3-MIF 842-1317. 
All samples contain aggregates (except of the last one which does not contain 
the correct protein), some additionally contain chaperones (or possibly 
uncleaved material), and additional contaminants. Contaminants influenced 
activity of the purified proteins in ATPase assays (CNOT1 constructs alone should 
not have ATPase activity). None of the purified proteins were suitable for use in 




Appendix 2 Figure 2-2 Purification of MA3-MIF 800-1312 aa CNOT1 construct  
Constructs cloned by Dr Lori Buetow with longer N-terminal limit and different tags (and 
their position) were assessed in test expression. Here, selected 4 constructs with 
different tags (tag and position indicated above each Coomassie stained gel; N-term – N-
terminal tag, C-term – C-terminal tag) are shown. aa – amino acid. Unrelated lanes from 
each gel removed.  
(figure legend continues on the next page) 
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The proteins were purified using agarose Ni2+ resin and numbers above each lane signify 
purification step: 1 – lysate (see Chapter 2.2 for lysate preparation) that was applied 
on agarose resin, 2 – flow through from the agarose resin, 3 -wash from the resin (wash 
1 out of 3 washes) (for buffer conditions see Chapter 2.2.2), 4 – elution from the resin 
(agarose resin split in two before elution), 5 – elution subjected to TEV cleavage to 
remove tags at 4°C over-night, 6 – TEV cleavage on the resin (the same condition as for 
cleavage of elution), 6 – elution after cleavage on the agarose resin. Arrows indicate 
proteins found in the lanes 4 to 7; bc – before cleavage or uncleaved product, low yield 
– correct protein but low yield in comparison to tag and contaminants, tag – the cleaved 
tag, MA3-MIF – the correct construct with acceptable yield, ? – unidentified 
contaminates (for example proteins that are of the size of cleaved final product but 
were already visible in lane 4 – before cleavage, signifying that this was not the final 
product). Other tests were performed, and the most promising construct C-term TEV-
GFP-HisSPR (bottom right corner) was used for large scale purification however, final 
product that could be used in assays was not obtained. Finally, the longer construct 
used in this thesis was obtained as a gift from Dr Lori Buetow (see Appendix 2 Figure 











Appendix 2 Figure 2-3 Linker between MA3 and MIF domains of CNOT1 is 
responsible for aggregation issues  
Protein marker sizes in kDa indicated on the left of the gel. FT – flow through, aa – 
amino acid, ResQ – ResourceQ anion exchange column. 
A. Comparison of purification of MA3 construct 800-999 aa, without the linker 
between the two domains, and MA3 construct 800-1057. Longer construct 
showed signs of aggregation and multiple proteins eluted with it from HisTrap HP 
(gel on the left). Purified MA3 800-999 aa used as a comparison for MA3 800-
1057, which cleavage was inefficient (additionally precipitation of protein was 
observed in the sample) (gel on the right).  
B. Purification of MA3 construct 842-1092 aa, which also contains linker between 
the two domains. Protein showed signs of aggregation in first steps of 
purification (left). Cleavage was inefficient and multiple contaminants were 





Appendix 2 Figure 2-4 CNOT1 MA3-MIF construct used in this thesis 
Gel performed by Dr Lori Buetow; construct purified by Dr Lori Buetow. This CNOT1 
construct was expressed with N-terminal His-SUMO-CL7-HRV3C tag and purified using 
Ni2+ agarose resin then a IM7 column with His-SUMO cleavage on the column, then 
cleavage of HRV3C tag by HRV3C protease and another run on IL7 column (flow through 
and wash were collected and concentrated), and final run on a size exclusion column. 
Lane 1 indicates protein eluted from the SEC column and used for subsequent studies 
(contaminations were present in the sample but no visible aggregation and ratio of 
proteins to contaminants is in favour of the protein), lane 2 indicates protein from lane 
1 subjected to concentration. Concentration caused the CNOT1 construct to aggregate, 
which caused problems with the available concentration (as well as amount) of MA3-MIF 




Appendix 2 Figure 2-5 Purification of DDX6 
A. Elution profiles of DDX6 from affinity chromatography (HisTrap HP column, left), 
cation exchange chromatography (HiTrap Heparin column, middle), and size 
exclusion chromatography (Superdex S200 HiLoad 16/600, right). Arrows indicate 
peak samples run on an SDS-PAGE. Purple arrow in ion exchange chromatogram 
indicates a peak that was pooled and run on a size exclusion column (this was 
based on an elution profile and concentration of KCl at which DDX6 was 
previously purified in the Bushell lab).  
B. Coomassie stained gel from purification of DDX6 (arrows correspond to the 
arrows in panel A). Protein marker sizes in kDa indicated on the left of the gel.  
C. Purified DDX6 protein on a Coomassie stained gel. Protein marker sizes in kDa 









Appendix 2 Figure 2-6 Purification of CNOT7 
Coomassie stained gels presented with protein marker on the left of each gel, sizes in 
kDa. Unrelated lanes removed. Chromatograms plotted using Plot Digitizer from a lab 
book photocopy.  
A. As the His-SUMO tag did not cleave of CNOT7 (lane 1 represents ULP1 protease, 
lane 2 represents His-SUMO-CNOT7 subjected to ULP1 cleavage), CNOT7 was 
purified with His-TEV tag.  
B. Affinity chromatography on HisTrap HP column of His-TEV-CNOT7. Tagged CNOT7 
eluted in a linear imidazole gradient.  
C. Coomassie stained gel of His-TEV-CNOT7 cleavage using TEV protease. Lane 1 – 
tagged CNOT7 before cleavage, lane 2 – CNOT7 after overnight digestion, lane 3 
– TEV protease.  
D. Ion exchange chromatography using ResourceQ column, of cleaved CNOT7. 
CNOT7 eluted in a linear KCl gradient.  
E. Size exclusion chromatography of cleaved CNOT7 on Superdex S200 HiLoad 
16/600.  











Appendix 3 Figure 3-1 eIF4A1 oligomerises in live cells through protein-
protein interaction 
A. Fluorophore tagged eIF4A1 oligomerises in live cells. On the left side of the 
panel, representative images from two independent paired (top and bottom) 
experiments are shown with a scale bar of 25 µm (right bottom corner of each 
image). Images are presented in the magenta fluorescence lifetime scale from 
3.9 to 3.6 ns; the change in the colour from magenta (top, donor-eIF4A1) to cyan 
(bottom, eIF4A1 with both donor and acceptor), corresponds to the decreased 
fluorescence lifetime of the donor in presence of acceptor. On the right side, 
averages of all fluorescence lifetimes from 9 individual experiments (2 technical 
duplicates each) are presented in a form of a box plot with a median (black bar). 
Total of 339 and 338 cells were measured for mTurqoise2-eIF4A1 and for co-
transfection of mTurqoise2-eIF4A1 and mCitrine-eIF4A1, respectively. The p-
value = 2.7 * 10-5 was calculated using T-test (two-tailed distribution, two-
sample equal variance) and the results were assessed to be statistically 
significant. (figure legend continues on the next page) 
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B. Transfection efficiency was assessed by Western botting, anti-vinculin antibody 
was used as a loading control. Transfected tagged-eIF4A1 levels were consistent 
for each combination of fluorophore and of similar expression level to WT.  
C. To understand whether eIF4A1-eIF4A1 interaction in cells happens through 
protein-protein interaction and knowing that the oligomerisation of eIF4A occurs 
only in presence of RNA, HeLa cells were either transfected with mTurqoise2-
eIF4A1 or co-transfected with mTurqoise2-eIF4A1 and mCitrine-eIF4A1. 
Presentation of the data in panel C is the same as in panel A. For these 
conditions, 4 individual experiments (two technical duplicates per experiment) 
were performed, with the total of 171 and 129 cells measured for donor and 
both donor and acceptor, respectively. p-value was calculated in the same 
manner as in panel A and the collected data were statistically significant (p-







Appendix 3 Figure 3-2 Investigation of eIF4G-binding deficient mutants of 
eIF4A1  
To test whether eIF4A1-eIF4A1 oligomerisation is mediated in cells by eIF4G, eIF4A1 
mutants deficient in eIF4G binding were used for further studies.  
(figure legend continues on the next page) 
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A. Immunoprecipitations (IP) with indicated antibodies of cell lysates from non-
transfected HeLa cells, and HeLa cells transfected with donor and acceptor 
tagged WT eIF4A1, as well as the eIF4G-binding deficient mutants D265R E268K 
and D296A T298K (mutations responsible for loss of eIF4G binding identified in 
Oberer, Marintchev and Wagner, 2005). Cell lysis performed in presence of 
Ribolock to preserve RNA integrity. Co-precipitation of eIF4A1 and eIF4G1 in 
eIF4A1 IP lane and no precipitation in GFP IP was detected for non-transfected 
HeLa cells. For the tagged eIF4A1 WT transfection, eIF4G1 co-precipitated with 
eIF4A1 in both eIF4A1 and GFP IP lanes. For the eIF4A1 mutants, eIF4G1 co-
precipitated with eIF4A1 in eIF4A1 IP lanes. No co-precipitation of eIF4G1 with 
eIF4A1 in GFP IP lane was observed for eIF4A1 D265R E268K, however eIF4G1 co-
precipitated with eIF4A1 in GFP IP lane for. No unspecific precipitation was 
detected in the IgG IP lanes.  
B. As eIF4G1 co-precipitation was detected in GFP IP lane for D296A T298K eIF4A1 
mutant, it was tested whether this interaction can be RNA mediated. For this IPs 
were performed in the same way as in panel A, however instead of Ribolock, 
RNase 1 was used to digest RNA. The obtained result was the same for all the IP 
lanes as in panel A, except the D296A T298K eIF4A1 mutant GFP IP lane. Upon 
RNA digestion, lower co-precipitation of eIF4G1 in GFP IP lane was detected. 
However, the amount of precipitated tagged-eIF4A1 D296A T298K mutant was 
also lower in the RNase 1 condition. Therefore, eIF4A1 D296A T298K mutant 
possibly retained its ability to interact with eIF4G1.  
C. RNA integrity test, for Ribolock (RL) and RNase 1 (R1) condition for the samples 
from panels A and B. All samples with RL had good quality of RNA, and RNA 










Appendix 3 Figure 3-3 eIF4A1 4G-mut oligomerises in live cells  
As in Figure Appendix 3-2 for eIF4A1 D265R E268K mutant (from now on designated as 
eIF4A1 4G-mut) no co-precipitation of eIF4G1 was observed, this mutant was used to 
study whether eIF4A1 can interact in cells without the influence of eIF4G1. Here, HeLa 
cells were transfected as described in Chapter 2.4.7, with the fluorophore-tagged 
eIF4A1 4G-mut. On the left side of the panel, representative images from two 
independent paired (top and bottom) experiments are shown with a scale bar of 25 µm. 
As in Appendix 3 Figure 3-1, the images are presented in the magenta fluorescence 
lifetime scale from 3.9 to 3.6 ns. On the right side, all fluorescence lifetimes from 2 
individual experiments (2 technical duplicates each) are presented in a form of a box 
plot with a median (black bar). Total of 38 and 59 cells were measured for the donor-
eIF4A1 4G-mut, and for the co-transfection, respectively. The p-value = 2.3 * 10-11 was 
calculated using T-test (two-tailed distribution, two-sample equal variance) and the 
results were assessed to be statistically significant. It should be noted however, that the 
cellular localisation of eIF4A1 4G-mut was in contrast to known localisation of eIF4A1 
WT (see nuclear both nuclear and cytoplasmic localisation of the mutant). Moreover, in 
case of co-transfection the change of fluorescence lifetime was mostly observed in the 
cytoplasm, this could mean that while in nucleus eIF4A1 does not perform the same 
function as in cytoplasm. This change of localisation and the large range of the 
measured fluorescence lifetimes could indicate that while the eIF4A1 4G-mut can 







Appendix 3 Figure 3-4 eIF4A1 mutant deficient in eIF4G binding can form 
oligomeric complexes  
As eIF4A1 4G-mut mutant localisation in cells was not restricted to the cytoplasm as is 
the case for WT eIF4A1, and the range of measured fluorescence lifetimes (Appendix 3 
Figure 3-3) was larger, the eIF4A1 4G-mut oligomerisation potential was investigated in 
vitro.  
A. Purification of eIF4A1 D265R E268K mutant (eIF4A1 4G-mut). Pre-cleared 
bacterial lysate was applied on HisTrap HP column (left), and the bound proteins 
were eluted in a linear imidazole gradient. Subsequently, the pooled fractions 
were subjected to His-SUMO tag cleavage by ULP1. Next, anion exchange 
chromatography was performed using ResourceQ column (middle left). eIF4A1 
4G-mut did not bind to the column resin as WT, instead flow-through was 
collected and concentrated. Then, the concentrated sample was loaded onto 
Superdex S200 HiLoad 16/600 (middle right). The eluted sample contained 
cleaved His-SUMO tag, visible on Coomassie stained gel in 1st and 2nd lane on the 
right from the marker (right). The sample was run on the HisTrap HP column 
again (using peristaltic pump) and flow through was collected (most right lane in 
the gel on the right). Protein concentration was measured (see Chapter 2.2) and 
it was deemed to be of good quality to use in subsequent experiments. Protein 
marker kDa size indicated on the left of the gel.  
B. Determination of eIF4A1 4G-mut RNA binding capacity and oligomerisation 
potential in vitro. EMSAs of eIF4A1 4G-mut titration on (AG)10 RNA (left) and 
(CAA)6CA RNA (right). Oligomers of eIF4A1 4G-mut similarly to eIF4A1 WT were 
detected on (AG)10 RNA and not on (CAA)6CA RNA. However, the calculated KD 
(from gel image quantification, see Chapter 2.3.1.1) was higher (lower affinity) 




Appendix 3 Figure 3-5 Monomeric eIF4A1 does not exhibit unwinding activity  
A. Unwinding activity of eIF4A1 in monomeric and oligomeric conditions presented 
as fraction unwound versus time. Monomeric eIF4A1 does not exhibit unwinding 
activity. Representative reactions (n = 3) for 2 µ eIF4A1 in presence of silvestrol 
on 5’(AG)10 overhang RNA shown with standard deviation from technical 
duplicate. Monomeric conditions created by adding excess of unlabelled (AG)10 
RNA to the reaction.  
B. ATPase activity of 5 µM eIF4A1 in oligomeric and monomeric conditions. 
Similarly, as is the case for eIF4A2 (Figure 3.10-2) monomeric eIF4A1 has 
greater ATPase activity than oligomer. High ATPase activity of monomer and lack 
of unwinding signifies that all eIF4A1 is active in the monomeric conditions, and 









Appendix 3 Figure 3-6 Sc eIF4A can form oligomers 
Increased contrast of the same EMSA image as in Figure 5.4-3, panel A right. Sc eIF4A 
binds RNA weaker than human eIF4A and its oligomerisation propensity is also lower, 
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